Doneer nu

Publicaties

Delen

Via het overzicht hiernaast kunt u door de wetenschappelijke publicaties van het Alzheimercentrum zoeken.

  1. Altomare D, Molinuevo JL, Ritchie C, Ribaldi F, Carrera E, Dubois B, Jessen F, McWhirter L, Scheltens P, van der Flier WM, Vellas B, Démonet JF, Frisoni GB; European Task Force for Brain Health Services. Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services-part 1 of 6. Alzheimers Res Ther. 2021 Oct 11;13(1):168. doi: 10.1186/s13195-021-00827-2. PMID: 34635163; PMCID: PMC8507194.
  1. Amariglio RE, Sikkes SAM, Marshall GA, Buckley RF, Gatchel JR, Johnson KA, Rentz DM, Donohue MC, Raman R, Sun CK, Yaari R, Holdridge KC, Sims JR, Grill JD, Aisen PS, Sperling RA. Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data. J Prev Alzheimers Dis. 2021;8(3):257-262. doi: 10.14283/jpad.2021.8. PMID: 34101781; PMCID: PMC8240963.

 

  1. Ashton NJ, Leuzy A, Karikari TK, Mattsson-Carlgren N, Dodich A, Boccardi M, Corre J, Drzezga A, Nordberg A, Ossenkoppele R, Zetterberg H, Blennow K, Frisoni GB, Garibotto V, Hansson O. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2140-2156. doi: 10.1007/s00259-021-05253-y. Epub 2021 Mar 6. PMID: 33677733; PMCID: PMC8175325.

 

  1. Baakman AC, Gavan C, van Doeselaar L, de Kam M, Broekhuizen K, Bajenaru O, Camps L, Swart EL, Kalisvaart K, Schoonenboom N, Lemstra E, Scheltens P, Cohen A, van Gerven J, Groeneveld GJ. Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer’s Disease. Br J Clin Pharmacol. 2021 Dec 28. doi: 10.1111/bcp.15206. Epub ahead of print. PMID: 34964149.

 

  1. Babapour Mofrad R, Fruijtier AD, Visser LNC, Hoogland N, van Dijk M, van Rossum F, Bouwman FH, Smets EMA, Teunissen CE, van der Flier WM. Lumbar puncture patient video increases knowledge and reduces uncertainty: An RCT. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12127. doi: 10.1002/trc2.12127. PMID: 33614895; PMCID: PMC7882513.

 

  1. Babapour Mofrad R, Scheltens P, Kim S, Kang S, Youn YC, An SSA, Tomassen J, van Berckel BNM, Visser PJ, van der Flier WM, Teunissen CE. Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status. Alzheimers Res Ther. 2021 Jul 26;13(1):133. doi: 10.1186/s13195-021-00873-w. PMID: 34311775; PMCID: PMC8311929.

 

  1. Bastiaans KM, Chatzopoulos D, Ge JF, Cho D, Tromp WO, van Ruitenbeek JM, Fischer MH, de Visser PJ, Thoen DJ, Driessen EFC, Klapwijk TM, Allan MP. Direct evidence for Cooper pairing without a spectral gap in a disordered superconductor above T(c). 2021 Oct 29;374(6567):608-611. doi: 10.1126/science.abe3987. Epub 2021 Oct 28. PMID: 34709897.

 

  1. Bauckneht M, Chincarini A, Brendel M, Rominger A, Beyer L, Bruffaerts R, Vandenberghe R, Kramberger MG, Trost M, Garibotto V, Nicastro N, Frisoni GB, Lemstra AW, van Berckel BNM, Pilotto A, Padovani A, Ochoa-Figueroa MA, Davidsson A, Camacho V, Peira E, Arnaldi D, Pardini M, Donegani MI, Raffa S, Miceli A, Sambuceti G, Aarsland D, Nobili F, Morbelli S. Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A European-DLB consortium project. Alzheimers Dement. 2021 Aug;17(8):1277-1286. doi: 10.1002/alz.12294. Epub 2021 Feb 2. PMID: 33528089.

 

  1. Bayoumy S, Verberk IMW, den Dulk B, Hussainali Z, Zwan M, van der Flier WM, Ashton NJ, Zetterberg H, Blennow K, Vanbrabant J, Stoops E, Vanmechelen E, Dage JL, Teunissen CE. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res Ther. 2021 Dec 4;13(1):198. doi: 10.1186/s13195-021-00939-9. PMID: 34863295; PMCID: PMC8645090.

 

  1. Beeldman E, Govaarts R, de Visser M, van Es MA, Pijnenburg YAL, Schmand BA, Raaphorst J. Screening for cognition in amyotrophic lateral sclerosis: test characteristics of a new screen. J Neurol. 2021 Jul;268(7):2533-2540. doi: 10.1007/s00415-021-10423-x. Epub 2021 Feb 6. PMID: 33547953; PMCID: PMC8217007.

 

  1. Beker N, Ganz A, Hulsman M, Klausch T, Schmand BA, Scheltens P, Sikkes SAM, Holstege H. Association of Cognitive Function Trajectories in Centenarians With Postmortem Neuropathology, Physical Health, and Other Risk Factors for Cognitive Decline. JAMA Netw Open. 2021 Jan 4;4(1):e2031654. doi: 10.1001/jamanetworkopen.2020.31654. PMID: 33449094; PMCID: PMC7811180.

 

  1. Berron D, van Westen D, Ossenkoppele R, Strandberg O, Hansson O. Corrigendum to: Medial temporal lobe connectivity and its associations with cognition in early Alzheimer’s disease. 2021 Oct 22;144(9):e84. doi: 10.1093/brain/awab244. Erratum for: Brain. 2020 Apr 1;143(4):1233-1248. PMID: 34259865; PMCID: PMC8536931.

 

  1. Bischof GN, Dodich A, Boccardi M, van Eimeren T, Festari C, Barthel H, Hansson O, Nordberg A, Ossenkoppele R, Sabri O, Giovanni BFG, Garibotto V, Drzezga A. Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2110-2120. doi: 10.1007/s00259-020-05156-4. Epub 2021 Feb 16. PMID: 33590274; PMCID: PMC8175320.

 

  1. Boada M, Rodrigo A, Jessen F, Wimblad B, Kramberger M, Visser PJ, Simó R, Rodríguez-Gomez O, Ciudin A, Georges J, Dumas A, Maguire P, Krivec D, Wimo A, Valero S, Alegret M, Jamilis L, Zwan M, Sannemann L, Arrufat J, Stomrud E, Johansson G, Shering C, Glaysher B, Stewart N, Belger M, Iradier F, Campo L; MOPEAD consortium. Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer’s disease: Results from the MOPEAD project. Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12441. Epub ahead of print. PMID: 34310061.

 

  1. Bocancea DI, van Loenhoud AC, Groot C, Barkhof F, van der Flier WM, Ossenkoppele R. Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis. Neurology. 2021 Sep 7;97(10):474-488. doi: 10.1212/WNL.0000000000012499. Epub 2021 Jul 15. PMID: 34266918; PMCID: PMC8448552.

 

  1. Boccardi M, Dodich A, Albanese E, Gayet-Ageron A, Festari C, Ashton NJ, Bischof GN, Chiotis K, Leuzy A, Wolters EE, Walter MA, Rabinovici GD, Carrillo M, Drzezga A, Hansson O, Nordberg A, Ossenkoppele R, Villemagne VL, Winblad B, Frisoni GB, Garibotto V. The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2070-2085. doi: 10.1007/s00259-020-05120-2. Epub 2021 Mar 10. Erratum in: Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4525-4531. PMID: 33688996; PMCID: PMC8175304.

 

  1. Boccardi M, Dodich A, Albanese E, Gayet-Ageron A, Festari C, Ashton NJ, Bischof GN, Chiotis K, Leuzy A, Wolters EE, Walter M, Rabinovici GD, Carrillo M, Drzezga A, Hansson O, Nordberg A, Ossenkoppele R, Villemagne VL, Winblad B, Frisoni G, Garibotto V. Correction to: The Strategic Biomarker Roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update. Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4525-4531. doi: 10.1007/s00259-021-05549-z. Erratum for: Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2070-2085. PMID: 34546388.

 

  1. Briels CT, Stam CJ, Scheltens P, Gouw AA. The predictive value of normal EEGs in dementia due to Alzheimer’s disease. Ann Clin Transl Neurol. 2021 May;8(5):1038-1048. doi: 10.1002/acn3.51339. Epub 2021 Apr 9. PMID: 33835723; PMCID: PMC8108419.

 

  1. Brioschi Guevara A, Bieler M, Altomare D, Berthier M, Csajka C, Dautricourt S, Démonet JF, Dodich A, Frisoni GB, Miniussi C, Molinuevo JL, Ribaldi F, Scheltens P, Chételat G. Protocols for cognitive enhancement. A user manual for Brain Health Services-part 5 of 6. Alzheimers Res Ther. 2021 Oct 11;13(1):172. doi: 10.1186/s13195-021-00844-1. PMID: 34635149; PMCID: PMC8507160.

 

  1. Bron EE, Klein S, Papma JM, Jiskoot LC, Venkatraghavan V, Linders J, Aalten P, De Deyn PP, Biessels GJ, Claassen JAHR, Middelkoop HAM, Smits M, Niessen WJ, van Swieten JC, van der Flier WM, Ramakers IHGB, van der Lugt A; Alzheimer’s Disease Neuroimaging Initiative; Parelsnoer Neurodegenerative Diseases study group. Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer’s disease. Neuroimage Clin. 2021;31:102712. doi: 10.1016/j.nicl.2021.102712. Epub 2021 Jun 4. PMID: 34118592; PMCID: PMC8203808.

 

  1. Cacciamani F, Houot M, Gagliardi G, Dubois B, Sikkes S, Sánchez-Benavides G, Denicolò E, Molinuevo JL, Vannini P, Epelbaum S. Awareness of Cognitive Decline in Patients With Alzheimer’s Disease: A Systematic Review and Meta-Analysis. Front Aging Neurosci. 2021 Aug 3;13:697234. doi: 10.3389/fnagi.2021.697234. PMID: 34413767; PMCID: PMC8370471.

 

  1. Campbell MR, Ashrafzadeh-Kian S, Petersen RC, Mielke MM, Syrjanen JA, van Harten AC, Lowe VJ, Jack CR Jr, Bornhorst JA, Algeciras-Schimnich A. P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status. Alzheimers Dement (Amst). 2021 May 18;13(1):e12190. doi: 10.1002/dad2.12190. PMID: 34027020; PMCID: PMC8129859.

 

  1. Campo MD, Pijnenburg YAL, Chen-Plotkin A, Irwin DJ, Grossman M, Twaalfhoven HAM, Hu WT, Meeter LH, van Swieten J, Vermunt L, Martens F, Heijboer AC, Teunissen CE. Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies. 2021 Oct 8;11(10):1484. doi: 10.3390/biom11101484. PMID: 34680117; PMCID: PMC8533538.

 

  1. Chard DT, Alahmadi AAS, Audoin B, Charalambous T, Enzinger C, Hulst HE, Rocca MA, Rovira À, Sastre-Garriga J, Schoonheim MM, Tijms B, Tur C, Gandini Wheeler-Kingshott CAM, Wink AM, Ciccarelli O, Barkhof F; MAGNIMS Study Group. Mind the gap: from neurons to networks to outcomes in multiple sclerosis. Nat Rev Neurol. 2021 Mar;17(3):173-184. doi: 10.1038/s41582-020-00439-8. Epub 2021 Jan 12. PMID: 33437067.

 

 

  1. Chia R, Sabir MS, Bandres-Ciga S, Saez-Atienzar S, Reynolds RH, Gustavsson E, Walton RL, Ahmed S, Viollet C, Ding J, Makarious MB, Diez-Fairen M, Portley MK, Shah Z, Abramzon Y, Hernandez DG, Blauwendraat C, Stone DJ, Eicher J, Parkkinen L, Ansorge O, Clark L, Honig LS, Marder K, Lemstra A, St George-Hyslop P, Londos E, Morgan K, Lashley T, Warner TT, Jaunmuktane Z, Galasko D, Santana I, Tienari PJ, Myllykangas L, Oinas M, Cairns NJ, Morris JC, Halliday GM, Van Deerlin VM, Trojanowski JQ, Grassano M, Calvo A, Mora G, Canosa A, Floris G, Bohannan RC, Brett F, Gan-Or Z, Geiger JT, Moore A, May P, Krüger R, Goldstein DS, Lopez G, Tayebi N, Sidransky E; American Genome Center, Norcliffe-Kaufmann L, Palma JA, Kaufmann H, Shakkottai VG, Perkins M, Newell KL, Gasser T, Schulte C, Landi F, Salvi E, Cusi D, Masliah E, Kim RC, Caraway CA, Monuki ES, Brunetti M, Dawson TM, Rosenthal LS, Albert MS, Pletnikova O, Troncoso JC, Flanagan ME, Mao Q, Bigio EH, Rodríguez-Rodríguez E, Infante J, Lage C, González-Aramburu I, Sanchez-Juan P, Ghetti B, Keith J, Black SE, Masellis M, Rogaeva E, Duyckaerts C, Brice A, Lesage S, Xiromerisiou G, Barrett MJ, Tilley BS, Gentleman S, Logroscino G, Serrano GE, Beach TG, McKeith IG, Thomas AJ, Attems J, Morris CM, Palmer L, Love S, Troakes C, Al-Sarraj S, Hodges AK, Aarsland D, Klein G, Kaiser SM, Woltjer R, Pastor P, Bekris LM, Leverenz JB, Besser LM, Kuzma A, Renton AE, Goate A, Bennett DA, Scherzer CR, Morris HR, Ferrari R, Albani D, Pickering- Brown S, Faber K, Kukull WA, Morenas-Rodriguez E, Lleó A, Fortea J, Alcolea D, Clarimon J, Nalls MA, Ferrucci L, Resnick SM, Tanaka T, Foroud TM, Graff-Radford NR, Wszolek ZK, Ferman T, Boeve BF, Hardy JA, Topol EJ, Torkamani A, Singleton AB, Ryten M, Dickson DW, Chiò A, Ross OA, Gibbs JR, Dalgard CL, Traynor BJ, Scholz SW. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat Genet. 2021 Mar;53(3):294-303. doi: 10.1038/s41588-021-00785-3. Epub 2021 Feb 15. PMID: 33589841; PMCID: PMC7946812.

 

  1. Chiotis K, Dodich A, Boccardi M, Festari C, Drzezga A, Hansson O, Ossenkoppele R, Frisoni G, Garibotto V, Nordberg A. Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2086-2096. doi: 10.1007/s00259-021-05277-4. Epub 2021 Mar 15. PMID: 33723628; PMCID: PMC8175292.

 

  1. Cho SH, Woo S, Kim C, Kim HJ, Jang H, Kim BC, Kim SE, Kim SJ, Kim JP, Jung YH, Lockhart S, Ossenkoppele R, Landau S, Na DL, Weiner M, Kim S, Seo SW. Disease progression modelling from preclinical Alzheimer’s disease (AD) to AD dementia. Sci Rep. 2021 Feb 18;11(1):4168. doi: 10.1038/s41598-021-83585-3. PMID: 33603015; PMCID: PMC7893024.

 

  1. Ciccarelli M, Dawson D, Falcao-Pires I, Giacca M, Hamdani N, Heymans S, Hooghiemstra A, Leeuwis A, Hermkens D, Tocchetti CG, van der Velden J, Zacchigna S, Thum T. Reciprocal organ interactions during heart failure: a position paper from the ESC Working Group on Myocardial Function. Cardiovasc Res. 2021 Nov 1;117(12):2416-2433. doi: 10.1093/cvr/cvab009. PMID: 3483724; PMCID: PMC8562335.

 

  1. Cicognola C, Hansson O, Scheltens P, Kvartsberg H, Zetterberg H, Teunissen CE, Blennow K. Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias. Alzheimers Res Ther. 2021 Feb 8;13(1):38. doi: 10.1186/s13195-020-00756-6. PMID: 33557920; PMCID: PMC7871566.

 

  1. Collij LE, Salvadó G, Shekari M, Lopes Alves I, Reimand J, Wink AM, Zwan M, Niñerola-Baizán A, Perissinotti A, Scheltens P, Ikonomovic MD, Smith APL, Farrar G, Molinuevo JL, Barkhof F, Buckley CJ, van Berckel BNM, Gispert JD; ALFA study; AMYPAD consortium. Visual assessment of [(18)F]flutemetamol PET images can detect early amyloid pathology and grade its extent. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2169-2182. doi: 10.1007/s00259-020-05174-2. Epub 2021 Feb 22. PMID: 33615397; PMCID: PMC8175297.

 

  1. Collij LE, Ingala S, Top H, Wottschel V, Stickney KE, Tomassen J, Konijnenberg E, Ten Kate M, Sudre C, Lopes Alves I, Yaqub MM, Wink AM, Van ‘t Ent D, Scheltens P, van Berckel BNM, Visser PJ, Barkhof F, Braber AD. White matter microstructure disruption in early stage amyloid pathology. Alzheimers Dement (Amst). 2021 Apr 1;13(1):e12124. doi: 10.1002/dad2.12124. PMID: 33816751; PMCID: PMC8015832.

 

  1. Collij LE, Mastenbroek SE, Salvadó G, Wink AM, Visser PJ, Barkhof F, van Berckel BNM, Lopes Alves I. Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals. Alzheimers Dement (Amst). 2021 Aug 2;13(1):e12216. doi: 10.1002/dad2.12216. PMID: 34368416; PMCID: PMC8327468.

 

  1. Coomans EM, Schoonhoven DN, Tuncel H, Verfaillie SCJ, Wolters EE, Boellaard R, Ossenkoppele R, den Braber A, Scheper W, Schober P, Sweeney SP, Ryan JM, Schuit RC, Windhorst AD, Barkhof F, Scheltens P, Golla SSV, Hillebrand A, Gouw AA, van Berckel BNM. In vivo tau pathology is associated with synaptic loss and altered synaptic function. Alzheimers Res Ther. 2021 Feb 5;13(1):35. doi: 10.1186/s13195-021-00772-0. PMID: 33546722; PMCID: PMC7866464.

 

  1. Corrêa DG, Tijms BM, Dicks E, Rêgo C, Alves-Leon SV, Marcondes J, Gasparetto EL, van Duinkerken E. Effects of seizure burden on structural global brain networks in patients with unilateral hippocampal sclerosis. Brain Behav. 2021 Aug;11(8):e2237. doi: 10.1002/brb3.2237. Epub 2021 Jun 9. PMID: 34105906; PMCID: PMC8413824.

 

  1. Cotta Ramusino M, Perini G, Altomare D, Barbarino P, Weidner W, Salvini Porro G, Barkhof F, Rabinovici GD, van der Flier WM, Frisoni GB, Garibotto V, Teipel S, Boccardi M. Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. Eur J Nucl Med Mol Imaging. 2021Jul;48(7):2157-2168. doi: 10.1007/s00259-020-05187-x. Epub 2021 Feb 17. PMID: 33594474; PMCID: PMC8175294.

 

  1. Cysique LA, Łojek E, Cheung TC, Cullen B, Egbert AR, Evans J, Garolera M, Gawron N, Gouse H, Hansen K, Holas P, Hyniewska S, Malinowska E, Marcopulos BA, Merkley TL, Muñoz-Moreno JA, Ramsden C, Salas C, Sikkes SAM, Silva AR, Zouhar I; NeuroCOVID International Neuropsychology Taskforce. Assessment of Neurocognitive Functions, Olfaction, Taste, Mental, and Psychosocial Health in COVID-19 in Adults: Recommendations for Harmonization of Research and Implications for Clinical Practice. J Int Neuropsychol Soc. 2021 Aug 9:1-19. doi: 10.1017/S1355617721000862. Epub ahead of print. PMID: 34365990.

 

  1. Damotte V, van der Lee SJ, Chouraki V, Grenier-Boley B, Simino J, Adams H, Tosto G, White C, Terzikhan N, Cruchaga C, Knol MJ, Li S, Schraen S, Grove ML, Satizabal C, Amin N, Berr C, Younkin S; Alzheimer’s Disease Neuroimaging Initiative, Gottesman RF, Buée L, Beiser A, Knopman DS, Uitterlinden A, DeCarli C, Bressler J, DeStefano A, Dartigues JF, Yang Q, Boerwinkle E, Tzourio C, Fornage M, Ikram MA, Amouyel P, de Jager P, Reitz C, Mosley TH, Lambert JC, Seshadri S, van Duijn CM. Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants. Alzheimers Dement. 2021 Oct;17(10):1663-1674. doi: 10.1002/alz.12333. Epub 2021 May 18. PMID: 34002480; PMCID: PMC8597077.

 

  1. 52: Dauwan M, Begemann MJH, Slot MIE, Lee EHM, Scheltens P, Sommer IEC. Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials. J Neurol. 2021 Apr;268(4):1222-1246. doi: 10.1007/s00415-019-09493-9. Epub 2019 Aug 14. PMID: 31414194; PMCID: PMC7990819.

 

  1. de Boer SCM, Riedl L, van der Lee SJ, Otto M, Anderl-Straub S, Landin-Romero R, Sorrentino F, Fieldhouse JLP, Reus LM, Vacaflor B, Halliday G, Galimberti D, Diehl-Schmid J, Ducharme S, Piguet O, Pijnenburg YAL. Differences in Sex Distribution Between Genetic and Sporadic Frontotemporal Dementia. J Alzheimers Dis. 2021;84(3):1153-1161. doi: 10.3233/JAD-210688. PMID: 34633319; PMCID: PMC8673542.

 

  1. de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B, Andrade V, Jansen IE, Pedersen NL, Stringa N, Zettergren A, Hernández I, Montrreal L, Antúnez C, Antonell A, Tankard RM, Bis JC, Sims R, Bellenguez C, Quintela I, González-Perez A, Calero M, Franco-Macías E, Macías J, Blesa R, Cervera-Carles L, Menéndez-González M, Frank-García A, Royo JL, Moreno F, Huerto Vilas R, Baquero M, Diez-Fairen M, Lage C, García-Madrona S, García-González P, Alarcón-Martín E, Valero S, Sotolongo-Grau O, Ullgren A, Naj AC, Lemstra AW, Benaque A, Pérez-Cordón A, Benussi A, Rábano A, Padovani A, Squassina A, de Mendonça A, Arias Pastor A, Kok AAL, Meggy A, Pastor AB Espinosa A, Corma-Gómez A, Martín Montes A, Sanabria Á, DeStefano AL, Schneider A, Haapasalo A, Kinhult Ståhlbom A, Tybjærg-Hansen A, Hartmann AM, Spottke A, Corbatón-Anchuelo A, Rongve A, Borroni B, Arosio B, Nacmias B, Nordestgaard BG, Kunkle BW, Charbonnier C, Abdelnour C, Masullo C, Martínez Rodríguez C, Muñoz-Fernandez C, Dufouil C, Graff C, Ferreira CB, Chillotti C, Reynolds CA, Fenoglio C, Van Broeckhoven C, Clark C, Pisanu C, Satizabal CL, Holmes C, Buiza-Rueda D, Aarsland D, Rujescu D, Alcolea D, Galimberti D, Wallon D, Seripa D, Grünblatt E, Dardiotis E, Düzel E, Scarpini E, Conti E, Rubino E, Gelpi E, Rodriguez-Rodriguez E, Duron E, Boerwinkle E, Ferri E, Tagliavini F, Küçükali F, Pasquier F, Sanchez-Garcia F, Mangialasche F, Jessen F, Nicolas G, Selbæk G, Ortega G, Chêne G, Hadjigeorgiou G, Rossi G, Spalletta G, Giaccone G, Grande G, Binetti G, Papenberg G, Hampel H, Bailly H, Zetterberg H, Soininen H, Karlsson IK, Alvarez I, Appollonio I, Giegling I, Skoog I, Saltvedt I, Rainero I, Rosas Allende I, Hort J, Diehl-Schmid J, Van Dongen J, Vidal JS, Lehtisalo J, Wiltfang J, Thomassen JQ, Kornhuber J, Haines JL, Vogelgsang J, Pineda JA, Fortea J, Popp J, Deckert J, Buerger K, Morgan K, Fließbach K, Sleegers K, Molina-Porcel L, Kilander L, Weinhold L, Farrer LA, Wang LS, Kleineidam L, Farotti L, Parnetti L, Tremolizzo L, Hausner L, Benussi L, Froelich L, Ikram MA, Deniz-Naranjo MC, Tsolaki M, Rosende-Roca M, Löwenmark M, Hulsman M, Spallazzi M, Pericak-Vance MA, Esiri M, Bernal Sánchez-Arjona M, Dalmasso MC, Martínez-Larrad MT, Arcaro M, Nöthen MM, Fernández-Fuertes M, Dichgans M, Ingelsson M, Herrmann MJ, Scherer M, Vyhnalek M, Kosmidis MH, Yannakoulia M, Schmid M, Ewers M, Heneka MT, Wagner M, Scamosci M, Kivipelto M, Hiltunen M, Zulaica M, Alegret M, Fornage M, Roberto N, van Schoor NM, Seidu NM, Banaj N, Armstrong NJ, Scarmeas N, Scherbaum N, Goldhardt O, Hanon O, Peters O, Skrobot OA, Quenez O, Lerch O, Bossù P, Caffarra P, Dionigi Rossi P, Sakka P, Hoffmann P, Holmans PA, Fischer P, Riederer P, Yang Q, Marshall R, Kalaria RN, Mayeux R, Vandenberghe R, Cecchetti R, Ghidoni R, Frikke-Schmidt R, Sorbi S, Hägg S, Engelborghs S, Helisalmi S, Botne Sando S, Kern S, Archetti S, Boschi S, Fostinelli S, Gil S, Mendoza S, Mead S, Ciccone S, Djurovic S, Heilmann-Heimbach S, Riedel-Heller S, Kuulasmaa T, Del Ser T, Lebouvier T, Polak T, Ngandu T, Grimmer T, Bessi V, Escott-Price V, Giedraitis V, Deramecourt V, Maier W, Jian X, Pijnenburg YAL; EADB contributors; GR@ACE study group; DEGESCO consortium; IGAP (ADGC, CHARGE, EADI, GERAD); PGC-ALZ consortia, Kehoe PG, Garcia-Ribas G, Sánchez-Juan P, Pastor P, Pérez-Tur J, Piñol-Ripoll G, Lopez de Munain A, García-Alberca JM, Bullido MJ, Álvarez V, Lleó A, Real LM, Mir P, Medina M, Scheltens P, Holstege H, Marquié M, Sáez ME, Carracedo Á, Amouyel P, Schellenberg GD, Williams J, Seshadri S, van Duijn CM, Mather KA, Sánchez-Valle R, Serrano-Ríos M, Orellana A, Tárraga L, Blennow K, Huisman M, Andreassen OA, Posthuma D, Clarimón J, Boada M, van der Flier WM, Ramirez A, Lambert JC, van der Lee SJ, Ruiz A. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores. Nat Commun. 2021 Jun 7;12(1):3417. doi: 10.1038/s41467-021-22491-8. PMID: 34099642; PMCID: PMC8184987.
  2. de Vries BM, Timmers T, Wolters EE, Ossenkoppele R, Verfaillie SCJ, Schuit RC, Scheltens P, van der Flier WM, Windhorst AD, van Berckel BNM, Boellaard R, Golla SSV. Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies. Mol Imaging Biol. 2021 Aug;23(4):550-559. doi: 10.1007/s11307-020-01572-y. Epub 2021 Jan 14. PMID: 33443720; PMCID: PMC8277631.

 

  1. Deelen J, Evans DS, Arking DE, Tesi N, Nygaard M, Liu X, Wojczynski MK, Biggs ML, van der Spek A, Atzmon G, Ware EB, Sarnowski C, Smith AV, Seppälä I, Cordell HJ, Dose J, Amin N, Arnold AM, Ayers KL, Barzilai N, Becker EJ, Beekman M, Blanché H, Christensen K, Christiansen L, Collerton JC, Cubaynes S, Cummings SR, Davies K, Debrabant B, Deleuze JF, Duncan R, Faul JD, Franceschi C, Galan P, Gudnason V, Harris TB, Huisman M, Hurme MA, Jagger C, Jansen I, Jylhä M, Kähönen M, Karasik D, Kardia SLR, Kingston A, Kirkwood TBL, Launer LJ, Lehtimäki T, Lieb W, Lyytikäinen LP, Martin-Ruiz C, Min J, Nebel A, Newman AB, Nie C, Nohr EA, Orwoll ES, Perls TT, Province MA, Psaty BM, Raitakari OT, Reinders MJT, Robine JM, Rotter JI, Sebastiani P, Smith J, Sørensen TIA, Taylor KD, Uitterlinden AG, van der Flier W, van der Lee SJ, van Duijn CM, van Heemst D, Vaupel JW, Weir D, Ye K, Zeng Y, Zheng W, Holstege H, Kiel DP, Lunetta KL, Slagboom PE, Murabito JM. Publisher Correction: A meta-analysis of genome-wide association studies identifies multiple longevity genes. Nat Commun. 2021 Apr 23;12(1):2463. doi: 10.1038/s41467-021-22613-2. Erratum for: Nat Commun. 2019 Aug 14;10(1):3669. PMID: 33893282; PMCID: PMC8065049.

 

  1. Delaby C, Teunissen CE, Blennow K, Alcolea D, Arisi I, Amar EB, Beaume A, Bedel A, Bellomo G, Bigot-Corbel E, Bjerke M, Blanc-Quintin MC, Boada M, Bousiges O, Chapman MD, DeMarco ML, D’Onofrio M, Dumurgier J, Dufour-Rainfray D, Engelborghs S, Esselmann H, Fogli A, Gabelle A, Galloni E, Gondolf C, Grandhomme F, Grau-Rivera O, Hart M, Ikeuchi T, Jeromin A, Kasuga K, Keshavan A, Khalil M, Körtvelyessy P, Kulczynska-Przybik A, Laplanche JL, Lewczuk P, Li QX, Lleó A, Malaplate C, Marquié M, Masters CL, Mroczko B, Nogueira L, Orellana A, Otto M, Oudart JB, Paquet C, Paoletti FP, Parnetti L, Perret-Liaudet A, Peoc’h K, Poesen K, Puig-Pijoan A, Quadrio I, Quillard-Muraine M, Rucheton B, Schraen S, Schott JM, Shaw LM, Suárez-Calvet M, Tsolaki M, Tumani H, Udeh-Momoh CT, Vaudran L, Verbeek MM, Verde F, Vermunt L, Vogelgsang J, Wiltfang J, Zetterberg H, Lehmann S. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer’s disease: An international overview. Alzheimers Dement. 2021 Dec 22. doi: 10.1002/alz.12545. Epub ahead of print. PMID: 34936194.

 

  1. Dijkstra AA, Haify SN, Verwey NA, Prins ND, van der Toorn EC, Rozemuller AJM, Bugiani M, den Dunnen WFA, Todd PK, Charlet-Berguerand N, Willemsen R, Hukema RK, Hoozemans JJM. Neuropathology of FMR1-premutation carriers presenting with dementia and neuropsychiatric symptoms. Brain Commun. 2021 Jan 27;3(1):fcab007. doi: 10.1093/braincomms/fcab007. PMID: 33709078; PMCID: PMC7936660.

 

  1. Dols A, Oudega ML, Korten N, Su T, Vijverberg E, Schouws S. Proactieve cognitieve psychiatrie bij het ouder worden . Tijdschr Psychiatr. 2021;63(2):120-124. Dutch. PMID: 33620723.

 

  1. Duits FH, Wesenhagen KEJ, Ekblad L, Wolters E, Willemse EAJ; ADNI, Scheltens P, van der Flier WM, Teunissen CE, Visser PJ, Tijms BM. Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts. Alzheimers Res Ther. 2021 Jan 4;13(1):2. doi: 10.1186/s13195-020-00713-3. PMID: 33397464; PMCID: PMC7780683.

 

  1. 73: Ebenau JL, van der Lee SJ, Hulsman M, Tesi N, Jansen IE, Verberk IMW, van Leeuwenstijn M, Teunissen CE, Barkhof F, Prins ND, Scheltens P, Holstege H, van Berckel BNM, van der Flier WM. Risk of dementia in APOEε4 carriers is mitigated by a polygenic risk score. Alzheimers Dement (Amst). 2021 Sep 14;13(1):e12229. doi: 10.1002/dad2.12229. PMID: 34541285; PMCID: PMC8438688.

 

  1. Eikelboom WS, van den Berg E, Singleton EH, Baart SJ, Coesmans M, Leeuwis AE, Teunissen CE, van Berckel BNM, Pijnenburg YAL, Scheltens P, van der Flier WM, Ossenkoppele R, Papma JM. Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations. 2021 Sep 28;97(13):e1276-e1287. doi: 10.1212/WNL.0000000000012598. Epub 2021 Aug 19. PMID: 34413181; PMCID: PMC8480405.

 

  1. Ekblad LL, Visser PJ, Tijms BM; Alzheimer´s Disease Neuroimaging Initiative. Proteomic correlates of cortical thickness in cognitively normal individuals with normal and abnormal cerebrospinal fluid beta-amyloid 1-42. Neurobiol Aging. 2021 Nov;107:42-52. doi: 10.1016/j.neurobiolaging.2021.07.003. Epub 2021 Jul 15. PMID: 34375908.

 

  1. Etminani K, Soliman A, Davidsson A, Chang JR, Martínez-Sanchis B, Byttner S, Camacho V, Bauckneht M, Stegeran R, Ressner M, Agudelo-Cifuentes M, Chincarini A, Brendel M, Rominger A, Bruffaerts R, Vandenberghe R, Kramberger MG, Trost M, Nicastro N, Frisoni GB, Lemstra AW, van Berckel BNM, Pilotto A, Padovani A, Morbelli S, Aarsland D, Nobili F, Garibotto V, Ochoa-Figueroa M. A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer’s disease, and mild cognitive impairment using brain 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2021 Jul 30. doi: 10.1007/s00259-021-05483-0. Epub ahead of print. PMID: 34328531.

 

  1. Ferreira D, Nedelska Z, Graff-Radford J, Przybelski SA, Lesnick TG, Schwarz CG, Botha H, Senjem ML, Fields JA, Knopman DS, Savica R, Ferman TJ, Graff-Radford NR, Lowe VJ, Jack CR, Petersen RC, Lemstra AW, van de Beek M, Barkhof F, Blanc F, Loureiro de Sousa P, Philippi N, Cretin B, Demuynck C, Hort J, Oppedal K, Boeve BF, Aarsland D, Westman E, Kantarci K. Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiol Aging. 2021 Sep;105:252-261. doi: 10.1016/j.neurobiolaging.2021.04.029. Epub 2021 May 14. PMID: 34130107; PMCID: PMC8338792.

 

  1. Fieldhouse JLP, Gossink FT, Feenstra TC, de Boer SCM, Lemstra AW, Prins ND, Bouwman F, Koene T, Rhodius-Meester HFM, Gillissen F, Teunissen CE, van der Flier WM, Scheltens P, Dols A, Vijverberg EGB, Pijnenburg YAL. Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. J Alzheimers Dis. 2021;82(1):381-390. doi: 10.3233/JAD-210179. PMID: 34024833; PMCID: PMC8293634.

 

  1. Florentinus-Mefailoski A, Bowden P, Scheltens P, Killestein J, Teunissen C, Marshall JG. The plasma peptides of Alzheimer’s disease. Clin Proteomics. 2021 Jun 28;18(1):17. doi: 10.1186/s12014-021-09320-2. PMID: 34182925; PMCID: PMC8240224.

 

  1. Fodor Z, Horváth A, Hidasi Z, Gouw AA, Stam CJ, Csukly G. EEG Alpha and Beta Band Functional Connectivity and Network Structure Mark Hub Overload in Mild Cognitive Impairment During Memory Maintenance. Front Aging Neurosci. 2021 Oct 7;13:680200. doi: 10.3389/fnagi.2021.680200. PMID: 34690735; PMCID: PMC8529331.

 

  1. Franzen S, Smith JE, van den Berg E, Rivera Mindt M, van Bruchem-Visser RL, Abner EL, Schneider LS, Prins ND, Babulal GM, Papma JM. Diversity in Alzheimer’s disease drug trials: The importance of eligibility criteria. Alzheimers Dement. 2021 Sep 30. doi: 10.1002/alz.12433. Epub ahead of print. PMID: 34590409.

 

  1. Franzmeier N, Ossenkoppele R, Brendel M, Rubinski A, Smith R, Kumar A, Mattsson-Carlgren N, Strandberg O, Duering M, Buerger K, Dichgans M, Hansson O, Ewers M; Alzheimer’s Disease Neuroimaging Initiative (ADNI)* and the Swedish BioFINDER study. The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline. Alzheimers Dement. 2021 Jun 1. doi: 10.1002/alz.12371. Epub ahead of print. PMID: 34060233.

 

  1. Frigerio I, Boon BDC, Lin CP, Galis-de Graaf Y, Bol J, Preziosa P, Twisk J, Barkhof F, Hoozemans JJM, Bouwman FH, Rozemuller AJM, van de Berg WDJ, Jonkman LE. Amyloid-β, p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer’s disease. Brain Commun. 2021 Nov 24;3(4):fcab281. doi: 10.1093/braincomms/fcab281. PMID: 34927073; PMCID: PMC8677327.

 

  1. Frisoni GB, Altomare D, Thal DR, Ribaldi F, van der Kant R, Ossenkoppele R, Blennow K, Cummings J, van Duijn C, Nilsson PM, Dietrich PY, Scheltens P, Dubois B. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci. 2022 Jan;23(1):53-66. doi: 10.1038/s41583-021-00533-w. Epub 2021 Nov 23. PMID: 34815562.

 

  1. Gerritsen AAJ, Bakker C, Bruls E, Verhey FRJ, Pijnenburg YAL, Millenaar JK, de Vugt ME, Koopmans RTCM. Psychotropic drug use in community-dwelling people with young-onset dementia: two-year course and determinants. Aging Ment Health. 2021 Jan;25(1):179-186. doi: 10.1080/13607863.2019.1691145. Epub 2019 Nov 20.PMID: 31746238.

 

  1. Gijs M, Ramakers IHGB, Visser PJ, Verhey FRJ, van de Waarenburg MPH, Schalkwijk CG, Nuijts RMMA, Webers CAB. Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration. Sci Rep. 2021 Nov 22;11(1):22675. doi: 10.1038/s41598-021-01993-x. PMID: 34811435; PMCID: PMC8608861.

 

  1. Gonzalez MC, Ashton NJ, Gomes BF, Tovar-Rios DA, Blanc F, Karikari TK, Mollenhauer B, Pilotto A, Lemstra A, Paquet C, Abdelnour C, Kramberger MG, Bonanni L, Vandenberghe R, Hye A, Blennow K, Zetterberg H, Aarsland D; European–Dementia With Lewy Bodies (E-DLB) Consortium. Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. JAMA Neurol. 2021 Nov 22:e214222. doi: 10.1001/jamaneurol.2021.4222. Epub ahead of print. PMID: 34807233; PMCID: PMC8609462.

 

  1. Gossink F, Dols A, Stek ML, Scheltens P, Nijmeijer B, Cohn Hokke P, Dijkstra A, Van Ruissen F, Aalfs C, Pijnenburg YAL. Early life involvement in C9orf72 repeat expansion carriers. J Neurol Neurosurg Psychiatry. 2022 Jan;93(1):93-100. doi: 10.1136/jnnp-2020-325994. Epub 2021 Apr 27. PMID: 33906932.

 

  1. Gouw AA, Hillebrand A, Schoonhoven DN, Demuru M, Ris P, Scheltens P, Stam CJ. Routine magnetoencephalography in memory clinic patients: A machine learning approach. Alzheimers Dement (Amst). 2021 Sep 18;13(1):e12227. doi: 10.1002/dad2.12227. PMID: 34568539; PMCID: PMC8449227.

 

  1. Graff-Radford J, Yong KXX, Apostolova LG, Bouwman FH, Carrillo M, Dickerson BC, Rabinovici GD, Schott JM, Jones DT, Murray ME. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol. 2021 Mar;20(3):222-234. doi: 10.1016/S1474-4422(20)30440-3. PMID: 33609479; PMCID: PMC8056394.

 

  1. Graff-Radford J, Jones DT, Wiste HJ, Cogswell PM, Weigand SD, Lowe V, Elder BD, Vemuri P, Van Harten A, Mielke MM, Knopman DS, Graff-Radford NR, Petersen RC, Jack CR Jr, Gunter JL. Cerebrospinal fluid dynamics and discordant amyloid biomarkers. Neurobiol Aging. 2021 Nov 1;110:27-36. doi: 10.1016/j.neurobiolaging.2021.10.017. Epub ahead of print. PMID: 34844077.

 

  1. Griffa A, Legdeur N, Badissi M, van den Heuvel MP, Stam CJ, Visser PJ, Hillebrand A. Magnetoencephalography Brain Signatures Relate to Cognition and Cognitive Reserve in the Oldest-Old: The EMIF-AD 90 + Study. Front Aging Neurosci. 2021 Nov 25;13:746373. doi: 10.3389/fnagi.2021.746373. PMID: 34899269; PMCID: PMC8656941.

 

  1. Groot C, Grothe MJ, Mukherjee S, Jelistratova I, Jansen I, van Loenhoud AC, Risacher SL, Saykin AJ, Mac Donald CL, Mez J, Trittschuh EH, Gryglewski G, Lanzenberger R, Pijnenburg YAL, Barkhof F, Scheltens P, van der Flier WM, Crane PK, Ossenkoppele R. Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer’s disease subgroups. Neuroimage Clin. 2021;30:102660. doi: 10.1016/j.nicl.2021.102660. Epub 2021 Apr 3. PMID: 33895633; PMCID: PMC8186562.

 

  1. Groot C, Risacher SL, Chen JQA, Dicks E, Saykin AJ, Mac Donald CL, Mez J, Trittschuh EH, Mukherjee S, Barkhof F, Scheltens P, van der Flier WM, Ossenkoppele R, Crane PK; Alzheimer’s disease neuroimaging initiative (ADNI). Differential trajectories of hypometabolism across cognitively-defined Alzheimer’s disease subgroups. Neuroimage Clin. 2021;31:102725. doi: 10.1016/j.nicl.2021.102725. Epub 2021 Jun 12. PMID: 34153688; PMCID: PMC8238088.

 

  1. Haytural H, Benfeitas R, Schedin-Weiss S, Bereczki E, Rezeli M, Unwin RD, Wang X, Dammer EB, Johnson ECB, Seyfried NT, Winblad B, Tijms BM, Visser PJ, Frykman S, Tjernberg LO. Insights into the changes in the proteome of Alzheimer disease elucidated by a meta-analysis. Sci Data. 2021 Dec 3;8(1):312. doi: 10.1038/s41597-021-01090-8. PMID: 34862388; PMCID: PMC8642431.

 

  1. Hendriks S, Peetoom K, Bakker C, van der Flier WM, Papma JM, Koopmans R, Verhey FRJ, de Vugt M, Köhler S; Young-Onset Dementia Epidemiology Study Group, Withall A, Parlevliet JL, Uysal-Bozkir Ö, Gibson RC, Neita SM, Nielsen TR, Salem LC, Nyberg J, Lopes MA, Dominguez JC, De Guzman MF, Egeberg A, Radford K, Broe T, Subramaniam M, Abdin E, Bruni AC, Di Lorenzo R, Smith K, Flicker L, Mol MO, Basta M, Yu D, Masika G, Petersen MS, Ruano L. Global Prevalence of Young-Onset Dementia: A Systematic Review and Meta-analysis. JAMA Neurol. 2021 Sep 1;78(9):1080-1090. doi: 10.1001/jamaneurol.2021.2161. PMID: 34279544; PMCID: PMC8290331.

 

  1. Hong S, Dobricic V, Ohlei O, Bos I, Vos SJB, Prokopenko D, Tijms BM, Andreasson U, Blennow K, Vandenberghe R, Gabel S, Scheltens P, Teunissen CE, Engelborghs S, Frisoni G, Blin O, Richardson JC, Bordet R; Alzheimer’s Disease Neuroimaging Initiative (ADNI), Lleó A, Alcolea D, Popp J, Clark C, Peyratout G, Martinez-Lage P, Tainta M, Dobson RJB, Legido-Quigley C, Sleegers K, Van Broeckhoven C, Tanzi RE, Ten Kate M, Wittig M, Franke A, Lill CM, Barkhof F, Lovestone S, Streffer J, Zetterberg H, Visser PJ, Bertram L. TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer’s disease biomarker levels. Alzheimers Dement. 2021 Oct;17(10):1628-1640. doi: 10.1002/alz.12330. Epub 2021 May 14. PMID: 33991015.

 

  1. Hung C, Tuck E, Stubbs V, van der Lee SJ, Aalfs C, van Spaendonk R, Scheltens P, Hardy J, Holstege H, Livesey FJ. SORL1 deficiency in human excitatory neurons causes APP-dependent defects in the endolysosome-autophagy network. Cell Rep. 2021 Jun 15;35(11):109259. doi: 10.1016/j.celrep.2021.109259. PMID: 34133918; PMCID: PMC8220253.

 

  1. Iaccarino L, La Joie R, Edwards L, Strom A, Schonhaut DR, Ossenkoppele R, Pham J, Mellinger T, Janabi M, Baker SL, Soleimani-Meigooni D, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD. Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer’s Disease Continuum. Cereb Cortex. 2021 Jan 1;31(1):1-14. doi: 10.1093/cercor/bhaa184. PMID: 32808011; PMCID: PMC7727356.

 

  1. Ingala S, De Boer C, Masselink LA, Vergari I, Lorenzini L, Blennow K, Chételat G, Di Perri C, Ewers M, van der Flier WM, Fox NC, Gispert JD, Haller S, Molinuevo JL, Muniz-Terrera G, Mutsaerts HJ, Ritchie CW, Ritchie K, Schmidt M, Schwarz AJ, Vermunt L, Waldman AD, Wardlaw J, Wink AM, Wolz R, Wottschel V, Scheltens P, Visser PJ, Barkhof F; EPAD consortium. Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimers Dement. 2021 Jul;17(7):1189-1204. doi: 10.1002/alz.12292. Epub 2021 Apr 3. PMID: 33811742; PMCID: PMC8359976.

 

  1. Ingala S, Tomassen J, Collij LE, Prent N, van ‘t Ent D, Ten Kate M, Konijnenberg E, Yaqub M, Scheltens P, de Geus EJC, Teunissen CE, Tijms B, Wink AM, Barkhof F, van Berckel BNM, Visser PJ, den Braber A. Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. Brain Commun. 2021 Sep 6;3(4):fcab201. doi: 10.1093/braincomms/fcab201. PMID: 34617016; PMCID: PMC8490784.

 

  1. Janssen O, Jansen WJ, Vos SJB, Boada M, Parnetti L, Gabryelewicz T, Fladby T, Molinuevo JL, Villeneuve S, Hort J, Epelbaum S, Lleó A, Engelborghs S, van der Flier WM, Landau S, Popp J, Wallin A, Scheltens P, Rikkert MO, Snyder PJ, Rowe C, Chételat G, Ruíz A, Marquié M, Chipi E, Wolfsgruber S, Heneka M, Boecker H, Peters O, Jarholm J, Rami L, Tort-Merino A, Binette AP, Poirier J, Rosa-Neto P, Cerman J, Dubois B, Teichmann M, Alcolea D, Fortea J, Sánchez-Saudinós MB, Ebenau J, Pocnet C, Eckerström M, Thompson L, Villemagne V, Buckley R, Burnham S, Delarue M, Freund-Levi Y, Wallin ÅK, Ramakers I, Tsolaki M, Soininen H, Hampel H, Spiru L; Alzheimer’s Disease Neuroimaging Initiative; FACEHBI study group; PREVENT-AD research group, Tijms B, Ossenkoppele R, Verhey FRJ, Jessen F, Visser PJ. Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimers Dement. 2021 Dec 8. doi: 10.1002/alz.12512. Epub ahead of print. PMID: 34877782.

 

  1. Jokinen H, Laakso HM, Ahlström M, Arola A, Lempiäinen J, Pitkänen J, Paajanen T, Sikkes SAM, Koikkalainen J, Lötjönen J, Korvenoja A, Erkinjuntti T, Melkas S. Synergistic associations of cognitive and motor impairments with functional outcome in covert cerebral small vessel disease. Eur J Neurol. 2022 Jan;29(1):158-167. doi: 10.1111/ene.15108. Epub 2021 Sep 26. PMID: 34528346.

 

  1. Jutten RJ, Sikkes SAM, Van der Flier WM, Scheltens P, Visser PJ, Tijms BM; Alzheimer’s Disease Neuroimaging Initiative. Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. 2021 Jun 1;96(22):e2673-e2684. doi: 10.1212/WNL.0000000000012022. PMID: 34550903; PMCID: PMC8205463.

 

  1. Konijnenberg E, Tomassen J, den Braber A, Ten Kate M, Yaqub M, Mulder SD, Nivard MG, Vanderstichele H, Lammertsma AA, Teunissen CE, van Berckel BNM, Boomsma DI, Scheltens P, Tijms BM, Visser PJ. Onset of Preclinical Alzheimer Disease in Monozygotic Twins. Ann Neurol. 2021 May;89(5):987-1000. doi: 10.1002/ana.26048. Epub 2021 Mar 4. PMID: 33583080; PMCID: PMC8251701.

 

  1. Krudop WA, Gossink F, Vijverberg EGB, Kerssens CJ, Prins ND, Schouws S, Dols A, Pijnenburg YAL. Diagnostiek van frontotemporale dementie in de psychiatrische praktijk: handvatten en valkuilen [Frontotemporal dementia diagnoses within the psychiatric practice: pitfalls and practical tools]. Tijdschr Psychiatr. 2021;63(5):366-373. Dutch. PMID: 34043226.

 

  1. Kuipers S, Biessels GJ, Greving JP, Amier RP, de Bresser J, Bron EE, van der Flier WM, van der Geest RJ, Hooghiemstra AM, van Oostenbrugge RJ, van Osch MJP, Kappelle LJ, Exalto LG; Heart-Brain Connection Consortium. Sex and Cardiovascular Function in Relation to Vascular Brain Injury in Patients with Cognitive Complaints. J Alzheimers Dis. 2021;84(1):261-271. doi: 10.3233/JAD-210360. PMID: 34511498.

 

  1. Larabi DI, Marsman JC, Aleman A, Tijms BM, Opmeer EM, Pijnenborg GHM, van der Meer L, van Tol MJ, Ćurčić-Blake B. Insight does not come at random: Individual gray matter networks relate to clinical and cognitive insight in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110251. doi: 10.1016/j.pnpbp.2021.110251. Epub 2021 Jan 23. PMID: 33493651.

 

  1. Legdeur N, Badissi M, Yaqub M, Beker N, Sudre CH, Ten Kate M, Gordon MF, Novak G, Barkhof F, van Berckel BNM, Holstege H, Muller M, Scheltens P, Maier AB, Visser PJ. What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. J Gerontol B Psychol Sci Soc Sci. 2021 Sep 13;76(8):1499-1511. doi: 10.1093/geronb/gbaa152. PMID: 32898275.

 

  1. Leuzy A, Pascoal TA, Strandberg O, Insel P, Smith R, Mattsson-Carlgren N, Benedet AL, Cho H, Lyoo CH, La Joie R, Rabinovici GD, Ossenkoppele R, Rosa-Neto P, Hansson O. A multicenter comparison of 18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2295-2305. doi: 10.1007/s00259-021-05401-4. Epub 2021 May 27. PMID: 34041562; PMCID: PMC8175317.

 

  1. Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, Borroni E, Janelidze S, Ohlsson T, Jögi J, Ossenkoppele R, Palmqvist S, Mattsson-Carlgren N, Klein G, Stomrud E, Hansson O. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurol. 2021 Dec 20. doi: 10.1001/jamaneurol.2021.4654. Epub ahead of print. PMID: 34928318.

 

  1. Leuzy A, Ashton NJ, Mattsson-Carlgren N, Dodich A, Boccardi M, Corre J, Drzezga A, Nordberg A, Ossenkoppele R, Zetterberg H, Blennow K, Frisoni GB, Garibotto V, Hansson O. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2121-2139. doi: 10.1007/s00259-021-05258-7. Epub 2021 Mar 5. PMID: 33674895; PMCID: PMC8175301.

 

  1. Madero EN, Anderson J, Bott NT, Hall A, Newton D, Fuseya N, Harrison JE, Myers JR, Glenn JM. Environmental Distractions during Unsupervised Remote Digital Cognitive Assessment. J Prev Alzheimers Dis. 2021;8(3):263-266. doi: 10.14283/jpad.2021.9. PMID: 34101782; PMCID: PMC7964516.

 

  1. Mank A, van Maurik IS, Bakker ED, van de Glind EMM, Jönsson L, Kramberger MG, Novak P, Diaz A, Gove D, Scheltens P, van der Flier WM, Visser LNC. Identifying relevant outcomes in the progression of Alzheimer’s disease; what do patients and care partners want to know about prognosis? Alzheimers Dement (NY). 2021 Aug 20;7(1):e12189. doi: 10.1002/trc2.12189. PMID: 34458555; PMCID: PMC8377775.

 

  1. Mok VCT, Pendlebury S, Wong A, Alladi S, Au L, Bath PM, Biessels GJ, Chen C, Cordonnier C, Dichgans M, Dominguez J, Gorelick PB, Kim S, Kwok T, Greenberg SM, Jia J, Kalaria R, Kivipelto M, Naegandran K, Lam LCW, Lam BYK, Lee ATC, Markus HS, O’Brien J, Pai MC, Pantoni L, Sachdev P, Senanarong V, Skoog I, Smith EE, Srikanth V, Suh GH, Wardlaw J, Ko H, Black SE, Scheltens P. Erratum. Alzheimers Dement. 2021 May;17(5):906-907. doi: 10.1002/alz.12307. Epub 2021 Apr 7. Erratum for: Alzheimers Dement. 2020 Nov;16(11):1571-1581. PMID: 33979036; PMCID: PMC8265323.

 

  1. Mol MO, Nijmeijer SWR, van Rooij JGJ, van Spaendonk RML, Pijnenburg YAL, van der Lee SJ, van Minkelen R, Donker Kaat L, Rozemuller AJM, Janse van Mantgem MR, van Rheenen W, van Es MA, Veldink JH, Hennekam FAM, Vernooij M, van Swieten JC, Cohn-Hokke PE, Seelaar H, Dopper EGP. Distinctive pattern of temporal atrophy in patients with frontotemporal dementia and the I383V variant in TARDBP. J Neurol Neurosurg Psychiatry. 2021 Jul;92(7):787-789. doi: 10.1136/jnnp-2020-325150. Epub 2021 Jan 15. PMID: 33452055; PMCID: PMC8223666.

 

  1. Mommaerts K, Willemse EAJ, Marchese M, Larue C, van der Flier WM, Betsou F, Teunissen CE. A Cystatin C Cleavage ELISA Assay as a Quality Control Tool for Determining Sub-Optimal Storage Conditions of Cerebrospinal Fluid Samples in Alzheimer’s Disease Research. J Alzheimers Dis. 2021;83(3):1367-1377. doi: 10.3233/JAD-210741. PMID: 34420976; PMCID: PMC8673510.

 

  1. Muurling M, de Boer C, Kozak R, Religa D, Koychev I, Verheij H, Nies VJM, Duyndam A, Sood M, Fröhlich H, Hannesdottir K, Erdemli G, Lucivero F, Lancaster C, Hinds C, Stravopoulos TG, Nikolopoulos S, Kompatsiaris I, Manyakov NV, Owens AP, Narayan VA, Aarsland D, Visser PJ; RADAR-AD Consortium. Remote monitoring technologies in Alzheimer’s disease: design of the RADAR-AD study. Alzheimers Res Ther. 2021 Apr 23;13(1):89. doi: 10.1186/s13195-021-00825-4. PMID: 33892789; PMCID: PMC8063580.

 

  1. Muurling M, Reus LM, de Boer C, Jagesar R, Vorstman JA, Kas MJ, Visser PJ. Social behavior assessment in cognitively impaired older adults using a passive and remote smartphone application. Alzheimers Dement. 2021 Dec;17 Suppl 11:e051698. doi: 10.1002/alz.051698. PMID: 34971036.

 

  1. Najar J, van der Lee SJ, Joas E, Wetterberg H, Hardy J, Guerreiro R, Bras J, Waern M, Kern S, Zetterberg H, Blennow K, Skoog I, Zettergren A. Polygenic risk scores for Alzheimer’s disease are related to dementia risk in APOE ɛ4 negatives. Alzheimers Dement (Amst). 2021 Jan 22;13(1):e12142. doi: 10.1002/dad2.12142. PMID: 33532541; PMCID: PMC7821873.

 

  1. Naudé PJW, Ramakers IHGB, van der Flier WM, Jiskoot LC, Reesink FE, Claassen JAHR, Koek HL, Eisel ULM, De Deyn PP. Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer’s disease dementia. Neurobiol Aging. 2021 Nov;107:1-10. doi: 10.1016/j.neurobiolaging.2021.07.001. Epub 2021 Jul 10. PMID: 34365256.

 

  1. Oort Q, Dirven L, Sikkes SAM, Aaronson N, Boele F, Brannan C, Egeter J, Grant R, Klein M, Lips I, Narita Y, Sato H, Sztankay M, Stockhammer G, Talacchi A, Uitdehaag BMJ, Reijneveld JC, Taphoorn MJB; EORTC Quality of Life Group. Development of an EORTC questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumours: phase I-III. Qual Life Res. 2021 May;30(5):1491-1502. doi: 10.1007/s11136-020-02738-5. Epub 2021 Jan 26. PMID: 33496902; PMCID: PMC8068708.

 

  1. Ossenkoppele R, Hansson O. Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer’s disease. Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12356. Epub ahead of print. PMID: 33984177.

 

  1. Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, Palmqvist S, Olsson T, Jögi J, Stormrud E, Cho H, Ryu YH, Choi JY, Boxer AL, Gorno-Tempini ML, Miller BL, Soleimani-Meigooni D, Iaccarino L, La Joie R, Baker S, Borroni E, Klein G, Pontecorvo MJ, Devous MD Sr, Jagust WJ, Lyoo CH, Rabinovici GD, Hansson O. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. JAMA Neurol. 2021 Aug 1;78(8):961-971. doi: 10.1001/jamaneurol.2021.1858. PMID: 34180956; PMCID: PMC8240013.

 

  1. Ossenkoppele R, Reimand J, Smith R, Leuzy A, Strandberg O, Palmqvist S, Stomrud E, Zetterberg H; Alzheimer’s Disease Neuroimaging Initiative, Scheltens P, Dage JL, Bouwman F, Blennow K, Mattsson-Carlgren N, Janelidze S, Hansson O. Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers. EMBO Mol Med. 2021 Aug 9;13(8):e14398. doi: 10.15252/emmm.202114398. Epub 2021 Jul 13. PMID: 34254442; PMCID: PMC8350902.

 

  1. Ossenkoppele R, Singleton EH, Groot C, Dijkstra AA, Eikelboom WS, Seeley WW, Miller B, Laforce RJ, Scheltens P, Papma JM, Rabinovici GD, Pijnenburg YAL. Research Criteria for the Behavioral Variant of Alzheimer Disease: A Systematic Review and Meta-analysis. JAMA Neurol. 2021 Dec 6:e214417. doi: 10.1001/jamaneurol.2021.4417. Epub ahead of print. PMID: 34870696; PMCID: PMC8649917.

 

  1. Özkan N, Koppers M, van Soest I, van Harten A, Jurriens D, Liv N, Klumperman J, Kapitein LC, Hoogenraad CC, Farías GG. ER – lysosome contacts at a pre-axonal region regulate axonal lysosome availability. Nat Commun. 2021 Jul 23;12(1):4493. doi: 10.1038/s41467-021-24713-5. PMID: 34301956; PMCID: PMC8302662.

 

  1. Pelkmans W, Legdeur N, Ten Kate M, Barkhof F, Yaqub MM, Holstege H, van Berckel BNM, Scheltens P, van der Flier WM, Visser PJ, Tijms BM. Amyloid-β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. Ann Clin Transl Neurol. 2021 Feb;8(2):348-358. doi:10.1002/acn3.51273. Epub 2021 Jan 9. PMID: 33421355; PMCID: PMC7886045.

 

  1. Pelkmans W, Ossenkoppele R, Dicks E, Strandberg O, Barkhof F, Tijms BM, Pereira JB, Hansson O. Tau-related grey matter network breakdown across the Alzheimer’s disease continuum. Alzheimers Res Ther. 2021 Aug 13;13(1):138. doi: 10.1186/s13195-021-00876-7. PMID: 34389066; PMCID: PMC8364121.

 

  1. Pereira JB, Janelidze S, Ossenkoppele R, Kvartsberg H, Brinkmalm A, Mattsson-Carlgren N, Stomrud E, Smith R, Zetterberg H, Blennow K, Hansson O. Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease. Brain. 2021 Feb 12;144(1):310-324. doi:10.1093/brain/awaa395. PMID: 33279949; PMCID: PMC8210638.

 

  1. Poos JM, van den Berg E, Visch-Brink E, Eikelboom WS, Franzen S, van Hemmen J, Pijnenburg YAL, Satoer D, Dopper EGP, van Swieten JC, Papma JM, Seelaar H, Jiskoot LC. Exploring Abstract Semantic Associations in the Frontotemporal Dementia Spectrum in a Dutch Population. Arch Clin Neuropsychol. 2021 Apr 15:acab022. doi: 10.1093/arclin/acab022. Epub ahead of print. PMID: 33856423.

 

  1. Poos JM, Russell LL, Peakman G, Bocchetta M, Greaves CV, Jiskoot LC, van der Ende EL, Seelaar H, Papma JM, van den Berg E, Pijnenburg YAL, Borroni B, Sanchez-Valle R, Moreno F, Laforce R, Graff C, Synofzik M, Galimberti D, Rowe JB, Masellis M, Tartaglia C, Finger E, Vandenberghe R, de Medonça A, Tagliavini F, Butler CR, Santana I, Ber IL, Gerhard A, Ducharme S, Levin J, Danek A, Otto M, Sorbi S, Pasquier F, van Swieten JC, Rohrer JD; Genetic FTD Initiative, GENF. Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimers Dement (Amst). 2021 May 13;13(1):e12185. doi: 10.1002/dad2.12185. PMID: 34027016; PMCID: PMC8116844.

 

  1. Poos JM, van der Ham IJM, Leeuwis AE, Pijnenburg YAL, van der Flier WM, Postma A. Short Digital Spatial Memory Test Detects Impairment in Alzheimer’s Disease and Mild Cognitive Impairment. Brain Sci. 2021 Oct 14;11(10):1350. doi: 10.3390/brainsci11101350. PMID: 34679414; PMCID: PMC8533689.

 

  1. Prins ND, Harrison JE, Chu HM, Blackburn K, Alam JJ, Scheltens P; REVERSE-SD Study Investigators. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease. Alzheimers Res Ther. 2021 May 27;13(1):106. doi: 10.1186/s13195-021-00843-2. PMID: 34044875; PMCID: PMC8157623.

 

  1. Provost K, Iaccarino L, Soleimani-Meigooni DN, Baker S, Edwards L, Eichenlaub U, Hansson O, Jagust W, Janabi M, La Joie R, Lesman-Segev O, Mellinger TJ, Miller BL, Ossenkoppele R, Pham J, Smith R, Sonni I, Strom A, Mattsson-Carlgren N, Rabinovici GD; Alzheimer’s Disease Neuroimaging Initiative (ADNI). Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2259-2271. doi: 10.1007/s00259-020-05152-8. Epub 2021 Jan 4. PMID: 33398408; PMCID: PMC8178158.

 

  1. Ranson JM, Rittman T, Hayat S, Brayne C, Jessen F, Blennow K, van Duijn C, Barkhof F, Tang E, Mummery CJ, Stephan BCM, Altomare D, Frisoni GB, Ribaldi F, Molinuevo JL, Scheltens P, Llewellyn DJ; European Task Force for Brain Health Services. Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services-part 2 of 6. Alzheimers Res Ther. 2021 Oct 11;13(1):169. doi: 10.1186/s13195-021-00895-4. PMID: 34635138; PMCID: PMC8507172.

 

  1. Reus LM, Pasaniuc B, Posthuma D, Boltz T; International FTD-Genomics Consortium, Pijnenburg YAL, Ophoff RA. Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biol Psychiatry. 2021 Apr 15;89(8):825-835. doi: 10.1016/j.biopsych.2020.12.023. Epub 2021 Jan 9. PMID: 33637304; PMCID: PMC8415425.

 

  1. Reus LM, Jansen IE, Mol MO, van Ruissen F, van Rooij J, van Schoor NM, Tesi N, Reinders MJT, Huisman MA, Holstege H, Visser PJ, de Boer SCM, Hulsman M, Ahmad S, Amin N, Uitterlinden AG, Ikram A, van Duijn CM, Seelaar H, Ramakers IHGB, Verhey FRJ, van der Lugt A, Claassen JAHR, Jan Biessels G, De Deyn PP, Scheltens P, van der Flier WM, van Swieten JC, Pijnenburg YAL, van der Lee SJ. Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. Transl Psychiatry. 2021 Sep 2;11(1):451. doi: 10.1038/s41398-021-01577-3. PMID: 34475377; PMCID: PMC8413318.

 

  1. Rhodius-Meester HF, Leeuwis AE, Van Gils AM, Bakker C, Peetoom K, Bouwman FH, Pijnenburg YA, de Vugt M, van der Flier WM; PRECODE-GP Consortium. Young-onset dementia in memory clinics in the Netherlands: PRECODE-GP. Alzheimers Dement. 2021 Dec;17 Suppl 8:e053524. doi: 10.1002/alz.053524. PMID: 34971291.

 

  1. Rodrigo A, Trigueros P, Jamilis L, Alegret M, Rodríguez O, Tárraga L, González-Pérez A, Kramberger M, Winblad B, Visser PJ, Jessen F, Campo L, Boada M; MOPEAD consortium. Identification of undiagnosed dementia cases using a web-based pre-screening tool: The MOPEAD project. Alzheimers Dement. 2021 Aug;17(8):1307-1316. doi: 10.1002/alz.12297. Epub 2021 Apr 15. PMID: 33860599; PMCID: PMC8453736.

 

  1. Rombach I, Iftikhar M, Jhuti GS, Gustavsson A, Lecomte P, Belger M, Handels R, Castro Sanchez AY, Kors J, Hopper L, Olde Rikkert M, Selbæk G, Stephan A, Sikkes SAM, Woods B, Gonçalves-Pereira M, Zanetti O, Ramakers IHGB, Verhey FRJ, Gallacher J, Actifcare Consortium, LeARN Consortium, Landeiro F, Gray AM; ROADMAP Consortium. Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study. Qual Life Res. 2021 Mar;30(3):867-879. doi: 10.1007/s11136-020-02670-8. Epub 2020 Oct 17. PMID: 33068236; PMCID: PMC7952290.

 

  1. Rosenberg A, Solomon A, Soininen H, Visser PJ, Blennow K, Hartmann T, Kivipelto M; LipiDiDiet clinical study group. Research diagnostic criteria for Alzheimer’s disease: findings from the LipiDiDiet randomized controlled trial. Alzheimers Res Ther. 2021 Mar 25;13(1):64. doi: 10.1186/s13195-021-00799-3. PMID: 33766132; PMCID: PMC7995792.

 

  1. Rossi M, Baiardi S, Teunissen CE, Quadalti C, van de Beek M, Mammana A, Stanzani-Maserati M, Van der Flier WM, Sambati L, Zenesini C, Caughey B, Capellari S, Lemstra AW, Parchi P. Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies. 2021 Aug 31;97(9):e930-e940. doi: 10.1212/WNL.0000000000012438. Epub 2021 Jul 1. PMID: 34210822; PMCID: PMC8408510.

 

  1. Salvadó G, Grothe MJ, Groot C, Moscoso A, Schöll M, Gispert JD, Ossenkoppele R; Alzheimer’s Disease Neuroimaging Initiative. Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2212-2224. doi: 10.1007/s00259-021-05192-8. Epub 2021 Feb 1. PMID: 33521872; PMCID: PMC8175302.

 

  1. Salvadó G, Ferreira D, Operto G, Cumplido-Mayoral I, Arenaza-Urquijo EM, Cacciaglia R, Falcon C, Vilor-Tejedor N, Minguillon C, Groot C, van der Flier WM, Barkhof F, Scheltens P, Ossenkoppele R, Kern S, Zettergren A, Skoog I, Hort J, Stomrud E, van Westen D, Hansson O, Molinuevo JL, Wahlund LO, Westman E, Gispert JD; ALFA study†, BioFINDER, ADNI. The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals. Alzheimers Dement. 2021 Dec 8. doi: 10.1002/alz.12487. Epub ahead of print. PMID: 34877786.

 

  1. Sannemann L, Müller T, Waterink L, Zwan M, Wimo A, Stomrud E, Pinó S, Arrufat J, Rodríguez-Gomez O, Benaque A, Bon J, Ferreira D, Johansson G, Dron A, Dumas A, Georges J, Kramberger MG, Visser PJ, Winblad B, Campo L, Boada M, Jessen F; MOPEAD consortium. General practitioners’ attitude toward early and pre-dementia diagnosis of AD in five European countries-A MOPEAD project survey. Alzheimers Dement (Amst). 2021 Feb 23;13(1):e12130. doi: 10.1002/dad2.12130. PMID: 33665337; PMCID: PMC7901232.

 

  1. Saris IMJ, Aghajani M, Reus LM, Visser PJ, Pijnenburg Y, van der Wee NJA, Bilderbeck AC, Raslescu A, Malik A, Mennes M, Koops S, Arrango C, Ayuso-Mateos JL, Dawson GR, Marston H, Kas MJ, Penninx BWJH; PRISM consortium. Social dysfunction is transdiagnostically associated with default mode network dysconnectivity in schizophrenia and Alzheimer’s disease. World J Biol Psychiatry. 2021 Sep 17:1-14. doi: 10.1080/15622975.2021.1966714. Epub ahead of print. PMID: 34378488.

 

  1. Scheijbeler EP, Schoonhoven DN, Engels MMA, Scheltens P, Stam CJ, Gouw AA, Hillebrand A. Generating diagnostic profiles of cognitive decline and dementia using magnetoencephalography. Neurobiol Aging. 2021 Nov 11:S0197-4580(21)00330-4. doi: 10.1016/j.neurobiolaging.2021.11.002. Epub ahead of print. PMID: 34906377.

 

  1. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer’s disease. Lancet. 2021 Apr 24;397(10284):1577-1590. doi: 10.1016/S0140-6736(20)32205-4. Epub 2021 Mar 2. PMID: 33667416; PMCID: PMC8354300.

 

  1. Scheltens P. Responding to responsive behaviour in Alzheimer’s disease – Author’s reply. Lancet. 2021 Sep 4;398(10303):842. doi: 10.1016/S0140-6736(21)01449-5. PMID: 34481569.

 

  1. Scheltens P, Vijverberg EGB. Commentary: Aducanumab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2021;8(4):412-413. doi: 10.14283/jpad.2021.45. PMID: 34585214.https://pubmed.ncbi.nlm.nih.gov/34585214/

 

  1. Shi L, Winchester LM, Westwood S, Baird AL, Anand SN, Buckley NJ, Hye A, Ashton NJ, Bos I, Vos SJB, Kate MT, Scheltens P, Teunissen CE, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lléo A, Sala I, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Legido-Quigley C, Barkhof F, Andreasson U, Blennow K, Zetterberg H, Streffer J, Lill CM, Bertram L, Visser PJ, Kolb HC, Narayan VA, Lovestone S, Nevado-Holgado AJ. Replication study of plasma proteins relating to Alzheimer’s pathology. Alzheimers Dement. 2021 Sep;17(9):1452-1464. doi: 10.1002/alz.12322. Epub 2021 Mar 31. PMID: 33792144.

 

  1. Shi L, Buckley NJ, Bos I, Engelborghs S, Sleegers K, Frisoni GB, Wallin , Lléo A, Popp J, Martinez-Lage P, Legido-Quigley C, Barkhof F, Zetterberg H, Visser PJ, Bertram L, Lovestone S, Nevado-Holgado AJ. Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies. Front Aging Neurosci. 2021 Jul 21;13:712545. doi:  3389/fnagi.2021.712545. PMID: 34366831; PMCID: PMC8335587.

 

  1. Singleton E, Hansson O, Pijnenburg YAL, La Joie R, Mantyh WG, Tideman P, Stomrud E, Leuzy A, Johansson M, Strandberg O, Smith R, Berendrecht E, Miller BL, Iaccarino L, Edwards L, Strom A, Wolters EE, Coomans E, Visser D, Golla SSV, Tuncel H, Bouwman F, Van Swieten JC, Papma JM, van Berckel B, Scheltens P, Dijkstra AA, Rabinovici GD, Ossenkoppele R. Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2021 Apr 13;92(8):872–80. doi: 10.1136/jnnp-2020-325497. Epub ahead of print. PMID: 33850001; PMCID: PMC8292599.

 

  1. Snyder PJ, Alber J, Alt C, Bain LJ, Bouma BE, Bouwman FH, DeBuc DC, Campbell MCW, Carrillo MC, Chew EY, Cordeiro MF, Dueñas MR, Fernández BM, Koronyo-Hamaoui M, La Morgia C, Carare RO, Sadda SR, van Wijngaarden P, Snyder HM. Retinal imaging in Alzheimer’s and neurodegenerative diseases. Alzheimers Dement. 2021 Jan;17(1):103-111. doi: 10.1002/alz.12179. Epub 2020 Oct 8. PMID: 33090722; PMCID: PMC8062064.

 

  1. Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, Hartmann T; LipiDiDiet clinical study group. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer’s disease. Alzheimers Dement. 2021 Jan;17(1):29-40. doi: 10.1002/alz.12172. Epub 2020 Sep 13. Erratum in: Alzheimers Dement. 2021 May;17(5):909. PMID: 32920957; PMCID: PMC7821311.

 

  1. Solomon A, Stephen R, Altomare D, Carrera E, Frisoni GB, Kulmala J, Molinuevo JL, Nilsson P, Ngandu T, Ribaldi F, Vellas B, Scheltens P, Kivipelto M; European Task Force for Brain Health Services. Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services-part 4 of 6. Alzheimers Res Ther. 2021 Oct 11;13(1):171. doi: 10.1186/s13195-021-00875-8. PMID: 34635167; PMCID: PMC8507202.

 

  1. Stockmann J, Verberk IMW, Timmesfeld N, Denz R, Budde B, Lange-Leifhelm J, Scheltens P, van der Flier WM, Nabers A, Teunissen CE, Gerwert K. Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline. Alzheimers Res Ther. 2021 Jan 15;13(1):25. doi: 10.1186/s13195-021-00770-2. Erratum for: Alzheimers Res Ther. 2020 Dec 24;12(1):169. PMID: 33451318; PMCID: PMC7809829.

 

  1. Stringer G, Leroi I, Sikkes SAM, Montaldi D, Brown LJE. Enhancing ‘meaningfulness’ of functional assessments: UK adaptation of the Amsterdam IADL questionnaire. Int Psychogeriatr. 2021 Jan;33(1):39-50. doi: 10.1017/S1041610219001881. Epub 2020 Apr 15. PMID: 32290875; PMCID: PMC8482374.

 

  1. Ter Schuur BJ, Overvliet GM, van Engelen ME, van Dellen E, Stam CJ, Pijnenburg YAL, Dols A. Examining electroencephalogram abnormalities in older adults with a mood disorder presenting at a memory clinic. 2021 Mar;21(2):243-245. doi: 10.1111/psyg.12637. Epub 2020 Dec 13. PMID: 33314417; PMCID: PMC7984069.

 

  1. Tesi N, van der Lee SJ, Hulsman M, Jansen IE, Stringa N, van Schoor NM, Scheltens P, van der Flier WM, Huisman M, Reinders MJT, Holstege H. Polygenic Risk Score of Longevity Predicts Longer Survival Across an Age Continuum. J Gerontol A Biol Sci Med Sci. 2021 Apr 30;76(5):750-759. doi: 10.1093/gerona/glaa289. PMID: 33216869; PMCID: PMC8087277.

 

  1. Tesi N, van der Lee S, Hulsman M, Holstege H, Reinders MJT. snpXplorer: a web application to explore human SNP-associations and annotate SNP-sets. Nucleic Acids Res. 2021 Jul 2;49(W1):W603-W612. doi: 10.1093/nar/gkab410. PMID: 34048563; PMCID: PMC8262737.

 

  1. Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, van der Flier WM, Mielke MM, Del Campo M. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 2022 Jan;21(1):66-77. doi: 10.1016/S1474-4422(21)00361-6. Epub 2021 Nov 24. PMID: 34838239.

 

  1. Thijssen EH, Verberk IMW, Vanbrabant J, Koelewijn A, Heijst H, Scheltens P, van der Flier W, Vanderstichele H, Stoops E, Teunissen CE. Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer’s disease. Sci Rep. 2021 May 6;11(1):9736. doi: 10.1038/s41598-021-89004-x. PMID: 33958661; PMCID: PMC8102604.

 

  1. Thorlacius-Ussing G, Bruun M, Gjerum L, Frederiksen KS, Rhodius-Meester HFM, van der Flier WM, Waldemar G, Hasselbalch SG. Comparing a Single Clinician Versus a Multidisciplinary Consensus Conference Approach for Dementia Diagnostics. J Alzheimers Dis. 2021;83(2):741-751. doi: 10.3233/JAD-210278. PMID: 34366342; PMCID: PMC8543265.

 

  1. Tijms BM, Gobom J, Teunissen C, Dobricic V, Tsolaki M, Verhey F, Popp J, Martinez-Lage P, Vandenberghe R, Lleó A, Molinuévo JL, Engelborghs S, Freund-Levi Y, Froelich L, Bertram L, Lovestone S, Streffer J, Vos S, Adni, Blennow K, Scheltens P, Zetterberg H, Visser PJ. CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. 2021 Aug 2;9(3):36. doi: 10.3390/proteomes9030036. PMID: 34449748; PMCID: PMC8396164.

 

  1. Tijms BM, Teunissen CE. Concatenating plasma p-tau to Alzheimer’s disease. Brain. 2021 Feb 12;144(1):14-17. doi: 10.1093/brain/awaa422. PMID: 33578422; PMCID: PMC7880662.

 

  1. Tuncel H, Visser D, Yaqub M, Timmers T, Wolters EE, Ossenkoppele R, van der Flier WM, van Berckel BNM, Boellaard R, Golla SSV. Effect of Shortening the Scan Duration on Quantitative Accuracy of [(18)F]Flortaucipir Studies. Mol Imaging Biol. 2021 Aug;23(4):604-613. doi: 10.1007/s11307-021-01581-5. Epub 2021 Jan 26. PMID: 33496930; PMCID: PMC8277654.

 

  1. Tuncel H, Boellaard R, Coomans EM, de Vries EF, Glaudemans AW, Feltes PK, García DV, Verfaillie SC, Wolters EE, Sweeney SP, Ryan JM, Ivarsson M, Lynch BA, Schober P, Scheltens P, Schuit RC, Windhorst AD, De Deyn PP, van Berckel BN, Golla SS. Kinetics and 28-day test-retest repeatability and reproducibility of [(11)C]UCB-J PET brain imaging. J Cereb Blood Flow Metab. 2021 Jun;41(6):1338-1350. doi: 10.1177/0271678X20964248. Epub 2020 Oct 8. PMID: 34013797; PMCID: PMC8138337.

 

  1. Ulugut Erkoyun H, van der Lee SJ, Nijmeijer B, van Spaendonk R, Nelissen A, Scarioni M, Dijkstra A, Samancı B, Gürvit H, Yıldırım Z, Tepgeç F, Bilgic B, Barkhof F, Rozemuller A, van der Flier WM, Scheltens P, Cohn-Hokke P, Pijnenburg Y. The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series. J Alzheimers Dis. 2021;79(3):1195-1201. doi: 3233/JAD-201191. PMID: 33427744; PMCID: PMC7990443.

 

  1. Ulugut H, Stek S, Wagemans LEE, Jutten RJ, Keulen MA, Bouwman FH, Prins ND, Lemstra AW, Krudop W, Teunissen CE, van Berckel BNM, Ossenkoppele R, Barkhof F, van der Flier WM, Scheltens P, Pijnenburg YAL. The natural history of primary progressive aphasia: beyond aphasia. J Neurol. 2021 Jul 3. doi: 10.1007/s00415-021-10689-1. Epub ahead of print. PMID: 34216263.

 

  1. Ulugut H, Dijkstra AA, Scarioni M; Netherlands Brain Bank, Barkhof F, Scheltens P, Rozemuller AJM, Pijnenburg YAL. Right temporal variant frontotemporal dementia is pathologically heterogeneous: a case-series and a systematic review. Acta Neuropathol Commun. 2021 Aug 3;9(1):131. doi: 10.1186/s40478-021-01229-z. PMID: 34344452; PMCID: PMC8330072.

 

  1. van Bokhoven P, de Wilde A, Vermunt L, Leferink PS, Heetveld S, Cummings J, Scheltens P, Vijverberg EGB. The Alzheimer’s disease drug development landscape. Alzheimers Res Ther. 2021 Nov 11;13(1):186. doi: 10.1186/s13195-021-00927-z. PMID: 34763720; PMCID: PMC8582156.

 

  1. van Dam M, Sikkes SA, Rammeloo E, Reinders E, Jelgerhuis JR, Geurts JJ, Uitdehaag BM, Hulst HE. https://pubmed.ncbi.nlm.nih.gov/34408904/Cognitive functioning in everyday life: The development of a questionnaire on instrumental activities of daily living in multiple sclerosis. Mult Scler J Exp Transl Clin. 2021 Aug 3;7(3):20552173211038027. doi: 10.1177/20552173211038027. PMID: 34408904; PMCID: PMC8365017.

 

  1. van de Beek M, van Steenoven I, van der Zande JJ, Porcelijn I, Barkhof F, Stam CJ, Raijmakers PGHM, Scheltens P, Teunissen CE, van der Flier WM, Lemstra AW. Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results. Alzheimers Res Ther. 2021 Feb 26;13(1):53. doi: 10.1186/s13195-021-00792-w. PMID: 33637117; PMCID: PMC7908769.

 

  1. van de Veen D, Bakker C, Peetoom K, Pijnenburg Y, Papma JM; PRECODE Study Group, de Vugt M, Koopmans R. An Integrative Literature Review on the Nomenclature and Definition of Dementia at a Young Age. J Alzheimers Dis. 2021;83(4):1891-1916. doi: 10.3233/JAD-210458. PMID: 34487041; PMCID: PMC8609678.

 

  1. van den Akker EB, Makrodimitris S, Hulsman M, Brugman MH, Nikolic T, Bradley T, Waisfisz Q, Baas F, Jakobs ME, de Jong D, Slagboom PE, Staal FJT, Reinders MJT, Holstege H. Dynamic clonal hematopoiesis and functional T-cell immunity in a supercentenarian. 2021 Jul;35(7):2125-2129. doi: 10.1038/s41375-020-01086-0. Epub 2020 Nov 12. PMID: 33184493; PMCID: PMC8257492.

 

  1. van den Bosch KA, Verberk IMW, Ebenau JL, van der Lee SJ, Jansen IE, Prins ND, Scheltens P, Teunissen CE, Van der Flier WM. BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiol Aging. 2021 Dec;108:146-154. doi: 1016/j.neurobiolaging.2021.08.018. Epub 2021 Sep 4. PMID: 34601245.

 

  1. van der Ende EL, Morenas-Rodriguez E, McMillan C, Grossman M, Irwin D, Sanchez-Valle R, Graff C, Vandenberghe R, Pijnenburg YAL, Laforce R, Ber IL, Lleo A, Haass C, Suarez-Calvet M, van Swieten JC, Seelaar H. CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. Neurobiol Aging. 2021 Jul;103:158.e1-158.e5. doi: 10.1016/j.neurobiolaging.2021.02.024. Epub 2021 Mar 4. PMID: 33896652.

 

  1. van der Ende EL, Bron EE, Poos JM, Jiskoot LC, Panman JL, Papma JM, Meeter LH, Dopper EGP, Wilke C, Synofzik M, Heller C, Swift IJ, Sogorb-Esteve A, Bouzigues A, Borroni B, Sanchez-Valle R, Moreno F, Graff C, Laforce R, Galimberti D, Masellis M, Tartaglia MC, Finger E, Vandenberghe R, Rowe JB, de Mendonça A, Tagliavini F, Santana I, Ducharme S, Butler CR, Gerhard A, Levin J, Danek A, Otto M, Pijnenburg YAL, Sorbi S, Zetterberg H, Niessen WJ, Rohrer JD, Klein S, van Swieten JC, Venkatraghavan V, Seelaar H; GENFI consortium. A data- driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain. 2021 Oct 11:awab382. doi: 10.1093/brain/awab382. Epub ahead of print. PMID: 34633446.

 

  1. van der Lee SJ, van Steenoven I, van de Beek M, Tesi N, Jansen IE, van Schoor NM, Reinders MJT, Huisman M, Scheltens P, Teunissen CE, Holstege H, van der Flier WM, Lemstra AW. Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. J Alzheimers Dis. 2021;83(1):269-279. doi: 10.3233/JAD-210365. PMID: 34308904; PMCID: PMC8461715.

 

  1. van der Linden RJ, Reus LM, De Witte W, Tijms BM, Olde Rikkert M, Visser PJ, Poelmans G. Genetic overlap between Alzheimer’s disease and blood lipid levels. Neurobiol Aging. 2021 Dec;108:189-195. doi: 10.1016/j.neurobiolaging.2021.06.019. Epub 2021 Jul 3. PMID: 34340865.

 

  1. van Engelen ME, Rozemuller AJM, Ulugut Erkoyun H, Groot C, Fieldhouse JLP, Koene T, Ossenkoppele R, Gossink FT, Krudop WA, Vijverberg EGB, Dols A, Barkhof F, Berckel BNMV, Scheltens P, Brain Bank N, Pijnenburg YAL. The bvFTD phenocopy syndrome: a case study supported by repeated MRI, [(18)F]FDG-PET and pathological assessment. 2021 Apr;27(2):181-189. doi: 10.1080/13554794.2021.1905855. Epub 2021 Apr 21. PMID: 33881963.

 

  1. van Gils AM, Visser LN, Hendriksen HM, Georges J, Muller M, Bouwman FH, van der Flier WM, Rhodius-Meester HF. Assessing the Views of Professionals, Patients, and Care Partners Concerning the Use of Computer Tools in Memory Clinics: International Survey Study. JMIR Form Res. 2021 Dec 3;5(12):e31053. doi: 10.2196/31053. PMID: 34870612.

 

 

  1. van Harten AC, Wiste HJ, Weigand SD, Mielke MM, Kremers WK, Eichenlaub U, Dyer RB, Algeciras-Schimnich A, Knopman DS, Jack CR Jr, Petersen RC. Detection of Alzheimer’s disease amyloid beta 1-42, p-tau, and t-tau assays. Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12406. Epub ahead of print. PMID: 34310035.

 

  1. van Maurik IS, Rhodius-Meester HFM, Teunissen CE, Scheltens P, Barkhof F, Palmqvist S, Hansson O, van der Flier WM, Berkhof J. Biomarker testing in MCI patients-deciding who to test. Alzheimers Res Ther. 2021 Jan 7;13(1):14. doi: 10.1186/s13195-020-00763-7. PMID: 33413634; PMCID: PMC7792312.

 

  1. van Olst L, Roks SJM, Kamermans A, Verhaar BJH, van der Geest AM, Muller M, van der Flier WM, de Vries HE. Contribution of Gut Microbiota to Immunological Changes in Alzheimer’s Disease. Front Immunol. 2021 May 31;12:683068. doi: 10.3389/fimmu.2021.683068. PMID: 34135909; PMCID: PMC8200826.

 

  1. Van’t Hooft JJ, Pijnenburg YAL, Sikkes SAM, Scheltens P, Spikman JM, Jaschke AC, Warren JD, Tijms BM. Frontotemporal dementia, music perception and social cognition share neurobiological circuits: A meta-analysis. Brain Cogn. 2021 Mar;148:105660. doi: 10.1016/j.bandc.2020.105660. Epub 2021 Jan 7. PMID: 33421942.

 

  1. Vijverberg EGB, Axelsen TM, Bihlet AR, Henriksen K, Weber F, Fuchs K, Harrison JE, Kühn-Wache K, Alexandersen P, Prins ND, Scheltens P. Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD. Alzheimers Res Ther. 2021 Aug 23;13(1):142. doi: 10.1186/s13195-021-00882-9. PMID: 34425883; PMCID: PMC8381483.

 

  1. Visser LNC, Dubbelman MA, Verrijp M, Wanders L, Pelt S, Zwan MD, Thijssen DHJ, Wouters H, Sikkes SAM, van Hout HPJ, van der Flier WM. The Cognitive Online Self-Test Amsterdam (COST-A): Establishing norm scores in a community-dwelling population. Alzheimers Dement (Amst). 2021 Sep 14;13(1):e12234. doi: 10.1002/dad2.12234. PMID: 34541288; PMCID: PMC8438682.

 

  1. Visser LNC, Minguillon C, Sánchez-Benavides G, Abramowicz M, Altomare D, Fauria K, Frisoni GB, Georges J, Ribaldi F, Scheltens P, van der Schaar J, Zwan M, van der Flier WM, Molinuevo JL. Dementia risk communication. A user manual for Brain Health Services-part 3 of 6. Alzheimers Res Ther. 2021 Oct 11;13(1):170. doi: 10.1186/s13195-021-00840-5. PMID: 34635169; PMCID: PMC8507171.

 

  1. Vogel JW, Young AL, Oxtoby NP, Smith R, Ossenkoppele R, Strandberg OT, La Joie R, Aksman LM, Grothe MJ, Iturria-Medina Y; Alzheimer’s Disease Neuroimaging Initiative, Pontecorvo MJ, Devous MD, Rabinovici GD, Alexander DC, Lyoo CH, Evans AC, Hansson O. Four distinct trajectories of tau deposition identified in Alzheimer’s disease. Nat Med. 2021 May;27(5):871-881. doi: 10.1038/s41591-021-01309-6. Epub 2021 Apr 29. PMID: 33927414; PMCID: PMC8686688.

 

  1. Wesselman LMP, van Lent DM, Schröder A, van de Rest O, Peters O, Menne F, Fuentes M, Priller J, Spruth EJ, Altenstein S, Schneider A, Fließbach K, Roeske S, Wolfsgruber S, Kleineidam L, Spottke A, Pross V, Wiltfang J, Vukovich R, Schild AK, Düzel E, Metzger CD, Glanz W, Buerger K, Janowitz D, Perneczky R, Tatò M, Teipel S, Kilimann I, Laske C, Buchmann M, Ramirez A, Sikkes SAM, Jessen F, van der Flier WM, Wagner M. Dietary patterns are related to cognitive functioning in elderly enriched with individuals at increased risk for Alzheimer’s disease. Eur J Nutr. 2021 Mar;60(2):849-860. doi: 10.1007/s00394-020-02257-6. Epub 2020 May 29. PMID: 32472387; PMCID: PMC7900077.

 

  1. Willemse EAJ, Scheltens P, Teunissen CE, Vijverberg EGB. A neurologist’s perspective on serum neurofilament light in the memory clinic: a prospective implementation study. Alzheimers Res Ther. 2021 May 18;13(1):101. doi: 1186/s13195-021-00841-4. PMID: 34006321; PMCID: PMC8132439.

 

  1. Willemse EAJ, Tijms BM, van Berckel BNM, Le Bastard N, van der Flier WM, Scheltens P, Teunissen CE. Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimers Dement (Amst). 2021 May 1;13(1):e12182. doi: 10.1002/dad2.12182. PMID: 33969174; PMCID: PMC8088096.

 

  1. Wimo A, Belger M, Bon J, Jessen F, Dumas A, Kramberger MG, Jamilis L, Johansson G, Rodrigo Salas A, Rodríguez Gómez O, Sannemann L, Stoekenbroek M, Gurruchaga Telleria M, Valero S, Vermunt L, Waterink L, Winblad B, Visser PJ, Zwan M, Boada M; Collaborators and members of the MOPEAD consortium. A Cost-Consequence Analysis of Different Screening Procedures in Alzheimer’s Disease: Results from the MOPEAD Project. J Alzheimers Dis. 2021;83(3):1149-1159. doi: 10.3233/JAD-210303. PMID: 34420954; PMCID: PMC8543247.

 

  1. Wolters EE, Dodich A, Boccardi M, Corre J, Drzezga A, Hansson O, Nordberg A, Frisoni GB, Garibotto V, Ossenkoppele R. Clinical validity of increased cortical uptake of [(18)F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker developmentframework. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2097-2109. doi: 10.1007/s00259-020-05118-w. Epub 2021 Feb 6. PMID: 33547556; PMCID: PMC8175307.

 

  1. Wolters EE, Papma JM, Verfaillie SCJ, Visser D, Weltings E, Groot C, van der Ende EL, Giannini LAA, Tuncel H, Timmers T, Boellaard R, Yaqub M, van Assema DME, Kuijper DA, Segbers M, Rozemuller AJM, Barkhof F, Windhorst AD, van der Flier WM, Pijnenburg YAL, Scheltens P, van Berckel BNM, van Swieten JC, Ossenkoppele R, Seelaar H. [(18)F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers. 2021 Sep 7;97(10):e1017-e1030. doi: 10.1212/WNL.0000000000012448. Epub 2021 Jul 1. PMID: 34210823; PMCID: PMC8448551.

 

  1. Xu J, Green R, Kim M, Lord J, Ebshiana A, Westwood S, Baird AL, Nevado-Holgado AJ, Shi L, Hye A, Snowden SG, Bos I, Vos SJB, Vandenberghe R, Teunissen CE, Kate MT, Scheltens P, Gabel S, Meersmans K, Blin O, Richardson J, De Roeck EE, Engelborghs S, Sleegers K, Bordet R, Rami L, Kettunen P, Tsolaki M, Verhey FRJ, Alcolea D, Lleó A, Peyratout G, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Frisoni GB, Molinuevo JL, Wallin A, Popp J, Martinez-Lage P, Bertram L, Blennow K, Zetterberg H, Streffer J, Visser PJ, Lovestone S, Proitsi P, Legido-Quigley C, On Behalf Of The European Medical Information Framework Consortium. Sex-Specific Metabolic Pathways Were Associated with Alzheimer’s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines. 2021 Nov 3;9(11):1610. doi: 10.3390/biomedicines9111610. PMID: 34829839; PMCID: PMC8615383.

 

  1. Zwan MD, van der Flier WM, Cleutjens S, Schouten TC, Vermunt L, Jutten RJ, van Maurik IS, Sikkes SAM, Flenniken D, Howell T, Weiner MW, Scheltens P, Prins ND. Dutch Brain Research Registry for study participant recruitment: Design and first results. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12132. doi: 10.1002/trc2.12132. PMID: 33614897; PMCID: PMC7882519.

 

Publications 2020

  1. Ahmad S, Milan MDC, Hansson O, Demirkan A, Agustin R, Sáez ME, Giagtzoglou N,Cabrera-Socorro A, Bakker MHM, Ramirez A, Hankemeier T, Stomrud E, Mattsson-Carlgren N, Scheltens P, van der Flier WM, Ikram MA, Malarstig A, Teunissen CE,Amin N, van Duijn CM. CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers. Sci Rep. 2020 May 19;10(1):8233. doi: 10.1038/s41598-020-65038-5. PMID: 32427856; PMCID: PMC7237496
  2. Amier RP, Marcks N, Hooghiemstra AM, Nijveldt R, van Buchem MA, de Roos A, Biessels GJ, Kappelle LJ, van Oostenbrugge RJ, van der Geest RJ, Bots ML, Greving JP, Niessen WJ, van Osch MJP, de Bresser J, van de Ven PM, van der Flier, WM, Brunner-La Rocca HP, van Rossum AC; Heart-Brain Connection Consortium. Hypertensive Exposure Markers by MRI in Relation to Cerebral Small Vessel Disease and Cognitive Impairment. JACC Cardiovasc Imaging. 2020 Sep 28:S1936-878X(20)30641-0. doi: 10.1016/j.jcmg.2020.06.040. Epub ahead of print. PMID: 33011127.
  3. Babapour Mofrad R, Tijms BM, Scheltens P, Barkhof F, van der Flier WM, Sikkes SAM, Teunissen CE. Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype. Neurology. 2020 Oct 27;95(17):e2378-e2388. doi: 10.1212/WNL.0000000000010629. Epub 2020 Aug 11. PMID: 32788242.
  4. Babiloni C, Blinowska K, Bonanni L, Cichocki A, De Haan W, Del Percio C, Dubois B, Escudero J, Fernández A, Frisoni G, Guntekin B, Hajos M, Hampel H, Ifeachor E, Kilborn K, Kumar S, Johnsen K, Johannsson M, Jeong J, LeBeau F, Lizio R, Lopes da Silva F, Maestú F, McGeown WJ, McKeith I, Moretti DV, Nobili F, Olichney J, Onofrj M, Palop JJ, Rowan M, Stocchi F, Struzik ZM, Tanila H, Teipel S, Taylor JP, Weiergräber M, Yener G, Young-Pearse T, Drinkenburg WH, Randall F. What electrophysiology tells us about Alzheimer’s disease: a window into the synchronization and connectivity of brain neurons. Neurobiol Aging. 2020 Jan;85:58-73. doi: 10.1016/j.neurobiolaging.2019.09.008. Epub 2019 Sep 19. PMID: 31739167.
  5. Banning LCP, Janssen EPCJ, Hamel REG, de Vugt M, Köhler S, Wolfs CAG, Oosterveld SM, Melis RJF, Olde Rikkert MGM, Kessels RPC, Pijnenburg YAL, Koene T, van der Flier WM, Scheltens P, Visser PJ, Verhey FRJ, Aalten P, Ramakers IHGB. Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia. J Geriatr Psychiatry Neurol. 2020 Sep;33(5):256-264. doi: 10.1177/0891988719882104. Epub 2019 Oct 23. PMID: 31645191; PMCID: PMC7361660.
  6. Banning LCP, Ramakers IHGB, Köhler S, Bron EE, Verhey FRJ, de Deyn PP, Claassen JAHR, Koek HL, Middelkoop HAM, van der Flier WM, van der Lugt A, Aalten P; Alzheimer’s Disease Neuroimaging Initiative; Parelsnoer Institute Neurodegenerative Diseases study group. The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer’s Disease Spectrum. Am J Geriatr Psychiatry. 2020 Jul;28(7):735-744. doi: 10.1016/j.jagp.2020.01.012. Epub 2020 Feb 20. PMID: 32088096.
  7. Bauermeister S, Orton C, Thompson S, Barker RA, Bauermeister JR, Ben-Shlomo Y, Brayne C, Burn D, Campbell A, Calvin C, Chandran S, Chaturvedi N, Chêne G, Chessell IP, Corbett A, Davis DHJ, Denis M, Dufouil C, Elliott P, Fox N, Hill D, Hofer SM, Hu MT, Jindra C, Kee F, Kim CH, Kim C, Kivimaki M, Koychev I, Lawson RA, Linden GJ, Lyons RA, Mackay C, Matthews PM, McGuiness B, Middleton L, Moody C, Moore K, Na DL, O’Brien JT, Ourselin S, Paranjothy S, Park KS, Porteous DJ, Richards M, Ritchie CW, Rohrer JD, Rossor MN, Rowe JB, Scahill R, Schnier C, Schott JM, Seo SW, South M, Steptoe M, Tabrizi SJ, Tales A, Tillin T, Timpso, NJ, Toga AW, Visser PJ, Wade-Martins R, Wilkinson T, Williams J, Wong A, Gallacher JEJ. The Dementias Platform UK (DPUK) Data Portal. Eur J Epidemiol. 2020 Jun;35(6):601-611. doi: 10.1007/s10654-020-00633-4. Epub 2020 Apr 23. PMID: 32328990; PMCID: PMC7320955.
  8. Beeldman E, Govaarts R, de Visser M, Klein Twennaar M, van der Kooi AJ, van den Berg LH, Veldink JH, Pijnenburg YAL, de Haan RJ, Schmand BA, Raaphorst J. Progression of cognitive and behavioural impairment in early amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2020 Jul;91(7):779-780. doi: 10.1136/jnnp-2020-322992. Epub 2020 May 13. PMID: 32404381; PMCID: PMC7361007.
  9. Beker N, Sikkes SAM, Hulsman M, Tesi N, van der Lee SJ, Scheltens P, Holstege H. Longitudinal Maintenance of Cognitive Health in Centenarians in the 100-plus Study. JAMA Netw Open. 2020 Feb 5;3(2):e200094. doi: 10.1001/jamanetworkopen.2020.0094. PMID: 32101309; PMCID: PMC7137688.
  10. Berron D, van Westen D, Ossenkoppele R, Strandberg O, Hansson O. Medial temporal lobe connectivity and its associations with cognition in early Alzheimer’s disease. Brain. 2020 Apr 1;143(4):1233-1248. Doi:10.1093/brain/awaa068. PMID: 32252068; PMCID: PMC7174043.
  11. Biessels GJ, Nobili F, Teunissen CE, Simó R, Scheltens P. Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. Lancet Neurol. 2020 Aug;19(8):699-710. doi: 10.1016/S1474-4422(20)30139-3. Epub 2020 May 20. PMID: 32445622.
  12. Bis JC, Jian X, Kunkle BW, Chen Y, Hamilton-Nelson KL, Bush WS, Salerno WJ, Lancour D, Ma Y, Renton AE, Marcora E, Farrell JJ, Zhao Y, Qu L, Ahmad S, Amin N, Amouyel P, Beecham GW, Below JE, Campion D, Cantwell L, Charbonnier C, Chung J, Crane PK, Cruchaga C, Cupples LA, Dartigues JF, Debette S, Deleuze JF, Fulton L, Gabriel SB, Genin E, Gibbs RA, Goate A, Grenier-Boley B, Gupta N, Haines JL, Havulinna AS, Helisalmi S, Hiltunen M, Howrigan DP, Ikram MA, Kaprio J, Konrad J, Kuzma A, Lander ES, Lathrop M, Lehtimäki T, Lin H, Mattila K, Mayeux R, Muzny DM, Nasser W, Neale B, Nho K, Nicolas G, Patel D, Pericak-Vance MA, Perola M, Psaty BM, Quenez O, Rajabli F, Redon R, Reitz C, Remes AM, Salomaa V, Sarnowski C, Schmidt H, Schmidt M, Schmidt R, Soininen H, Thornton TA, Tosto G, Tzourio C, van der Lee SJ, van Duijn CM, Valladares O, Vardarajan B, Wang LS, Wang W, Wijsman E, Wilson RK, Witten D, Worley KC, Zhang X; Alzheimer’s Disease Sequencing Project, Bellenguez C, Lambert JC, Kurki MI, Palotie A, Daly M, Boerwinkle E, Lunetta KL, Destefano AL, Dupuis J, Martin ER, Schellenberg GD, Seshadri S, Naj AC, Fornage M, Farrer LA. Whole exome sequencing study identifies novel rare and common Alzheimer’s-Associated variants involved in immune response and transcriptional regulation. Mol Psychiatry. 2020 Aug;25(8):1859-1875. doi: 10.1038/s41380-018-0112-7. Epub 2018 Aug 14. Erratum in: Mol Psychiatry. 2019 Oct 21;: PMID: 30108311; PMCID: PMC6375806.
    Bis JC, Jian X, Kunkle BW, Chen Y, Hamilton-Nelson KL, Bush WS, Salerno WJ, Lancour D, Ma Y, Renton AE, Marcora E, Farrell JJ, Zhao Y, Qu L, Ahmad S, Amin N, Amouyel P, Beecham GW, Below JE, Campion D, Cantwell L, Charbonnier C, Chung J, Crane PK, Cruchaga C, Cupples LA, Dartigues JF, Debette S, Deleuze JF, Fulton L, Gabriel SB, Genin E, Gibbs RA, Goate A, Grenier-Boley B, Gupta N, Haines JL, Havulinna AS, Helisalmi S, Hiltunen M, Howrigan DP, Ikram MA, Kaprio J, Konrad J, Kuzma A, Lander ES, Lathrop M, Lehtimäki T, Lin H, Mattila K, Mayeux R, Muzny, DM, Nasser W, Neale B, Nho K, Nicolas G, Patel D, Pericak-Vance MA, Perola M, Psaty BM, Quenez O, Rajabli F, Redon R, Reitz C, Remes AM, Salomaa V, Sarnowski C, Schmidt H, Schmidt M, Schmidt R, Soininen H, Thornton TA, Tosto G, Tzourio C, van der Lee SJ, van Duijn CM, Valladares O, Vardarajan B, Wang LS, Wang W, Wijsman E, Wilson RK, Witten D, Worley KC, Zhang X; Alzheimer’s Disease Sequencing Project, Bellenguez C, Lambert JC, Kurki MI, Palotie A, Daly M, Boerwinkle E, Lunetta KL, Destefano AL, Dupuis J, Martin ER, Schellenberg GD, Seshadri S, Naj AC, Fornage M, Farrer LA. Correction: Whole exome sequencing study identifies novel rare and common Alzheimer’s-Associated variants involved in immune response and transcriptional regulation. Mol Psychiatry. 2020 Aug;25(8):1901-1903. doi: 10.1038/s41380-019-0529-7. Erratum for: Mol Psychiatry. 2020 Aug;25(8):1859-1875. PMID: 31636380; PMCID: PMC7387240.
  13. Blenkinsop A, van der Flier WM, Wolk D, Lehmann M, Howard R, Frost C, Barnes. J. Non-memory cognitive symptom development in Alzheimer’s disease. Eur J Neurol. 2020 Jun;27(6):995-1002. doi: 10.1111/ene.14185. Epub 2020 Mar 29. PMID: 32078209.
  14. Boelaarts L, de Jonghe JFM, Scheltens P. Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited. Dement Geriatr Cogn Disord. 2020;49(1):2-7. doi: 10.1159/000506332. Epub 2020 Mar 30. PMID: 32224618; PMCID: PMC7592944.
  15. Boomsma JMF, Exalto LG, Barkhof F, Chen CLH, Hilal S, Leeuwis AE, Prins ND, Saridin FN, Scheltens P, Teunissen CE, Verwer JH, Weinstein HC, van der Flier WM, Biessels GJ; TRACE‐VCI study group. Prediction of poor clinical outcome in vascular cognitive impairment: TRACE-VCI study. Alzheimers Dement (Amst). 2020 Aug 10;12(1):e12077. doi: 10.1002/dad2.12077. PMID: 32789162; PMCID: PMC7416669.
  16. Boon BDC, Bulk M, Jonker AJ, Morrema THJ, van den Berg E, Popovic M, Walte J, Kumar S, van der Lee SJ, Holstege H, Zhu X, Van Nostrand WE, Natté R, van der Weerd L, Bouwman FH, van de Berg WDJ, Rozemuller AJM, Hoozemans JJM. The coarse-grained plaque: a divergent Aβ plaque-type in early-onset Alzheimer’s disease. Acta Neuropathol. 2020 Dec;140(6):811-830. doi: 10.1007/s00401-020-02198-8. Epub 2020 Sep 14. PMID: 32926214; PMCID: PMC7666300.
  17. Briels CT, Stam CJ, Scheltens P, Bruins S, Lues I, Gouw AA. In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer’s disease. Clin Neurophysiol. 2020 Jan;131(1):88-95. doi: 10.1016/j.clinph.2019.09.014. Epub 2019 Nov 4. PMID: 31759193.
  18. Briels CT, Schoonhoven DN, Stam CJ, de Waal H, Scheltens P, Gouw AA. Reproducibility of EEG functional connectivity in Alzheimer’s disease. Alzheimers Res Ther. 2020 Jun 3;12(1):68. doi: 10.1186/s13195-020-00632-3. PMID: 32493476; PMCID: PMC7271479.
  19. Briels CT, Eertink JJ, Stam CJ, van der Flier WM, Scheltens P, Gouw AA. Profound regional spectral, connectivity, and network changes reflect visual deficits in posterior cortical atrophy: an EEG study. Neurobiol Aging. 2020 Dec;96:1-11. doi: 10.1016/j.neurobiolaging.2020.07.029. Epub 2020 Aug 5. PMID: 32905950.
  20. Bruderer-Hofstetter M, Sikkes SAM, Münzer T, Niedermann K. Development of a model on factors affecting instrumental activities of daily living in people with mild cognitive impairment – a Delphi study. BMC Neurol. 2020 Jul 1;20(1):264. doi: 10.1186/s12883-020-01843-9. PMID: 32611388; PMCID: PMC7329426.
  21. Bruderer-Hofstetter M, Dubbelman MA, Meichtry A, Koehn F, Münzer T, Jutten RJ, Scheltens P, Sikkes SAM, Niedermann K. Cross-cultural adaptation and validation of the Amsterdam Instrumental Activities of Daily Living questionnaire short version German for Switzerland. Health Qual Life Outcomes. 2020 Oct 2;18(1):323. doi: 10.1186/s12955-020-01576-w. PMID: 33008394; PMCID: PMC7530958.
  22. Bruffaerts R, Schaeverbeke J, De Weer AS, Nelissen N, Dries E, Van Bouwel K, Sieben A, Bergmans B, Swinnen C, Pijnenburg Y, Sunaert S, Vandenbulcke M, Vandenberghe R. Multivariate analysis reveals anatomical correlates of naming errors in primary progressive aphasia. Neurobiol Aging. 2020 Apr;88:71-82. doi: 10.1016/j.neurobiolaging.2019.12.016. Epub 2019 Dec 20. PMID: 31955981.
  23. Bruinsma J, Peetoom K, Millenaar J, Köhler S, Bakker C, Koopmans R, Pijnenburg Y, Verhey F, de Vugt M. The quality of the relationship perceived by spouses of people with young-onset dementia. Int Psychogeriatr. 2020 Mar 10:1-10. doi: 10.1017/S1041610220000332. Epub ahead of print. PMID: 32151300.
  24. Calvin CM, de Boer C, Raymont V, Gallacher J, Koychev I; European Prevention of Alzheimer’s Dementia (EPAD) Consortium. Prediction of Alzheimer’s disease biomarker status defined by the ‘ATN framework’ among cognitively healthy individuals: results from the EPAD longitudinal cohort study. Alzheimers Res Ther. 2020 Nov 9;12(1):143. doi: 10.1186/s13195-020-00711-5. PMID: 33168064; PMCID: PMC7650169.
  25. Chatterjee M, van Steenoven I, Huisman E, Oosterveld L, Berendse H, van der Flier WM, Del Campo M, Lemstra AW, van de Berg WDJ, Teunissen CE. Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson’s Disease Patients and Is Present within Lewy Bodies. Biomolecules. 2020 Aug 12;10(8):1177. doi: 10.3390/biom10081177. PMID: 32806791; PMCID: PMC7463939.
  26. Chen JQA, Scheltens P, Groot C, Ossenkoppele R. Associations Between Caffeine Consumption, Cognitive Decline, and Dementia: A Systematic Review. J Alzheimers Dis. 2020 Nov 4. doi: 10.3233/JAD-201069. Epub ahead of print. PMID: 33185612.
  27. Chételat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, van de Giessen E, Agosta F, Barkhof F, Brooks DJ, Carrillo MC, Dubois B, Fjell AM, Frisoni GB, Hansson O, Herholz K, Hutton BF, Jack CR Jr, Lammertsma AA, Landau SM, Minoshima S, Nobili F, Nordberg A, Ossenkoppele R, Oyen WJG, Perani D, Rabinovici GD, Scheltens P, Villemagne VL, Zetterberg H, Drzezga A. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. Lancet Neurol. 2020 Nov;19(11):951-962. doi: 10.1016/S1474-4422(20)30314-8. PMID: 33098804.
  28. Collij LE, Heeman F, Salvadó G, Ingala S, Altomare D, de Wilde A, Konijnenberg E, van Buchem M, Yaqub M, Markiewicz P, Golla SSV, Wottschel V, Wink AM, Visser PJ, Teunissen CE, Lammertsma AA, Scheltens P, van der Flier WM, Boellaard R, van Berckel BNM, Molinuevo JL, Gispert JD, Schmidt ME, Barkhof F, Lopes Alves I; ALFA Study, for the Alzheimer’s Disease Neuroimaging Initiative; AMYPAD Consortium. Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology. 2020 Sep 15;95(11):e1538-e1553. doi: 10.1212/WNL.0000000000010256. Epub 2020 Jul 16. PMID: 32675080; PMCID:PMC7713745.
  29. Collorone S, Prados F, Hagens MH, Tur C, Kanber B, Sudre CH, Lukas C, Gasperini C, Oreja-Guevara C, Andelova M, Ciccarelli O, Wattjes MP, Ourselin S, Altmann DR, Tijms BM, Barkhof F, Toosy AT; MAGNIMS Study Group. Single-subject structural cortical networks in clinically isolated syndrome. Mult Scler. 2020 Oct;26(11):1392-1401. doi: 10.1177/1352458519865739. Epub 2019 Jul 24. PMID: 31339446.
  30. Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, Fillit H, Harrison JE, Schneider LS, Scheltens P, de Haan W, Grundman M, van Dyck CH, Izzo NJ, Catalano SM; Synaptic Health Endpoints Working Group. The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease. Alzheimers Res Ther. 2020 Mar 2;12(1):21. doi: 10.1186/s13195-020-00588-4. PMID: 32122400; PMCID: PMC7053087.
  31. Costa B, Manzoni C, Bernal-Quiros M, Kia DA, Aguilar M, Alvarez I, Alvare V, Andreassen O, Anfossi M, Bagnoli S, Benussi L, Bernardi L, Binetti G, Blackburn D, Boada M, Borroni B, Bowns L, Bråthen G, Bruni AC, Chiang HH, Clarimon J, Colville S, Conidi ME, Cope TE, Cruchaga C, Cupidi C, Di Battista ME, Diehl-Schmid J, Diez-Fairen M, Dols-Icardo O, Durante E, Flisar D, Frangipane F, Galimberti D, Gallo M, Gallucci M, Ghidoni R, Graff C, Grafman JH, Grossman M, Hardy J, Hernández I, Holloway GJ, Huey ED, Illán-Gala I, Karydas A, Khoshnood B, Kramberger MG, Kristiansen M, Lewis PA, Lleó A, Madhan GK, Maletta R, Maver A, Menendez-Gonzalez M, Milan G, Miller B, Mol MO, Momeni P, Moreno- Grau S, Morris CM, Nacmias B, Nilsson C, Novelli V, Öijerstedt L, Padovani A, Pal S, Panchbhaya Y, Pastor P, Peterlin B, Piaceri I, Pickering-Brown S, Pijnenburg YA, Puca AA, Rainero I, Rendina A, Richardson AM, Rogaeva E, Rogelj B, Rollinson S, Rossi G, Rossmeier C, Rowe JB, Rubino E, Ruiz A, Sanchez-Valle R, Sando SB, Santillo AF, Saxon J, Scarpini E, Serpente M, Smirne N, Sorbi S, Suh E, Tagliavini F, Thompson JC, Trojanowski JQ, Van Deerlin VM, Van der Zee J, Van Broeckhoven C, van Rooij J, Van Swieten JC, Veronesi A, Vitale E, Waldö ML, Woodward C, Yokoyama J, Escott-Price V, Polke JM, Ferrari R; International FTD- Genetics Consortium (IFGC). C9orf72, AAO and ancestry help discriminating behavioural from language variants in FTLD cohorts. Neurology. 2020 Sep 17:10.1212/WNL.0000000000010914. doi: 10.1212/WNL.0000000000010914. Epub ahead of print. PMID: 32943482.
  32. Dasgupta, I., Odudu, A., Baharani, J., Fergusson, N., Griffiths, H., Harrison, J.E., Maruff, P., Thomas, G.N., Woodhall, G., Youssef, S., Tadros, G. Evaluation of the Effect of Cooled Haemodialysis on cognitive Function in Patients suffering with End-stage Kidney Disease (E-CHECKED): Feasibility Randomised Control Trial Protocol. Trials. 2020 Sep 30;21(1):820. doi: 10.1186/s13063-020-04725-0.
  33. de Leeuw FA, van der Flier WM, Tijms BM, Scheltens P, Mendes VM, Manadas B, Bierau J, van Wijk N, van den Heuvel EGHM, Mohajeri MH, Teunissen CE, Kester MI. Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. J Am Med Dir Assoc. 2020 Oct;21(10):1513.e1-1513.e17. doi: 10.1016/j.jamda.2019.12.009. Epub 2020 Jan 27. PMID: 32001171.
  34. de Leeuw FA, van de Rest O, Doorduijn AS, Fieldhouse JLP, de van der Schueren MAE, Visser M, van den Heuvel EGHM, Scheltens P, Teunissen CE, Kester MI, van der Flier WM. Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. J Am Med Dir Assoc. 2020 Oct;21(10):1436-1438. doi:10.1016/j.jamda.2020.04.031. Epub 2020 Jul 5. PMID: 32641272.
  35. de Leeuw FA, Karamujić-Čomić H, Tijms BM, Peeters CFW, Kester MI, Scheltens P, Ahmad S, Vojinovic D, Adams HHH, Hankemeier T, Bos D, van der Lugt A, Vernooij MW, Ikram MA, Amin N, Barkhof F, Teunissen CE, van Duijn CM, van der Flier WM. Circulating metabolites are associated with brain atrophy and white matter hyperintensities. Alzheimers Dement. 2020 Sep 4. doi: 10.1002/alz.12180. Epub ahead of print. PMID: 32886448.
  36. de Vent NR, Agelink van Rentergem JA, Huizenga HM, van der Flier WM, Sikkes SAM, Murre JMJ, van den Bosch KA, Scheltens P, Schmand BA. An Operational Definition of ‘Abnormal Cognition’ to Optimize the Prediction of Progression to Dementia: What Are Optimal Cut-Off Points for Univariate and Multivariate Normative Comparisons? J Alzheimers Dis. 2020;77(4):1693-1703. doi: 10.3233/JAD-200811. PMID: 32925072; PMCID: PMC7683061.
  37. de Vos F, Schouten TM, Koini M, Bouts MJRJ, Feis RA, Lechner A, Schmidt R, van Buchem MA, Verhey FRJ, Olde Rikkert MGM, Scheltens P, de Rooij M, van der Grond J, Rombouts SARB. Pre-trained MRI-based Alzheimer’s disease classification models to classify memory clinic patients. Neuroimage Clin. 2020;27:102303. doi: 10.1016/j.nicl.2020.102303. Epub 2020 Jun 4. PMID: 32554321; PMCID: PMC7303669.
  38. de Vries BM, Golla SSV, Ebenau J, Verfaillie SCJ, Timmers T, Heeman F, Cysouw MCF, van Berckel BNM, van der Flier WM, Yaqub M, Boellaard R; Alzheimer’s Disease Neuroimaging Initiative. Classification of negative and positive (18)F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network. Eur J Nucl Med Mol Imaging. 2020 Sep 2. doi: 10.1007/s00259-020-05006-3. Epub ahead of print. PMID: 32875431.
  39. Di Censo R, Abdelnour C, Blanc F, Bousiges O, Lemstra AW, van Steenoven I, Onofrj M, Aarsland D, Bonanni L; European DLB consortium. CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2020 Jan;91(1):109-110. doi: 10.1136/jnnp-2019-320980. Epub 2019 Jul 31. PMID: 31366604.
  40. Dicks E, van der Flier WM, Scheltens P, Barkhof F, Tijms BM; Alzheimer’s Disease Neuroimaging Initiative. Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer’s disease. Neurobiol Aging. 2020 Oct;94:71-80. doi: 10.1016/j.neurobiolaging.2020.05.008. Epub 2020 May 21. PMID: 32585492.
  41. Dicks E, Vermunt L, van der Flier WM, Barkhof F, Scheltens Ph, Tijms BM, Alzheimer’s Disease Neuroimaging Initiative. Grey matter network trajectories across the Alzheimer’s disease continuum and relation to cognition. Brain Communicatons. 2020 Oct 20;2(2): fcaa177. doi:10.1093/braincomms/fcaa177
  42. Dijkstra AA, Gami-Patel P, Rozemuller AJM, Bugiani M, Pijnenburg YAL, Smit GAB, Dols A, Hoozemans JJM. Reduction of GABA subunit theta-containing cortical neurons in schizophrenia. Schizophr Res. 2020 Nov 23:S0920-9964(20)30577-6. Doi 10.1016/j.schres.2020.11.037. Epub ahead of print. PMID: 33243715.
  43. Dols A, Lemstra AW. Parkinsonism and Bipolar Disorder. Bipolar Disord. 2020 Jun;22(4):413-415. doi: 10.1111/bdi.12888. Epub 2020 Jan 30. PMID: 31954093; PMCID: PMC7317540.
  44. Doorduijn AS, de van der Schueren MAE, van de Rest O, de Leeuw FA, Fieldhouse JLP, Kester MI, Teunissen CE, Scheltens P, van der Flier WM, Visser M, Boesveldt S. Olfactory and gustatory functioning and food preferences of patients with Alzheimer’s disease and mild cognitive impairment compared to controls: the NUDAD project. J Neurol. 2020 Jan;267(1):144-152. doi: 10.1007/s00415-019-09561-0. Epub 2019 Oct 8. PMID: 31595376; PMCID: PMC6954901.
  45. Doorduijn AS, de van der Schueren MAE, van de Rest O, de Leeuw FA, Hendriksen HMA, Teunissen CE, Scheltens P, van der Flier WM, Visser M. Energy intake and expenditure in patients with Alzheimer’s disease and mild cognitive impairment: the NUDAD project. Alzheimers Res Ther. 2020 Sep 26;12(1):116. doi: 10.1186/s13195-020-00687-2. PMID: 32979927; PMCID: PMC7520025.
  46. Doorduijn AS, de van der Schueren MAE, van de Rest O, de Leeuw FA, Hendriksen HMA, Teunissen CE, Scheltens P, van der Flier WM, Visser M. Nutritional Status Is Associated With Clinical Progression in Alzheimer’s Disease: The NUDAD Project. J Am Med Dir Assoc. 2020 Nov 15:S1525-8610(20)30895-1. doi: 10.1016/j.jamda.2020.10.020. Epub ahead of print. PMID: 33239240.
  47. Dubbelman MA, Verrijp M, Facal D, Sánchez-Benavides G, Brown LJE, van der Flier WM, Jokinen H, Lee A, Leroi I, Lojo-Seoane C, Milošević V, Molinuevo JL, Pereiro Rozas AX, Ritchie C, Salloway S, Stringer G, Zygouris S, Dubois B, Epelbaum S, Scheltens P, Sikkes SAM. The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries. Alzheimers Dement (Amst). 2020 May 13;12(1):e12021. doi: 10.1002/dad2.12021. PMID: 32420446; PMCID: PMC7219786.
  48. Dubbelman MA, Jutten RJ, Tomaszewski Farias SE, Amariglio RE, Buckley RF, Visser PJ, Rentz DM, Johnson KA, Properzi MJ, Schultz A, Donovan N, Gatchell JR, Teunissen CE, Van Berckel BNM, Van der Flier WM, Sperling RA, Papp KV, Scheltens P, Marshall GA, Sikkes SAM; Alzheimer Disease Neuroimaging Initiative, National Alzheimer’s Coordinating Center, the Harvard Aging Brain Study, the Alzheimer Dementia Cohort. Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum. Alzheimers Res Ther. 2020 Oct 29;12(1):138. doi: 10.1186/s13195-020-00706-2. PMID: 33121534; PMCID: PMC7597034.
  49. Ducharme S, Dols A, Laforce R, Devenney E, Kumfor F, van den Stock J, Dallaire-Théroux C, Seelaar H, Gossink F, Vijverberg E, Huey E, Vandenbulcke M, Masellis M, Trieu C, Onyike C, Caramelli P, de Souza LC, Santillo A, Waldö ML, Landin-Romero R, Piguet O, Kelso W, Eratne D, Velakoulis D, Ikeda M, Perry D, Pressman P, Boeve B, Vandenberghe R, Mendez M, Azuar C, Levy R, Le Ber I, Baez S, Lerner A, Ellajosyula R, Pasquier F, Galimberti D, Scarpini E, van Swieten J, Hornberger M, Rosen H, Hodges J, Diehl-Schmid J, Pijnenburg Y. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. 2020 Jun 1;143(6):1632-1650. doi: 10.1093/brain/awaa018. PMID: 32129844.
  50. Duits FH, Wesenhagen KEJ, Ekblad L, Wolters E, Willemse EAJ; ADNI, Scheltens P, van der Flier WM, Teunissen CE, Visser PJ, Tijms BM. Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts. Alzheimers Res Ther. 2021 Jan 4;13(1):2. doi: 10.1186/s13195-020-00713-3. PMID: 33397464; PMCID: PMC7780683.
  51. Ebenau JL, Verfaillie SCJ, van den Bosch KA, Timmers T, Wesselman LMP, van Leeuwenstijn M, Tuncel H, Golla SVS, Yaqub MM, Windhorst AD, Prins ND, Barkhof F, Scheltens P, van der Flier WM, van Berckel BNM. Grey zone amyloid burden affects memory function: the SCIENCe project. Eur J Nucl Med Mol Imaging. 2020 Sep 4. doi: 10.1007/s00259-020-05012-5. Epub ahead of print. PMID: 32888039.
  52. Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, van Harten AC, Teunissen CE, Barkhof F, van den Bosch KA, van Leeuwenstijn M, Tomassen J, Braber AD, Visser PJ, Prins ND, Sikkes SAM, Scheltens P, van Berckel BNM, van der Flier WM. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. 2020 Jul 7;95(1):e46-e58. doi: 10.1212/WNL.0000000000009724. Epub 2020 Jun 10. PMID: 32522798; PMCID: PMC7371376.
  53. Exalto LG, Boomsma JMF, Babapour Mofrad R, Barkhof F, Groeneveld ON, Heinen R, Kuijf HJ, Leeuwis AE, Prins ND, Biessels GJ, Vd Flier WM; TRACE‐VCI study group. Sex differences in memory clinic patients with possible vascular cognitive impairment. Alzheimers Dement (Amst). 2020 Aug 25;12(1):e12090. doi: 10.1002/dad2.12090. PMID: 32875057; PMCID: PMC7447910.
  54. Fathy YY, Hoogers SE, Berendse HW, van der Werf YD, Visser PJ, de Jong FJ, van de Berg WDJ. Differential insular cortex sub-regional atrophy in neurodegenerative diseases: a systematic review and meta-analysis. Brain Imaging Behav. 2020 Dec;14(6):2799-2816. doi: 10.1007/s11682-019-00099-3. PMID: 31011951; PMCID: PMC7648006.
  55. Faura J, Bustamante A, Penalba A, Giralt D, Simats A, Martínez-Sáez E, Alcolea D, Fortea J, Lleó A, Teunissen CE, van der Flier WM, Ibañez L, Harari O, Cruchaga C, Hernández-Guillamón M, Delgado P, Montaner J. CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer’s Disease. J Alzheimers Dis. 2020;73(4):1585-1595. doi: 10.3233/JAD-190753. PMID: 31958084.
  56. Ferreira D, Przybelski SA, Lesnick TG, Lemstra AW, Londos E, Blanc F, Nedelska Z, Schwarz CG, Graff-Radford J, Senjem ML, Fields JA, Knopman DS, Savica R, Ferman TJ, Graff-Radford NR, Lowe VJ, Jack CR Jr, Petersen RC, Mollenhauer B, Garcia-Ptacek S, Abdelnour C, Hort J, Bonanni L, Oppedal K, Kramberger MG, Boeve BF, Aarsland D, Westman E, Kantarci K. Amyloid-β and tau biomarkers and clinical phenotype in dementia with Lewy bodies. 2020 Sep 28:10.1212/WNL.0000000000010943. doi: 10.1212/WNL.0000000000010943. Epub ahead of print. PMID: 32989106.
  57. Ferro DA, van den Brink H, Exalto LG, Boomsma JMF, Barkhof F, Prins ND, van der Flier WM, Biessels GJ. Author response: Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. Neurology. 2020 Feb 18;94(7):330. doi: 10.1212/WNL.0000000000008974. PMID: 32066642.
  58. Ferro D, van den Brink H, Amier R, van Buchem M, de Bresser J, Bron E, Brunner-La Rocca HP, Hooghiemstra A, Marcks N, van Rossum A, Biessels GJ; Heart- Brain Connection Consortium. Cerebral cortical microinfarcts: A novel MRI marker of vascular brain injury in patients with heart failure. Int J Cardiol. 2020 Jul 1;310:96-102. doi: 10.1016/j.ijcard.2020.04.032. Epub 2020 Apr 13. PMID: 32331904.
  59. Fieldhouse JLP, Doorduijn AS, de Leeuw FA, Verhaar BJH, Koene T, Wesselman LMP, Schueren MV, Visser M, Rest OV, Scheltens P, Kester MI, Flier WMV. A Suboptimal Diet is Associated with Poorer Cognition: The NUDAD Project. 2020 Mar 6;12(3):703. doi: 10.3390/nu12030703. PMID: 32155876; PMCID: PMC7146357.
  60. Franzmeier N, Neitzel J, Rubinski A, Smith R, Strandberg O, Ossenkoppele R, Hansson O, Ewers M; Alzheimer’s Disease Neuroimaging Initiative (ADNI). Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease. Nat Commun. 2020 Jan 17;11(1):347. doi: 10.1038/s41467-019-14159-1. PMID: 31953405; PMCID: PMC6969065.
  61. Franzmeier N, Dewenter A, Frontzkowski L, Dichgans M, Rubinski A, Neitzel J, Smith R, Strandberg O, Ossenkoppele R, Buerger K, Duering M, Hansson O, Ewers M. Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer’s disease. Sci Adv. 2020 Nov 27;6(48):eabd1327. doi: 10.1126/sciadv.abd1327. PMID: 33246962; PMCID: PMC7695466.
  62. Frisoni GB, Molinuevo JL, Altomare D, Carrera E, Barkhof F, Berkhof J, Delrieu J, Dubois B, Kivipelto M, Nordberg A, Schott JM, van der Flier WM, Vellas B, Jessen F, Scheltens P, Ritchie C. Precision prevention of Alzheimer’s and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. Alzheimers Dement. 2020 Oct;16(10):1457-1468. doi: 10.1002/alz.12132. Epub 2020 Aug 20. PMID: 32815289.
  63. Galasko D, Scheltens P. A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future. Alzheimers Res Ther. 2020 May 30;12(1):67. doi: 10.1186/s13195-020-00629-y. PMID: 32473646; PMCID: PMC7260791.
  64. Golla SS, Wolters EE, Timmers T, Ossenkoppele R, van der Weijden CW, Scheltens P, Schwarte L, Mintun MA, Devous MD Sr, Schuit RC, Windhorst AD, Lammertsma AA, Yaqub M, van Berckel BN, Boellaard R. Parametric methods for [18F]flortaucipir PET. J Cereb Blood Flow Metab. 2020 Feb;40(2):365-373. doi: 10.1177/0271678X18820765. Epub 2018 Dec 20. PMID: 30569813; PMCID: PMC7044757.
  65. Gregory S, Bunnik EM, Callado AB, Carrie I, De Boer C, Duffus J, Fauria K, Forster S, Gove D, Knezevic I, Laquidain A, Pennetier D, Saunders S, Sparks S, Rice J, Ritchie CW, Milne R. Involving research participants in a pan-European research initiative: the EPAD participant panel experience. Res Involv Engagem. 2020 Oct 15;6:62. doi: 10.1186/s40900-020-00236-z. PMID: 33088590; PMCID: PMC7566117.
  66. Groot C, Yeo BTT, Vogel JW, Zhang X, Sun N, Mormino EC, Pijnenburg YAL Miller BL, Rosen HJ, La Joie R, Barkhof F, Scheltens P, van der Flier WM, Rabinovici GD, Ossenkoppele R. Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. 2020 Sep 22;95(12):e1672-e1685. doi: 10.1212/WNL.0000000000010362. Epub 2020 Jul 16. PMID: 32675078; PMCID: PMC7713727.
  67. Groot C, Doré V, Robertson J, Burnham SC, Savage G, Ossenkoppele R, Rowe CC, Villemagne VL. Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid-β-negative cognitively normal individuals. Neurobiol Aging. 2020 Oct 1;97:41-48. doi: 10.1016/j.neurobiolaging.2020.09.017. Epub ahead of print. PMID: 33130455.
  68. Gupta VB, Chitranshi N, den Haan J, Mirzaei M, You Y, Lim JK, Basavarajapp D, Godinez A, Di Angelantonio S, Sachdev P, Salekdeh GH, Bouwman F, Graham S, Gupta V. Retinal changes in Alzheimer’s disease- integrated prospects of imaging, functional and molecular advances. Prog Retin Eye Res. 2020 Sep 2:100899. doi: 10.1016/j.preteyeres.2020.100899. Epub ahead of print. PMID: 32890742.
  69. Hagenbeek FA, Pool R, van Dongen J, Draisma HHM, Jan Hottenga J, Willemsen G, Abdellaoui A, Fedko IO, den Braber A, Visser PJ, de Geus EJCN, Willems van Dijk K, Verhoeven A, Suchiman HE, Beekman M, Slagboom PE, van Duijn CM; BBMRI Metabolomics Consortium, Harms AC, Hankemeier T, Bartels M, Nivard MG, Boomsma DI. Heritability estimates for 361 blood metabolites across 40 genome-wide association studies. Nat Commun. 2020 Jan 7;11(1):39. doi: 10.1038/s41467-019-13770-6. Erratum in: Nat Commun. 2020 Mar 31;11(1):1702. PMID: 31911595; PMCID: PMC6946682.
    Hagenbeek FA, Pool R, van Dongen J, Draisma HM, Jan Hottenga J, Willemsen G, Abdellaoui A, Fedko IO, den Braber A, Visser PJ, de Geus EJCN, Willems van Dijk K, Verhoeven A, Suchiman HE, Beekman M, Slagboom PE, van Duijn CM; BBMRI Metabolomics Consortium, Harms AC, Hankemeier T, Bartels M, Nivard MG, Boomsma DI. Author Correction: Heritability estimates for 361 blood metabolites across 40 genome-wide association studies. Nat Commun. 2020 Mar 31;11(1):1702. doi: 10.1038/s41467-020-15276-y. Erratum for: Nat Commun. 2020 Jan 7;11(1):39. PMID: 32235831; PMCID: PMC7109051.
  70. Hallett M, de Haan W, Deco G, Dengler R, Di Iorio R, Gallea C, Gerloff C, Grefkes C, Helmich RC, Kringelbach ML, Miraglia F, Rektor I, Strýček O, Vecchio F, Volz LJ, Wu T, Rossini PM. Human brain connectivity: Clinical applications for clinical neurophysiology. Clin Neurophysiol. 2020 Jul;131(7):1621-1651. doi: 10.1016/j.clinph.2020.03.031. Epub 2020 Apr 21. PMID: 32417703.
  71. Hanes J, Kovac A, Kvartsberg H, Kontsekova E, Fialova L, Katina S, Kovacech B, Stevens E, Hort J, Vyhnalek M, Boonkamp L, Novak M, Zetterberg H, Hansson O, Scheltens P, Blennow K, Teunissen CE, Zilka N. Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. 2020 Dec 1;95(22):e3026-e3035. doi: 10.1212/WNL.0000000000010814. Epub 2020 Sep 24. PMID: 32973122.
  72. Hanseeuw BJ, Scott MR, Sikkes SAM, Properzi M, Gatchel JR, Salmon E, Marshall GA, Vannini P; Alzheimer’s Disease Neuroimaging Initiative. Evolution of anosognosia in alzheimer’s disease and its relationship to amyloid. Ann Neurol. 2020 Feb;87(2):267-280. doi: 10.1002/ana.25649. Epub 2019 Dec 5. PMID: 31750553; PMCID: PMC6980336
  73. Harrison Commentary: Composite cognitive and functional measures for early stage Alzheimer’s disease trials. Cog Beh Assess. May 15 2020. https://doi.org/10.1002/dad2.12009
  74. Harrison, J. E. (In press) Keith Andrew Wesnes in memorium. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring.
  75. Heeman F, Hendriks J, Lopes Alves I, Ossenkoppele R, Tolboom N, van Berckel BNM, Lammertsma AA, Yaqub M; AMYPAD Consortium. [11C]PIB amyloid quantification: effect of reference region selection. EJNMMI Res. 2020 Oct 19;10(1):123. doi: 10.1186/s13550-020-00714-1. PMID: 33074395; PMCID: PMC7572969.
  76. Heinen R, Groeneveld ON, Barkhof F, de Bresser J, Exalto LG, Kuijf HJ, Prins ND, Scheltens P, van der Flier WM, Biessels GJ; TRACE‐VCI study group. Small vessel disease lesion type and brain atrophy: The role of co-occurring amyloid. Alzheimers Dement (Amst). 2020 Jul 13;12(1):e12060. doi: 10.1002/dad2.12060. PMID: 32695872; PMCID: PMC7364862.
  77. Hijazi S, Heistek TS, Scheltens P, Neumann U, Shimshek DR, Mansvelder HD, Smit AB, van Kesteren RE. Early restoration of parvalbumin interneuron activity prevents memory loss and network hyperexcitability in a mouse model of Alzheimer’s disease. Mol Psychiatry. 2020 Dec;25(12):3380-3398. doi: 10.1038/s41380-019-0483-4. Epub 2019 Aug 20. PMID: 31431685.
  78. Hofer E, Roshchupkin GV, Adams HHH, Knol MJ, Lin H, Li S, Zare H, Ahmad S, Armstrong NJ, Satizabal CL, Bernard M, Bis JC, Gillespie NA, Luciano M, Mishra A, Scholz M, Teumer A, Xia R, Jian X, Mosley TH, Saba Y, Pirpamer L, Seiler S, Becker JT, Carmichael O, Rotter JI, Psaty BM, Lopez OL, Amin N, van der Lee SJ, Yang Q, Himali JJ, Maillard P, Beiser AS, DeCarli C, Karama S, Lewis L, Harris M, Bastin ME, Deary IJ, Veronica Witte A, Beyer F, Loeffler M, Mather KA, Schofield PR, Thalamuthu A, Kwok JB, Wright MJ, Ames D, Trollor J, Jiang J, Brodaty H, Wen W, Vernooij MW, Hofman A, Uitterlinden AG, Niessen WJ, Wittfeld K, Bülow R, Völker U, Pausova Z, Bruce Pike G, Maingault S, Crivello F, Tzourio C, Amouyel P, Mazoyer B, Neale MC, Franz CE, Lyons MJ, Panizzon MS, Andreassen OA, Dale AM, Logue M, Grasby KL, Jahanshad N, Painter JN, Colodro-Conde L, Bralten J, Hibar DP, Lind PA, Pizzagalli F, Stein JL, Thompson PM, Medland SE; ENIGMA consortium, Sachdev PS, Kremen WS, Wardlaw JM, Villringer A, van Duijn CM, Grabe HJ, Longstreth WT Jr, Fornage M, Paus T, Debette S, Arfan Ikram M, Schmidt H, Schmidt R, Seshadri S. Genetic correlations and genome-wide associations of cortical structure in general population samples of 22,824 adults. Nat Commun. 2020 Sep 22;11(1):4796. doi: 10.1038/s41467-020-18367-y. PMID: 32963231; PMCID: PMC7508833.
  79. Holstege H, Hulsman M, van der Lee SJ, van den Akker EB. The Role of Age- Related Clonal Hematopoiesis in Genetic Sequencing Studies. Am J Hum Genet. 2020 Sep 3;107(3):575-576. doi: 10.1016/j.ajhg.2020.07.011. PMID: 32888507; PMCID: PMC7477003.
  80. Hong S, Prokopenko D, Dobricic V, Kilpert F, Bos I, Vos SJB, Tijms BM, Andreasson U, Blennow K, Vandenberghe R, Cleynen I, Gabel S, Schaeverbeke J, Scheltens P, Teunissen CE, Niemantsverdriet E, Engelborghs S, Frisoni G, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L; Alzheimer’s Disease Neuroimaging Initiative (ADNI), Kettunen P, Wallin A, Lleó A, Sala I, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Dobson RJB, Legido-Quigley C, Sleegers K, Van Broeckhoven C, Ten Kate M, Barkhof F, Zetterberg H, Lovestone S, Streffer J, Wittig M, Franke A, Tanzi RE, Visser PJ, Bertram L. Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Transl Psychiatry. 2020 Nov 22;10(1):403. doi: 10.1038/s41398-020-01074-z. PMID: 33223526; PMCID: PMC7680793.
  81. Huber M, Beyer L, Prix C, Schönecker S, Palleis C, Rauchmann BS, Morbelli S, Chincarini A, Bruffaerts R, Vandenberghe R, Van Laere K, Kramberger MG, Trost M, Grmek M, Garibotto V, Nicastro N, Frisoni GB, Lemstra AW, van der Zande J, Pilotto A, Padovani A, Garcia-Ptacek S, Savitcheva I, Ochoa-Figueroa MA, Davidsson A, Camacho V, Peira E, Arnaldi D, Bauckneht M, Pardini M, Sambuceti G, Vöglein J, Schnabel J, Unterrainer M, Perneczky R, Pogarell O, Buerger K, Catak C, Bartenstein P, Cumming P, Ewers M, Danek A, Levin J, Aarsland D, Nobili F, Rominger A, Brendel M. Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. Mov Disord. 2020 Apr;35(4):595-605. doi: 10.1002/mds.27945. Epub 2019 Dec 16. PMID: 31840326.
  82. Iaccarino L, La Joie R, Edwards L, Strom A, Schonhaut DR, Ossenkoppele R, Pham J, Mellinger T, Janabi M, Baker SL, Soleimani-Meigooni D, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD. Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer’s Disease Continuum. Cereb Cortex. 2020 Aug 18:bhaa184. doi: 10.1093/cercor/bhaa184. Epub ahead of print. PMID: 32808011.
  83. Ingala S, Mazzai L, Sudre CH, Salvadó G, Brugulat-Serrat A, Wottschel V, Falcon C, Operto G, Tijms B, Gispert JD, Molinuevo JL, Barkhof F; ALFA Study. The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals. Neurobiol Aging. 2020 Nov;95:104-114. doi: 10.1016/j.neurobiolaging.2020.06.015. Epub 2020 Jun 29. PMID: 32791423.
    Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, Hägg S, Athanasiu L, Voyle N, Proitsi P, Witoelar A, Stringer S, Aarsland D, Almdahl IS, Andersen F, Bergh S, Bettella F, Bjornsson S, Brækhus A, Bråthen G, de Leeuw C, Desikan RS, Djurovic S, Dumitrescu L, Fladby T, Hohman TJ, Jonsson PV, Kiddle SJ, Rongve A, Saltvedt I, Sando SB, Selbæk G, Shoai M, Skene NG, Snaedal J, Stordal E, Ulstein ID, Wang Y, White LR, Hardy J, Hjerling-Leffler J, Sullivan PF, van der Flier WM, Dobson R, Davis LK, Stefansson H, Stefansson K, Pedersen NL, Ripke S, Andreassen OA, Posthuma D. Author Correction: Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat Genet. 2020 Mar;52(3):354. doi: 10.1038/s41588-019-0573-x. Erratum for: Nat Genet. 2019 Mar;51(3):404-413. PMID: 32029921.
  84. Janssen O, Vos SJB, Handels R, Vermunt L, Verheij R, Verhey FRJ, van Hout H, Visser PJ, Joling KJ. Duration of Care Trajectories in Persons With Dementia Differs According to Demographic and Clinical Characteristics. J Am Med Dir Assoc. 2020 Aug;21(8):1102-1107.e6. doi: 10.1016/j.jamda.2020.01.008. Epub 2020 Feb 27. PMID: 32113914.
  85. Janssen O, Vos SJB, García-Negredo G, Tochel C, Gustavsson A, Smith M, Ly A, Nelson M, Baldwin H, Sudlow C, Bexelius C, Jindra C, Vaci N, Bauermeister S, Gallacher J, Ponjoan A, Dufouil C, Garre Olmo J, Pedersen L, Skoog I, Hottgenroth A, Visser PJ, van der Lei J, Diaz C. Real-world evidence in Alzheimer’s disease: The ROADMAP Data Cube. Alzheimers Dement. 2020 Mar;16(3):461-471. doi: 10.1016/j.jalz.2019.09.087. Epub 2020 Jan 6. PMID: 32157788.
  86. Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, Rabin L, Rentz DM, Rodriguez-Gomez O, Saykin AJ, Sikkes SAM, Smart CM, Wolfsgruber S, Wagner M. The characterisation of subjective cognitive decline. Lancet Neurol. 2020 Mar;19(3):271-278. doi: 10.1016/S1474-4422(19)30368-0. Epub 2020 Jan 17. PMID: 31958406; PMCID: PMC7062546.
  87. Jokinen H, Koikkalainen J, Laakso HM, Melkas S, Nieminen T, Brander A, Korvenoja A, Rueckert D, Barkhof F, Scheltens P, Schmidt R, Fazekas F, Madureira S, Verdelho A, Wallin A, Wahlund LO, Waldemar G, Chabriat H, Hennerici M, O’Brien J, Inzitari D, Lötjönen J, Pantoni L, Erkinjuntti T. Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline. Stroke. 2020 Jan;51(1):170-178. doi: 10.1161/STROKEAHA.119.026170. Epub 2019 Nov 8. PMID: 31699021; PMCID: PMC6924941.
  88. Joling KJ, Janssen O, Francke AL, Verheij RA, Lissenberg-Witte BI, Visser PJ, van Hout HPJ. Time from diagnosis to institutionalization and death in people with dementia. Alzheimers Dement. 2020 Apr;16(4):662-671. doi: 10.1002/alz.12063. Epub 2020 Feb 18. PMID: 32072728.
  89. Jones E, Hummerich H, Viré E, Uphill J, Dimitriadis A, Speedy H, Campbell T, Norsworthy P, Quinn L, Whitfield J, Linehan J, Jaunmuktane Z, Brandner S, Jat P, Nihat A, How Mok T, Ahmed P, Collins S, Stehmann C, Sarros S, Kovacs GG, Geschwind MD, Golubjatnikov A, Frontzek K, Budka H, Aguzzi A, Karamujić-Čomić H, van der Lee SJ, Ibrahim-Verbaas CA, van Duijn CM, Sikorska B, Golanska E, Liberski PP, Calero M, Calero O, Sanchez-Juan P, Salas A, Martinón-Torres F, Bouaziz-Amar E, Haïk S, Laplanche JL, Brandel JP, Amouyel P, Lambert JC, Parchi P, Bartoletti-Stella A, Capellari S, Poleggi A, Ladogana A, Pocchiari M, Aneli S, Matullo G, Knight R, Zafar S, Zerr I, Booth S, Coulthart MB, Jansen GH, Glisic K, Blevins J, Gambetti P, Safar J, Appleby B, Collinge J, Mead S. Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol. 2020 Oct;19(10):840-848. doi: 10.1016/S1474-4422(20)30273-8. Epub 2020 Sep 16. PMID:32949544.
  90. Jongs N, Jagesar R, van Haren NEM, Penninx BWJH, Reus L, Visser PJ, van der Wee NJA, Koning IM, Arango C, Sommer IEC, Eijkemans MJC, Vorstman JA, Kas MJ. A framework for assessing neuropsychiatric phenotypes by using smartphone-based location data. Transl Psychiatry. 2020 Jul 1;10(1):211. doi: 10.1038/s41398-020-00893-4. PMID: 32612118; PMCID: PMC7329884.
  91. Jutten RJ, Harrison JE, Brunner AJ, Vreeswijk R, van Deelen RAJ, de Jong FJ, Opmeer EM, Ritchie CW, Aleman A, Scheltens P, Sikkes SAM. The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort. Alzheimers Dement (N Y). 2020 Apr 17;6(1):e12020. doi: 10.1002/trc2.12020. PMID: 32313832; PMCID:PMC7164406.
  92. Jutten RJ, Grandoit E, Foldi NS, Sikkes SAM, Jones RN, Choi SE, Lamar ML, Louden DKN, Rich J, Tommet D, Crane PK, Rabin LA. Lower practice effects as a marker of cognitive performance and dementia risk: A literature review. Alzheimers Dement (Amst). 2020 Jul 9;12(1):e12055. doi: 10.1002/dad2.12055. PMID: 32671181; PMCID: PMC7346865.
  93. Jutten RJ, Sikkes SAM, Amariglio RE, Buckley RF, Properzi MJ, Marshall GA, Rentz DM, Johnson KA, Teunissen CE, Van Berckel BNM, Van der Flier WM, Scheltens P, Sperling RA, Papp KV; Alzheimer Disease Neuroimaging Initiative; National Alzheimer’s Coordinating Center, the Harvard Aging Brain Study, and the Alzheimer Dementia Cohort. Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer’s Disease. J Int Neuropsychol Soc. 2020 Oct 13:1-13. doi: 10.1017/S1355617720000934. Epub ahead of print. PMID:33046162.
  94. Kivipelto M, Mangialasche F, Snyder HM, Allegri R, Andrieu S, Arai H, Baker L, Belleville S, Brodaty H, Brucki SM, Calandri I, Caramelli P, Chen C, Chertkow H, Chew E, Choi SH, Chowdhary N, Crivelli L, Torre R, Du Y, Dua T, Espeland M, Feldman HH, Hartmanis M, Hartmann T, Heffernan M, Henry CJ, Hong CH, Håkansson K, Iwatsubo T, Jeong JH, Jimenez-Maggiora G, Koo EH, Launer LJ, Lehtisalo J, Lopera F, Martínez-Lage P, Martins R, Middleton L, Molinuevo JL, Montero-Odasso M, Moon SY, Morales-Pérez K, Nitrini R, Nygaard HB, Park YK, Peltonen M, Qiu C, Quiroz YT, Raman R, Rao N, Ravindranath V, Rosenberg A, Sakurai T, Salinas RM, Scheltens P, Sevlever G, Soininen H, Sosa AL, Suemoto CK, Tainta-Cuezva M, Velilla L, Wang Y, Whitmer R, Xu X, Bain LJ, Solomon A, Ngandu T, Carrillo MC. World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimers Dement. 2020 Jul;16(7):1078-1094. doi: 10.1002/alz.12123. Epub 2020 Jul 5. PMID: 32627328.
  95. Kleineidam L, Chouraki V, Próchnicki T, van der Lee SJ, Madrid-Márquez L, Wagner-Thelen H, Karaca I, Weinhold L, Wolfsgruber S, Boland A, Martino Adami PV, Lewczuk P, Popp J, Brosseron F, Jansen IE, Hulsman M, Kornhuber J, Peters O, Berr C, Heun R, Frölich L, Tzourio C, Dartigues JF, Hüll M, Espinosa A, Hernández I, de Rojas I, Orellana A, Valero S, Stringa N, van Schoor NM, Huisman M, Scheltens P; Alzheimer’s Disease Neuroimaging Initiative (ADNI), Rüther E, Deleuze JF, Wiltfang J, Tarraga L, Schmid M, Scherer M, Riedel-Heller S, Heneka MT, Amouyel P, Jessen F, Boada M, Maier W, Schneider A, González-Pérez A, van der Flier WM, Wagner M, Lambert JC, Holstege H, Sáez ME, Latz E, Ruiz A, Ramirez PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathol. 2020 Jun;139(6):1025-1044. doi: 10.1007/s00401-020-02138-6. Epub 2020 Mar 12. PMID:32166339; PMCID: PMC7244617.
  96. Knol MJ, Lu D, Traylor M, Adams HH, Rafael J Romero J, Smith AV, Fornage M, Hofer E, Liu J, Hostettler IC, Luciano M, Trompet S, Giese AK, Hilal S, van den Akker EB, Vojinovic D, Li S, Sigurdsson S, van der Lee SJ, Jack CR Jr, Wilson D, Yilmaz P, Satizabal CL, Liewald DCM, van der Grond J, Chen C, Saba Y, van der Lugt A, Bastin ME, Windham BG, Cheng CY, Pirpamer L, Kantarci K, Himali JJ, Yang Q, Morris Z, Beiser AS, Tozer DJ, Vernooij MW, Amin N, Beekman M, Koh JY, Stott DJ, Houlden H, Schmidt R, Gottesman RF, MacKinnon AD, DeCarli C, Gudnason V, Deary IJ, van Duijn CM, Slagboom PE, Wong TY, Rost NS, Jukema JW, Mosley TH, Werring DJ, Schmidt H, Wardlaw JM, Ikram MA, Seshadri S, Launer LJ, Markus HS; Alzheimer’s Disease Neuroimaging Initiative. Association of common genetic variants with brain microbleeds: A Genome-wide Association Study. Neurology. 2020 Sep 10:10.1212/WNL.0000000000010852. doi: 10.1212/WNL.0000000000010852. Epub ahead of print. PMID: 32913026.
  97. Konijnenberg E, Tijms BM, Gobom J, Dobricic V, Bos I, Vos S, Tsolaki M, Verhey F, Popp J, Martinez-Lage P, Vandenberghe R, Lleó A, Frölich L, Lovestone S, Streffer J, Bertram L, Blennow K, Teunissen CE, Veerhuis R, Smit AB, Scheltens P, Zetterberg H, Visser PJ. APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease. Alzheimers Res Ther. 2020 May 27;12(1):65. doi: 10.1186/s13195-020-00628-z. PMID: 32460813; PMCID: PMC7254647.
  98. Leeuwis AE, Hooghiemstra AM, Bron EE, Kuipers S, Oudeman EA, Kalay T, Brunner-La Rocca HP, Kappelle LJ, van Oostenbrugge RJ, Greving JP, Niessen WJ, van Buchem MA, van Osch MJP, van Rossum AC, Prins ND, Biessels GJ, Barkhof F; Heart–Brain Connection consortium, van der Flier WM. Cerebral blood flow and cognitive functioning in patients with disorders along the heart-brain axis: Cerebral blood flow and the heart-brain axis. Alzheimers Dement (N Y). 2020 May 12;6(1):e12034. doi: 10.1002/trc2.12034. PMID: 32995468; PMCID: PMC7507476.
  99. Lee JS, Lee H, Park S, Choe Y, Park YH, Cheon BK, Hahn A, Ossenkoppele R, Kim HJ, Kim S, Yoo H, Jang H, Cho SH, Kim SJ, Kim JP, Jung YH, Park KC, DeCarli C, Weiner MW, Na DL, Seo SW. Association between APOE ε2 and Aβ burden in patients with Alzheimer- and vascular-type cognitive impairment. 2020 Oct 27;95(17):e2354-e2365. doi: 10.1212/WNL.0000000000010811. Epub 2020 Sep 14. PMID: 32928967; PMCID: PMC7682916.
  100. Legdeur N, Tijms BM, Konijnenberg E, den Braber A, Ten Kate M, Sudre CH, Tomassen J, Badissi M, Yaqub M, Barkhof F, van Berckel BN, Boomsma DI, Scheltens P, Holstege H, Maier AB, Visser PJ. Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60-102 Years. J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1609-1617. doi: 10.1093/gerona/glz180. PMID: 31411322; PMCID: PMC7494041.
  101. Legdeur N, Badissi M, Yaqub M, Beker N, Sudre CH, Ten Kate M, Gordon MF, Novak G, Barkhof F, van Berckel BNM, Holstege H, Muller M, Scheltens P, Maier AB, Visser PJ. What determines cognitive functioning in the oldest-old? The EMIF-AD 90+ Study. J Gerontol B Psychol Sci Soc Sci. 2020 Sep 8:gbaa152. doi: 10.1093/geronb/gbaa152. Epub ahead of print. PMID: 32898275.
  102. Leijenaar JF, Groot C, Sudre CH, Bergeron D, Leeuwis AE, Cardoso MJ, Carrasco FP, Laforce R Jr, Barkhof F, van der Flier WM, Scheltens P, Prins ND, Ossenkoppele R. Comorbid amyloid-β pathology affects clinical and imaging features in VCD. Alzheimers Dement. 2020 Feb;16(2):354-364. doi: 10.1016/j.jalz.2019.08.190. Epub 2020 Jan 4. PMID: 31786129.
  103. Leijenaar JF, Groeneveld GJ, Klaassen ES, Leeuwis AE, Scheltens P, Weinstein HC, van Gerven JMA, Barkhof F, van der Flier WM, Prins ND. Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI. Alzheimers Res Ther. 2020 Jan 7;12(1):10. doi: 10.1186/s13195-019-0567-z. PMID: 31910895; PMCID: PMC6947990.
  104. Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, Ohlsson T, Jögi J, Palmqvist S, Mattsson-Carlgren N, Strandberg O, Stomrud E, Hansson O. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurol. 2020 Aug 1;77(8):955-965. doi: 10.1001/jamaneurol.2020.0989. PMID: 32391858; PMCID: PMC7215644.
  105. Leuzy A, Lilja J, Buckley CJ, Ossenkoppele R, Palmqvist S, Battle M, Farrar G, Thal DR, Janelidze S, Stomrud E, Strandberg O, Smith R, Hansson O. Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load. Neurology. 2020 Nov 24;95(21):e2834-e2844. doi: 10.1212/WNL.0000000000011031. Epub 2020 Oct 19. PMID: 33077542.
  106. Linthorst J, Meert W, Hestand MS, Korlach J, Vermeesch JR, Reinders MJT, Holstege H. Extreme enrichment of VNTR-associated polymorphicity in human subtelomeres: genes with most VNTRs are predominantly expressed in the brain. Transl Psychiatry. 2020 Nov 2;10(1):369. doi: 10.1038/s41398-020-01060-5. PMID: 33139705; PMCID: PMC7608644.
  107. Lopes Alves I, Collij LE, Altomare D, Frisoni GB, Saint-Aubert L, Payoux P, Kivipelto M, Jessen F, Drzezga A, Leeuwis A, Wink AM, Visser PJ, van Berckel BNM, Scheltens P, Gray KR, Wolz R, Stephens A, Gismondi R, Buckely C, Gispert JD, Schmidt M, Ford L, Ritchie C, Farrar G, Barkhof F, Molinuevo JL; AMYPAD Consortium. Quantitative amyloid PET in Alzheimer’s disease: the AMYPAD prognostic and natural history study. Alzheimers Dement. 2020 May;16(5):750-758. doi: 10.1002/alz.12069. Epub 2020 Apr 12. PMID: 32281303.
  108. Marizzoni M, Ferrari C, Babiloni C, Albani D, Barkhof F, Cavaliere L, Didic M, Forloni G, Fusco F, Galluzzi S, Hensch T, Jovicich J, Marra C, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Ranjeva JP, Ribaldi F, Rolandi E, Rossini PM, Salvatore M, Soricelli A, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB. CSF cutoffs for MCI due to AD depend on APOEε4 carrier status. Neurobiol Aging. 2020 May;89:55-62. doi: 10.1016/j.neurobiolaging.2019.12.019. Epub 2019 Dec 30. PMID: 32029236.
  109. Marshall GA, Sikkes SAM, Amariglio RE, Gatchel JR, Rentz DM, Johnson KA, Langford O, Sun CK, Donohue MC, Raman R, Aisen PS, Sperling RA, Galasko DR; Full listing of A4 Study team and site personnel available at A4STUDY.org. Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. Alzheimers Dement (Amst). 2020 Oct 30;12(1):e12118. doi: 10.1002/dad2.12118. PMID: 33163609; PMCID: PMC7596668.
  110. Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, Zetterberg H, Rosen HJ, Rabinovici G, Chai X, Blennow K, Dage JL, Stomrud E, Smith R, Palmqvist S, Hansson O. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease. Sci Adv. 2020 Apr 15;6(16):eaaz2387. doi: 10.1126/sciadv.aaz2387. PMID: 32426454; PMCID: PMC7159908.
  111. Mok VCT, Pendlebury S, Wong A, Alladi S, Au L, Bath PM, Biessels GJ, Che C, Cordonnier C, Dichgans M, Dominguez J, Gorelick PB, Kim S, Kwok T, Greenber SM, Jia J, Kalaria R, Kivipelto M, Naegandran K, Lam LCW, Lam BYK, Lee ATC, Markus HS, O’Brien J, Pai MC, Pantoni L, Sachdev P, Skoog I, Smith EE, Srikant V, Suh GH, Wardlaw J, Ko H, Black SE, Scheltens P. Tackling challenges in car of Alzheimer’s disease and other dementias amid the COVID-19 pandemic, now and in the future. Alzheimers Dement. 2020 Nov;16(11):1571-1581. doi: 10.1002/alz.12143. Epub 2020 Aug 12. PMID: 32789951; PMCID: PMC7436526.
  112. Muurling M, Rhodius-Meester HFM, Pärkkä J, van Gils M, Frederiksen KS, Bruun M, Hasselbalch SG, Soininen H, Herukka SK, Hallikainen M, Teunissen CE, Visser PJ, Scheltens P, van der Flier WM, Mattila J, Lötjönen J, de Boer C. Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. J Alzheimers Dis. 2020;76(3):1061-1070. doi: 10.3233/JAD-200225. PMID: 32597806; PMCID: PMC7505008.
  113. Orme T, Hernandez D, Ross OA, Kun-Rodrigues C, Darwent L, Shepherd CE, Parkkinen L, Ansorge O, Clark L, Honig LS, Marder K, Lemstra A, Rogaeva E, S George-Hyslop P, Londos E, Zetterberg H, Morgan K, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, Trojanowski JQ, Serrano GE, Beach TG, Lesage S, Galasko D, Masliah E, Santana I, Pastor P, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, Ferman TJ, Escott-Price V, Graff-Radford N, Cairns NJ, Morris JC, Pickering-Brown S, Mann D, Halliday G, Stone DJ, Dickson DW, Hardy J, Singleton A, Guerreiro R, Bras J. Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathol Commun. 2020 Jan 29;8(1):5. doi: 10.1186/s40478-020-0879-z. PMID: 31996268; PMCID: PMC6990558.
  114. Ossenkoppele R, Lyoo CH, Sudre CH, van Westen D, Cho H, Ryu YH, Choi JY, Smith R, Strandberg O, Palmqvist S, Westman E, Tsai R, Kramer J, Boxer AL, Gorno-Tempini ML, La Joie R, Miller BL, Rabinovici GD, Hansson O. Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease. Alzheimers Dement. 2020 Feb;16(2):335-344. doi: 10.1016/j.jalz.2019.08.201. Epub 2020 Jan 4. PMID: 31672482; PMCID: PMC7012375.
  115. Ossenkoppele R, Lyoo CH, Jester-Broms J, Sudre CH, Cho H, Ryu YH, Choi JY, Smith R, Strandberg O, Palmqvist S, Kramer J, Boxer AL, Gorno-Tempini ML, Miller BL, La Joie R, Rabinovici GD, Hansson O. Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurol. 2020 May 1;77(5):632-642. doi: 10.1001/jamaneurol.2019.5154. PMID: 32091549; PMCID: PMC7042808.
  116. Ossenkoppele R, Leuzy A, Cho H, Sudre CH, Strandberg O, Smith R, Palmqvist S, Mattsson-Carlgren N, Olsson T, Jögi J, Stormrud E, Ryu YH, Choi JY; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD research group, Boxer AL, Gorno-Tempini ML, Miller BL, Soleimani-Meigooni D, Iaccarino L, La Joie R, Borroni E, Klein G, Pontecorvo MJ, Devous MD Sr, Villeneuve S, Lyoo CH, Rabinovici GD, Hansson O. The impact of demographic, clinical, genetic, and imaging variables on tau PET status. Eur J Nucl Med Mol Imaging. 2020 Nov 19. doi: 10.1007/s00259-020-05099-w. Epub ahead of print. PMID: 33215319.
  117. Overbeek JM, Korten N, Gossink F, Fieldhouse J, van de Beek M, Reus L, Dols A, Pijnenburg Y, Schouws S. The Value of Neuropsychological Assessment in the Differentiation Between Behavioral Variant Frontotemporal Dementia and Late- Onset Psychiatric Disorders. J Clin Psychiatry. 2020 Feb 4;81(1):19m12811. doi: 10.4088/JCP.19m12811. PMID: 32023367.
  118. Pereira JB, Janelidze S, Ossenkoppele R, Kvartsberg H, Brinkmalm A, Mattsson-Carlgren N, Stomrud E, Smith R, Zetterberg H, Blennow K, Hansson O. Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease. Brain. 2020 Dec 5:awaa395. doi: 10.1093/brain/awaa395. Epub ahead of print. PMID: 33279949.
  119. Perera G, Rijnbeek PR, Alexander M, Ansell D, Avillach P, Duarte-Salles T, Gordon MF, Lapi F, Mayer MA, Pasqua A, Pedersen L, van Der Lei J, Visser PJ, Stewart R. Vascular and metabolic risk factor differences prior to dementia diagnosis: a multidatabase case-control study using European electronic health records. BMJ Open. 2020 Nov 14;10(11):e038753. doi: 10.1136/bmjopen-2020-038753. PMID: 33191253; PMCID: PMC7668358.
  120. Pitkänen J, Koikkalainen J, Nieminen T, Marinkovic I, Curtze S, Sibolt G, Jokinen H, Rueckert D, Barkhof F, Schmidt R, Pantoni L, Scheltens P, Wahlund LO, Korvenoja A, Lötjönen J, Erkinjuntti T, Melkas S. Evaluating severity of white matter lesions from computed tomography images with convolutional neural network. 2020 Oct;62(10):1257-1263. doi: 10.1007/s00234-020-02410-2. Epub 2020 Apr 13. PMID: 32281028; PMCID: PMC7478948.
  121. Poos JM, Jiskoot LC, Leijdesdorff SMJ, Seelaar H, Panman JL, van der Ende EL, Mol MO, Meeter LHH, Pijnenburg YAL, Donker Kaat L, de Jong FJ, van Swieten JC, Papma JM, van den Berg E. Cognitive profiles discriminate between genetic variants of behavioral frontotemporal dementia. J Neurol. 2020 Jun;267(6):1603-1612. doi: 10.1007/s00415-020-09738-y. Epub 2020 Feb 12. Erratum sin: J Neurol. 2020 Mar 26;: PMID: 32052166; PMCID: PMC7293665.
    Poos JM, Jiskoot LC, Leijdesdorff SMJ, Seelaar H, Panman JL, van der Ende EL, Mol MO, Meeter LHH, Pijnenburg YAL, Donker Kaat L, de Jong FJ, van Swieten JC, Papma JM, van den Berg E. Correction to: Cognitive profiles discriminate between genetic variants of behavioral frontotemporal dementia. J Neurol. 2020 Jun;267(6):1613-1614. doi: 10.1007/s00415-020-09784-6. Erratum for: J Neurol. 2020 Jun;267(6):1603-1612. PMID: 32219556; PMCID: PMC7293670.
  122. Quattrini G, Pievani M, Jovicich J, Aiello M, Bargalló N, Barkhof F,Bartres-Faz D, Beltramello A, Pizzini FB, Blin O, Bordet R, Caulo M, Constantinides M, Didic M, Drevelegas A, Ferretti A, Fiedler U, Floridi P, Gros- Dagnac H, Hensch T, Hoffmann KT, Kuijer JP, Lopes R, Marra C, Müller BW, Nobili F, Parnetti L, Payoux P, Picco A, Ranjeva JP, Roccatagliata L, Rossini PM, Salvatore M, Schonknecht P, Schott BH, Sein J, Soricelli A, Tarducci R, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Frisoni GB, Marizzoni M; PharmaCog Consortium. Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. Neuroimage. 2020 Sep;218:116932. doi: 10.1016/j.neuroimage.2020.116932. Epub 2020 May 13. PMID: 32416226.
  123. Rabin JS, Neal TE, Nierle HE, Sikkes SAM, Buckley RF, Amariglio RE, Papp KV, Rentz DM, Schultz AP, Johnson KA, Sperling RA, Hedden T. Multiple markers contribute to risk of progression from normal to mild cognitive impairment. Neuroimage Clin. 2020 Aug 28;28:102400. doi: 10.1016/j.nicl.2020.102400. Epub ahead of print. PMID: 32919366; PMCID: PMC7491146.
  124. Reimand J, Groot C, Teunissen CE, Windhorst AD, Boellaard R, Barkhof F, Nazarenko S, van der Flier WM, van Berckel BNM, Scheltens P, Ossenkoppele R, Bouwman F. Why Is Amyloid-β PET Requested After Performing CSF Biomarkers? J Alzheimers Dis. 2020;73(2):559-569. doi: 10.3233/JAD-190836. PMID: 31796674; PMCID: PMC7081099.
  125. Reimand J, Collij L, Scheltens P, Bouwman F, Ossenkoppele R; Alzheimer’s Disease Neuroimaging Initiative. Association of amyloid-β CSF/PET discordance and tau load 5 years later. Neurology. 2020 Nov 10;95(19):e2648-e2657. doi: 10.1212/WNL.0000000000010739. Epub 2020 Sep 10. PMID: 32913020.
  126. Reimand J, Boon BDC, Collij LE, Teunissen CE, Rozemuller AJM, van Berckel BNM, Scheltens P, Ossenkoppele R, Bouwman F. Amyloid-β PET and CSF in a autopsy-confirmed cohort. Ann Clin Transl Neurol. 2020 Nov;7(11):2150-2160. doi: 10.1002/acn3.51195. Epub 2020 Oct 20. PMID: 33080124; PMCID: PMC7664271.
  127. Reus LM, Stringer S, Posthuma D, Teunissen CE, Scheltens P, Pijnenburg YAL, Visser PJ, Tijms BM; Alzheimer’s Disease Neuroimaging Initiative. Degree of genetic liability for Alzheimer’s disease associated with specific proteomic profiles in cerebrospinal fluid. Neurobiol Aging. 2020 Sep;93:144.e1-144.e15. doi: 10.1016/j.neurobiolaging.2020.03.012. Epub 2020 Mar 24. PMID: 32307133.
  128. Rhodius-Meester HFM, van Maurik IS, Koikkalainen J, Tolonen A, Frederiksen KS, Hasselbalch SG, Soininen H, Herukka SK, Remes AM, Teunissen CE, Barkhof F Pijnenburg YAL, Scheltens P, Lötjönen J, van der Flier WM. Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. PLoS One. 2020 Jan 15;15(1):e0226784. doi: 10.1371/journal.pone.0226784. PMID: 31940390; PMCID: PMC6961870.
  129. Rhodius-Meester HFM, Paajanen T, Koikkalainen J, Mahdiani S, Bruun M, Baroni M, Lemstra AW, Scheltens P, Herukka SK, Pikkarainen M, Hall A, Hänninen T, Ngandu T, Kivipelto M, van Gils M, Hasselbalch SG, Mecocci P, Remes A, Soininen H, van der Flier WM, Lötjönen J. cCOG: A web-based cognitive test tool for detecting neurodegenerative disorders. Alzheimers Dement (Amst). 2020 Aug 25;12(1):e12083. doi: 10.1002/dad2.12083. PMID: 32864411; PMCID: PMC7446945.
  130. Ribaldi F, Altomare D, Jovicich J, Ferrari C, Picco A, Pizzini FB, Soricelli A, Mega A, Ferretti A, Drevelegas A, Bosch B, Müller BW, Marra C, Cavaliere C, Bartrés-Faz D, Nobili F, Alessandrini F, Barkhof F, Gros-Dagnac H, Ranjeva JP, Wiltfang J, Kuijer J, Sein J, Hoffmann KT, Roccatagliata L, Parnetti L, Tsolaki M, Constantinidis M, Aiello M, Salvatore M, Montalti M, Caulo M, Didic M, Bargallo N, Blin O, Rossini PM, Schonknecht P, Floridi P, Payoux P, Visser PJ, Bordet R, Lopes R, Tarducci R, Bombois S, Hensch T, Fiedler U, Richardson JC, Frisoni GB, Marizzoni M. Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. Magn Reson Imaging. 2020 Nov 19;76:108-115. doi: 10.1016/j.mri.2020.11.008. Epub ahead of print. PMID: 33220450.
  131. Robin J, Harrison JE, Kaufman LD, Rudzicz F, Simpson W, Yancheva M. Evaluation of Speech-Based Digital Biomarkers: Review and Recommendations. Digit Biomark. 2020 Oct 19;4(3):99-108. doi: 10.1159/000510820. PMID: 33251474; PMCID: PMC7670321.
  132. Rutten JW, Hack RJ, Duering M, Gravesteijn G, Dauwerse JG, Overzier M, van den Akker EB, Slagboom E, Holstege H, Nho K, Saykin A, Dichgans M, Malik R, Lesnik Oberstein SAJ. Broad phenotype of cysteine-altering NOTCH3 variants in UK Biobank: CADASIL to nonpenetrance. 2020 Sep 29;95(13):e1835-e1843. doi: 10.1212/WNL.0000000000010525. Epub 2020 Jul 30. PMID: 32732295; PMCID: PMC7682826.
  133. Saridin FN, Hilal S, Villaraza SG, Reilhac A, Gyanwali B, Tanaka T, Stephenson MC, Ng SL, Vrooman H, van der Flier WM, Chen CLH. Brain amyloid β cerebral small vessel disease, and cognition: A memory clinic study. 2020 Nov 24;95(21):e2845-e2853. doi: 10.1212/WNL.0000000000011029. Epub 2020 Oct 12. PMID: 33046617.
  134. Scarioni M, Gami-Patel P, Timar Y, Seelaar H, van Swieten JC, Rozemuller AJM, Dols A, Scarpini E, Galimberti D; Netherlands Brain Bank, Hoozemans JJM, Pijnenburg YAL, Dijkstra AA. Frontotemporal Dementia: Correlations Between Psychiatric Symptoms and Pathology. Ann Neurol. 2020 Jun;87(6):950-961. doi: 10.1002/ana.25739. Epub 2020 Apr 25. PMID: 32281118; PMCID: PMC7318614.
  135. Scarioni M, Arighi A, Fenoglio C, Sorrentino F, Serpente M, Rotondo E, Mercurio M, Marotta G, Dijkstra AA, Pijnenburg YAL, Scarpini E, Galimberti D. Late-onset presentation and phenotypic heterogeneity of the rare R377W PSEN1 mutation. Eur J Neurol. 2020 Dec;27(12):2630-2634. doi: 10.1111/ene.14506. Epub 2020 Oct 12. PMID: 32894632.
  136. Schutte MJL, Linszen MMJ, Marschall TM, Ffytche DH, Koops S, van Dellen E, Heringa SM, Slooter AJC, Teunisse R, van den Heuvel OA, Lemstra AW, Foncke EMJ, Slotema CW, de Jong J, Rossell SL, Sommer IEC. Hallucinations and other psychotic experiences across diagnoses: A comparison of phenomenological features. Psychiatry Res. 2020 Oct;292:113314. doi: 10.1016/j.psychres.2020.113314. Epub 2020 Jul 22. PMID: 32731082.
  137. Shi L, Winchester LM, Liu BY, Killick R, Ribe EM, Westwood S, Baird AL, Buckley NJ, Hong S, Dobricic V, Kilpert F, Franke A, Kiddle S, Sattlecker M, Dobson R, Cuadrado A, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Ten Kate M, Scheltens P, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lleó A, Alcolea D, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Teunissen CE, Freund-Levi Y, Frölich L, Legido-Quigley C, Barkhof F, Blennow K, Rasmussen KL, Nordestgaard BG, Frikke-Schmidt R, Nielsen SF, Soininen H, Vellas B, Kloszewska I, Mecocci P, Zetterberg H, Morgan BP, Streffer J, Visser PJ, Bertram L, Nevado-Holgado AJ, Lovestone S. Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer’s Disease Pathology. J Alzheimers Dis. 2020;77(3):1353-1368. doi: 10.3233/JAD-200208. PMID: 32831200; PMCID: PMC7683080.
  138. Sikkes SAM, Tang Y, Jutten RJ, Wesselman LMP, Turkstra LS, Brodaty H, Clare L, Cassidy-Eagle E, Cox KL, Chételat G, Dautricourt S, Dhana K, Dodge H, Dröes RM, Hampstead BM, Holland T, Lampit A, Laver K, Lutz A, Lautenschlager NT, McCurry SM, Meiland FJM, Morris MC, Mueller KD, Peters R, Ridel G, Spector A, van der Steen JT, Tamplin J, Thompson Z; ISTAART Non-pharmacological Interventions Professional Interest Area, Bahar-Fuchs A. Toward a theory-based specification of non-pharmacological treatments in aging and dementia: Focused reviews and methodological recommendations. Alzheimers Dement. 2020 Nov 20. doi: 10.1002/alz.12188. Epub ahead of print. PMID: 33215876.
  139. Singleton EH, Pijnenburg YAL, Sudre CH, Groot C, Kochova E, Barkhof F, La Joie R, Rosen HJ, Seeley WW, Miller B, Cardoso MJ, Papma J, Scheltens P, Rabinovici GD, Ossenkoppele R. Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease. Alzheimers Res Ther. 2020 Nov 14;12(1):148. doi: 10.1186/s13195-020-00717-z. PMID: 33189136; PMCID: PMC7666520.
  140. Smith R, Strandberg O, Mattsson-Carlgren N, Leuzy A, Palmqvist S, Pontecorvo MJ, Devous MD, Ossenkoppele R, Hansson O. The accumulation rate of tau aggregates is higher in females and younger amyloidpositive subjects. Brain. 2020 Dec 1; awaa327. https://doi.org/10.1093/brain/awaa327
  141. Snyder PJ, Alber J, Alt C, Bain LJ, Bouma BE, Bouwman FH, DeBuc DC, Campbell MCW, Carrillo MC, Chew EY, Cordeiro MF, Dueñas MR, Fernández BM, Koronyo-Hamaoui M, La Morgia C, Carare RO, Sadda SR, van Wijngaarden P, Snyder HM. Retinal imaging in Alzheimer’s and neurodegenerative diseases. Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12179. Epub ahead of print. PMID: 33090722.
  142. Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, Hartmann T; LipiDiDiet clinical study group. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer’s disease. Alzheimers Dement. 2020 Sep 13. doi: 10.1002/alz.12172. Epub ahead of print. PMID: 32920957.
  143. Staekenborg SS, Kelly N, Schuur J, Koster P, Scherder E, Tielkes CEM, Scheltens P, Claus JJ. Education as Proxy for Cognitive Reserve in a Large Elderly Memory Clinic: ‘Window of Benefit’. J Alzheimers Dis. 2020;76(2):671-679. doi: 10.3233/JAD-191332. PMID: 32538838.
  144. Stringa N, Milaneschi Y, van Schoor NM, Suanet B, van der Lee S, Holstege H, Reinders MJT, Beekman ATF, Huisman M. Genetic Liability for Depression, Social Factors and Their Interaction Effect in Depressive Symptoms and Depression Over Time in Older Adults. Am J Geriatr Psychiatry. 2020 Aug;28(8):844-855. doi: 10.1016/j.jagp.2020.02.011. Epub 2020 Mar 8. PMID: 32278746.
  145. Stringer G, Leroi I, Sikkes SAM, Montaldi D, Brown LJE. Enhancing ‘meaningfulness’ of functional assessments: UK adaptation of the Amsterdam IADL questionnaire. Int Psychogeriatr. 2020 Apr 15:1-12. doi: 10.1017/S1041610219001881. Epub ahead of print. PMID: 32290875.
  146. Terrera GM, Harrison JE, Ritchie CW, Ritchie K. Cognitive Functions as Predictors of Alzheimer’s Disease Biomarker Status in the European Prevention of Alzheimer’s Dementia Cohort. J Alzheimers Dis. 2020;74(4):1203-1210. doi: 10.3233/JAD-191108. PMID: 32144988.
  147. Tesi N, van der Lee SJ, Hulsman M, Jansen IE, Stringa N, van Schoor NM, Scheltens P, van der Flier WM, Huisman M, Reinders MJT, Holstege H. Polygenic risk score of longevity predicts longer survival across an age-continuum. J Gerontol A Biol Sci Med Sci. 2020 Nov 20:glaa289. doi: 10.1093/gerona/glaa289. Epub ahead of print. PMID: 33216869.
  148. Tesi N, van der Lee SJ, Hulsman M, Jansen IE, Stringa N, van Schoor NM, Scheltens P, van der Flier WM, Huisman M, Reinders MJT, Holstege H. Immune response and endocytosis pathways are associated with the resilience against Alzheimer’s disease. Transl Psychiatry. 2020 Sep 29;10(1):332. doi: 10.1038/s41398-020-01018-7. PMID: 32994401; PMCID: PMC7524800.
  149. Tijms BM, Gobom J, Reus L, Jansen I, Hong S, Dobricic V, Kilpert F, Ten Kate M, Barkhof F, Tsolaki M, Verhey FRJ, Popp J, Martinez-Lage P, Vandenberghe R, Lleó A, Molinuevo JL, Engelborghs S, Bertram L, Lovestone S, Streffer J, Vos S, Bos I; Alzheimer’s Disease Neuroimaging Initiative (ADNI), Blennow K, Scheltens P, Teunissen CE, Zetterberg H, Visser PJ. Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics. Brain. 2020 Dec 1;143(12):3776-3792. doi: 10.1093/brain/awaa325. PMID: 33439986; PMCID: PMC7805814.
  150. Timmers T, Ossenkoppele R, Visser D, Tuncel H, Wolters EE, Verfaillie SC, van der Flier WM, Boellaard R, Golla SS, van Berckel BN. Test-retest repeatability of [18F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals. J Cereb Blood Flow Metab. 2020 Dec;40(12):2464-2474. doi: 10.1177/0271678X19879226. Epub 2019 Oct 1. PMID: 31575335.
  151. Trieu C, Gossink F, Stek ML, Scheltens P, Pijnenburg YAL, Dols A. Effectiveness of Pharmacological Interventions for Symptoms of Behavioral Variant Frontotemporal Dementia: A Systematic Review. Cogn Behav Neurol. 2020 Mar;33(1):1-15. doi: 10.1097/WNN.0000000000000217. PMID: 32132398.
  152. Ulugut Erkoyun H, Groot C, Heilbron R, Nelissen A, van Rossum J, Jutten R, Koene T, van der Flier WM, Wattjes MP, Scheltens P, Ossenkoppele R, Barkhof F, Pijnenburg Y. A clinical-radiological framework of the right temporal variant of frontotemporal dementia. 2020 Sep 1;143(9):2831-2843. doi: 10.1093/brain/awaa225. PMID: 32830218.
  153. van Bentum RE, Baniaamam M, Kinaci-Tas B, van de Kreeke JA, Kocyigit M, Tomassen J, den Braber A, Visser PJ, Ter Wee MM, Serné EH, Verbraak FD, Nurmohamed MT, van der Horst-Bruinsma IE. Microvascular changes of the retina in ankylosing spondylitis, and the association with cardiovascular disease – the eye for a heart study. Semin Arthritis Rheum. 2020 Sep 2:S0049-0172(20)30241-9. doi: 10.1016/j.semarthrit.2020.08.013. Epub ahead of print. PMID: 32967777.
  154. van de Beek M, van Steenoven I, van der Zande JJ, Barkhof F, Teunissen CE, van der Flier WM, Lemstra AW. Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression. Mov Disord. 2020 May;35(5):859-867. doi: 10.1002/mds.27997. Epub 2020 Feb 11. PMID: 32048343; PMCID: PMC7317511.
  155. van de Beek M, Babapour Mofrad R, van Steenoven I, Vanderstichele H, Scheltens P, Teunissen CE, Lemstra AW, van der Flier WM. Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies. Alzheimers Res Ther. 2020 Apr 17;12(1):44. doi: 10.1186/s13195-020-00610-9. PMID: 32303272; PMCID: PMC7165383.
  156. van de Kreeke JA, Nguyen HT, Konijnenberg E, Tomassen J, den Braber A, Ten Kate M, Yaqub M, van Berckel B, Lammertsma AA, Boomsma DI, Tan SH, Verbraak F, Visser PJ. Optical coherence tomography angiography in preclinical Alzheimer’s disease. Br J Ophthalmol. 2020 Feb;104(2):157-161. doi: 10.1136/bjophthalmol-2019-314127. Epub 2019 May 22. PMID: 31118186; PMCID: PMC7025728.
  157. van de Kreeke JA, Legdeur N, Badissi M, Nguyen HT, Konijnenberg E, Tomassen J, Ten Kate M, den Braber A, Maier AB, Tan HS, Verbraak FD, Visser PJ. Ocular biomarkers for cognitive impairment in nonagenarians; a prospective cross-sectional study. BMC Geriatr. 2020 Apr 28;20(1):155. doi: 10.1186/s12877-020-01556-1. PMID: 32345233; PMCID: PMC7189586.
  158. van de Kreeke JA, Nguyen HT, Konijnenberg E, Tomassen J, den Braber A, Ten Kate M, Yaqub M, van Berckel B, Lammertsma AA, Boomsma DI, Tan HS, Visser PJ, Verbraak FD. Longitudinal retinal layer changes in preclinical Alzheimer’s disease. Acta Ophthalmol. 2020 Oct 18. doi: 10.1111/aos.14640. Epub ahead of print. PMID: 33073531.
  159. van den Akker EB, Makrodimitris S, Hulsman M, Brugman MH, Nikolic T, Bradley T, Waisfisz Q, Baas F, Jakobs ME, de Jong D, Slagboom PE, Staal FJT, Reinders MJT, Holstege H. Dynamic clonal hematopoiesis and functional T-cell immunity in a supercentenarian. Leukemia. 2020 Nov 12. doi: 10.1038/s41375-020-01086-0. Epub ahead of print. PMID: 33184493.
  160. van der Ende EL, Xiao M, Xu D, Poos JM, Panman JL, Jiskoot LC, Meeter LH, Dopper EG, Papma JM, Heller C, Convery R, Moore K, Bocchetta M, Neason M, Peakman G, Cash DM, Teunissen CE, Graff C, Synofzik M, Moreno F, Finger E, Sánchez-Valle R, Vandenberghe R, Laforce R Jr, Masellis M, Tartaglia MC, Rowe JB, Butler CR, Ducharme S, Gerhard A, Danek A, Levin J, Pijnenburg YA, Otto M, Borroni B, Tagliavini F, de Mendonca A, Santana I, Galimberti D, Seelaar H, Rohrer JD, Worley PF, van Swieten JC; Genetic Frontotemporal Dementia Initiative (GENFI). Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):612-621. doi: 10.1136/jnnp-2019-322493. Epub 2020 Apr 9. PMID: 32273328; PMCID: PMC7279197.
  161. van der Kant R, Goldstein LSB, Ossenkoppele R. Amyloid-β-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci. 2020 Jan;21(1):21-35. doi: 10.1038/s41583-019-0240-3. Epub 2019 Nov 28. PMID: 31780819.
    van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then BerghF, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto- Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff- Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathol. 2020 May;139(5):959-962. doi: 10.1007/s00401-019-02107-8. Erratumfor: Acta Neuropathol. 2019 Aug;138(2):237-250. PMID: 31955222; PMCID:PMC7181435.
  162. van der Zande JJ, Joling M, Happach IG, Vriend C, Scheltens P, Booij J, Lemstra AW. Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer’s disease pathology: An 123I-FP-CIT SPECT study. Neuroimage Clin. 2020;25:102062. doi: 10.1016/j.nicl.2019.102062. Epub 2019 Nov 1. PMID: 31790878; PMCID: PMC6909333.
  163. van der Zande JJ, Gouw AA, van Steenoven I, van de Beek M, Scheltens P, Stam CJ, Lemstra AW. Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies. Neurology. 2020 Aug 11;95(6):e662-e670. doi: 10.1212/WNL.0000000000009977. Epub 2020 Jul 7. PMID: 32636325.
  164. van Engelen ME, Gossink FT, de Vijlder LS, Meursing JRA, Scheltens P, Dols A, Pijnenburg YAL. End Stage Clinical Features and Cause of Death of Behavioral Variant Frontotemporal Dementia and Young-Onset Alzheimer’s Disease. J Alzheimers Dis. 2020;77(3):1169-1180. doi: 10.3233/JAD-200337. PMID: 32925036; PMCID: PMC7683069.
  165. Van Harten AC, Wiste HJ, Weigand SD, Mielke MM, Kremers WK, Eichenlaub U, Batrla-Utermann R, Dyer RB, Algeciras-Schimnich A, Knopman DS, Jack CR Jr, Petersen RC. CSF biomarkers in Olmsted County: Evidence of 2 subclasses and associations with demographics. Neurology. 2020 Jul 21;95(3):e256-e267. doi: 10.1212/WNL.0000000000009874. Epub 2020 Jun 26. PMID: 32591471; PMCID: PMC7455353.
  166. van Loenhoud AC, Habeck C, van der Flier WM, Ossenkoppele R, Stern Y. Identifying a task-invariant cognitive reserve network using task potency. 2020 Apr 15;210:116593. doi: 10.1016/j.neuroimage.2020.116593. Epub 2020 Jan 30. PMID: 32007499.
  167. van Maurik IS, Bakker ED, van den Buuse S, Gillissen F, van de Beek M, Lemstra E, Mank A, van den Bosch KA, van Leeuwenstijn M, Bouwman FH, Scheltens P, van der Flier WM. Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline. Front Psychiatry. 2020 Oct 26;11:585686. doi: 10.3389/fpsyt.2020.585686. PMID: 33192733; PMCID: PMC7649118.
  168. van Steenoven I, Koel-Simmelink MJA, Vergouw LJM, Tijms BM, Piersma SR, Pham TV, Bridel C, Ferri GL, Cocco C, Noli B, Worley PF, Xiao MF, Xu D, Oeckl P, Otto M, van der Flier WM, de Jong FJ, Jimenez CR, Lemstra AW, Teunissen CE. Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. Mol Neurodegener. 2020 Jun 18;15(1):36. doi: 10.1186/s13024-020-00388-2. PMID: 32552841; PMCID: PMC7301448.
  169. Vannini P, Hanseeuw BJ, Gatchel JR, Sikkes SAM, Alzate D, Zuluaga Y, Moreno S, Mendez L, Baena A, Ospina-Lopera P, Tirado V, Henao E, Acosta-Baena N, Giraldo M, Lopera F, Quiroz YT. Trajectory of Unawareness of Memory Decline in Individuals With Autosomal Dominant Alzheimer Disease. JAMA Netw Open. 2020 Dec 1;3(12):e2027472. doi: 10.1001/jamanetworkopen.2020.27472. PMID: 33263761; PMCID: PMC7711319.
  170. Verberk IMW, Teunissen CE, Van der Flier WM. Reply to “Usefulness of Plasma Amyloid as Prescreener of the Earliest Alzheimer Pathological Changes Depends on the Study Population”. Ann Neurol. 2020 Jan;87(1):155. doi: 10.1002/ana.25633. Epub 2019 Nov 14. PMID: 31675120.
  171. Verberk IMW, Hendriksen HMA, van Harten AC, Wesselman LMP, Verfaillie SCJ, van den Bosch KA, Slot RER, Prins ND, Scheltens P, Teunissen CE, Van der Flier WM. Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiol Aging. 2020 May;89:99-107. doi: 10.1016/j.neurobiolaging.2020.01.007. Epub 2020 Jan 15. PMID: 32081465.
  172. Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A, Zwan MD, Verfaillie SCJ, Ossenkoppele R, Barkhof F, van Berckel BNM, Scheltens P, van der Flier WM, Stoops E, Vanderstichele HM, Teunissen CE. Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020 Sep 28;12(1):118. doi: 10.1186/s13195-020-00682-7. PMID: 32988409; PMCID: PMC7523295.
  173. Verfaillie SC, Golla SS, Timmers T, Tuncel H, van der Weijden CW, Schober P, Schuit RC, van der Flier WM, Windhorst AD, Lammertsma AA, van Berckel BN, Boellaard R. Repeatability of parametric methods for [18F]florbetapir imaging in Alzheimer’s disease and healthy controls: A test-retest study. J Cereb Blood Flow Metab. 2020 Apr 22:271678X20915403. doi: 10.1177/0271678X20915403. Epub ahead of print. PMID: 32321347.
  174. Vergouw LJM, Bosman B, van de Beek M, Salomé M, Hoogers SE, van Steenoven I, Roks G, Bonifati V, van Swieten JC, Lemstra AW, de Jong FJ. Family History is Associated with Phenotype in Dementia with Lewy Bodies. J Alzheimers Dis. 2020;73(1):269-275. doi: 10.3233/JAD-190825. PMID: 31771063; PMCID: PMC7029358.
  175. Verhaar BJH, de Leeuw FA, Doorduijn AS, Fieldhouse JLP, van de Rest O Teunissen CE, van Berckel BNM, Barkhof F, Visser M, de van der Schueren MAE, Scheltens P, Kester MI, Muller M, van der Flier WM. Nutritional status an structural brain changes in Alzheimer’s disease: The NUDAD project. Alzheimers Dement (Amst). 2020 Aug 11;12(1):e12063. doi: 10.1002/dad2.12063. PMID: 32793798; PMCID: PMC7418890.
  176. Vermunt L, Muniz-Terrera G, Ter Meulen L, Veal C, Blennow K, Campbell A, Carrié I, Delrieu J, Fauria K, Huesa Rodríguez G, Ingala S, Jenkins N, Molinuevo JL, Ousset PJ, Porteous D, Prins ND, Solomon A, Tom BD, Zetterberg H, Zwan M, Ritchie CW, Scheltens P, Luscan G, Brookes AJ, Visser PJ; IMI-EPAD collaborators. Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. Alzheimers Res Ther. 2020 Jan 6;12(1):8. doi: 10.1186/s13195-019-0576-y. PMID: 31907067; PMCID: PMC6945608.
  177. Vermunt L, Dicks E, Wang G, Dincer A, Flores S, Keefe SJ, Berman SB, Cash DM, Chhatwal JP, Cruchaga C, Fox NC, Ghetti B, Graff-Radford NR, Hassenstab J, Karch CM, Laske C, Levin J, Masters CL, McDade E, Mori H, Morris JC, Noble JM, Perrin RJ, Schofield PR, Xiong C, Scheltens P, Visser PJ, Bateman RJ, Benzinger TLS, Tijms BM, Gordon BA; Dominantly Inherited Alzheimer Network (DIAN). Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer’s disease. Brain Commun. 2020 Jul 15;2(2):fcaa102. doi: 10.1093/braincomms/fcaa102. PMID: 32954344; PMCID: PMC7475695.
  178. Vignoli A, Paciotti S, Tenori L, Eusebi P, Biscetti L, Chiasserini D, Scheltens P, Turano P, Teunissen C, Luchinat C, Parnetti L. Fingerprinting Alzheimer’s Disease by <sup>1</sup>H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid. J Proteome Res. 2020 Apr 3;19(4):1696-1705. doi: 10.1021/acs.jproteome.9b00850. Epub 2020 Mar 12. PMID: 32118444.
  179. Visser D, Wolters EE, Verfaillie SCJ, Coomans EM, Timmers T, Tuncel H Reimand J, Boellaard R, Windhorst AD, Scheltens P, van der Flier WM, Ossenkoppele R, van Berckel BNM. Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3165-3175. doi: 10.1007/s00259-020-04831-w. Epub 2020 May 27. PMID: 32462397; PMCID: PMC7680306.
  180. Visser LNC, Pelt SAR, Kunneman M, Bouwman FH, Claus JJ, Kalisvaart KJ Hempenius L, de Beer MH, Roks G, Boelaarts L, Kleijer M, van der Flier WM, Smets EMA, Hillen MA. Communicating uncertainties when disclosing diagnostic test results for (Alzheimer’s) dementia in the memory clinic: The ABIDE project Health Expect. 2020 Feb;23(1):52-62. doi: 10.1111/hex.12964. Epub 2019 Oct 22. PMID: 31638322; PMCID: PMC6978856.
  181. Visser LNC, van Maurik IS, Bouwman FH, Staekenborg S, Vreeswijk R Hempenius L, de Beer MH, Roks G, Boelaarts L, Kleijer M, van der Flier WM, Smets EMA. Clinicians’ communication with patients receiving a MCI diagnosis: The ABIDE project. PLoS One. 2020 Jan 21;15(1):e0227282. doi: 10.1371/journal.pone.0227282. PMID: 31961882; PMCID: PMC6974141.
  182. Visser PJ, Reus LM, Gobom J, Jansen I, Dicks E, Tsolaki M, Verhey FRJ, Popp J, Martinez-Lage P, Vandenberghe R, Lleó A, Molinuevo JL, Engelborghs S, Freund- Levi Y, Froelich L, Sleegers K, Dobricic V, Hong S, Lovestone S, Streffer J, Vos SJB, Bos I, Smit AB, Blennow K, Scheltens P, Teunissen CE, Bertram L, Zetterberg H, Tijms BM. Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer’s disease. medRxiv . 2020 Nov 3:2020.10.29.20211920. doi: 10.1101/2020.10.29.20211920. PMID: 33173883; PMCID: PMC7654872.
  183. Wesenhagen KEJ, Teunissen CE, Visser PJ, Tijms BM. Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer’s disease: A literature review. Crit Rev Clin Lab Sci. 2020 Mar;57(2):86-98. doi: 10.1080/10408363.2019.1670613. Epub 2019 Nov 7. PMID: 31694431.
  184. Wesselman LMP, Schild AK, Hooghiemstra AM, Meiberth D, Drijver AJ, Leeuwenstijn-Koopman MV, Prins ND, Brennan S, Scheltens P, Jessen F, van der Flier WM, Sikkes SAM. Targeting Lifestyle Behavior to Improve Brain Health: User-Experiences of an Online Program for Individuals with Subjective Cognitive Decline. J Prev Alzheimers Dis. 2020;7(3):184-194. doi: 10.14283/jpad.2020.9. PMID: 32463072.
  185. Wesselman LMP, van Lent DM, Schröder A, van de Rest O, Peters O, Menne F, Fuentes M, Priller J, Spruth EJ, Altenstein S, Schneider A, Fließbach K, Roeske S, Wolfsgruber S, Kleineidam L, Spottke A, Pross V, Wiltfang J, Vukovich R, Schild AK, Düzel E, Metzger CD, Glanz W, Buerger K, Janowitz D, Perneczky R, Tatò M, Teipel S, Kilimann I, Laske C, Buchmann M, Ramirez A, Sikkes SAM, Jessen F, van der Flier WM, Wagner M. Dietary patterns are related to cognitive functioning in elderly enriched with individuals at increased risk for Alzheimer’s disease. Eur J Nutr. 2020 May 29. doi: 10.1007/s00394-020-02257-6. Epub ahead of print. PMID: 32472387.
  186. Westwood S, Baird AL, Anand SN, Nevado-Holgado AJ, Kormilitzin A, Shi L, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Baker S, Buckley NJ, Ten Kate M, Scheltens P, Teunissen CE, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lléo A, Sala I, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Legido-Quigley C, Bertram L, Barkhof F, Zetterberg H, Morgan BP, Streffer J, Visser PJ, Lovestone S. Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort. J Alzheimers Dis. 2020;74(1):213-225. doi: 10.3233/JAD-190434. PMID: 31985466; PMCID: PMC7175945.
  187. Wolters EE, Ossenkoppele R, Golla SS, Verfaillie SC, Timmers T, Visser D, Tuncel H, Coomans EM, Windhorst AD, Scheltens P, van der Flier WM, Boellaard R, van Berckel BN. Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico- pathological relationships. Neuroimage Clin. 2020;25:102113. doi: 10.1016/j.nicl.2019.102113. Epub 2019 Dec 2. PMID: 31835238; PMCID: PMC6920114.
  188. Wolters EE, Ossenkoppele R, Verfaillie SCJ, Coomans EM, Timmers T, Visser D, Tuncel H, Golla SSV, Windhorst AD, Boellaard R, van der Flier WM, Teunissen CE, Scheltens P, van Berckel BNM. Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2866-2878. doi: 10.1007/s00259-020-04758-2. Epub 2020 Apr 14. Erratum in: Eur J Nucl Med Mol Imaging. 2020 May 9: PMID: 32291510; PMCID: PMC7567681.
    Wolters EE, Ossenkoppele R, Verfaillie SCJ, Coomans EM, Timmers T, Visser D, Tuncel H, Golla SSV, Windhorst AD, Boellaard R, van der Flier WM, Teunissen CE, Scheltens P, van Berckel BNM. Correction to: Regiona [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2934-2935. doi: 10.1007/s00259-020-04849-0. Erratum for: Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2866-2878. PMID: 32388611.
  189. Wolters EE, van de Beek M, R. Ossenkoppele R, Golla SSV, Verfaillie SCJ, Coomans EM, Timmers T, Visser D, Tuncel H, Barkhof F, Boellaard R, Windhorst AD, van der Flier WM, Scheltens Ph, Lemstra AW, van Berckel BNM. Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study. NeuroImage Clin. 2020; 28:102504. https://doi.org/10.1016//.nicl.2020.10250/

Publicaties 2019

  1. Albani D, Marizzoni M, Ferrari C, Fusco F, Boeri L, Raimondi I, Jovicich J, Babiloni C, Soricelli A, Lizio R, Galluzzi S, Cavaliere L, Didic M, Schönknecht P, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Bocchio L, Salvatore M, Rossini PM, Tsolaki M, Visser PJ, Richardson JC, Wiltfang J, Bordet R, Blin O, Forloni G, Frisoni GB; PharmaCog Consortium. Plasma Aβ42 as a Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. J Alzheimers Dis. 2019;69(1):37-48. doi: 10.3233/JAD-180321. PubMed PMID: 30149449.
  2. Altomare D, de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, van Maurik I, Zwan M, Yaqub M, Barkhof F, van Berckel BN, Teunissen CE, Frisoni GB, Scheltens P, van der Flier WM. Applying the ATN scheme in a memory clinic population: The ABIDE project. 2019 Oct 22;93(17):e1635-e1646. doi: 10.1212/WNL.0000000000008361. Epub 2019 Oct 9. PubMed PMID: 31597710.
  3. Altomare D, Ferrari C, Caroli A, Galluzzi S, Prestia A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall A, Carter SF, Schöll M, Choo ILH, Grimmer T, Redolfi A, Nordberg A, Scheltens P, Drzezga A, Frisoni GB; Alzheimer’s Disease Neuroimaging Initiative. Prognostic value of Alzheimer’s  biomarkers in mild cognitive impairment: the effect of age at onset. J Neurol. 2019 Jul 2. doi: 10.1007/s00415-019-09441-7. PubMed PMID: 31267207.
  4. Ashton NJ, Suárez-Calvet M, Heslegrave A, Hye A, Razquin C, Pastor P, Sanchez-Valle R, Molinuevo JL, Visser PJ, Blennow K, Hodges AK, Zetterberg H. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimers Res Ther. 2019 Nov 28;11(1):94. doi: 10.1186/s13195-019-0545-5. PubMed PMID: 31779670; PubMed Central PMCID: PMC6883551
  5. Babapour Mofrad R, van der Flier WM. Nature and implications of seks differences in AD pathology. Nat Rev Neurol. 2019 Jan;15(1):6-8. doi: 10.1038/s41582-018-0115-7. PubMed PMID: 30542072.
  6. Babapour Mofrad R, Visser LNC, Fruijtier AD, Scheltens P, Smets EEMA, van der Flier WM, Teunissen CE. Cerebrospinal fluid collection: An informative animation video for patients and caregivers. Alzheimers Dement (Amst). 2019 Jun 12;11:435-438. doi: 10.1016/j.dadm.2019.04.005. eCollection 2019 Dec. PubMed PMID: 31211216; PubMed Central PMCID: PMC6562320.
  7. Babapour Mofrad R, Schoonenboom NSM, Tijms BM, Scheltens P, Visser PJ, van der Flier WM, Teunissen CE. Decision tree supports the interpretation of CSF biomarkers in Alzheimer’s disease. Alzheimers Dement (Amst). 2018 Nov 12;11:1-9.  doi: 10.1016/j.dadm.2018.10.004. eCollection 2019 Dec. PubMed PMID: 30569013; PubMed Central PMCID: PMC6287084.
  8. Babiloni C, Blinowska K, Bonanni L, Cichocki A, De Haan W, Del Percio C, Dubois B, Escudero J, Fernández A, Frisoni G, Guntekin B, Hajos M, Hampel H, Ifeachor E, Kilborn K, Kumar S, Johnsen K, Johannsson M, Jeong J, LeBeau F, Lizio R, Lopes da Silva F, Maestú F, McGeown WJ, McKeith I, Moretti DV, Nobili F, Olichney J, Onofrj M, Palop JJ, Rowan M, Stocchi F, Struzik ZM, Tanila H, Teipel S, Taylor JP, Weiergräber M, Yener G, Young-Pearse T, Drinkenburg WH, Randall F. What electrophysiology tells us about Alzheimer’s disease: a window into the synchronization and connectivity of brain neurons. Neurobiol Aging. 2020 Jan;85:58-73. doi: 10.1016/j.neurobiolaging.2019.09.008. Epub 2019 Sep 19. Review. PubMed PMID: 31739167.
  9. Babulal GM, Quiroz YT, Albensi BC, Arenaza-Urquijo E, Astell AJ, Babiloni C, Bahar-Fuchs A, Bell J, Bowman GL, Brickman AM, Chételat G, Ciro C, Cohen AD, Dilworth-Anderson P, Dodge HH, Dreux S, Edland S, Esbensen A, Evered L, Ewers M, Fargo KN, Fortea J, Gonzalez H, Gustafson DR, Head E, Hendrix JA, Hofer SM, Johnson LA, Jutten R, Kilborn K, Lanctôt KL, Manly JJ, Martins RN, Mielke MM, Morris MC, Murray ME, Oh ES, Parra MA, Rissman RA, Roe CM, Santos OA, Scarmeas N, Schneider LS, Schupf N, Sikkes S, Snyder HM, Sohrabi HR, Stern Y, Strydom A, Tang Y, Terrera GM, Teunissen C, Melo van Lent D, Weinborn M, Wesselman L, Wilcock DM, Zetterberg H, O’Bryant SE; International Society to Advance Alzheimer’s Research and Treatment, Alzheimer’s Association. Perspectives on ethnic and racial disparities in Alzheimer’s disease and related dementias: Update and areas of immediate need. Alzheimers Dement. 2019 Feb;15(2):292-312. doi: 10.1016/j.jalz.2018.09.009. Epub 2018 Dec 13. PubMed PMID: 30555031; PubMed Central PMCID: PMC6368893.
  10. Banning LCP, Janssen EPCJ, Hamel REG, de Vugt M, Köhler S, Wolfs CAG, Oosterveld SM, Melis RJF, Olde Rikkert MGM, Kessels RPC, Pijnenburg YAL, Koene T, van der Flier WM, Scheltens P, Visser PJ, Verhey FRJ, Aalten P, Ramakers IHGB. Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia. J Geriatr Psychiatry Neurol. 2019 Oct 23:891988719882104. doi: 10.1177/0891988719882104. PubMed PMID: 31645191.
  11. Beker N, Claar D, van der Maarel-Wierink, de Baat C, Holstege H. Self-reported oral health in the Dutch 100-plus Study of cognitively healthy centenarians: an observational cohort study. Accepted in BMC Geriatrics.
  12. Beker N, Sikkes SAM, Hulsman M, Schmand B, Scheltens P, Holstege H. Neuropsychological Test Performance of Cognitively Healthy Centenarians: Normative Data From the Dutch 100-Plus Study. J Am Geriatr Soc. 2019 Apr;67(4):759-767. doi: 10.1111/jgs.15729. Epub 2018 Dec 27. PubMed PMID: 30592018.
  13. Bertens D, Vos S, Kehoe P, Wolf H, Nobili F, Mendonça A, van Rossum I, Hort J, Molinuevo JL, Heneka M, Petersen R, Scheltens P, Visser PJ. Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. Alzheimers Res Ther. 2019 Aug 22;11(1):74. doi: 10.1186/s13195-019-0525-9. PubMed PMID: 31439020; PubMed Central PMCID: PMC6706888.
  14. Boelaarts L, Meyer SRA, Scheltens P, de Jonghe JFM. Testing Episodic Memory in Elderly Subjects: Not as Simple as It Looks. Dement Geriatr Cogn Dis Extra. 2019  Jun 18;9(2):207-216. doi: 10.1159/000499836. eCollection 2019 May-Aug. PubMed PMID: 31275346; PubMed Central PMCID: PMC6600035.
  15. Boomsma JMF, Exalto LG, Barkhof F, van den Berg E, de Bresser J, Heinen R, Leeuwis AE, Prins ND, Scheltens P, Weinstein HC, van der Flier WM, Biessels GJ; behalf of the TRACE-VCI study group. How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. J  Alzheimers Dis. 2019;68(3):1273-1286. doi: 10.3233/JAD-180696. PubMed PMID: 30909212.
  16. Bos I, Vos SJB, Schindler SE, Hassenstab J, Xiong C, Grant E, Verhey F, Morris JC, Visser PJ, Fagan AM. Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer’s disease. Alzheimers Dement. 2019 Aug 1. pii: S1552-5260(19)30122-0. doi: 10.1016/j.jalz.2019.04.015. PubMed PMID: 31378575.
  17. Bos I, Vos S, Verhey F, Scheltens P, Teunissen C, Engelborghs S, Sleegers K, Frisoni G, Blin O, Richardson JC, Bordet R, Tsolaki M, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Lleó A, Johannsen P, Freund-Levi Y, Frölich L, Vandenberghe R, Westwood S, Dobricic V, Barkhof F, Legido-Quigley C, Bertram L, Lovestone S, Streffer J, Andreasson U, Blennow K, Zetterberg H, Visser PJ. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer’s disease spectrum. Alzheimers Dement. 2019 May;15(5):644-654. doi: 10.1016/j.jalz.2019.01.004. Epub  2019 Mar 8. PubMed PMID: 30853464.
  18. Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL  Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig  S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild  EJ. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol. 2019 Jun 17. doi:  10.1001/jamaneurol.2019.1534. PubMed PMID: 31206160; PubMed Central PMCID: PMC6580449.
  19. Briels CT, Stam CJ, Scheltens P, Bruins S, Lues I, Gouw AA. In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer’s disease. Clin Neurophysiol. 2019 Nov 4;131(1):88-95. doi: 10.1016/j.clinph.2019.09.014. PubMed PMID: 31759193.
  20. Bruffaerts R, Schaeverbeke J, de Weer AS, Nelissen N, Dries E, van Bouwel K, Sieben A, Bergans B, Swinnen C, Pijnenburg Y, Sunaert S, Vandenbulcke M, Vandenberghe R. Multivariate analysis reveals anatomical correlates of naming errors in Primary Progressive Aphasia Corresponding. Accepted in Neurobiol Aging.
  21. Brugnolo A, De Carli F, Pagani M, Morbelli S, Jonsson C, Chincarini A, Frisoni GB, Galluzzi S, Perneczky R, Drzezga A, van Berckel BNM, Ossenkoppele R, Didic M, Guedj E, Arnaldi D, Massa F, Grazzini M, Pardini M, Mecocci P, Dottorini ME, Bauckneht M, Sambuceti G, Nobili F. Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer’s Disease. J Alzheimers Dis. 2019;68(1):383-394. doi: 10.3233/JAD-181022. PubMed PMID: 30776000.
  22. Bruun M, Frederiksen KS, Rhodius-Meester HFM, Baroni M, Gjerum L, Koikkalainen J, Urhemaa T, Tolonen A, van Gils M, Rueckert D, Dyremose N, Andersen BB, Lemstra AW, Hallikainen M, Kurl S, Herukka SK, Remes AM, Waldemar G, Soininen H, Mecocci  P, van der Flier WM, Lötjönen J, Hasselbalch SG. Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective  validation study. Alzheimers Res Ther. 2019 Mar 20;11(1):25. doi:10.1186/s13195-019-0482-3. PubMed PMID: 30894218; PubMed Central PMCID: PMC6425602.
  23. Bruun M, Frederiksen KS, Rhodius-Meester HFM, Baroni M, Gjerum L, Koikkalainen J, Urhemaa T, Tolonen A, van Gils M, Tong T, Guerrero R, Rueckert D, Dyremose N, Andersen BB, Simonsen AH, Lemstra A, Hallikainen M, Kurl S, Herukka SK, Remes AM, Waldemar G, Soininen H, Mecocci P, van der Flier WM, Lötjönen J, Hasselbalch SG. Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. Curr Alzheimer Res. 2019;16(2):91-101. doi: 10.2174/1567205016666190103152425. PubMed PMID: 30605060
  24. Bruun M, Koikkalainen J, Rhodius-Meester HFM, Baroni M, Gjerum L, van Gils M, Soininen H, Remes AM, Hartikainen P, Waldemar G, Mecocci P, Barkhof F, Pijnenburg Y, van der Flier WM, Hasselbalch SG, Lötjönen J, Frederiksen KS. Detecting frontotemporal dementia syndromes using MRI biomarkers. Neuroimage Clin. 2019;22:101711. doi: 10.1016/j.nicl.2019.101711. Epub 2019 Feb 4. PubMed PMID: 30743135; PubMed Central PMCID: PMC6369219.
  25. Buckley RF, Sikkes S, Villemagne VL, Mormino EC, Rabin JS, Burnham S, Papp KV, Doré V, Masters CL, Properzi MJ, Schultz AP, Johnson KA, Rentz DM, Sperling RA, Amariglio RE. Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. Alzheimers Dement (Amst). 2019 Sep 25;11:670-678. doi: 10.1016/j.dadm.2019.08.004. eCollection 2019 Dec. PubMed PMID: 31673597; PubMed Central PMCID: PMC6816447.
  26. Cha, D.S., Carmona, N.E., Cha, R.H., Zhou, A.J., Subramanipillai, M., Mansur, R.B., Lee, Y., Le, J.H., Lee, J.G., Alageel, A., Rosenblat, J.D., Shekotikhina, M., Rong, C., Harrison, J.E., McIntyre, R.S. Perceived sleep quality predicts cognitive function in adults with major depressive disorder independent of depression severity. Annals of Clinical Psychiatry. 2019:31(1):17-26.
  27. Collij LE, Konijnenberg E, Reimand J, Kate MT, Braber AD, Alves IL, Zwan M, Yaqub M, van Assema DME, Wink AM, Lammertsma AA, Scheltens P, Visser PJ, Barkhof  F, van Berckel BNM. Assessing Amyloid Pathology in Cognitively Normal Subjects Using (18)F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. J  Nucl Med. 2019 Apr;60(4):541-547. doi: 10.2967/jnumed.118.211532. Epub 2018 Oct 12. PubMed PMID: 30315145; PubMed Central PMCID: PMC6448465.
  28. Collorone S, Prados F, Hagens MH, Tur C, Kanber B, Sudre CH, Lukas C, Gasperini C, Oreja-Guevara C, Andelova M, Ciccarelli O, Wattjes MP, Ourselin S, Altmann DR, Tijms BM, Barkhof F, Toosy AT; MAGNIMS Study Group. Single-subject structural cortical networks in clinically isolated syndrome. Mult Scler. 2019 Jul 24:1352458519865739. doi: 10.1177/1352458519865739. PubMed PMID: 31339446.
  29. Cummings J, Feldman HH, Scheltens P. The “rights” of precision drug development for Alzheimer’s disease. Alzheimers Res Ther. 2019 Aug 31;11(1):76. doi: 10.1186/s13195-019-0529-5. Review. PubMed PMID: 31470905; PubMed Central PMCID: PMC6717388.
  30. Dauwan M, Begemann MJH, Slot MIE, Lee EHM, Scheltens P, Sommer IEC. Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials. J Neurol. 2019 Aug 14. doi: 10.1007/s00415-019-09493-9. Review. PubMed PMID: 31414194.
  31. Deelen J, Evans DS, Arking DE, Tesi N, Nygaard M, Liu X, Wojczynski MK, Biggs ML, van der Spek A, Atzmon G, Ware EB, Sarnowski C, Smith AV, Seppälä I, Cordell HJ, Dose J, Amin N, Arnold AM, Ayers KL, Barzilai N, Becker EJ, Beekman M, Blanché H, Christensen K, Christiansen L, Collerton JC, Cubaynes S, Cummings SR, Davies K, Debrabant B, Deleuze JF, Duncan R, Faul JD, Franceschi C, Galan P, Gudnason V, Harris TB, Huisman M, Hurme MA, Jagger C, Jansen I, Jylhä M, Kähönen M, Karasik D, Kardia SLR, Kingston A, Kirkwood TBL, Launer LJ, Lehtimäki T, Lieb W, Lyytikäinen LP, Martin-Ruiz C, Min J, Nebel A, Newman AB, Nie C, Nohr EA, Orwoll ES, Perls TT, Province MA, Psaty BM, Raitakari OT, Reinders MJT, Robine JM, Rotter JI, Sebastiani P, Smith J, Sørensen TIA, Taylor KD, Uitterlinden AG, van der Flier W, van der Lee SJ, van Duijn CM, van Heemst D, Vaupel JW, Weir D, Ye K, Zeng Y, Zheng W, Holstege H, Kiel DP, Lunetta KL, Slagboom PE, Murabito JM. A meta-analysis of genome-wide association studies identifies multiple longevity genes. Nat Commun. 2019 Aug 14;10(1):3669. doi: 10.1038/s41467-019-11558-2. PubMed PMID: 31413261; PubMed Central PMCID: PMC6694136.
  32. de Haan W, Boon L, Foncke EM. Drooping Eyelid After Vomiting. JAMA Neurol. 2019 Jul 1;76(7):862-863. doi: 10.1001/jamaneurol.2019.1417. PubMed PMID: 31157830.
  33. den Haan J, Csinscik L, Parker T, Paterson RW, Slattery CF, Foulkes A, Bouwman FH, Verbraak FD, Scheltens P, Peto T, Lengyel I, Schott JM, Crutch SJ, Shakespeare TJ, Yong KXX. Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer’s disease. Alzheimers Res Ther. 2019 Jul 18;11(1):62. doi: 10.1186/s13195-019-0516-x. PubMed PMID: 31319885; PubMed Central PMCID: PMC6639972.
  34. De Leeuw FA, van der Flier WM, Tijms BM, Scheltens P, Mendes VM, Manadas B, Bierau N, van Wijk N, van den Heuvel EGHM, Mohajeri MH, Teunissen CE, Kester KI. Specific nutrient profiles in mild cognitive impairment and subjective cognitive decline are associated with clinical progression: the NUDAD project. Accepted in J Am Med Dir Assoc.
  35. de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, van Maurik I, Zwan M, Yaqub M, Barkhof F, Lammertsma AA, Biessels GJ, Scheltens P, van Berckel BN, van der Flier WM. Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. Alzheimers Dement. 2019 Nov;15(11):1458-1467. doi: 10.1016/j.jalz.2019.07.003. Epub 2019 Oct 6. PubMed PMID: 31594684.
  36. de Wilde A, Reimand J, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, van der Flier WM, Scheltens P, van Berckel BNM, Bouwman F, Ossenkoppele R. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences. Alzheimers Res Ther. 2019 Sep 12;11(1):78. doi: 10.1186/s13195-019-0532-x. PubMed PMID: 31511058; PubMed Central PMCID: PMC6739952.
  37. Di Censo R, Abdelnour C, Blanc F, Bousiges O, Lemstra AW, van Steenoven I, Onofrj M, Aarsland D, Bonanni L; European DLB consortium. CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2019 Jul 31. pii: jnnp-2019-320980. doi: 10.1136/jnnp-2019-320980. PubMed PMID: 31366604.
  38. Dicks E, Vermunt L, van der Flier WM, Visser PJ, Barkhof F, Scheltens P, Tijms BM; Alzheimer’s Disease Neuroimaging Initiative. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer’s disease. Neuroimage Clin. 2019;22:101786. doi: 10.1016/j.nicl.2019.101786. Epub 2019 Mar 19. PubMed PMID: 30921610; PubMed Central PMCID: PMC6439228.
  39. Doorduijn AS, Visser M, van de Rest O, Kester MI, de Leeuw FA, Boesveldt S, Fieldhouse JLP, van den Heuvel EGHM, Teunissen CE, Scheltens P, van der Flier WM, de van der Schueren MAE. Associations of AD Biomarkers and Cognitive Performance  with Nutritional Status: The NUDAD Project. Nutrients. 2019 May 23;11(5). pii: E1161. doi: 10.3390/nu11051161. PubMed PMID: 31126170; PubMed Central PMCID: PMC6566264.
  40. Doorduijn AS, van de Rest O, van der Flier WM, Visser M, de van der Schueren MAE. Energy and Protein Intake of Alzheimer’s Disease Patients Compared to Cognitively Normal Controls: Systematic Review. J Am Med Dir Assoc. 2019 Jan;20(1):14-21. doi: 10.1016/j.jamda.2018.06.019. Epub 2018 Aug 9. Review. PubMed PMID: 30100233.
  41. Doorduijn AS, van der Schueren MAE, van de Rest O, de Leeuw FA, Fieldhouse JLP, Kester MI, Teunissen CE, Scheltens P, van der Flier WM, Visser M, Boesveldt S. Olfactory and gustatory functioning and food preferences of patients with Alzheimer’s disease and mild cognitive impairment compared to controls: the NUDAD project. J Neurol. 2019 Oct 8. doi: 10.1007/s00415-019-09561-0. PubMed PMID: 31595376.
  42. Douw L, van Dellen E, Gouw AA, Griffa A, de Haan W, van den Heuvel M, Hillebrand A, Van Mieghem P, Nissen IA, Otte WM, Reijmer YD, Schoonheim MM, Senden M, van Straaten ECW, Tijms BM, Tewarie P, Stam CJ. The road ahead in clinical network neuroscience. Netw Neurosci. 2019 Sep 1;3(4):969-993. doi: 10.1162/netn_a_00103. eCollection 2019. Review. PubMed PMID: 31637334; PubMed Central PMCID: PMC6777944.
  43. Ducharme S, Dols A, Laforce R, Devenney E, Kumfor F, van den Stock J, Dallaire-Théroux C, Seelaar H, Gossink F, Vijverberg E, Huey E, Vandenbulcke M, Masellis M, Trieu C, Onyike C, Caramelli P, Cruz de Souza L, Santillo A, Landqvist Waldö M, Landin-Romero R, Piguet O, Kelso W, Eratne D, Velakoulis D, Ikeda M, Perry D, Pressman P, Boeve B, Vandenberghe R, Mendez M, Azuar C, Levy R, LeBer I, Baez S, Lerner A, Ratnavalli E, Pasquier F, Galimberti D, Scarpini E, van Swieten J, Hornberger M, Rosen H, Hodges J, Diehl-Schmid J, Pijnenburg Y. Recommendations to Distinguish Behavioral Variant Frontotemporal Dementia from Psychiatric Disorders. Accepted in Brain.
  44. Ducharme S, Pearl-Dowler L, Gossink F, McCarthy J, Lai J, Dickerson BC, Chertkow H, Rapin L, Vijverberg E, Krudop W, Dols A, Pijnenburg Y. The Frontotemporal Dementia versus Primary Psychiatric Disorder (FTD versus PPD) Checklist: A Bedside Clinical Tool to Identify Behavioral Variant FTD in Patients with Late-Onset Behavioral Changes. J Alzheimers Dis. 2019;67(1):113-124. doi: 10.3233/JAD-180839. PubMed PMID: 30584146.
  45. Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, van Harten AC, Teunissen CE, Barkhof F, van den Bosch KA, van Leeuwenstijn M, Tomassen J, den Braber A, Visser PJ, Prins ND, Sikkes SAM, Scheltens P, van Bercke BNM, van der Flier WM. ATN-classification and clinical progression in subjective cognitive decline: the SCIENCe project. Accepted in Neurology.
  46. Eikelboom WS, Singleton E, van den Berg E, Coesmans M, Mattace Raso F, van Bruchem RL, Goudzwaard JA, de Jong FJ, Koopmanschap M, den Heijer T, Driesen JJM, Vroegindeweij LJHM, Thomeer EC, Hoogers SE, Dijkstra AA, Zuidema SU, Pijnenburg YAL, Scheltens P, van Swieten JC, Ossenkoppele R, Papma JM. Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer’s disease: protocol of the BEAT-IT study. Alzheimers Res Ther. 2019 May 24;11(1):48. doi: 10.1186/s13195-019-0503-2. PubMed PMID: 31122267; PubMedCentral PMCID: PMC6533693.
  47. Fathy YY, Hoogers SE, Berendse HW, van der Werf YD, Visser PJ, de Jong FJ, van de Berg WDJ. Differential insular cortex sub-regional atrophy in neurodegenerative diseases: a systematic review and meta-analysis. Brain Imaging  Behav. 2019 Apr 23. doi: 10.1007/s11682-019-00099-3. Review. PubMed PMID: 31011951.
  48. Femminella, G.D., Harrison, J.E. et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study). BMC Trials. 2019; 20:191.
  49. Ferro DA, van den Brink H, Exalto LG, Boomsma JMF, Barkhof F, Prins ND, van der Flier WM, Biessels GJ; TRACE-VCI study group. Clinical relevance of acute  cerebral microinfarcts in vascular cognitive impairment. 2019 Apr 2;92(14):e1558-e1566. doi: 10.1212/WNL.0000000000007250. Epub 2019 Mar 8. PubMed  PMID: 30850444.
  50. Fredericks CA, Brown JA, Deng J, Kramer A, Ossenkoppele R, Rankin K, Kramer JH, Miller BL, Rabinovici GD, Seeley WW. Intrinsic connectivity networks in posterior cortical atrophy: A role for the pulvinar? Neuroimage Clin. 2019;21:101628. doi: 10.1016/j.nicl.2018.101628. Epub 2018 Dec 3. PubMed PMID: 30528957; PubMed Central PMCID: PMC6411779.
  51. Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, Collij L, Drzezga A, Farrar G, Garibotto V, Gismondi R, Gispert JD, Jessen F, Kivipelto  M, Lopes Alves I, Molinuevo JL, Nordberg A, Payoux P, Ritchie C, Savicheva I, Scheltens P, Schmidt ME, Schott JM, Stephens A, van Berckel B, Vellas B, Walker Z, Raffa N. AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimers Dement. 2019 Mar;15(3):388-399. doi: 10.1016/j.jalz.2018.09.003. Epub 2018 Oct 16. PubMed PMID: 30339801.
  52. Frisoni GB, Ritchie C, Carrera E, Nilsson P, Ousset PJ, Molinuevo JL, Dubois B, Scheltens P, Minoshima S. Re-aligning scientific and lay narratives of Alzheimer’s disease. Lancet Neurol. 2019 Oct;18(10):918-919. doi: 10.1016/S1474-4422(19)30323-0. PubMed PMID: 31526751.
  53. Fruijtier AD, Visser LNC, van Maurik IS, Zwan MD, Bouwman FH, van der Flier WM, Smets EMA. ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics. Alzheimers Res Ther. 2019 Aug 31;11(1):77. doi: 10.1186/s13195-019-0531-y. PubMed PMID: 31472676; PubMed Central PMCID:
  54. Fuermaier ABM, Piersma D, de Waard D, Davidse RJ, de Groot J, Doumen MJA, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, De Deyn PP, Brouwer WH, Tucha O. Driving Difficulties Among Patients with Alzheimer’s Disease and Other Neurodegenerative Disorders. J Alzheimers Dis. 2019;69(4):1019-1030. doi: 10.3233/JAD-181095. PubMed PMID: 31045516.
  55. Gallacher J, de Reydet de Vulpillieres F, Amzal B, Angehrn Z, Bexelius C, Bintener C, Bouvy JC, Campo L, Diaz C, Georges J, Gray A, Hottgenroth A, Jonsson  P, Mittelstadt B, Potashman MH, Reed C, Sudlow C, Thompson R, Tockhorn-Heidenreich A, Turner A, van der Lei J, Visser PJ; ROADMAP Consortium. Challenges for Optimizing Real-World Evidence in Alzheimer’s Disease: The ROADMAP Project. J Alzheimers Dis. 2019;67(2):495-501. doi: 10.3233/JAD-180370. PubMed PMID: 30584137; PubMed Central PMCID: PMC6398537.
  56. Gami-Patel P, van Dijken I, van Swieten JC, Pijnenburg YAL; Netherlands Brain Bank, Rozemuller AJM, Hoozemans JJM, Dijkstra AA. Von Economo neurons are part of a larger neuronal population that are selectively vulnerable in C9orf72 frontotemporal dementia. Neuropathol Appl Neurobiol. 2019 May 7. doi: 10.1111/nan.12558. Review. PubMed PMID: 31066065.
  57. Gardiner SL, Harder AVE, Campman YJM, Trompet S, Gussekloo J, van Belzen MJ, Boogaard MW, Roos RAC, Jansen IE, Pijnenburg YAL, Scheltens P, van der Flier WM, Aziz NA. Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer’s disease. Neurobiol Aging. 2019 Jan;73:230.e9-230.e17. doi: 10.1016/j.neurobiolaging.2018.09.007. Epub 2018 Sep 15. PubMed PMID: 30314815.
  58. Gerritsen AAJ, Bakker C, Bruls E, Verhey FRJ, Pijnenburg YAL, Millenaar JK, de Vugt ME, Koopmans RTCM. Psychotropic drug use in community-dwelling people with young-onset dementia: two-year course and determinants. Aging Ment Health. 2019 Nov 20:1-8. doi: 1080/13607863.2019.1691145. PubMed PMID: 31746238.
  59. Gerritsen AAJ, Bakker C, Verhey FRJ, Pijnenburg YAL, Millenaar JK, de Vugt ME, Koopmans RTCM. Survival and life-expectancy in a young-onset dementia cohort with six years of follow-up: the NeedYD-study. Int Psychogeriatr. 2019 Mar 27:1-9. doi: 10.1017/S1041610219000152. PubMed PMID: 30915930.
  60. Geut H, Vergouw LJM, Galis Y, Ingrassia A, de Jong FJ, Quadri M, Bonifati V, Lemstra AW, Rozemuller AJM, van de Berg WDJ. Neuropathological and genetic characteristics of a post-mortem series of cases with dementia with Lewy bodies clinically suspected of Creutzfeldt-Jakob’s disease. Parkinsonism Relat Disord. 2019 Jun;63:162-168. doi: 10.1016/j.parkreldis.2019.02.011. Epub 2019 Feb 13. PubMed PMID: 30777654.
  61. Gordon BA, Tijms BM. Elevated tau PET signal depends on abnormal amyloid levels and is uncommon in unimpaired individuals. 2019 Oct 1;142(10):2903-2904. doi: 10.1093/brain/awz278. PubMed PMID: 31560059.
  62. Gossink FT, Vijverberg E, Krudop W, Scheltens P, Stek ML, Pijnenburg YAL, Dols A. Predicting progression in the late onset frontal lobe syndrome. Int Psychogeriatr. 2019 May;31(5):743-748. doi: 10.1017/S1041610218001242. Epub 2018 Oct 26. PubMed PMID: 30362933.
  63. Groeneveld ON, Moneti C, Heinen R, de Bresser J, Kuijf HJ, Exalto LG, Boomsma JMF, Kappelle LJ, Barkhof F, Prins ND, Scheltens P, van der Flier WM, Biessels GJ; TRACE-VCI study group. The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. J Alzheimers Dis. 2019;68(1):311-322. doi: 10.3233/JAD-180914. PubMed PMID: 30775988.
  64. Gruters AAA, Ramakers IHGB, Kessels RPC, Bouwman FH, Olde Rikkert MGM, Blom MM, de Vugt ME, Verhey FRJ. Development of memory clinics in the Netherlands over the last 20 years. Int J Geriatr Psychiatry. 2019 Aug;34(8):1267-1274. doi: 10.1002/gps.5132. Epub 2019 May 20. PubMed PMID: 31034652.
  65. Haaksma ML, Rizzuto D, Ramakers IHGB, Garcia-Ptacek S, Marengoni A, van der Flier WM, Verhey FRJ, Olde Rikkert MGM, Melis RJF. The Impact of Frailty and Comorbidity on Institutionalization and Mortality in Persons With Dementia: A Prospective Cohort Study. J Am Med Dir Assoc. 2019 Feb;20(2):165-170.e2. doi: 10.1016/j.jamda.2018.06.020. Epub 2018 Aug 23. PubMed PMID: 30145169.
  66. Haan JD, van de Kreeke JA, Konijnenberg E, Kate MT, Braber AD, Barkhof F, van Berckel BN, Teunissen CE, Scheltens P, Visser PJ, Verbraak FD, Bouwman FH. Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer’s disease. Alzheimers Dement (Amst). 2019 Jun 18;11:463-471. doi: 10.1016/j.dadm.2019.05.002. eCollection 2019 Dec. PubMed PMID: 31249859; PubMed Central PMCID: PMC6584766.
  67. Haan JD, van de Kreeke JA, van Berckel BN, Barkhof F, Teunissen CE, Scheltens P, Verbraak FD, Bouwman FH. Is retinal vasculature a biomarker in amyloid proven  Alzheimer’s disease? Alzheimers Dement (Amst). 2019 May 10;11:383-391. doi: 10.1016/j.dadm.2019.03.006. eCollection 2019 Dec. PubMed PMID: 31193094; PubMed Central PMCID: PMC6517376.
  68. Hahn A, Strandberg TO, Stomrud E, Nilsson M, van Westen D, Palmqvist S, Ossenkoppele R, Hansson O. Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. Cereb Cortex. 2019 May 1;29(5):2173-2182. doi: 10.1093/cercor/bhz020. PubMed PMID: 30877785; PubMed Central PMCID: PMC6458901.
  69. Haijes HA, Willemse EAJ, Gerrits J, van der Flier WM, Teunissen CE, Verhoeven-Duif NM, Jans JJM. Assessing the Pre-Analytical Stability of Small-Molecule Metabolites in Cerebrospinal Fluid Using Direct-Infusion Metabolomics. Metabolites. 2019 Oct 18;9(10). pii: E236. doi: 10.3390/metabo9100236. PubMed PMID: 31635433; PubMed Central PMCID: PMC6835587
  70. Hanseeuw BJ, Scott MR, Sikkes SAM, Properzi M, Gatchel JR, Salmon E, Marshall GA, Vannini P; Alzheimer’s Disease Neuroimaging Initiative. Evolution of anosognosia in alzheimer’s disease and its relationship to amyloid. Ann Neurol. 2019 Nov 21. doi: 10.1002/ana.25649. PubMed PMID: 31750553.
  71. Harrison, J.E., (2019) The assessment of cognitive dysfunction in Major Depressive Disorder. In Baune, B. & Harmer, C. (eds) Cognitive Dimensions of Major Depressive Disorder (Oxford, Oxford University Press).
  72. Harrison, J.E. Screening and measurement of cognitive impairment in psychiatry. CNS Spectrums (Special edition): ‘Cognition in Psychiatry – A Transdiagnostic Phenomenological Domain’. 2019:24(1):144-153. https://doi.org/10.1017/S1092852918001657.
  73. Harrison, J.E. & Hendrix, S. (2019) The assessment of cognition in translational medicine: A contrast between the approaches used in Alzheimer’s disease and Major Depressive Disorder. In Nomikos, G., (ed.) Translational Medicine in CNS Drug Development: Handbook of Behavioral Neuroscience, volume 25 (Elsevier, Amsterdam):297-308.
  74. Heinen R, Steenwijk MD, Barkhof F, Biesbroek JM, van der Flier WM, Kuijf HJ, Prins ND, Vrenken H, Biessels GJ, de Bresser J; TRACE-VCI study group. Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset. Sci Rep. 2019 Nov 14;9(1):16742. doi:10.1038/s41598-019-52966-0. PubMed PMID: 31727919.
  75. Hendrix SB, Soininen H, van Hees AMJ, Ellison N, Visser PJ, Solomon A, Attali A, Blennow K, Kivipelto M, Hartmann T. Alzheimer’s Disease Composite Score: A Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer’s Disease. J Prev Alzheimers Dis. 2019;6(4):232-236. doi: 10.14283/jpad.2019.33. PubMed PMID: 31686094.
  76. Hijazi S, Heistek TS, Scheltens P, Neumann U, Shimshek DR, Mansvelder HD, Smit AB, van Kesteren RE. Early restoration of parvalbumin interneuron activity prevents memory loss and network hyperexcitability in a mouse model of Alzheimer’s disease. Mol Psychiatry. 2019 Aug 20. doi: 10.1038/s41380-019-0483-4. PubMed PMID: 31431685.
  77. Hooghiemstra AM, Leeuwis AE, Bertens AS, Biessels GJ, Bots ML, Brunner-La Rocca HP, Greving JP, Kappelle LJ, van Oostenbrugge RJ, van Rossum AC, van der Flier WM. Frequent Cognitive Impairment in Patients With Disorders Along the Heart-Brain Axis. Stroke. 2019 Dec;50(12):3369-3375. doi: 10.1161/STROKEAHA.119.026031. Epub 2019 Nov 5. PubMed PMID: 31684846.
  78. Hooghiemstra AM, Wesselman LMP, Franken L, van der Flier WM, Lemstra AW. Een interactieve website voor Alzheimercentrum Amsterdam: Wat vindt de gebruiker? Alzheimercentrum Amsterdam 2019; http://bit.ly/hooghiemstra2019.
  79. Hu X, Teunissen CE, Spottke A, Heneka MT, Düzel E, Peters O, Li S, Priller J, Buerger K, Teipel S, Laske C, Verfaillie SCJ, Barkhof F, Coll-Padrós N, Rami L, Molinuevo JL, van der Flier WM, Jessen F. Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer’s disease-Data from three memory clinic studies. Alzheimers Dement. 2019 Feb;15 (2):185-193. doi: 10.1016/j.jalz.2018.09.002. Epub 2018 Oct 12. PubMed PMID: 30321506.
  80. Jagust W, Jack CR Jr, Bennett DA, Blennow K, Haeberlein SB, Holtzman DM, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe  CC, Scheltens P, Siemers E, Sperling R. “Alzheimer’s disease” is neither “Alzheimer’s clinical syndrome” nor “dementia”. Alzheimers Dement. 2019 Jan;15(1):153-157. doi: 10.1016/j.jalz.2018.11.002. PubMed PMID: 30642435.
  81. Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, Hägg S, Athanasiu L, Voyle N, Proitsi P, Witoelar A, Stringer S,  Aarsland D, Almdahl IS, Andersen F, Bergh S, Bettella F, Bjornsson S, Brækhus A,  Bråthen G, de Leeuw C, Desikan RS, Djurovic S, Dumitrescu L, Fladby T, Hohman TJ, Jonsson PV, Kiddle SJ, Rongve A, Saltvedt I, Sando SB, Selbæk G, Shoai M, Skene NG, Snaedal J, Stordal E, Ulstein ID, Wang Y, White LR, Hardy J, Hjerling-Leffler J, Sullivan PF, van der Flier WM, Dobson R, Davis LK, Stefansson H, Stefansson K, Pedersen NL, Ripke S, Andreassen OA, Posthuma D. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat Genet. 2019 Mar;51(3):404-413. doi: 10.1038/s41588-018-0311-9. Epub 2019 Jan  7. PubMed PMID: 30617256.
  82. Janssen O, Vos SJB, García-Negredo G, Tochel C, Gustavsson A, Smith M, Ly A, Nelson M, Baldwin H, Sudlow C, Bexelius C, Jindra C, Vaci N, Bauermeister S, Gallacher J, Ponjoan A, Dufouil C, Garre Olmo J, Pedersen L, Skoog I, Hottgenroth A, Visser PJ, van der Lei J, Diaz C. Real-world evidence in Alzheimer’s disease: The ROADMAP Data Cube. Alzheimers Dement. 2019 Nov 27. pii: S1552-5260(19)35487-1. doi: 10.1016/j.jalz.2019.09.087. PubMed PMID: 31786128.
  83. Jokinen H, Koikkalainen J, Laakso HM, Melkas S, Nieminen T, Brander A. Korvenoja A, Rueckert D, Barkhof F, Scheltens P, Schmidt R, Fazekas F, Madureira S, Verdelho A, Wallin A, Wahlund LO, Waldemar G, Chabriat H, Hennerici M, O’Brien J, Inzitari D, Lötjönen J, Pantoni L, Erkinjuntti T. Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline. 2019 Nov 8:STROKEAHA119026170. doi: 10.1161/STROKEAHA.119.026170. PubMed PMID: 31699021.
  84. Joling M, Vriend C, Raijmakers PGHM, van der Zande JJ, Lemstra AW, Berendse HW, Booij J, van den Heuvel OA. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson’s disease and dementia with Lewy bodies, compared with healthy controls: An (123)I-FP-CIT SPECT study. Neuroimage Clin. 2019;22:101755. doi: 10.1016/j.nicl.2019.101755. Epub 2019 Mar 12. PubMed PMID: 30884365; PubMed Central PMCID: PMC6424141.
  85. Jovicich J, Babiloni C, Ferrari C, Marizzoni M, Moretti DV, Del Percio C, Lizio R, Lopez S, Galluzzi S, Albani D, Cavaliere L, Minati L, Didic M, Fiedler U, Forloni G, Hensch T, Molinuevo JL, Bartrés Faz D, Nobili F, Orlandi D, Parnetti L, Farotti L, Costa C, Payoux P, Rossini PM, Marra C, Schönknecht P, Soricelli A, Noce G, Salvatore M, Tsolaki M, Visser PJ, Richardson JC, Wiltfang J, Bordet R, Blin O, Frisoniand GB; and the PharmaCog Consortium. Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. J Alzheimers Dis. 2019;69(1):15-35. doi: 10.3233/JAD-180158. PubMed PMID: 30400088.
  86. Jutten RJ, Harrison JE, Lee Meeuw Kjoe PR, Ingala S, Vreeswijk R, van Deelen  RAJ, de Jong FJ, Opmeer EM, Aleman A, Ritchie CW, Scheltens P, Sikkes SAM. Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. Alzheimers Res Ther. 2019 May 15;11(1):45. doi: 10.1186/s13195-019-0500-5. PubMed PMID: 31092277; PubMed Central PMCID: PMC6521452.
  87. Jutten RJ, Dicks E, Vermaat L, Barkhof F, Scheltens P, Tijms BM, Sikkes SAM.  Impairment in complex activities of daily living is related to neurodegeneration  in Alzheimer’s disease-specific regions. Neurobiol Aging. 2019 Mar;75:109-116. doi: 10.1016/j.neurobiolaging.2018.11.018. Epub 2018 Nov 26. PubMed PMID: 30557769.
  88. Kenkhuis B, Jonkman LE, Bulk M, Buijs M, Boon BDC, Bouwman FH, Geurts JJG, van de Berg WDJ, van der Weerd L. 7T MRI allows detection of disturbed cortical lamination of the medial temporal lobe in patients with Alzheimer’s disease. Neuroimage Clin. 2019;21:101665. doi: 10.1016/j.nicl.2019.101665. Epub 2019 Jan PubMed PMID: 30642758; PubMed Central PMCID: PMC6413344.
  89. Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, Westwood S, Baird A, Proitsi P, Nevado-Holgado A, Hye A, Bos I, Vos S, Vandenberghe R, Teunissen C, Ten Kate M, Scheltens P, Gabel S, Meersmans K, Blin O, Richardson J, De Roeck E,  Sleegers K, Bordet R, Rami L, Kettunen P, Tsolaki M, Verhey F, Sala I, Lléo A, Peyratout G, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Engelborghs S, Frisoni GB, Molinuevo JL, Wallin A, Popp J, Martinez-Lage P, Bertram L, Barkhof F, Ashton N, Blennow K, Zetterberg H, Streffer J, Visser PJ, Lovestone S, Legido-Quigley C. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort. Alzheimers Dement. 2019 Jun;15(6):817-827. doi: 10.1016/j.jalz.2019.03.004. Epub 2019 May 8. PubMed PMID: 31078433.
  90. Kleipool EEF, Trappenburg MC, Rhodius-Meester HFM, Lemstra AW, van der Flier  WM, Peters MJL, Muller M. Orthostatic Hypotension: An Important Risk Factor for Clinical Progression to Mild Cognitive Impairment or Dementia. The Amsterdam Dementia Cohort. J Alzheimers Dis. 2019 Jul 27. doi: 10.3233/JAD-190402. PubMed PMID: 31381517.
  91. Koikkalainen JR, Rhodius-Meester HFM, Frederiksen KS, Bruun M, Hasselbalch SG, Baroni M, Mecocci P, Vanninen R, Remes A, Soininen H, van Gils M, van der Flier WM, Scheltens P, Barkhof F, Erkinjuntti T, Lötjönen JMP; Alzheimer’s Disease Neuroimaging Initiative. Automatically computed rating scales from MRI for patients with cognitive disorders. Eur Radiol. 2019 Sep;29(9):4937-4947. doi: 10.1007/s00330-019-06067-1. Epub 2019 Feb 22. PubMed PMID: 30796570.
  92. Konijnenberg E, den Braber A, Ten Kate M, Tomassen J, Mulder SD, Yaqub M, Teunissen CE, Lammertsma AA, van Berckel BNM, Scheltens P, Boomsma DI, Visser PJ. Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. Neurobiol Aging. 2019 May;77:58-65. doi: 10.1016/j.neurobiolaging.2019.01.006. Epub 2019 Jan 21. PubMed PMID: 30784813.
  93. Leeuwis AE, Weaver NA, Biesbroek JM, Exalto LG, Kuijf HJ, Hooghiemstra AM, Prins ND, Scheltens P, Barkhof F, van der Flier WM, Biessels GJ; TRACE-VCI study  group. Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion–symptom mapping study. J Psychiatry Neurosci. 2019 Jul 1;44(4):E1-E10. PubMed PMID: 31021068; PubMed Central PMCID: PMC6606429.
  94. Legdeur N, Tijms BM, Konijnenberg E, den Braber A, Ten Kate M, Sudre CH, Tomassen J, Badissi M, Yaqub M, Barkhof F, van Berckel BN, Boomsma DI, Scheltens P, Holstege H, Maier AB, Visser PJ. Associations of brain pathology, cognitive and physical markers with age in cognitively normal individuals aged 60-102 years. J Gerontol A Biol Sci Med Sci. 2019 Aug 14. pii: glz180. doi: 10.1093/gerona/glz180. PubMed PMID: 31411322.
  95. Legdeur N, van der Lee SJ, de Wilde M, van der Lei J, Muller M, Maier AB, Visser PJ. The association of vascular disorders with incident dementia in different age groups. Alzheimers Res Ther. 2019 May 17;11(1):47. doi: 10.1186/s13195-019-0496-x. PubMed PMID: 31097030; PubMed Central PMCID: PMC6524321.
  96. Legdeur N, Visser PJ, Woodworth DC, Muller M, Fletcher E, Maillard P, Scheltens P, DeCarli C, Kawas CH, Corrada MM. White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study. J Am Geriatr Soc. 2019 Jun 6. doi: 10.1111/jgs.15990. PubMed PMID: 31169919.
  97. Leijenaar JF, Groot C, Sudre CH, Bergeron D, Leeuwis AE, Cardoso MJ, Carrasco FP, Laforce R Jr, Barkhof F, van der Flier WM, Scheltens P, Prins ND, Ossenkoppele R. Comorbid amyloid-β pathology affects clinical and imaging features in VCD. Alzheimers Dement. 2019 Nov 27. pii: S1552-5260(19)35350-6. doi: 10.1016/j.jalz.2019.08.190. PubMed PMID: 31786129.
  98. Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P, Scheltens P, Poirier J, Saftig P, Bateman RJ, Breitner J, Hock C, Multhaup G. Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression. Nat Commun. 2019 May 20;10(1):2240. doi: 10.1038/s41467-019-10152-w. PubMed PMID: 31110178; PubMed Central PMCID: PMC6527709.
  99. Linszen MMJ, van Zanten GA, Teunisse RJ, Brouwer RM, Scheltens P, Sommer IE.  Auditory hallucinations in adults with hearing impairment: a large prevalence study. Psychol Med. 2019 Jan;49(1):132-139. doi: 10.1017/S0033291718000594. Epub  2018 Mar 20. PubMed PMID: 29554989.
  100. Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, Vandenbergue R, Freund-Levi Y, Verhey FRJ, Clarimón J, Fortea J, Frolich L, Santana I, Molinuevo JL, Lehmann S, Visser PJ, Teunissen CE, Zetterberg H, Blennow K. Longitudinal cerebrospinal fluid biomarker trajectories  along the Alzheimer’s disease continuum in the BIOMARKAPD study. Alzheimers Dement. 2019 Jun;15(6):742-753. doi: 10.1016/j.jalz.2019.01.015. Epub 2019 Apr 6. PubMed PMID: 30967340.
  101. Marizzoni M, Ferrari C, Jovicich J, Albani D, Babiloni C, Cavaliere L, Didic  M, Forloni G, Galluzzi S, Hoffmann KT, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Ribaldi F, Rossini PM, Schönknecht P, Salvatore M, Soricelli A, Hensch T, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB; PharmaCog Consortium. Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease: Structural Brain Biomarkers. J Alzheimers Dis. 2019;69(1):3-14. doi: 10.3233/JAD-180152. PubMed PMID: 29914031.
  102. Marizzoni M, Ferrari C, Macis A, Jovicich J, Albani D, Babiloni C, Cavaliere L, Didic M, Forloni G, Galluzzi S, Hoffmann KT, Molinuevo JL, Nobili F, Parnetti  L, Payoux P, Pizzini F, Rossini PM, Salvatore M, Schönknecht P, Soricelli A, Del  Percio C, Hensch T, Hegerl U, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB; PharmaCog Consortium. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease. J Alzheimers Dis. 2019;69(1):49-58. doi: 10.3233/JAD-181016. PubMed PMID: 30958351.
  103. Mattsson N, Insel PS, Donohue M, Jögi J, Ossenkoppele R, Olsson T, Schöll M, Smith R, Hansson O. Predicting diagnosis and cognition with (18)F-AV-1451 tau PET and structural MRI in Alzheimer’s disease. Alzheimers Dement. 2019 Apr;15(4):570-580. doi: 10.1016/j.jalz.2018.12.001. Epub 2019 Jan 25. PubMed PMID: 30639421.
  104. Meeter LHH, Steketee RME, Salkovic D, Vos ME, Grossman M, McMillan CT, Irwin DJ, Boxer AL, Rojas JC, Olney NT, Karydas A, Miller BL, Pijnenburg YAL, Barkhof F, Sánchez-Valle R, Lladó A, Borrego-Ecija S, Diehl-Schmid J, Grimmer T, Goldhardt O, Santillo AF, Hansson O, Vestberg S, Borroni B, Padovani A, Galimberti D, Scarpini E, Rohrer JD, Woollacott IOC, Synofzik M, Wilke C, de Mendonca A, Vandenberghe R, Benussi L, Ghidoni R, Binetti G, Niessen WJ, Papma JM, Seelaar H, Jiskoot LC, de Jong FJ, Donker Kaat L, Del Campo M, Teunissen CE, Bron EE, Van den Berg E, Van Swieten JC. Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. J Neurol Neurosurg Psychiatry. 2019 May 2. pii: jnnp-2018-319784. doi: 10.1136/jnnp-2018-319784. PubMed PMID: 31123142.
  105. Morbelli S, Chincarini A, Brendel M, Rominger A, Bruffaerts R, Vandenberghe R, Kramberger MG, Trost M, Garibotto V, Nicastro N, Frisoni GB, Lemstra AW, van der Zande J, Pilotto A, Padovani A, Garcia-Ptacek S, Savitcheva I, Ochoa-Figueroa MA, Davidsson A, Camacho V, Peira E, Arnaldi D, Bauckneht M, Pardini M, Sambuceti G, Aarsland D, Nobili F. Metabolic patterns across core features in dementia with lewy bodies. Ann Neurol. 2019 May;85(5):715-725. doi: 10.1002/ana.25453. Epub 2019 Mar 22. PubMed PMID: 30805951.
  106. Morgan AR, Touchard S, Leckey C, O’Hagan C, Nevado-Holgado AJ; NIMA Consortium, Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, Engelborghs S, Frisoni G, Frölich L, Gabel S, Johannsen P, Kettunen P, Kłoszewska I, Legido-Quigley C, Lleó A, Martinez-Lage P, Mecocci P, Meersmans K, Molinuevo JL,  Peyratout G, Popp J, Richardson J, Sala I, Scheltens P, Streffer J, Soininen H, Tainta-Cuezva  M, Teunissen C, Tsolaki M, Vandenberghe R, Visser PJ, Vos S, Wahlund LO, Wallin A, Westwood S, Zetterberg H, Lovestone S, Morgan BP; Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer’s Disease. Inflammatory biomarkers in Alzheimer’s disease plasma. Alzheimers Dement. 2019 Jun;15(6):776-787. doi:  10.1016/j.jalz.2019.03.007. Epub  2019 Apr 30. PubMed PMID: 31047856; PubMed Central PMCID: PMC6565806.
  107. Oort Q, Taphoorn MJB, Sikkes SAM, Uitdehaag BMJ, Reijneveld JC, Dirven L. Evaluation of the  content coverage of questionnaires containing basic and instrumental activities of daily living (ADL) used in adult patients with brain tumors. J Neurooncol. 2019 May;143(1):1-13. doi: 10.1007/s11060-019-03136-9. Epub 2019 Mar 18.
  108. Oppedal K, Ferreira D, Cavallin L, Lemstra AW, Ten Kate M, Padovani A, Rektorova I, Bonanni L, Wahlund LO, Engedal K, Nobili F, Kramberger M, Taylor JP, Hort J, Snædal J, Blanc F, Walker Z, Antonini A, Westman E, Aarsland D; Alzheimer’s Disease Neuroimaging Initiative. A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. Alzheimers Dement. 2019 Mar;15(3):400-409. doi: 10.1016/j.jalz.2018.09.011. Epub 2018 Nov 12. PubMed PMID: 30439333.
  109. Ossenkoppele R, Iaccarino L, Schonhaut DR, Brown JA, La Joie R, O’Neil JP, Janabi M, Baker SL, Kramer JH, Gorno-Tempini ML, Miller BL, Rosen HJ, Seeley WW,  Jagust WJ, Rabinovici GD. Tau covariance patterns in Alzheimer’s disease patients match intrinsic connectivity networks in the healthy brain. Neuroimage Clin. 2019 May 2;23:101848. doi: 10.1016/j.nicl.2019.101848. PubMed PMID: 31077982; PubMed Central PMCID: PMC6510968.
  110. Ossenkoppele R, Lyoo CH, Sudre CH, van Westen D, Cho H, Ryu YH, Choi JY, Smith R, Strandberg O, Palmqvist S, Westman E, Tsai R, Kramer J, Boxer AL, Gorno-Tempini ML, La Joie R, Miller BL, Rabinovici GD, Hansson O. Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease. Alzheimers Dement. 2019 Oct 28. pii: S1552-5260(19)35375-0. doi: 10.1016/j.jalz.2019.08.201. PubMed PMID: 31672482.
  111. Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, Palmqvist S, Hansson O. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. 2019 Feb 5;92(6):e601-e612. doi: 10.1212/WNL.0000000000006875. Epub 2019 Jan 9. PubMed PMID: 30626656; PubMed Central PMCID: PMC6382060.
  112. Oudeman EA, Greving JP, Hooghiemstra AM, Brunner-La Rocca HP, Biessels GJ, Kappelle LJ; Heart-Brain Connection Consortium. Nonfocal transient neurological attacks are related to cognitive impairment in patients with heart failure. J Neurol. 2019 Aug;266(8):2035-2042. doi: 10.1007/s00415-019-09376-z. Epub 2019 May 21.
  113. Pelkmans W, Dicks E, Barkhof F, Vrenken H, Scheltens P, van der Flier WM, Tijms BM. Gray matter T1-w/T2-w ratios are higher in Alzheimer’s disease. Hum Brain Mapp. 2019 Sep;40(13):3900-3909. doi: 10.1002/hbm.24638. Epub 2019 Jun 3. PubMed PMID: 31157938.
  114. Pereira JB, Ossenkoppele R, Palmqvist S, Strandberg TO, Smith R, Westman E, Hansson O. Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. Elife. 2019 Dec 9;8. pii: e50830. doi: 10.7554/eLife.50830. PubMed PMID: 31815669.
  115. Reimand J, Groot C, Teunissen CE, Windhorst AD, Boellaard R, Barkhof F, Nazarenko S, van der Flier WM, van Berckel BNM, Scheltens P, Ossenkoppele R, Bouwman F. Why Is Amyloid-β PET Requested After Performing Cerebrospinal Fluid Biomarkers? J Alzheimers Dis. 2019 Nov 25. doi: 10.3233/JAD-190836. PubMed PMID: 31796674.
  116. Reimand J, de Wilde A, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, Barkhof F, van der Flier WM, Scheltens P, van Berckel BNM, Ossenkoppele R, Bouwman F. PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases. Alzheimers Res Ther. 2019 Dec 7;11(1):100. doi: 10.1186/s13195-019-0561-5. PubMed PMID: 31810489.
  117. Rhodius-Meester HFM, van Maurik IS, Koikkalainen J, Tolonen A, Frederiksen KS, Hasselbach SG, Soininen H, Herukka SK, Remes AM, Teunissen CE, Barkhof F, Pijnenburg YAL, Scheltens P, Lotjonen J, van der Flier WM. Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. PlosOne, in press.
  118. Rhodius-Meester HFM, Tijms BM, Lemstra AW, Prins ND, Pijnenburg YAL, Bouwman  F, Scheltens P, van der Flier WM. Survival in memory clinic cohort is short, even in young-onset dementia. J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):726-728. doi: 10.1136/jnnp-2018-318820. Epub 2018 Jul 25. PubMed PMID: 30045942; PubMed Central PMCID: PMC6581097.
  119. Rimkus CM, Schoonheim MM, Steenwijk MD, Vrenken H, Eijlers AJ, Killestein J, Wattjes MP, Leite CC, Barkhof F, Tijms BM. Gray matter networks and cognitive impairment in multiple sclerosis. Mult Scler. 2019 Mar;25(3):382-391. doi: 10.1177/1352458517751650. Epub 2018 Jan 11. PubMed PMID: 29320933; PubMed Central PMCID: PMC6393954.
  120. Rodríguez-Gómez O, Rodrigo A, Iradier F, Santos-Santos MA, Hundemer H, Ciudin  A, Sannemann L, Zwan M, Glaysher B, Wimo A, Bonn J, Johansson G, Rodriguez I, Alegret M, Gove D, Pinó S, Trigueros P, Kivipelto M, Mathews B, Ciudad A, Ferreira D, Bintener C, Gurruchaga M, Westman E, Belger M, Valero S, Maguire P, Krivec D, Kramberger M, Simó R, Garro IP, Visser PJ, Dumas A, Georges J, Jessen F, Winblad B, Shering C, Stewart N, Campo L, Boada M; MOPEAD Consortium. The MOPEAD project: Advancing patient engagement for the detection of “hidden” undiagnosed cases of Alzheimer’s disease in the community. Alzheimers Dement. 2019 Jun;15(6):828-839. doi: 10.1016/j.jalz.2019.02.003. Epub 2019 May 7. Review. PubMed PMID: 31076376
  121. Rongve A, Witoelar A, Ruiz A, Athanasiu L, Abdelnour C, Clarimon J, Heilmann-Heimbach S, Hernández I, Moreno-Grau S, de Rojas I, Morenas-Rodríguez E, Fladby T, Sando SB, Bråthen G, Blanc F, Bousiges O, Lemstra AW, van Steenoven I, Londos E, Almdahl IS, Pålhaugen L, Eriksen JA, Djurovic S, Stordal E, Saltvedt I, Ulstein ID, Bettella F, Desikan RS, Idland AV, Toft M, Pihlstrøm L, Snaedal J, Tárraga L, Boada M, Lleó A, Stefánsson H, Stefánsson K, Ramírez A, Aarsland D, Andreassen OA. GBA and APOE ε4 associate with sporadic dementia with Lewy bodies in European genome wide association study. Sci Rep. 2019 May 7;9(1):7013. doi: 10.1038/s41598-019-43458-2. Erratum in: Sci Rep. 2019 Oct 17;9(1):15168. PubMed PMID: 31065058; PubMed Central PMCID: PMC6504850.
  122. Rongve A, Witoelar A, Ruiz A, Athanasiu L, Abdelnour C, Clarimon J, Heilmann-Heimbach S, Hernández I, Moreno-Grau S, de Rojas I, Morenas-Rodríguez E, Fladby T, Sando SB, Bråthen G, Blanc F, Bousiges O, Lemstra AW, van Steenoven I, Londos E, Almdahl IS, Pålhaugen L, Eriksen JA, Djurovic S, Stordal E, Saltvedt I, Ulstein ID, Bettella F, Desikan RS, Idland AV, Toft M, Pihlstrøm L, Snaedal J, Tárraga L, Boada M, Lleó A, Stefánsson H, Stefánsson K, Ramírez A, Aarsland D, Andreassen OA. Author Correction: GBA and APOE ε4 associate with sporadic dementia with Lewy bodies in European genome wide association study. Sci Rep. 2019 Oct 17;9(1):15168. doi: 10.1038/s41598-019-51827-0. PubMed PMID: 31619746; PubMed Central PMCID: PMC6795898.
  123. Sabbagh, M.N., Hendrix, S. & Harrison, J.E. FDA position statement “Early Alzheimer’s disease: developing drugs for treatment, Guidance for Industry”. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2019:5:13-19.
  124. Scheltens NME, Briels CT, Yaqub M, Barkhof F, Boellaard R, van der Flier WM, Schwarte LA, Teunissen CE, Attali A, Broersen LM, van Berckel BNM, Scheltens P. Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer’s disease. Alzheimers Dement (N Y). 2019 Sep 27;5:492-500. doi: 10.1016/j.trci.2019.08.002. eCollection 2019. PubMed PMID: 31650005; PubMed Central PMCID: PMC6804721.
  125. Shi L, Westwood S, Baird AL, Winchester L, Dobricic V, Kilpert F, Hong S, Franke A, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Buckley NJ, Kate MT, Scheltens P, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lleó A, Alcolea D, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Teunissen CE, Freund-Levi Y, Frölich L, Legido-Quigley C, Barkhof F, Blennow K, Zetterberg H, Baker S, Morgan BP, Streffer J, Visser PJ, Bertram L, Lovestone S, Nevado-Holgado AJ. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimers Dement. 2019 Nov;15(11):1478-1488. doi: 10.1016/j.jalz.2019.06.4951. Epub 2019 Sep 5. PubMed PMID: 31495601; PubMed Central PMCID: PMC6880298.
  126. Sikkes SAM, Dubbelman MA, Verrijp M, Jutten RJ, Gillissen F, Pijnenburg YAL, Scheltens P. (2019). Het meten van problemen in het dagelijks leven bij beginnende dementie: De Amsterdam IADL-vragenlijst. Tijdschrift voor Neuropsychologie, 14(2), 126-137.
  127. Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, Dardiotis E, Guillo-Benarous F, Hampel H, Kochan NA, Lista S, Luck T, Maruff P, Molinuevo JL,  Kornhuber J, Reisberg B, Riedel-Heller SG, Risacher SL, Roehr S, Sachdev PS, Scarmeas N, Scheltens P, Shulman MB, Saykin AJ, Verfaillie SCJ, Visser PJ, Vos SJB, Wagner M, Wolfsgruber S, Jessen F; Alzheimer’s Disease Neuroimaging Initiative; DESCRIPA working group; INSIGHT-preAD study group; SCD-I working group, van der Flier WM. Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia. Alzheimers Dement. 2019 Mar;15(3):465-476. doi: 10.1016/j.jalz.2018.10.003. Epub 2018 Dec 13. PubMed PMID: 30555032; PubMed Central PMCID: PMC6465066.
  128. Slot RER, Kester MI, Van Harten AC, Jongbloed W, Bouwman FH, Teunissen CE, Scheltens P, van der Flier WM, Veerhuis R. ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF  Aβ42, levels in non-demented elderly. Neurobiol Aging. 2019 Jul;79:101-109. doi:  10.1016/j.neurobiolaging.2019.02.017. Epub 2019 Mar 1. PubMed PMID: 31029938.
  129. Stern Y, Chételat G, Habeck C, Arenaza-Urquijo EM, Vemuri P, Estanga A, Bartrés-Faz D, Cantillon M, Clouston SAP, Elman JA, Gold BT, Jones R, Kempermann  G, Lim YY, van Loenhoud A, Martínez-Lage P, Morbelli S, Okonkwo O, Ossenkoppele R, Pettigrew C, Rosen AC, Scarmeas N, Soldan A, Udeh-Momoh C, Valenzuela M, Vuoksimaa E. Mechanisms underlying resilience in ageing. Nat Rev Neurosci. 2019 Apr;20(4):246. doi: 10.1038/s41583-019-0138-0. PubMed PMID: 30814677.
  130. Tesi N, van der Lee SJ, Hulsman M, Jansen IE, Stringa N, van Schoor N, Meijers-Heijboer H, Huisman M, Scheltens P, Reinders MJT, van der Flier WM, Holstege H. Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer’s disease. Eur J Hum Genet. 2019 Feb;27(2):244-253. doi: 10.1038/s41431-018-0273-5. Epub 2018 Sep  26. PubMed PMID: 30258121; PubMed Central PMCID: PMC6336855.
  131. Timmers T, Ossenkoppele R, Wolters EE, Verfaillie SCJ, Visser D, Golla SSV, Barkhof F, Scheltens P, Boellaard R, van der Flier WM, van Berckel BNM. Associations between  quantitative [(18)F]flortaucipir tau PET and atrophy across  the Alzheimer’s disease spectrum. Alzheimers Res Ther. 2019 Jul 4;11(1):60. doi:  10.1186/s13195-019-0510-3. PubMed PMID: 31272512; PubMed Central PMCID: PMC6610969.
  132. Timmers T, Ossenkoppele R, Verfaillie SCJ, van der Weijden CWJ, Slot RER, Wesselman LMP, Windhorst AD, Wolters EE, Yaqub M, Prins ND, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BNM. Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project. Neurobiol Aging. 2019 Jul;79:50-58. doi: 10.1016/j.neurobiolaging.2019.02.020. Epub 2019 Mar 8. PubMed  PMID: 31026622.
  133. Timmers T, Ossenkoppele R, Visser D, Tuncel H, Wolters EE, Verfaillie SC, van der Flier WM, Boellaard R, Golla SS, van Berckel BN. Test-retest repeatability of [(18)F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals. J Cereb Blood Flow Metab. 2019 Oct 1:271678X19879226. doi: 10.1177/0271678X19879226. PubMed PMID: 31575335.
  134. van de Beek M, van Steenoven I, Ramakers IHGB, Aalten P, Koek HL, Olde Rikkert MGM, Manniën J, Papma JM, de Jong FJ, Lemstra AW, van der Flier WM. Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer’s Disease. J Alzheimers Dis. 2019;70(2):389-397. doi: 10.3233/JAD-190041. PubMed PMID: 31177218.
  135. van de Kreeke JA, Nguyen HT, den Haan J, Konijnenberg E, Tomassen J, den Braber A, Ten Kate M, Collij L, Yaqub M, van Berckel B, Lammertsma AA, Boomsma DI, Tan HS, Verbraak FD, Visser PJ. Retinal layer thickness in preclinical Alzheimer’s disease. Acta Ophthalmol. 2019 May 6. doi: 10.1111/aos.14121. PubMed PMID: 31058465.
  136. van de Kreeke JA, Nguyen HT, Konijnenberg E, Tomassen J, den Braber A, Ten Kate M, Yaqub M, van Berckel B, Lammertsma AA, Boomsma DI, Tan SH, Verbraak F, Visser PJ. Optical coherence tomography angiography in preclinical Alzheimer’s disease. Br J Ophthalmol. 2019 May 22. pii: bjophthalmol-2019-314127. doi: 10.1136/bjophthalmol-2019-314127. PubMed PMID: 31118186.
  137. van der Ende EL, Meeter LH, Poos JM, Panman JL, Jiskoot LC, Dopper EGP, Papma JM, de Jong FJ, Verberk IMW, Teunissen C, Rizopoulos D, Heller C, Convery RS, Moore KM, Bocchetta M, Neason M, Cash DM, Borroni B, Galimberti D, Sanchez-Valle R, Laforce R Jr, Moreno F, Synofzik M, Graff C, Masellis M, Carmela Tartaglia M, Rowe JB, Vandenberghe R, Finger E, Tagliavini F, de Mendonça A, Santana I, Butler C, Ducharme S, Gerhard A, Danek A, Levin J, Otto M, Frisoni GB, Cappa S, Pijnenburg YAL, Rohrer JD, van Swieten JC; Genetic Frontotemporal dementia Initiative (GENFI). Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol. 2019 Dec;18(12):1103-1111. doi: 10.1016/S1474-4422(19)30354-0. PubMed PMID: 31701893.
  138. van der Ende EL, Meeter LH, Stingl C, van Rooij JGJ, Stoop MP, Nijholt DAT, Sanchez-Valle R, Graff C, Öijerstedt L, Grossman M, McMillan C, Pijnenburg YAL, Laforce R Jr, Binetti G, Benussi L, Ghidoni R, Luider TM, Seelaar H, van Swieten  JC. Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. Ann Clin Transl Neurol. 2019 Mar 7;6(4):698-707. doi: 10.1002/acn3.745. eCollection 2019 Apr. PubMed PMID: 31019994; PubMed Central PMCID: PMC6469343.
  139. van der Kant R, Goldstein LSB, Ossenkoppele R. Amyloid-β-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci. 2019 Nov 28. doi: 10.1038/s41583-019-0240-3. Review. PubMed PMID: 31780819.
  140. van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer  M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk  and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga  L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathol. 2019 Aug;138(2):237-250. doi: 10.1007/s00401-019-02026-8. Epub 2019  May 27. PubMed PMID: 31131421.
  141. van der Zande JJ, Joling M, Happach IG, Vriend C, Scheltens P, Booij J, Lemstra AW. Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer’s disease pathology: An (123)I-FP-CIT SPECT study. Neuroimage Clin. 2019 Nov 1;25:102062. doi: 10.1016/j.nicl.2019.102062. PubMed PMID: 31790878.
  142. Van Loenhoud AC, de Boer C, Wols K, Pijnenburg YA, Lemstra AW, Bouwman FH, Prins ND, Scheltens P, Ossenkoppele R, van der Flier WM. High occurrence of transportation and logistics occupations among vascular dementia patients: an observational study. Accepted in Alzheimers Res Ther.
  143. van Loenhoud AC, van der Flier WM, Wink AM, Dicks E, Groot C, Twisk J, Barkhof F, Scheltens P, Ossenkoppele R; Alzheimer’s Disease Neuroimaging Initiative. Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship. 2019 Jul 23;93(4):e334-e346. doi: 10.1212/WNL.0000000000007821. Epub 2019 Jul 2. PubMed PMID: 31266904.
  144. van Maurik IS, Visser LN, Pel-Littel RE, van Buchem MM, Zwan MD, Kunneman M,  Pelkmans W, Bouwman FH, Minkman M, Schoonenboom N, Scheltens P, Smets EM, van der Flier WM. Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease. JMIR Form Res. 2019 Jul 8;3(3):e13417. doi: 10.2196/13417. PubMed PMID: 31287061; PubMed Central PMCID: PMC6643768.
  145. van Maurik IS, Slot RER, Verfaillie SCJ, Zwan MD, Bouwman FH, Prins ND, Teunissen CE, Scheltens P, Barkhof F, Wattjes MP, Molinuevo JL, Rami L, Wolfsgruber S, Peters O, Jessen F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative. Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project. Alzheimers Res Ther. 2019 Apr 16;11(1):33. doi: 10.1186/s13195-019-0487-y. PubMed PMID: 30987684; PubMed Central PMCID: PMC6466790.
  146. van Maurik IS, van der Kall LM, de Wilde A, Bouwman FH, Scheltens P, van Berckel BNM, Berkhof J, van der Flier WM. Added value of amyloid PET in individualized risk predictions for MCI patients. Alzheimers Dement (Amst). 2019 Jul 29;11:529-537. doi: 10.1016/j.dadm.2019.04.011. eCollection 2019 Dec. PubMed PMID: 31388557; PubMed Central PMCID: PMC6667768.
  147. van Maurik IS, Vos SJ, Bos I, Bouwman FH, Teunissen CE, Scheltens P, Barkhof F, Frolich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Frisoni GB, Spiru L, Freund-Levi Y, Wallin AK, Hampel H, Soininen H, Tsolaki M, Verhey F, Kłoszewska I, Mecocci P, Vellas B, Lovestone S, Galluzzi S, Herukka SK, Santana I, Baldeiras I, de Mendonça A, Silva D, Chetelat G, Egret S, Palmqvist S, Hansson O, Visser PJ, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurol. 2019 Nov;18(11):1034-1044. doi: 10.1016/S1474-4422(19)30283-2. Epub 2019 Sep 13. PubMed PMID: 31526625.
  148. Van Someren EJW, Oosterman JM, Van Harten B, Vogels RL, Gouw AA, Weinstein HC, Poggesi A, Scheltens P, Scherder EJA. Medial temporal lobe atrophy relates more strongly to sleep-wake rhythm fragmentation than to age or any other known risk. Neurobiol Learn Mem. 2019 Apr;160:132-138. doi: 10.1016/j.nlm.2018.05.017.  Epub 2018 Jun 1. PubMed PMID: 29864525.
  149. van Steenoven I, Noli B, Cocco C, Ferri GL, Oeckl P, Otto M, Koel-Simmelink MJA, Bridel C, van der Flier WM, Lemstra AW, Teunissen CE. VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. Int J Mol Sci. 2019 Sep 20;20(19). pii: E4674. doi: 10.3390/ijms20194674. PubMed PMID: 31547145; PubMed Central PMCID: PMC6801397
  150. van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Alzheimers Res Ther. 2019 Oct 10;11(1):83. doi: 10.1186/s13195-019-0537-5. PubMed PMID: 31601267; PubMed Central PMCID:
  151. Verberk IMW, Teunissen CE, Van der Flier WM. Reply to “Usefulness of Plasma Amyloid as Prescreener of the Earliest Alzheimer Pathological Changes Depends on the Study Population”. Ann Neurol. 2019 Nov 1. doi: 10.1002/ana.25633. PubMed PMID: 31675120.
  152. Verfaillie SCJ, Witteman J, Slot RER, Pruis IJ, Vermaat LEW, Prins ND, Schiller NO, van de Wiel M, Scheltens P, van Berckel BNM, van der Flier WM, Sikkes SAM. High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. 2019 Aug;131:184-192. doi: 10.1016/j.neuropsychologia.2019.05.006. Epub 2019 May 7. PubMed PMID: 31075283.
  153. Verfaillie SCJ, Timmers T, Slot RER, van der Weijden CWJ, Wesselman LMP, Prins ND, Sikkes SAM, Yaqub M, Dols A, Lammertsma AA, Scheltens P, Ossenkoppele R, van Berckel BNM, van der Flier WM. Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive  Decline: The SCIENCe Project. Front Aging Neurosci. 2019 Jan 25;11:7. doi: 10.3389/fnagi.2019.00007. eCollection 2019. PubMed PMID: 30760996; PubMed Central PMCID: PMC6362417.
  154. Vergouw LJM, Bosman B, van de Beek M, Salomé M, Hoogers SE, van Steenoven I, Roks G, Bonifati V, van Swieten JC, Lemstra AW, de Jong FJ. Family History Is Associated with Phenotype in Dementia with Lewy Bodies. J Alzheimers Dis. 2019 Nov 19. doi: 10.3233/JAD-190825. PubMed PMID: 31771063.
  155. Vermunt L, van Paasen AJL, Teunissen CE, Scheltens P, Visser PJ, Tijms BM; Alzheimer’s Disease Neuroimaging Initiative. Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. 2019 Jun 4;92(23):e2699-e2705. doi: 10.1212/WNL.0000000000007609. Epub 2019 May 8. PubMed  PMID: 31068481; PubMed Central PMCID: PMC6556092.
  156. Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM,  Kern S, Ousset PJ, Maruff P, Skoog I, Verhey FRJ, Freund-Levi Y, Tsolaki M, Wallin ÅK, Olde Rikkert M, Soininen H, Spiru L, Zetterberg H, Blennow K, Scheltens P, Muniz-Terrera G, Visser PJ; Alzheimer Disease Neuroimaging Initiative; AIBL Research Group; ICTUS/DSA study groups. Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019 Jul;15(7):888-898. doi: 10.1016/j.jalz.2019.04.001. Epub 2019 Jun 1. PubMed PMID: 31164314; PubMed Central PMCID: PMC6646097.
  157. Verwey NA, Teunissen CE, Hoozemans JJM, Rozemuller AJM, Scheltens P, Pijnenburg YAL. Cerebrospinal Fluid Amyloid-β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study. J Alzheimers Dis. 2019 Jul 22. doi: 10.3233/JAD-190344. PubMed PMID: 31356209.
  158. Villeneuve SC, Houot M, Cacciamani F, Verrijp M, Dubois B, Sikkes S, Epelbaum S; MEMENTO study group and the INSIGHT-preAD study group. Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer’s disease. Alzheimers Dement (N Y). 2019 Oct 8;5:553-562. doi: 10.1016/j.trci.2019.08.009. eCollection 2019. PubMed PMID: 31650012; PubMed Central PMCID: PMC6804616.
  159. Visser LNC, Kunneman M, Murugesu L, van Maurik I, Zwan M, Bouwman FH, Schuur J, Wind HA, Blaauw MSJ, Kragt JJ, Roks G, Boelaarts L, Schipper AC, Schooneboom N, Scheltens P, van der Flier WM, Smets EMA. Clinician-patient communication during the diagnostic workup: The ABIDE project. Alzheimers Dement (Amst). 2019 Jul 29;11:520-528. doi: 10.1016/j.dadm.2019.06.001. eCollection 2019 Dec. PubMed PMID: 31388556; PubMed Central PMCID: PMC6667786.
  160. Visser LNC, Pelt SAR, Kunneman M, Bouwman FH, Claus JJ, Kalisvaart KJ, Hempenius L, de Beer MH, Roks G, Boelaarts L, Kleijer M, van der Flier WM, Smets EMA, Hillen MA. Communicating uncertainties when disclosing diagnostic test results for (Alzheimer’s) dementia in the memory clinic: The ABIDE project. Health Expect. 2019 Oct 22. doi: 10.1111/hex.12964. PubMed PMID: 31638322.
  161. Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O, Ossenkoppele R; Alzheimer’s Disease Neuroimaging Initiative; Swedish BioFINDER Study. Data-driven approaches for tau-PET imaging biomarkers in Alzheimer’s disease. Hum Brain Mapp. 2019 Feb 1;40(2):638-651. doi: 10.1002/hbm.24401. Epub 2018 Oct 19. PubMed PMID: 30368979.
  162. Wang Y, Haaksma ML, Ramakers IHGB, Verhey FRJ, van de Flier WM, Scheltens P,  van Maurik I, Olde Rikkert MGM, Leoutsakos JS, Melis RJF. Cognitive and functional progression of dementia in two longitudinal studies. Int J Geriatr Psychiatry. 2019 Jul 18. doi: 10.1002/gps.5175. PubMed PMID: 31318090.
  163. Weaver NA, Doeven T, Barkhof F, Biesbroek JM, Groeneveld ON, Kuijf HJ, Prins ND, Scheltens P, Teunissen CE, van der Flier WM, Biessels GJ; TRACE-VCI study group. Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. Neurobiol Aging. 2019 Aug 9. pii: S0197-4580(19)30279-9. doi: 10.1016/j.neurobiolaging.2019.08.001. PubMed PMID: 31500909.
  164. Wesenhagen KEJ, Teunissen CE, Visser PJ, Tijms BM. Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer’s disease: A literature review. Crit Rev Clin Lab Sci. 2019 Nov 7:1-13. doi: 10.1080/10408363.2019.1670613. PubMed PMID: 31694431.
  165. Wesselman LMP, Doorduijn AS, de Leeuw FA, Verfaillie SCJ, van Leeuwenstijn-Koopman M, Slot RER, Kester MI, Prins ND, van de Rest O, de van der  Schueren MAE, Scheltens P, Sikkes SAM, van der Flier WM. Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCe Project. 2019 May 11;11(5). pii: E1057. doi: 10.3390/nu11051057. PubMed PMID: 31083522; PubMed Central PMCID: PMC6566666.
  166. Wesselman LM, Hooghiemstra AM, Schoonmade LJ, de Wit MC, van der Flier WM, Sikkes SA. Web-Based Multidomain Lifestyle Programs for Brain Health: Comprehensive Overview and Meta-Analysis. JMIR Ment Health. 2019 Apr 9;6(4):e12104. doi: 10.2196/12104. Review. PubMed PMID: 30964438; PubMed Central  PMCID: PMC6477576.
  167. Wesselman LMP, Schild AK, Hooghiemstra AM, Meiberth D, Drijver AJ, van Leeuwenstijn-Koopman M, Prins ND, Brennan S, Scheltens P, Jessen F, van der Flier WM, Sikkes SAM. Targeting lifestyle behavrior to improve brain health: User-experiences of an online program for individuals with subjective cognitive decline. Accepted in J Prev Alzheimers Dis.
  168. Willemse EAJ, Vermeiren Y, Garcia-Ayllon MS, Bridel C, De Deyn PP, Engelborghs S, van der Flier WM, Jansen EEW, Lopez-Font IB, Mendes V, Manadas B, de Roeck N, Saez-Valero J, Struys EA, Vanmechelen E, Andreasson U, Teunissen CE.  Pre-analytical stability of novel cerebrospinal fluid biomarkers. Clin Chim Acta.2019 Jul 23. pii: S0009-8981(19)31974-6. doi: 10.1016/j.cca.2019.07.024. PubMed PMID: 31348908.
  169. Wolfsgruber S, Molinuevo JL, Wagner M, Teunissen CE, Rami L, Coll-Padrós N, Bouwman FH, Slot RER, Wesselman LMP, Peters O, Luther K, Buerger K, Priller J, Laske C, Teipel S, Spottke A, Heneka MT, Düzel E, Drzezga A, Wiltfang J, Sikkes SAM, van der Flier WM, Jessen F; Euro-SCD working group. Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. Alzheimers Res Ther. 2019 Jan 17;11(1):8. doi: 10.1186/s13195-018-0463-y. PubMed PMID: 30654834; PubMed Central PMCID: PMC6337830.
  170. Wolters EE, Ossenkoppele R, Golla SS, Verfaillie SC, Timmers T, Visser D, Tuncel H, Coomans EM, Windhorst AD, Scheltens P, van der Flier WM, Boellaard R, van Berckel BN. Hippocampal [(18)F]flortaucipir BP(ND) corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. Neuroimage Clin. 2019 Dec 2;25:102113. doi: 10.1016/j.nicl.2019.102113. PubMed PMID: 31835238.
  171. Wong TH, van der Lee SJ, van Rooij JGJ, Meeter LHH, Frick P, Melhem S, Seelaar H, Ikram MA, Rozemuller AJ, Holstege H, Hulsman M, Uitterlinden A, Neumann M, Hoozemans JJM, van Duijn CM, Rademakers R, van Swieten JC. EIF2AK3 variants in Dutch patients with Alzheimer’s disease. Neurobiol Aging. 2019 Jan;73:229.e11-229.e18. doi: 10.1016/j.neurobiolaging.2018.08.016. Epub 2018 Aug 24.
  172. Zhutovsky P, Vijverberg EGB, Bruin WB, Thomas RM, Wattjes MP, Pijnenburg YAL, van Wingen GA, Dols A. Individual Prediction of Behavioral Variant Frontotemporal Dementia Development Using Multivariate Pattern Analysis of Magnetic Resonance Imaging Data. J Alzheimers Dis. 2019;68(3):1229-1241. doi: 10.3233/JAD-181004. PubMed PMID: 30909224.

Publicaties 2018

  1. Agosta, F., Altomare, D., Festari, C., Orini, S., Gandolfo, F., Boccardi, M., Arbizu, J., Bouwman, F., Drzezga, A., Nestor, P., Nobili, F., Walker, Z., Pagani, M., 2018. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease. Eur. J. Nucl. Med. Mol. Imaging 45, 1546–1556. https://doi.org/10.1007/s00259-018-4033-0
  2. Aisen, P.S., Siemers, E., Michelson, D., Salloway, S., Sampaio, C., Carrillo, M.C., Sperling, R., Doody, R., Scheltens, P., Bateman, R., Weiner, M., Vellas, B., 2018. What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force. J. Prev. Alzheimer’s Dis. 5, 171–174. https://doi.org/10.14283/jpad.2018.23
  3. Albani, D., Marizzoni, M., Ferrari, C., Fusco, F., Boeri, L., Raimondi, I., Jovicich, J., Babiloni, C., Soricelli, A., Lizio, R., Galluzzi, S., Cavaliere, L., Didic, M., Schonknecht, P., Molinuevo, J.L., Nobili, F., Parnetti, L., Payoux, P., Bocchio, L., Salvatore, M., Rossini, P.M., Tsolaki, M., Visser, P.J., Richardson, J.C., Wiltfang, J., Bordet, R., Blin, O., Forloni, G., Frisoni, G.B., Consortium, P., 2018. Plasma Abeta42 as Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. J. Alzheimers. Dis. https://doi.org/10.3233/JAD-180321
  4. Amier, R.P., Smulders, M.W., van der Flier, W.M., Bekkers, S.C.A.M., Zweerink, A., Allaart, C.P., Demirkiran, A., Roos, S.T., Teunissen, P.F.A., Appelman, Y., van Royen, N., Kim, R.J., van Rossum, A.C., Nijveldt, R., 2018. Long-Term Prognostic Implications of Previous Silent Myocardial Infarction in Patients Presenting With Acute Myocardial Infarction. JACC. Cardiovasc. Imaging 11, 1773–1781. https://doi.org/10.1016/j.jcmg.2018.02.009
  5. Arbizu, J., Festari, C., Altomare, D., Walker, Z., Bouwman, F., Rivolta, J., Orini, S., Barthel, H., Agosta, F., Drzezga, A., Nestor, P., Boccardi, M., Frisoni, G.B., Nobili, F., 2018. Clinical utility of FDG-PET for the clinical diagnosis in MCI. Eur. J. Nucl. Med. Mol. Imaging 45, 1497–1508. https://doi.org/10.1007/s00259-018-4039-7
  6. Barnes, J., Bartlett, J.W., Wolk, D.A., van der Flier, W.M., Frost, C., 2018. Disease Course Varies According to Age and Symptom Length in Alzheimer’s Disease. J. Alzheimers. Dis. 64, 631–642. https://doi.org/10.3233/JAD-170841
  7. Beeldman, E., Raaphorst, J., Klein Twennaar, M., Govaarts, R., Pijnenburg, Y.A.L., de Haan, R.J., de Visser, M., Schmand, B.A., 2018. The cognitive profile of behavioural variant FTD and its similarities with ALS: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 89, 995–1002. https://doi.org/10.1136/jnnp-2017-317459
  8. Bergeron, D., Gorno-Tempini, M.L., Rabinovici, G.D., Santos-Santos, M.A., Seeley, W., Miller, B.L., Pijnenburg, Y., Keulen, M.A., Groot, C., van Berckel, B.N.M., van der Flier, W.M., Scheltens, P., Rohrer, J.D., Warren, J.D., Schott, J.M., Fox, N.C., Sanchez-Valle, R., Grau-Rivera, O., Gelpi, E., Seelaar, H., Papma, J.M., van Swieten, J.C., Hodges, J.R., Leyton, C.E., Piguet, O., Rogalski, E.J., Mesulam, M.M., Koric, L., Nora, K., Pariente, J., Dickerson, B., Mackenzie, I.R., Hsiung, G.-Y.R., Belliard, S., Irwin, D.J., Wolk, D.A., Grossman, M., Jones, M., Harris, J., Mann, D., Snowden, J.S., Chrem-Mendez, P., Calandri, I.L., Amengual, A.A., Miguet-Alfonsi, C., Magnin, E., Magnani, G., Santangelo, R., Deramecourt, V., Pasquier, F., Mattsson, N., Nilsson, C., Hansson, O., Keith, J., Masellis, M., Black, S.E., Matias-Guiu, J.A., Cabrera-Martin, M.-N., Paquet, C., Dumurgier, J., Teichmann, M., Sarazin, M., Bottlaender, M., Dubois, B., Rowe, C.C., Villemagne, V.L., Vandenberghe, R., Granadillo, E., Teng, E., Mendez, M., Meyer, P.T., Frings, L., Lleo, A., Blesa, R., Fortea, J., Seo, S.W., Diehl-Schmid, J., Grimmer, T., Frederiksen, K.S., Sanchez-Juan, P., Chetelat, G., Jansen, W., Bouchard, R.W., Laforce, R.J., Visser, P.J., Ossenkoppele, R., 2018. Prevalence of amyloid-beta pathology in distinct variants of primary progressive  aphasia. Ann. Neurol. 84, 729–740. https://doi.org/10.1002/ana.25333
  9. Bergeron, D., Ossenkoppele, R., Jr Laforce, R., 2018. Evidence-based Interpretation of Amyloid-beta PET Results: A Clinician’s Tool. Alzheimer Dis. Assoc. Disord. 32, 28–34. https://doi.org/10.1097/WAD.0000000000000239
  10. Boon, B.D.C., Hoozemans, J.J.M., Lopuhaa, B., Eigenhuis, K.N., Scheltens, P., Kamphorst, W., Rozemuller, A.J.M., Bouwman, F.H., 2018. Neuroinflammation is increased in the parietal cortex of atypical Alzheimer’s disease. J. Neuroinflammation 15, 170. https://doi.org/10.1186/s12974-018-1180-y
  11. Bos, I., Verhey, F.R., Ramakers, I.H.G.B., Jacobs, H.I.L., Soininen, H., Freund-Levi, Y., Hampel, H., Tsolaki, M., Wallin, A.K., van Buchem, M.A., Oleksik, A., Verbeek, M.M., Rikkert, M.O., van der Flier, W.M., Scheltens, P., Aalten, P., Visser, P.J., Vos, S.J.B., 2018. Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimers. Res. Ther. https://doi.org/10.1186/s13195-018-0391-x
  12. Bos, I., Vos, S.J.B., Jansen, W.J., Vandenberghe, R., Gabel, S., Estanga, A., Ecay-Torres, M., Tomassen, J., den Braber, A., Lleo, A., Sala, I., Wallin, A., Kettunen, P., Molinuevo, J.L., Rami, L., Chetelat, G., de la Sayette, V., Tsolaki, M., Freund-Levi, Y., Johannsen, P., Novak, G.P., Ramakers, I., Verhey, F.R., Visser, P.J., 2018. Amyloid-beta, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. Front. Aging Neurosci. 10, 193. https://doi.org/10.3389/fnagi.2018.00193
  13. Bos, I., Vos, S., Vandenberghe, R., Scheltens, P., Engelborghs, S., Frisoni, G., Molinuevo, J.L., Wallin, A., Lleo, A., Popp, J., Martinez-Lage, P., Baird, A., Dobson, R., Legido-Quigley, C., Sleegers, K., Van Broeckhoven, C., Bertram, L., Ten Kate, M., Barkhof, F., Zetterberg, H., Lovestone, S., Streffer, J., Visser, P.J., 2018. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimers. Res. Ther. 10, 64. https://doi.org/10.1186/s13195-018-0396-5
  14. Bouts, M.J.R.J., Moller, C., Hafkemeijer, A., van Swieten, J.C., Dopper, E., van der Flier, W.M., Vrenken, H., Wink, A.M., Pijnenburg, Y.A.L., Scheltens, P., Barkhof, F., Schouten, T.M., de Vos, F., Feis, R.A., van der Grond, J., de Rooij, M., Rombouts, S.A.R.B., 2018. Single Subject Classification of Alzheimer’s Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. J. Alzheimers. Dis. 62, 1827–1839. https://doi.org/10.3233/JAD-170893
  15. Bouwman, F., Orini, S., Gandolfo, F., Altomare, D., Festari, C., Agosta, F., Arbizu, J., Drzezga, A., Nestor, P., Nobili, F., Walker, Z., Morbelli, S., Boccardi, M., 2018. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. Eur. J. Nucl. Med. Mol. Imaging 45, 1526–1533. https://doi.org/10.1007/s00259-018-4034-z
  16. Bruun, M., Rhodius-Meester, H.F.M., Koikkalainen, J., Baroni, M., Gjerum, L., Lemstra, A.W., Barkhof, F., Remes, A.M., Urhemaa, T., Tolonen, A., Rueckert, D., van Gils, M., Frederiksen, K.S., Waldemar, G., Scheltens, P., Mecocci, P., Soininen, H., Lotjonen, J., Hasselbalch, S.G., van der Flier, W.M., 2018. Evaluating combinations of diagnostic tests to discriminate different dementia types. Alzheimer’s Dement. 10, 509–518. https://doi.org/10.1016/j.dadm.2018.07.003
  17. Chakraborty, A., Chatterjee, M., Twaalfhoven, H., Del Campo Milan, M., Teunissen, C.E., Scheltens, P., Fontijn, R.D., van Der Flier, W.M., de Vries, H.E., 2018. Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia. Alzheimers. Res. Ther. 10, 58. https://doi.org/10.1186/s13195-018-0385-8
  18. Chakraborty, A., Kamermans, A., van Het Hof, B., Castricum, K., Aanhane, E., van Horssen, J., Thijssen, V.L., Scheltens, P., Teunissen, C.E., Fontijn, R.D., van der Flier, W.M., de Vries, H.E., 2018. Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. Brain 141, 3377–3388. https://doi.org/10.1093/brain/awy274
  19. Chatterjee, M., Del Campo, M., Morrema, T.H.J., de Waal, M., van der Flier, W.M., Hoozemans, J.J.M., Teunissen, C.E., 2018. Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer’s disease. Alzheimers. Res. Ther. 10, 52. https://doi.org/10.1186/s13195-018-0383-x
  20. Ciliz, M., Sartor, J., Lindig, T., Pilotto, A., Schaffer, E., Weiss, M., Scheltens, P., Becker, S., Hobert, M.A., Berg, D., Liepelt-Scarfone, I., Maetzler, W., 2018. Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson’s Disease. J. Parkinsons. Dis. 8, 455–462. https://doi.org/10.3233/JPD-181351
  21. Claus, J.J., Coenen, M., Staekenborg, S.S., Schuur, J., Tielkes, C.E.M., Koster, P., Scheltens, P., 2018. Cerebral White Matter Lesions have Low Impact on Cognitive Function in a Large Elderly Memory Clinic Population. J. Alzheimers. Dis. 63, 1129–1139. https://doi.org/10.3233/JAD-171111
  22. Cohn-Hokke, P.E., van Swieten, J.C., Pijnenburg, Y.A.L., Tibben, A., Meijers-Heijboer, H., Kievit, A., 2018. The Effect of Predictive Testing in Adult-Onset Neurodegenerative Diseases on Social and Personal Life. J. Genet. Couns. 27, 947–954. https://doi.org/10.1007/s10897-017-0195-3
  23. Collij, L., Konijnenberg, E., Reimand, J., Ten Kate, M., Den Braber, A., Lopes Alves, I., Zwan, M., Yaqub, M., Van Assema, D., Wink, A.M., Lammertsma, A., Scheltens, P., Visser, P.J., Barkhof, F., Van Berckel, B., 2018. Assessing Amyloid Pathology in Cognitively Normal Subjects using [(18)F]Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. J. Nucl. Med. https://doi.org/10.2967/jnumed.118.211532
  24. Dauwan, M., Linszen, M.M.J., Lemstra, A.W., Scheltens, P., Stam, C.J., Sommer, I.E., 2018. EEG-based neurophysiological indicators of hallucinations in Alzheimer’s disease: Comparison with dementia with Lewy bodies. Neurobiol. Aging 67, 75–83. https://doi.org/10.1016/j.neurobiolaging.2018.03.013
  25. de Wilde, A., van Buchem, M.M., Otten, R.H.J., Bouwman, F., Stephens, A., Barkhof, F., Scheltens, P., van der Flier, W.M., 2018. Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimers. Res. Ther. 10, 72. https://doi.org/10.1186/s13195-018-0398-3
  26. de Wilde, A., van der Flier, W.M., Pelkmans, W., Bouwman, F., Verwer, J., Groot, C., van Buchem, M.M., Zwan, M., Ossenkoppele, R., Yaqub, M., Kunneman, M., Smets, E.M.A., Barkhof, F., Lammertsma, A.A., Stephens, A., van Lier, E., Biessels, G.J., van Berckel, B.N., Scheltens, P., 2018. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. JAMA Neurol. 75, 1062–1070. https://doi.org/10.1001/jamaneurol.2018.1346
  27. Del Campo, M., Galimberti, D., Elias, N., Boonkamp, L., Pijnenburg, Y.A., van Swieten, J.C., Watts, K., Paciotti, S., Beccari, T., Hu, W., Teunissen, C.E., 2018. Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. Ann. Clin. Transl. Neurol. 5, 1163–1175. https://doi.org/10.1002/acn3.629
  28. den Haan, J., Janssen, S.F., van de Kreeke, J.A., Scheltens, P., Verbraak, F.D., Bouwman, F.H., 2018. Retinal thickness correlates with parietal cortical atrophy in early-onset Alzheimer’s disease and controls. Alzheimer’s Dement. (Amsterdam, Netherlands) 10, 49–55. https://doi.org/10.1016/j.dadm.2017.10.005
  29. den Haan, J., Morrema, T.H.J., Rozemuller, A.J., Bouwman, F.H., Hoozemans, J.J.M., 2018. Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics. Acta Neuropathol. Commun. 6, 75. https://doi.org/10.1186/s40478-018-0577-2
  30. Dicks, E., Tijms, B.M., Ten Kate, M., Gouw, A.A., Benedictus, M.R., Teunissen, C.E., Barkhof, F., Scheltens, P., van der Flier, W.M., 2018. Gray matter network measures are associated with cognitive decline in mild cognitive impairment. Neurobiol. Aging 61, 198–206. https://doi.org/10.1016/j.neurobiolaging.2017.09.029
  31. Doorduijn, A.S., van de Rest, O., van der Flier, W.M., Visser, M., de van der Schueren, M.A.E., 2018. Energy and Protein Intake of Alzheimer’s Disease Patients Compared to Cognitively Normal Controls: Systematic Review. J. Am. Med. Dir. Assoc. https://doi.org/10.1016/j.jamda.2018.06.019
  32. Drzezga, A., Altomare, D., Festari, C., Arbizu, J., Orini, S., Herholz, K., Nestor, P., Agosta, F., Bouwman, F., Nobili, F., Walker, Z., Frisoni, G.B., Boccardi, M., 2018. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging 45, 1487–1496. https://doi.org/10.1007/s00259-018-4032-1
  33. Dufresne, J., Bowden, P., Thavarajah, T., Florentinus-Mefailoski, A., Chen, Z.Z., Tucholska, M., Norzin, T., Ho, M.T., Phan, M., Mohamed, N., Ravandi, A., Stanton, E., Slutsky, A.S., Dos Santos, C.C., Romaschin, A., Marshall, J.C., Addison, C., Malone, S., Heyland, D., Scheltens, P., Killestein, J., Teunissen, C., Diamandis, E.P., Siu, K.W.M., Marshall, J.G., 2018. The plasma peptidome. Clin. Proteomics 15, 39. https://doi.org/10.1186/s12014-018-9211-3
  34. Duits, F.H., Brinkmalm, G., Teunissen, C.E., Brinkmalm, A., Scheltens, P., Van der Flier, W.M., Zetterberg, H., Blennow, K., 2018. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease. Alzheimers. Res. Ther. 10, 5. https://doi.org/10.1186/s13195-017-0335-x
  35. Eikelboom, W.S., van Rooij, J.G.J., van den Berg, E., Coesmans, M., Jiskoot, L.C., Singleton, E., Ossenkoppele, R., van Swieten, J.C., Seelaar, H., Papma, J.M., 2018. Neuropsychiatric Symptoms Complicating the Diagnosis of Alzheimer’s Disease: A Case Report. J. Alzheimers. Dis. https://doi.org/10.3233/JAD-180700
  36. Facal, D., Carabias, M.A.R., Pereiro, A.X., Lojo-Seoane, C., Campos-Magdaleno, M., Jutten, R.J., Sikkes, S.A.M., Juncos-Rabadan, O., 2018. Assessing Everyday Activities Across the Dementia Spectrum with the Amsterdam IADL Questionnaire. Curr. Alzheimer Res. 15, 1261–1266. https://doi.org/10.2174/1567205015666180925113411
  37. Fredericks, C.A., Brown, J.A., Deng, J., Kramer, A., Ossenkoppele, R., Rankin, K., Kramer, J.H., Miller, B.L., Rabinovici, G.D., Seeley, W.W., 2018. Intrinsic connectivity networks in posterior cortical atrophy: A role for the pulvinar? NeuroImage. Clin. https://doi.org/10.1016/j.nicl.2018.101628
  38. Frisoni, G.B., Barkhof, F., Altomare, D., Berkhof, J., Boccardi, M., Canzoneri, E., Collij, L., Drzezga, A., Farrar, G., Garibotto, V., Gismondi, R., Gispert, J.-D., Jessen, F., Kivipelto, M., Alves, I.L., Molinuevo, J.-L., Nordberg, A., Payoux, P., Ritchie, C., Savicheva, I., Scheltens, P., Schmidt, M.E., Schott, J., Stephens, A., van Berckel, B., Vellas, B., Walker, Z., Raffa, N., 2018. AMYPAD Diagnostic and Patient Management Study: Rationale and design.Alzheimers. Dement. https://doi.org/10.1016/j.jalz.2018.09.003
  39. Ganz, A.B., Beker, N., Hulsman, M., Sikkes, S., Bank, N.B., Scheltens, P., Smit, A.B., Rozemuller, A.J.M., Hoozemans, J.J.M., Holstege, H., 2018. Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. Acta Neuropathol. Commun. 6, 64. https://doi.org/10.1186/s40478-018-0558-5
  40. Gardiner, S.L., Harder, A.V.E., Campman, Y.J.M., Trompet, S., Gussekloo, J., van Belzen, M.J., Boogaard, M.W., Roos, R.A.C., Jansen, I.E., Pijnenburg, Y.A.L., Scheltens, P., van der Flier, W.M., Aziz, N.A., 2019. Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer’s disease. Neurobiol. Aging 73, 230.e9-230.e17. https://doi.org/10.1016/j.neurobiolaging.2018.09.007
  41. Geijselaers, S.L.C., Aalten, P., Ramakers, I.H.G.B., De Deyn, P.P., Heijboer, A.C., Koek, H.L., OldeRikkert, M.G.M., Papma, J.M., Reesink, F.E., Smits, L.L., Stehouwer, C.D.A., Teunissen, C.E., Verhey, F.R.J., van der Flier, W.M., Biessels, G.J., 2018. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer’s Disease. J. Alzheimers. Dis. 61, 309–320. https://doi.org/10.3233/JAD-170522
  42. Gerritsen, A.A.J., Bakker, C., Verhey, F.R.J., Bor, H., Pijnenburg, Y.A.L., de Vugt, M.E., Koopmans, R.T.C.M., 2018. The Progression of Dementia and Cognitive Decline in a Dutch 2-Year Cohort Study  of People with Young-Onset Dementia. J. Alzheimers. Dis. 63, 343–351. https://doi.org/10.3233/JAD-170859
  43. Golla, S.S., Verfaillie, S.C., Boellaard, R., Adriaanse, S.M., Zwan, M.D., Schuit, R.C., Timmers, T., Groot, C., Schober, P., Scheltens, P., van der Flier, W.M., Windhorst, A.D., van Berckel, B.N., Lammertsma, A.A., 2018. Quantification of [(18)F]florbetapir: A test-retest tracer kinetic modelling study. J. Cereb. Blood Flow Metab. 271678X18783628. https://doi.org/10.1177/0271678X18783628
  44. Gossink, F.T., Vijverberg, E., Krudop, W., Scheltens, P., Stek, M.L., Pijnenburg, Y.A.L., Dols, A., 2018. Predicting progression in the late onset frontal lobe syndrome. Int. psychogeriatrics 1–6. https://doi.org/10.1017/S1041610218001242
  45. Gossink, F., Pijnenburg, Y., Scheltens, P., Pera, A., Kleverwal, R., Korten, N., Stek, M., Droes, R.-M., Dols, A., 2018. An intervention programme for caregivers of dementia patients with frontal behavioural changes: an explorative study with controlled effect on sense of competence. Psychogeriatrics 18, 451–459. https://doi.org/10.1111/psyg.12351
  46. Gossink, F., Schouws, S., Krudop, W., Scheltens, P., Stek, M., Pijnenburg, Y., Dols, A., 2018. Social Cognition Differentiates Behavioral Variant Frontotemporal Dementia From Other Neurodegenerative Diseases and Psychiatric Disorders. Am. J. Geriatr. Psychiatry 26, 569–579. https://doi.org/10.1016/j.jagp.2017.12.008
  47. Groot, C., Sudre, C.H., Barkhof, F., Teunissen, C.E., van Berckel, B.N.M., Seo, S.W., Ourselin, S., Scheltens, P., Cardoso, M.J., van der Flier, W.M., Ossenkoppele, R., 2018. Clinical phenotype, atrophy, and small vessel disease in APOEepsilon2 carriers with Alzheimer disease. Neurology 91, e1851–e1859. https://doi.org/10.1212/WNL.0000000000006503
  48. Groot, C., Tolboom, N., Ikonomovic, M.D., Lammertsma, A.A., Boon, B.D.C., Barkhof, F., Scheltens, P., Klunk, W.E., Rozemuller, A.J.M., Ossenkoppele, R., van Berckel, B.N.M., 2018. Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. J. Alzheimers. Dis. 65, 71–77. https://doi.org/10.3233/JAD-180316
  49. Groot, C., van Loenhoud, A.C., Barkhof, F., van Berckel, B.N.M., Koene, T., Teunissen, C.C., Scheltens, P., van der Flier, W.M., Ossenkoppele, R., 2018. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology 90, e149–e156. https://doi.org/10.1212/WNL.0000000000004802
  50. Guerreiro, R., Ross, O.A., Kun-Rodrigues, C., Hernandez, D.G., Orme, T., Eicher, J.D., Shepherd, C.E., Parkkinen, L., Darwent, L., Heckman, M.G., Scholz, S.W., Troncoso, J.C., Pletnikova, O., Ansorge, O., Clarimon, J., Lleo, A., Morenas-Rodriguez, E., Clark, L., Honig, L.S., Marder, K., Lemstra, A., Rogaeva, E., St George-Hyslop, P., Londos, E., Zetterberg, H., Barber, I., Braae, A., Brown, K., Morgan, K., Troakes, C., Al-Sarraj, S., Lashley, T., Holton, J., Compta, Y., Van Deerlin, V., Serrano, G.E., Beach, T.G., Lesage, S., Galasko, D., Masliah, E., Santana, I., Pastor, P., Diez-Fairen, M., Aguilar, M., Tienari, P.J., Myllykangas, L., Oinas, M., Revesz, T., Lees, A., Boeve, B.F., Petersen, R.C., Ferman, T.J., Escott-Price, V., Graff-Radford, N., Cairns, N.J., Morris, J.C., Pickering-Brown, S., Mann, D., Halliday, G.M., Hardy, J., Trojanowski, J.Q., Dickson, D.W., Singleton, A., Stone, D.J., Bras, J., 2018. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage  genome-wide association study. Lancet. Neurol. 17, 64–74. https://doi.org/10.1016/S1474-4422(17)30400-3
  51. Haaksma, M.L., Rizzuto, D., Ramakers, I.H.G.B., Garcia-Ptacek, S., Marengoni, A., van der Flier, W.M., Verhey, F.R.J., Olde Rikkert, M.G.M., Melis, R.J.F., 2018. The Impact of Frailty and Comorbidity on Institutionalization and Mortality in Persons With Dementia: A Prospective Cohort Study. J. Am. Med. Dir. Assoc. https://doi.org/10.1016/j.jamda.2018.06.020
  52. Harrison, J.E. Cognition comes of age: Comments on the new FDA draft guidance for early Alzheimer’s disease. Alzheimer’s Research & Therapy. 2018:10;61.
  53. Harrison, J.E., Barry, H., Baune, B.T., Best, M.W., Bowie, C.R., Cha, D.S., Culpepper, L., Fossati, P., Greer, T.L., Harmer, C., Klag, E., Lam, R.W., Lee, Y., Mansur, R.B., Wittchen, H.U., McIntyre, R. Stability, reliability and validity of the THINC-it screening tool for cognitive impairment in depression: A psychometric exploration in healthy volunteers. International Journal of Methods in Psychiatric Research. 2018:7;e1736. doi: 10.1002/mpr.1736.
  54. Harrison, J.E., Rentz, D., Brashear, H.R., Arrighi, H.M., Ropacki, M., Liu, E. Psychometric evaluation of the Neuropsychological Test Battery in individuals with normal cognition, Mild Cognitive Impairment, or mild to moderate Alzheimer’s disease: Results from a longitudinal study. Journal for the Prevention of Alzheimer’s disease. 2018:5;236-244. doi: 10.14283/jpad.2018.31.
  55. Holstege, H., Beker, N., Dijkstra, T., Pieterse, K., Wemmenhove, E., Schouten, K., Thiessens, L., Horsten, D., Rechtuijt, S., Sikkes, S., van Poppel, F.W.A., Meijers-Heijboer, H., Hulsman, M., Scheltens, P., 2018. The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. Eur. J. Epidemiol. 33, 1229–1249. https://doi.org/10.1007/s10654-018-0451-3
  56. Hu, X., Teunissen, C.E., Spottke, A., Heneka, M.T., Duzel, E., Peters, O., Li, S., Priller, J., Buerger, K., Teipel, S., Laske, C., Verfaillie, S.C.J., Barkhof, F., Coll-Padros, N., Rami, L., Molinuevo, J.L., van der Flier, W.M., Jessen, F., 2018. Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer’s disease-Data from three memory clinic studies. Alzheimers. Dement. https://doi.org/10.1016/j.jalz.2018.09.002
  57. Iaccarino, L., Tammewar, G., Ayakta, N., Baker, S.L., Bejanin, A., Boxer, A.L., Gorno-Tempini, M.L., Janabi, M., Kramer, J.H., Lazaris, A., Lockhart, S.N., Miller, B.L., Miller, Z.A., O’Neil, J.P., Ossenkoppele, R., Rosen, H.J., Schonhaut, D.R., Jagust, W.J., Rabinovici, G.D., 2018. Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer’s Disease. NeuroImage. Clin. 17, 452–464. https://doi.org/10.1016/j.nicl.2017.09.016
  58. Jack, C.R.J., Bennett, D.A., Blennow, K., Carrillo, M.C., Dunn, B., Haeberlein, S.B., Holtzman, D.M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J.L., Montine, T., Phelps, C., Rankin, K.P., Rowe, C.C., Scheltens, P., Siemers, E., Snyder, H.M., Sperling, R., 2018. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers. Dement. 14, 535–562. https://doi.org/10.1016/j.jalz.2018.02.018
  59. Jansen, W.J., Ossenkoppele, R., Tijms, B.M., Fagan, A.M., Hansson, O., Klunk, W.E., van der Flier, W.M., Villemagne, V.L., Frisoni, G.B., Fleisher, A.S., Lleo, A., Mintun, M.A., Wallin, A., Engelborghs, S., Na, D.L., Chetelat, G., Molinuevo, J.L., Landau, S.M., Mattsson, N., Kornhuber, J., Sabri, O., Rowe, C.C., Parnetti, L., Popp, J., Fladby, T., Jagust, W.J., Aalten, P., Lee, D.Y., Vandenberghe, R., Resende de Oliveira, C., Kapaki, E., Froelich, L., Ivanoiu, A., Gabryelewicz, T., Verbeek, M.M., Sanchez-Juan, P., Hildebrandt, H., Camus, V., Zboch, M., Brooks, D.J., Drzezga, A., Rinne, J.O., Newberg, A., de Mendonca, A., Sarazin, M., Rabinovici, G.D., Madsen, K., Kramberger, M.G., Nordberg, A., Mok, V., Mroczko, B., Wolk, D.A., Meyer, P.T., Tsolaki, M., Scheltens, P., Verhey, F.R.J., Visser, P.J., Aarsland, D., Alcolea, D., Alexander, M., Almdahl, I.S., Arnold, S.E., Baldeiras, I., Barthel, H., van Berckel, B.N.M., Blennow, K., van Buchem, M.A., Cavedo, E., Chen, K., Chipi, E., Cohen, A.D., Forster, S., Fortea, J., Frederiksen, K.S., Freund-Levi, Y., Gkatzima, O., Gordon, M.F., Grimmer, T., Hampel, H., Hausner, L., Hellwig, S., Herukka, S.-K., Johannsen, P., Klimkowicz-Mrowiec, A., Kohler, S., Koglin, N., van Laere, K., de Leon, M., Lisetti, V., Maier, W., Marcusson, J., Meulenbroek, O., Mollergard, H.M., Morris, J.C., Nordlund, A., Novak, G.P., Paraskevas, G.P., Perera, G., Peters, O., Ramakers, I.H.G.B., Rami, L., Rodriguez-Rodriguez, E., Roe, C.M., Rot, U., Ruther, E., Santana, I., Schroder, J., Seo, S.W., Soininen, H., Spiru, L., Stomrud, E., Struyfs, H., Teunissen, C.E., Vos, S.J.B., van Waalwijk van Doorn, L.J.C., Waldemar, G., Wallin, A.K., Wiltfang, J., Zetterberg, H., 2018. Association of Cerebral Amyloid-beta Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA psychiatry 75, 84–95. https://doi.org/10.1001/jamapsychiatry.2017.3391
  60. Jansen, W.J., Wilson, R.S., Visser, P.J., Nag, S., Schneider, J.A., James, B.D., Leurgans, S.E., Capuano, A.W., Bennett, D.A., Boyle, P.A., 2018. Age and the association of dementia-related pathology with trajectories of cognitive decline. Neurobiol. Aging 61, 138–145. https://doi.org/10.1016/j.neurobiolaging.2017.08.029
  61. Jiskoot, L.C., Bocchetta, M., Nicholas, J.M., Cash, D.M., Thomas, D., Modat, M., Ourselin, S., Rombouts, S.A.R.B., Dopper, E.G.P., Meeter, L.H., Panman, J.L., van Minkelen, R., van der Ende, E.L., Donker Kaat, L., Pijnenburg, Y.A.L., Borroni, B., Galimberti, D., Masellis, M., Tartaglia, M.C., Rowe, J., Graff, C., Tagliavini, F., Frisoni, G.B., Laforce, R.J., Finger, E., de Mendonca, A., Sorbi, S., Papma, J.M., van Swieten, J.C., Rohrer, J.D., 2018. Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: A cross-sectional diffusion tensor imaging study. Ann. Clin. Transl. Neurol. 5, 1025–1036. https://doi.org/10.1002/acn3.601
  62. Joling, M., Vriend, C., van der Zande, J.J., Lemstra, A.W., van den Heuvel, O.A., Booij, J., Berendse, H.W., 2018. Lower (123)I-FP-CIT binding to the striatal dopamine transporter, but not to the  extrastriatal serotonin transporter, in Parkinson’s disease compared with dementia with Lewy bodies. NeuroImage. Clin. 19, 130–136. https://doi.org/10.1016/j.nicl.2018.04.009
  63. Jovicich, J., Babiloni, C., Ferrari, C., Marizzoni, M., Moretti, D. V, Del Percio, C., Lizio, R., Lopez, S., Galluzzi, S., Albani, D., Cavaliere, L., Minati, L., Didic, M., Fiedler, U., Forloni, G., Hensch, T., Molinuevo, J.L., Bartres Faz, D., Nobili, F., Orlandi, D., Parnetti, L., Farotti, L., Costa, C., Payoux, P., Rossini, P.M., Marra, C., Schonknecht, P., Soricelli, A., Noce, G., Salvatore, M., Tsolaki, M., Visser, P.J., Richardson, J.C., Wiltfang, J., Bordet, R., Blin, O., Frisoniand, G.B., 2018. Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. J. Alzheimers. Dis. https://doi.org/10.3233/JAD-180158
  64. Jutten, R.J., Harrison, J., Lee Meeuw Kjoe, P.R., Opmeer, E.M., Schoonenboom, N.S.M., de Jong, F.J., Ritchie, C.W., Scheltens, P., Sikkes, S.A.M., 2018. A novel cognitive-functional composite measure to detect changes in early Alzheimer’s disease: Test-retest reliability and feasibility. Alzheimer’s Dement. (Amsterdam, Netherlands) 10, 153–160. https://doi.org/10.1016/j.dadm.2017.12.002
  65. Konijnenberg, E., Carter, S.F., Ten Kate, M., den Braber, A., Tomassen, J., Amadi, C., Wesselman, L., Nguyen, H.-T., van de Kreeke, J.A., Yaqub, M., Demuru, M., Mulder, S.D., Hillebrand, A., Bouwman, F.H., Teunissen, C.E., Serne, E.H., Moll, A.C., Verbraak, F.D., Hinz, R., Pendleton, N., Lammertsma, A.A., van Berckel, B.N.M., Barkhof, F., Boomsma, D.I., Scheltens, P., Herholz, K., Visser, P.J., 2018. The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimers. Res. Ther. 10, 75. https://doi.org/10.1186/s13195-018-0406-7
  66. Kun-Rodrigues, C., Orme, T., Carmona, S., Hernandez, D.G., Ross, O.A., Eicher, J.D., Shepherd, C., Parkkinen, L., Darwent, L., Heckman, M.G., Scholz, S.W., Troncoso, J.C., Pletnikova, O., Dawson, T., Rosenthal, L., Ansorge, O., Clarimon, J., Lleo, A., Morenas-Rodriguez, E., Clark, L., Honig, L.S., Marder, K., Lemstra, A., Rogaeva, E., St George-Hyslop, P., Londos, E., Zetterberg, H., Barber, I., Braae, A., Brown, K., Morgan, K., Troakes, C., Al-Sarraj, S., Lashley, T., Holton, J., Compta, Y., Van Deerlin, V., Serrano, G.E., Beach, T.G., Lesage, S., Galasko, D., Masliah, E., Santana, I., Pastor, P., Diez-Fairen, M., Aguilar, M., Tienari, P.J., Myllykangas, L., Oinas, M., Revesz, T., Lees, A., Boeve, B.F., Petersen, R.C., Ferman, T.J., Escott-Price, V., Graff-Radford, N., Cairns, N.J., Morris, J.C., Pickering-Brown, S., Mann, D., Halliday, G.M., Hardy, J., Trojanowski, J.Q., Dickson, D.W., Singleton, A., Stone, D.J., Guerreiro, R., Bras, J., 2018. A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiol. Aging. https://doi.org/10.1016/j.neurobiolaging.2018.10.019
  67. Laforce, R.J., Soucy, J.-P., Sellami, L., Dallaire-Theroux, C., Brunet, F., Bergeron, D., Miller, B.L., Ossenkoppele, R., 2018. Molecular imaging in dementia: Past, present, and future. Alzheimers. Dement. 14, 1522–1552. https://doi.org/10.1016/j.jalz.2018.06.2855
  68. Leeuwis, A.E., Prins, N.D., Hooghiemstra, A.M., Benedictus, M.R., Scheltens, P., Barkhof, F., van der Flier, W.M., 2018. Microbleeds are associated with depressive symptoms in Alzheimer’s disease. Alzheimer’s Dement. (Amsterdam, Netherlands) 10, 112–120. https://doi.org/10.1016/j.dadm.2017.11.006
  69. Leeuwis, A.E., Smith, L.A., Melbourne, A., Hughes, A.D., Richards, M., Prins, N.D., Sokolska, M., Atkinson, D., Tillin, T., Jager, H.R., Chaturvedi, N., van der Flier, W.M., Barkhof, F., 2018. Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic  Cohort: The SABRE Study.Front. Aging Neurosci. 10, 279. https://doi.org/10.3389/fnagi.2018.00279
  70. Legdeur, N., Heymans, M.W., Comijs, H.C., Huisman, M., Maier, A.B., Visser, P.J., 2018. Age dependency of risk factors for cognitive decline. BMC Geriatr. 18, 187. https://doi.org/10.1186/s12877-018-0876-2
  71. Legdeur, N., Badissi, M., Carter, S.F., de Crom, S., van de Kreeke, A., Vreeswijk, R., Trappenburg, M.C., Oudega, M.L., Koek, H.L., van Campen, J.P., Keijsers, C.J.P.W., Amadi, C., Hinz, R., Gordon, M.F., Novak, G., Podhorna, J., Serne, E., Verbraak, F., Yaqub, M., Hillebrand, A., Griffa, A., Pendleton, N., Kramer, S.E., Teunissen, C.E., Lammertsma, A., Barkhof, F., van Berckel, B.N.M., Scheltens, P., Muller, M., Maier, A.B., Herholz, K., Visser, P.J., 2018. Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatr. 18, 289. https://doi.org/10.1186/s12877-018-0984-z
  72. Leijenaar, J.F., Groeneveld, G.J., van der Flier, W.M., Scheltens, P., Klaassen, E.S., Weinstein, H.C., Biessels, G.J., Barkhof, F., Prins, N.D., 2018. Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. JMIR Res. Protoc. 7, e80. https://doi.org/10.2196/resprot.9192
  73. Lewczuk, P., Riederer, P., O’Bryant, S.E., Verbeek, M.M., Dubois, B., Visser, P.J., Jellinger, K.A., Engelborghs, S., Ramirez, A., Parnetti, L., Jack, C.R.J., Teunissen, C.E., Hampel, H., Lleo, A., Jessen, F., Glodzik, L., de Leon, M.J., Fagan, A.M., Molinuevo, J.L., Jansen, W.J., Winblad, B., Shaw, L.M., Andreasson, U., Otto, M., Mollenhauer, B., Wiltfang, J., Turner, M.R., Zerr, I., Handels, R., Thompson, A.G., Johansson, G., Ermann, N., Trojanowski, J.Q., Karaca, I., Wagner, H., Oeckl, P., van Waalwijk van Doorn, L., Bjerke, M., Kapogiannis, D., Kuiperij, H.B., Farotti, L., Li, Y., Gordon, B.A., Epelbaum, S., Vos, S.J.B., Klijn, C.J.M., Van Nostrand, W.E., Minguillon, C., Schmitz, M., Gallo, C., Lopez Mato, A., Thibaut, F., Lista, S., Alcolea, D., Zetterberg, H., Blennow, K., Kornhuber, J., 2018. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J. Biol. Psychiatry 19, 244–328. https://doi.org/10.1080/15622975.2017.1375556
  74. Linszen, M.M.J., van Zanten, G.A., Teunisse, R.J., Brouwer, R.M., Scheltens, P., Sommer, I.E., 2018. Auditory hallucinations in adults with hearing impairment: a large prevalence study. Psychol. Med. 1–8. https://doi.org/10.1017/S0033291718000594
  75. Linszen, M.M.J., Lemstra, A.W., Dauwan, M., Brouwer, R.M., Scheltens, P., Sommer, I.E.C., 2018. Understanding hallucinations in probable Alzheimer’s disease: Very low prevalence rates in a tertiary memory clinic. Alzheimer’s Dement. (Amsterdam, Netherlands) 10, 358–362. https://doi.org/10.1016/j.dadm.2018.03.005
  76. Liu, E., Wang, D., Sperling, R., Salloway, S., Fox, N.C., Blennow, K., Scheltens, P., Schmidt, M.E., Streffer, J., Novak, G., Einstein, S., Booth, K., Ketter, N., Brashear, H.R., 2018. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology 90, e877–e886. https://doi.org/10.1212/WNL.0000000000005060
  77. Marizzoni, M., Ferrari, C., Jovicich, J., Albani, D., Babiloni, C., Cavaliere, L., Didic, M., Forloni, G., Galluzzi, S., Hoffmann, K.-T., Molinuevo, J.L., Nobili, F., Parnetti, L., Payoux, P., Ribaldi, F., Rossini, P.M., Schonknecht, P., Soricelli, A., Hensch, T., Tsolaki, M., Visser, P.J., Wiltfang, J., Richardson, J.C., Bordet, R., Blin, O., Frisoni, G.B., 2018. Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease: Structural Brain Biomarkers. J. Alzheimers. Dis. https://doi.org/10.3233/JAD-180152
  78. Mattsson, N., Groot, C., Jansen, W.J., Landau, S.M., Villemagne, V.L., Engelborghs, S., Mintun, M.M., Lleo, A., Molinuevo, J.L., Jagust, W.J., Frisoni, G.B., Ivanoiu, A., Chetelat, G., Resende de Oliveira, C., Rodrigue, K.M., Kornhuber, J., Wallin, A., Klimkowicz-Mrowiec, A., Kandimalla, R., Popp, J., Aalten, P.P., Aarsland, D., Alcolea, D., Almdahl, I.S., Baldeiras, I., van Buchem, M.A., Cavedo, E., Chen, K., Cohen, A.D., Forster, S., Fortea, J., Frederiksen, K.S., Freund-Levi, Y., Gill, K.D., Gkatzima, O., Grimmer, T., Hampel, H., Herukka, S.-K., Johannsen, P., van Laere, K., de Leon, M.J., Maier, W., Marcusson, J., Meulenbroek, O., Mollergard, H.M., Morris, J.C., Mroczko, B., Nordlund, A., Prabhakar, S., Peters, O., Rami, L., Rodriguez-Rodriguez, E., Roe, C.M., Ruther, E., Santana, I., Schroder, J., Seo, S.W., Soininen, H., Spiru, L., Stomrud, E., Struyfs, H., Teunissen, C.E., Verhey, F.R.J., Vos, S.J.B., van Waalwijk van Doorn, L.J.C., Waldemar, G., Wallin, A.K., Wiltfang, J., Vandenberghe, R., Brooks, D.J., Fladby, T., Rowe, C.C., Drzezga, A., Verbeek, M.M., Sarazin, M., Wolk, D.A., Fleisher, A.S., Klunk, W.E., Na, D.L., Sanchez-Juan, P., Lee, D.Y., Nordberg, A., Tsolaki, M., Camus, V., Rinne, J.O., Fagan, A.M., Zetterberg, H., Blennow, K., Rabinovici, G.D., Hansson, O., van Berckel, B.N.M., van der Flier, W.M., Scheltens, P., Visser, P.J., Ossenkoppele, R., 2018. Prevalence of the apolipoprotein E epsilon4 allele in amyloid beta positive subjects across the spectrum of Alzheimer’s disease. Alzheimers. Dement. 14, 913–924. https://doi.org/10.1016/j.jalz.2018.02.009
  79. Mattsson, N., Ossenkoppele, R., Smith, R., Strandberg, O., Ohlsson, T., Jogi, J., Palmqvist, S., Stomrud, E., Hansson, O., 2018. Greater tau load and reduced cortical thickness in APOE epsilon4-negative Alzheimer’s disease: a cohort study. Alzheimers. Res. Ther. 10, 77. https://doi.org/10.1186/s13195-018-0403-x
  80. Meeter, L.H.H., Gendron, T.F., Sias, A.C., Jiskoot, L.C., Russo, S.P., Donker Kaat, L., Papma, J.M., Panman, J.L., van der Ende, E.L., Dopper, E.G., Franzen, S., Graff, C., Boxer, A.L., Rosen, H.J., Sanchez-Valle, R., Galimberti, D., Pijnenburg, Y.A.L., Benussi, L., Ghidoni, R., Borroni, B., Laforce, R.J., Del Campo, M., Teunissen, C.E., van Minkelen, R., Rojas, J.C., Coppola, G., Geschwind, D.H., Rademakers, R., Karydas, A.M., Oijerstedt, L., Scarpini, E., Binetti, G., Padovani, A., Cash, D.M., Dick, K.M., Bocchetta, M., Miller, B.L., Rohrer, J.D., Petrucelli, L., van Swieten, J.C., Lee, S.E., 2018. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann. Clin. Transl. Neurol. 5, 583–597. https://doi.org/10.1002/acn3.559
  81. Meeter, L.H.H., Vijverberg, E.G., Del Campo, M., Rozemuller, A.J.M., Donker Kaat, L., de Jong, F.J., van der Flier, W.M., Teunissen, C.E., van Swieten, J.C., Pijnenburg, Y.A.L., 2018. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology 90, e1231–e1239. https://doi.org/10.1212/WNL.0000000000005261
  82. Molinuevo, J.L., Ayton, S., Batrla, R., Bednar, M.M., Bittner, T., Cummings, J., Fagan, A.M., Hampel, H., Mielke, M.M., Mikulskis, A., O’Bryant, S., Scheltens, P., Sevigny, J., Shaw, L.M., Soares, H.D., Tong, G., Trojanowski, J.Q., Zetterberg, H., Blennow, K., 2018. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol. 136, 821–853. https://doi.org/10.1007/s00401-018-1932-x
  83. Nestor, P.J., Altomare, D., Festari, C., Drzezga, A., Rivolta, J., Walker, Z., Bouwman, F., Orini, S., Law, I., Agosta, F., Arbizu, J., Boccardi, M., Nobili, F., Frisoni, G.B., 2018. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur. J. Nucl. Med. Mol. Imaging 45, 1509–1525. https://doi.org/10.1007/s00259-018-4035-y
  84. Nobili, F., Arbizu, J., Bouwman, F., Drzezga, A., Agosta, F., Nestor, P., Walker, Z., Boccardi, M., 2018. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain (18) F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur. J. Neurol. 25, 1201–1217. https://doi.org/10.1111/ene.13728
  85. Nobili, F., Festari, C., Altomare, D., Agosta, F., Orini, S., Van Laere, K., Arbizu, J., Bouwman, F., Drzezga, A., Nestor, P., Walker, Z., Boccardi, M., 2018. Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. Eur. J. Nucl. Med. Mol. Imaging 45, 1557–1566. https://doi.org/10.1007/s00259-018-4030-3
  86. Oppedal, K., Ferreira, D., Cavallin, L., Lemstra, A.W., Ten Kate, M., Padovani, A., Rektorova, I., Bonanni, L., Wahlund, L.-O., Engedal, K., Nobili, F., Kramberger, M., Taylor, J.-P., Hort, J., Snaedal, J., Blanc, F., Walker, Z., Antonini, A., Westman, E., Aarsland, D., 2018. A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on  333 patients from the European DLB consortium. Alzheimers. Dement. https://doi.org/10.1016/j.jalz.2018.09.011
  87. Ossenkoppele, R., Hansson, O., 2018. Genetic characterization of amyloid-beta and tau network spread. Nat. Med. 24, 1790–1792. https://doi.org/10.1038/s41591-018-0277-2
  88. Ossenkoppele, R., Rabinovici, G.D., Smith, R., Cho, H., Scholl, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., Ohlsson, T., Jogi, J., Tsai, R., La Joie, R., Kramer, J., Boxer, A.L., Gorno-Tempini, M.L., Miller, B.L., Choi, J.Y., Ryu, Y.H., Lyoo, C.H., Hansson, O., 2018. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 320, 1151–1162. https://doi.org/10.1001/jama.2018.12917
  89. Ostrowitzki, S., Lasser, R.A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., Delmar, P., Klein, G., Andjelkovic, M., Dubois, B., Boada, M., Blennow, K., Santarelli, L., Fontoura, P., 2018. Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers. Res. Ther. https://doi.org/10.1186/s13195-018-0409-4
  90. Pendergrass, J.C., Targum, S.D, Harrison, J.E. Cognitive Impairment Associated with Cancer: A brief Review. Innovations in Clinical Neuroscience. 2018:15;36-44.
  91. Perera, G., Pedersen, L., Ansel, D., Alexander, M., Arrighi, H.M., Avillach, P., Foskett, N., Gini, R., Gordon, M.F., Gungabissoon, U., Mayer, M.-A., Novak, G., Rijnbeek, P., Trifiro, G., van der Lei, J., Visser, P.J., Stewart, R., 2018. Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource. Alzheimers. Dement. 14, 130–139. https://doi.org/10.1016/j.jalz.2017.06.2270
  92. Piersma, D., Fuermaier, A.B.M., de Waard, D., De Deyn, P.P., Davidse, R.J., de Groot, J., Doumen, M.J.A., Bredewoud, R.A., Claesen, R., Lemstra, A.W., Vermeeren, A., Ponds, R., Verhey, F., Brouwer, W.H., Tucha, O., 2018. The MMSE should not be the sole indicator of fitness to drive in mild Alzheimer’s dementia. Acta Neurol. Belg. 118, 637–642. https://doi.org/10.1007/s13760-018-1036-3
  93. Piersma, D., Fuermaier, A.B.M., De Waard, D., Davidse, R.J., De Groot, J., Doumen, M.J.A., Bredewoud, R.A., Claesen, R., Lemstra, A.W., Scheltens, P., Vermeeren, A., Ponds, R., Verhey, F., De Deyn, P.P., Brouwer, W.H., Tucha, O., 2018. Assessing Fitness to Drive in Patients With Different Types of Dementia. Alzheimer Dis. Assoc. Disord. 32, 70–75. https://doi.org/10.1097/WAD.0000000000000221
  94. Pijnenburg, Y.A.L., Dols, A., 2018. Meaning of psychiatric symptoms in frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry. https://doi.org/10.1136/jnnp-2017-317556
  95. Reus, L.M., Vijverberg, E.G., Tijms, B.M., Kate, M. Ten, Gossink, F., Krudop, W.A., Campo, M. Del, Teunissen, C.E., Barkhof, F., van der Flier, W.M., Visser, P.J., Dols, A., Pijnenburg, Y. Al, 2018. Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. J. Psychiatr. Res. 104, 183–191. https://doi.org/10.1016/j.jpsychires.2018.07.014
  96. Rhodius-Meester, H.F.M., Liedes, H., Koene, T., Lemstra, A.W., Teunissen, C.E., Barkhof, F., Scheltens, P., van Gils, M., Lotjonen, J., van der Flier, W.M., 2018. Disease-related determinants are associated with mortality in dementia due to Alzheimer’s disease. Alzheimers. Res. Ther. 10, 23. https://doi.org/10.1186/s13195-018-0348-0
  97. Rhodius-Meester, H.F.M., Tijms, B.M., Lemstra, A.W., Prins, N.D., Pijnenburg, Y.A.L., Bouwman, F., Scheltens, P., van der Flier, W.M., 2018. Survival in memory clinic cohort is short, even in young-onset dementia. J. Neurol. Neurosurg. Psychiatry. https://doi.org/10.1136/jnnp-2018-318820
  98. Rimkus, C.M., Schoonheim, M.M., Steenwijk, M.D., Vrenken, H., Eijlers, A.J., Killestein, J., Wattjes, M.P., Leite, C.C., Barkhof, F., Tijms, B.M., 2018. Gray matter networks and cognitive impairment in multiple sclerosis. Mult. Scler. 1352458517751650. https://doi.org/10.1177/1352458517751650
  99. Saridin, F.N., Schouws, S.N.T.M., de Jong, J., Pijnenburg, Y.A.L., Dols, A., 2018. Secondary mania as a possible presentation of a C9orf72 hexanucleotide repeat expansion. Bipolar Disord. https://doi.org/10.1111/bdi.12724
  100. Schaeverbeke, J., Evenepoel, C., Declercq, L., Gabel, S., Meersmans, K., Bruffaerts, R., Adamczuk, K., Dries, E., Van Bouwel, K., Sieben, A., Pijnenburg, Y., Peeters, R., Bormans, G., Van Laere, K., Koole, M., Dupont, P., Vandenberghe, R., 2018. Distinct [(18)F]THK5351 binding patterns in primary progressive aphasia variants. Eur. J. Nucl. Med. Mol. Imaging 45, 2342–2357. https://doi.org/10.1007/s00259-018-4075-3
  101. Schaeverbeke, J., Gabel, S., Meersmans, K., Bruffaerts, R., Liuzzi, A.G., Evenepoel, C., Dries, E., Van Bouwel, K., Sieben, A., Pijnenburg, Y., Peeters, R., Bormans, G., Van Laere, K., Koole, M., Dupont, P., Vandenberghe, R., 2018. Single-word comprehension deficits in the nonfluent variant of primary progressive aphasia. Alzheimers. Res. Ther. 10, 68. https://doi.org/10.1186/s13195-018-0393-8
  102. Scheltens, N.M.E., Tijms, B.M., Heymans, M.W., Rabinovici, G.D., Cohn-Sheehy, B.I., Miller, B.L., Kramer, J.H., Wolfsgruber, S., Wagner, M., Kornhuber, J., Peters, O., Scheltens, P., van der Flier, W.M., 2018. Prominent Non-Memory Deficits in Alzheimer’s Disease Are Associated with Faster Disease Progression. J. Alzheimers. Dis. 65, 1029–1039. https://doi.org/10.3233/JAD-171088
  103. Scheltens, N.M.E., van der Weijden, K., Adriaanse, S.M., van Assema, D., Oomen, P.P., Krudop, W.A., Lammertsma, A.A., Barkhof, F., Koene, T., Teunissen, C.E., Scheltens, P., van der Flier, W.M., Pijnenburg, Y.A.L., Yaqub, M., Ossenkoppele, R., van Berckel, B.N.M., 2018. Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer’s disease. NeuroImage. Clin. 19, 625–632. https://doi.org/10.1016/j.nicl.2018.05.024
  104. Scheltens, P., Hallikainen, M., Grimmer, T., Duning, T., Gouw, A.A., Teunissen, C.E., Wink, A.M., Maruff, P., Harrison, J., van Baal, C.M., Bruins, S., Lues, I., Prins, N.D., 2018. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimers. Res. Ther. 10, 107. https://doi.org/10.1186/s13195-018-0431-6
  105. Scheltens, P., Prins, N., Lammertsma, A., Yaqub, M., Gouw, A., Wink, A.M., Chu, H.-M., van Berckel, B.N.M., Alam, J., 2018. An exploratory clinical study of p38alpha kinase inhibition in Alzheimer’s disease. Ann. Clin. Transl. Neurol. 5, 464–473. https://doi.org/10.1002/acn3.549
  106. Schindler, S.E., Sutphen, C.L., Teunissen, C., McCue, L.M., Morris, J.C., Holtzman, D.M., Mulder, S.D., Scheltens, P., Xiong, C., Fagan, A.M., 2018.Upward drift in cerebrospinal fluid amyloid beta 42 assay values for more than 10 years. Alzheimers. Dement. 14, 62–70. https://doi.org/10.1016/j.jalz.2017.06.2264
  107. Slot, R.E.R., Verfaillie, S.C.J., Overbeek, J.M., Timmers, T., Wesselman, L.M.P., Teunissen, C.E., Dols, A., Bouwman, F.H., Prins, N.D., Barkhof, F., Lammertsma, A.A., Van Berckel, B.N.M., Scheltens, P., Sikkes, S.A.M., Van der Flier, W.M., 2018. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimers. Res. Ther. 10, 76. https://doi.org/10.1186/s13195-018-0390-y
  108. Taskesen, E., Mishra, A., van der Sluis, S., Ferrari, R., Veldink, J.H., van Es, M.A., Smit, A.B., Posthuma, D., Pijnenburg, Y., 2018. Author Correction: Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS. Sci. Rep. https://doi.org/10.1038/s41598-018-21308-x
  109. Ten Kate, M., Dicks, E., Visser, P.J., van der Flier, W.M., Teunissen, C.E., Barkhof, F., Scheltens, P., Tijms, B.M., 2018. Atrophy subtypes in prodromal Alzheimer’s disease are associated with cognitive decline. Brain 141, 3443–3456. https://doi.org/10.1093/brain/awy264
  110. Ten Kate, M., Ingala, S., Schwarz, A.J., Fox, N.C., Chetelat, G., van Berckel, B.N.M., Ewers, M., Foley, C., Gispert, J.D., Hill, D., Irizarry, M.C., Lammertsma, A.A., Molinuevo, J.L., Ritchie, C., Scheltens, P., Schmidt, M.E., Visser, P.J., Waldman, A., Wardlaw, J., Haller, S., Barkhof, F., 2018. Secondary prevention of Alzheimer’s dementia: neuroimaging contributions. Alzheimers. Res. Ther. 10, 112. https://doi.org/10.1186/s13195-018-0438-z
  111. Ten Kate, M., Redolfi, A., Peira, E., Bos, I., Vos, S.J., Vandenberghe, R., Gabel, S., Schaeverbeke, J., Scheltens, P., Blin, O., Richardson, J.C., Bordet, R., Wallin, A., Eckerstrom, C., Molinuevo, J.L., Engelborghs, S., Van Broeckhoven, C., Martinez-Lage, P., Popp, J., Tsolaki, M., Verhey, F.R.J., Baird, A.L., Legido-Quigley, C., Bertram, L., Dobricic, V., Zetterberg, H., Lovestone, S., Streffer, J., Bianchetti, S., Novak, G.P., Revillard, J., Gordon, M.F., Xie, Z., Wottschel, V., Frisoni, G., Visser, P.J., Barkhof, F., 2018. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimers. Res. Ther. 10, 100. https://doi.org/10.1186/s13195-018-0428-1
  112. Ten Kate, M., Sudre, C.H., den Braber, A., Konijnenberg, E., Nivard, M.G., Cardoso, M.J., Scheltens, P., Ourselin, S., Boomsma, D.I., Barkhof, F., Visser, P.J., 2018. White matter hyperintensities and vascular risk factors in monozygotic twins. Neurobiol. Aging 66, 40–48. https://doi.org/10.1016/j.neurobiolaging.2018.02.002
  113. Ten Kate, M., Visser, P.J., Bakardjian, H., Barkhof, F., Sikkes, S.A.M., van der Flier, W.M., Scheltens, P., Hampel, H., Habert, M.-O., Dubois, B., Tijms, B.M., 2018. Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. Front. Aging Neurosci. 10, 67. https://doi.org/10.3389/fnagi.2018.00067
  114. Tesi, N., van der Lee, S.J., Hulsman, M., Jansen, I.E., Stringa, N., van Schoor, N., Meijers-Heijboer, H., Huisman, M., Scheltens, P., Reinders, M.J.T., van der Flier, W.M., Holstege, H., 2018. Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer’s disease. Eur. J. Hum. Genet. https://doi.org/10.1038/s41431-018-0273-5
  115. Teunissen, C.E., Chiu, M.-J., Yang, C.-C., Yang, S.-Y., Scheltens, P., Zetterberg, H., Blennow, K., 2018. Plasma Amyloid-beta (Abeta42) Correlates with Cerebrospinal Fluid Abeta42 in Alzheimer’s Disease. J. Alzheimers. Dis. 62, 1857–1863. https://doi.org/10.3233/JAD-170784
  116. Tijms, B.M., Ten Kate, M., Gouw, A.A., Borta, A., Verfaillie, S., Teunissen, C.E., Scheltens, P., Barkhof, F., van der Flier, W.M., 2018. Gray matter networks and clinical progression in subjects with predementia Alzheimer’s disease. Neurobiol. Aging 61, 75–81. https://doi.org/10.1016/j.neurobiolaging.2017.09.011
  117. Tijms, B.M., Vermunt, L., Zwan, M.D., van Harten, A.C., van der Flier, W.M., Teunissen, C.E., Scheltens, P., Visser, P.J., 2018. Pre-amyloid stage of Alzheimer’s disease in cognitively normal individuals. Ann. Clin. Transl. Neurol. 5, 1037–1047. https://doi.org/10.1002/acn3.615
  118. Tijms, B.M., Visser, P.J., 2018. Capturing the Alzheimer’s disease pathological cascade. Lancet. Neurol. 17, 199–200. https://doi.org/10.1016/S1474-4422(18)30043-7
  119. Tijms, B.M., Visser, P.J., 2018. Chasing the start of sporadic Alzheimer’s disease running in families. Brain 141, 1589–1591. https://doi.org/10.1093/brain/awy113
  120. Tijms, B.M., Willemse, E.A.J., Zwan, M.D., Mulder, S.D., Visser, P.J., van Berckel, B.N.M., van der Flier, W.M., Scheltens, P., Teunissen, C.E., 2018. Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-beta  1-42 Analysis Results. Clin. Chem. 64, 576–585. https://doi.org/10.1373/clinchem.2017.281055
  121. Timmers, T., van Berckel, B.N.M., Lammertsma, A.A., Ossenkoppele, R., 2018. Quantification of Tau Load in Alzheimer’s Disease Clinical Trials Using Positron  Emission Tomography. Methods Mol. Biol. 1750, 221–229. https://doi.org/10.1007/978-1-4939-7704-8_15
  122. Tolonen, A., Rhodius-Meester, H.F.M., Bruun, M., Koikkalainen, J., Barkhof, F., Lemstra, A.W., Koene, T., Scheltens, P., Teunissen, C.E., Tong, T., Guerrero, R., Schuh, A., Ledig, C., Baroni, M., Rueckert, D., Soininen, H., Remes, A.M., Waldemar, G., Hasselbalch, S.G., Mecocci, P., van der Flier, W.M., Lotjonen, J., 2018. Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. Front. Aging Neurosci. 10, 111. https://doi.org/10.3389/fnagi.2018.00111
  123. van de Kreeke, J.A., Nguyen, H.T., Konijnenberg, E., Tomassen, J., den Braber, A., Ten Kate, M., Sudre, C.H., Barkhof, F., Boomsma, D.I., Tan, H.S., Verbraak, F.D., Visser, P.J., 2018. Retinal and Cerebral Microvasculopathy: Relationships and Their Genetic Contributions. Invest. Ophthalmol. Vis. Sci. 59, 5025–5031. https://doi.org/10.1167/iovs.18-25341
  124. van den Kommer, T.N., Deeg, D.J.H., van der Flier, W.M., Comijs, H.C., 2018. Time Trend in Persistent Cognitive Decline: Results From the Longitudinal Aging Study Amsterdam. J. Gerontol. B. Psychol. Sci. Soc. Sci. 73, S57–S64. https://doi.org/10.1093/geronb/gbx151
  125. van der Flier, W.M., Scheltens, P., 2018. Amsterdam Dementia Cohort: Performing Research to Optimize Care. J. Alzheimers. Dis. 62, 1091–1111. https://doi.org/10.3233/JAD-170850
  126. van der Flier, W.M., Skoog, I., Schneider, J.A., Pantoni, L., Mok, V., Chen, C.L.H., Scheltens, P., 2018. Vascular cognitive impairment. Nat. Rev. Dis. Prim. 4, 18003. https://doi.org/10.1038/nrdp.2018.3
  127. van der Lee, S.J., Teunissen, C.E., Pool, R., Shipley, M.J., Teumer, A., Chouraki, V., Melo van Lent, D., Tynkkynen, J., Fischer, K., Hernesniemi, J., Haller, T., Singh-Manoux, A., Verhoeven, A., Willemsen, G., de Leeuw, F.A., Wagner, H., van Dongen, J., Hertel, J., Budde, K., Willems van Dijk, K., Weinhold, L., Ikram, M.A., Pietzner, M., Perola, M., Wagner, M., Friedrich, N., Slagboom, P.E., Scheltens, P., Yang, Q., Gertzen, R.E., Egert, S., Li, S., Hankemeier, T., van Beijsterveldt, C.E.M., Vasan, R.S., Maier, W., Peeters, C.F.W., Jorgen Grabe, H., Ramirez, A., Seshadri, S., Metspalu, A., Kivimaki, M., Salomaa, V., Demirkan, A., Boomsma, D.I., van der Flier, W.M., Amin, N., van Duijn, C.M., 2018. Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. Alzheimers. Dement. 14, 707–722. https://doi.org/10.1016/j.jalz.2017.11.012
  128. van der Zande, J.J., Gouw, A.A., van Steenoven, I., Scheltens, P., Stam, C.J., Lemstra, A.W., 2018. EEG Characteristics of Dementia With Lewy Bodies, Alzheimer’s Disease and Mixed Pathology. Front. Aging Neurosci. 10, 190. https://doi.org/10.3389/fnagi.2018.00190
  129. van der Zande, J.J., Steenwijk, M.D., Ten Kate, M., Wattjes, M.P., Scheltens, P., Lemstra, A.W., 2018. Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer’s disease pathology. Neurobiol. Aging 71, 171–178. https://doi.org/10.1016/j.neurobiolaging.2018.07.005
  130. van Loenhoud, A.C., Groot, C., Vogel, J.W., van der Flier, W.M., Ossenkoppele, R., 2018. Is intracranial volume a suitable proxy for brain reserve? Alzheimers. Res. Ther. 10, 91. https://doi.org/10.1186/s13195-018-0408-5
  131. Van Someren, E.J.W., Oosterman, J.M., Van Harten, B., Vogels, R.L., Gouw, A.A., Weinstein, H.C., Poggesi, A., Scheltens, P., Scherder, E.J.A., 2018. Medial temporal lobe atrophy relates more strongly to sleep-wake rhythm fragmentation than to age or any other known risk. Neurobiol. Learn. Mem. https://doi.org/10.1016/j.nlm.2018.05.017
  132. van Steenoven, I., Majbour, N.K., Vaikath, N.N., Berendse, H.W., van der Flier, W.M., van de Berg, W.D.J., Teunissen, C.E., Lemstra, A.W., El-Agnaf, O.M.A., 2018. alpha-Synuclein species as potential cerebrospinal fluid biomarkers for dementia  with lewy bodies. Mov. Disord. 33, 1724–1733. https://doi.org/10.1002/mds.111
  133. Verberk, I.M.W., Slot, R.E., Verfaillie, S.C.J., Heijst, H., Prins, N.D., van Berckel, B.N.M., Scheltens, P., Teunissen, C.E., van der Flier, W.M., 2018. Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. Ann. Neurol. 84, 648–658. https://doi.org/10.1002/ana.25334
  134. Verfaillie, S.C.J., Pichet Binette, A., Vachon-Presseau, E., Tabrizi, S., Savard, M., Bellec, P., Ossenkoppele, R., Scheltens, P., van der Flier, W.M., Breitner, J.C.S., Villeneuve, S., 2018. Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer’s Disease. Biol. psychiatry. Cogn. Neurosci. neuroimaging 3, 463–472. https://doi.org/10.1016/j.bpsc.2017.11.012
  135. Verfaillie, S.C.J., Slot, R.E.R., Dicks, E., Prins, N.D., Overbeek, J.M., Teunissen, C.E., Scheltens, P., Barkhof, F., van der Flier, W.M., Tijms, B.M., 2018. A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. Hum. Brain Mapp. 39, 3143–3151. https://doi.org/10.1002/hbm.24065
  136. Verfaillie, S.C.J., Slot, R.E., Tijms, B.M., Bouwman, F., Benedictus, M.R., Overbeek, J.M., Koene, T., Vrenken, H., Scheltens, P., Barkhof, F., van der Flier, W.M., 2018. Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. Neurobiol. Aging 61, 238–244. https://doi.org/10.1016/j.neurobiolaging.2017.09.009
  137. Vermunt, L., Veal, C.D., Ter Meulen, L., Chrysostomou, C., van der Flier, W., Frisoni, G.B., Guessous, I., Kivipelto, M., Marizzoni, M., Martinez-Lage, P., Molinuevo, J.L., Porteous, D., Ritchie, K., Scheltens, P., Ousset, P.-J., Ritchie, C.W., Luscan, G., Brookes, A.J., Visser, P.J., 2018. European Prevention of Alzheimer’s Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimers. Dement. 14, 837–842. https://doi.org/10.1016/j.jalz.2018.02.010
  138. Vijverberg, E.G.B., Gossink, F., Krudop, W., Dols, A., Pijnenburg, Y.A.L., 2018. . Ned. Tijdschr. Geneeskd. 162.
  139. Vogel, J.W., Mattsson, N., Iturria-Medina, Y., Strandberg, O.T., Scholl, M., Dansereau, C., Villeneuve, S., van der Flier, W.M., Scheltens, P., Bellec, P., Evans, A.C., Hansson, O., Ossenkoppele, R., 2018. Data-driven approaches for tau-PET imaging biomarkers in Alzheimer’s disease. Hum. Brain Mapp. https://doi.org/10.1002/hbm.24401
  140. Vos, S.J.B., Visser, P.J., 2018. Preclinical Alzheimer’s Disease: Implications for Refinement of the Concept. J. Alzheimers. Dis. 64, S213–S227. https://doi.org/10.3233/JAD-179943
  141. Walker, Z., Gandolfo, F., Orini, S., Garibotto, V., Agosta, F., Arbizu, J., Bouwman, F., Drzezga, A., Nestor, P., Boccardi, M., Altomare, D., Festari, C., Nobili, F., 2018. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia. Eur. J. Nucl. Med. Mol. Imaging 45, 1534–1545. https://doi.org/10.1007/s00259-018-4031-2
  142. Weintraub, S., Carrillo, M.C., Farias, S.T., Goldberg, T.E., Hendrix, J.A., Jaeger, J., Knopman, D.S., Langbaum, J.B., Park, D.C., Ropacki, M.T., Sikkes, S.A.M., Welsh-Bohmer, K.A., Bain, L.J., Brashear, R., Budur, K., Graf, A., Martenyi, F., Storck, M.S., Randolph, C., 2018. Measuring cognition and function in the preclinical stage of Alzheimer’s disease. Alzheimer’s Dement. (New York, N. Y.) 4, 64–75. https://doi.org/10.1016/j.trci.2018.01.003
  143. Wesselman, L.M.P., Schild, A.-K., Coll-Padros, N., van der Borg, W.E., Meurs, J.H.P., Hooghiemstra, A.M., Slot, R.E.R., Sannemann, L., Rami, L., Molinuevo, J.L., Bouwman, F.H., Jessen, F., van der Flier, W.M., Sikkes, S.A.M., 2018. Wishes and preferences for an online lifestyle program for brain health-A mixed methods study. Alzheimer’s Dement. (New York, N. Y.) 4, 141–149. https://doi.org/10.1016/j.trci.2018.03.003
  144. Willemse, E.A.J., De Vos, A., Herries, E.M., Andreasson, U., Engelborghs, S., van der Flier, W.M., Scheltens, P., Crimmins, D., Ladenson, J.H., Vanmechelen, E., Zetterberg, H., Fagan, A.M., Blennow, K., Bjerke, M., Teunissen, C.E., 2018. Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. Clin. Chem. 64, 927–937. https://doi.org/10.1373/clinchem.2017.283028
  145. Willemse, E.A.J., van Maurik, I.S., Tijms, B.M., Bouwman, F.H., Franke, A., Hubeek, I., Boelaarts, L., Claus, J.J., Korf, E.S.C., van Marum, R.J., Roks, G., Schoonenboom, N., Verwey, N., Zwan, M.D., Wahl, S., van der Flier, W.M., Teunissen, C.E., 2018. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer’s disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. Alzheimer’s Dement. (Amsterdam, Netherlands) 10, 563–572. https://doi.org/10.1016/j.dadm.2018.08.006
  146. Wink, A.M., Tijms, B.M., Ten Kate, M., Raspor, E., de Munck, J.C., Altena, E., Ecay-Torres, M., Clerigue, M., Estanga, A., Garcia-Sebastian, M., Izagirre, A., Martinez-Lage Alvarez, P., Villanua, J., Barkhof, F., Sanz-Arigita, E., 2018. Functional brain network centrality is related to APOE genotype in cognitively normal elderly. Brain Behav. 8, e01080. https://doi.org/10.1002/brb3.1080
  147. Wolters, E.E., Golla, S.S. V, Timmers, T., Ossenkoppele, R., van der Weijden, C.W.J., Scheltens, P., Schwarte, L., Schuit, R.C., Windhorst, A.D., Barkhof, F., Yaqub, M., Lammertsma, A.A., Boellaard, R., van Berckel, B.N.M., 2018. A novel partial volume correction method for accurate quantification of [(18)F] flortaucipir in the hippocampus. EJNMMI Res. 8, 79. https://doi.org/10.1186/s13550-018-0432-2
  148. Wong, T.H., van der Lee, S.J., van Rooij, J.G.J., Meeter, L.H.H., Frick, P., Melhem, S., Seelaar, H., Ikram, M.A., Rozemuller, A.J., Holstege, H., Hulsman, M., Uitterlinden, A., Neumann, M., Hoozemans, J.J.M., van Duijn, C.M., Rademakers, R., van Swieten, J.C., 2019. EIF2AK3 variants in Dutch patients with Alzheimer’s disease. Neurobiol. Aging 73, 229.e11-229.e18. https://doi.org/10.1016/j.neurobiolaging.2018.08.016
  149. Zhang, M., Ferrari, R., Tartaglia, M.C., Keith, J., Surace, E.I., Wolf, U., Sato, C., Grinberg, M., Liang, Y., Xi, Z., Dupont, K., McGoldrick, P., Weichert, A., McKeever, P.M., Schneider, R., McCorkindale, M.D., Manzoni, C., Rademakers, R., Graff-Radford, N.R., Dickson, D.W., Parisi, J.E., Boeve, B.F., Petersen, R.C., Miller, B.L., Seeley, W.W., van Swieten, J.C., van Rooij, J., Pijnenburg, Y., van der Zee, J., Van Broeckhoven, C., Le Ber, I., Van Deerlin, V., Suh, E., Rohrer, J.D., Mead, S., Graff, C., Oijerstedt, L., Pickering-Brown, S., Rollinson, S., Rossi, G., Tagliavini, F., Brooks, W.S., Dobson-Stone, C., Halliday, G.M., Hodges, J.R., Piguet, O., Binetti, G., Benussi, L., Ghidoni, R., Nacmias, B., Sorbi, S., Bruni, A.C., Galimberti, D., Scarpini, E., Rainero, I., Rubino, E., Clarimon, J., Lleo, A., Ruiz, A., Hernandez, I., Pastor, P., Diez-Fairen, M., Borroni, B., Pasquier, F., Deramecourt, V., Lebouvier, T., Perneczky, R., Diehl-Schmid, J., Grafman, J., Huey, E.D., Mayeux, R., Nalls, M.A., Hernandez, D., Singleton, A., Momeni, P., Zeng, Z., Hardy, J., Robertson, J., Zinman, L., Rogaeva, E., 2018. A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain 141, 2895–2907. https://doi.org/10.1093/brain/awy238

Publicaties 2017

  1. Aalfs CM, Vervenne-van Spaendonk R, Pijnenburg YAL, Cohn-Hokke PE, Meijers HJ, Scheltens P. DNA diagnostics in dementia. Ned Tijdschr Geneeskd. 2017;161(0):D1774. Dutch.
  2. Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Wang P, Shen L, Tolar M. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease Suggest Disease Modification Potential. J Prev Alzheimers Dis. 2017;4(3):149-156. doi: 10.14283/jpad.2017.26.
  3. Aisen PS, Cummings J, Jack CR Jr, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B. On the path to 2025: understanding the Alzheimer’s disease continuum. Alzheimers Res Ther. 2017 Aug 9;9(1):60. doi: 10.1186/s13195-017-0283-5. Review.
  4. Babapour Mofrad R, Bouwman FH, Slot RER, Timmers T, van der Flier WM, Scheltens P, Teunissen CE. Lumbar puncture in patients with neurologic conditions. Alzheimers Dement (Amst). 2017 May 18;8:108-110. doi: 10.1016/j.dadm.2017.04.008.
  5. Benedictus MR, Leeuwis AE, Binnewijzend MA, Kuijer JP, Scheltens P, Barkhof F, van der Flier WM, Prins ND. Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer’s disease. Eur Radiol. 2017 Mar;27(3):1169-1175. doi: 10.1007/s00330-016-4450-z.
  6. Bertens D, Tijms BM, Scheltens Ph, Teunissen CE, Visser PJ. Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population. Alzheimer’s Research & Therapy.2017;9(8).DOI: 10.1186/s13195-016-0233-7
  7. Bertens D, Tijms BM, Vermunt L, Prins ND, Scheltens P, Visser PJ. The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer’s disease: Implications for trial design. Alzheimers Dement (N Y). 2017 Sep 21;3(4):513-523. doi: 10.1016/j.trci.2017.08.005.
  8. Boomsma JMF, Exalto LG, Barkhof F, van den Berg E, de Bresser J, Heinen R, Koek HL, Prins ND, Scheltens P, Weinstein HC, van der Flier WM, Biessels GJ. Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the “Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment” (TRACE-VCI) Study.  JMIR Res Protoc. 2017 Apr 19;6(4):e60. doi: 10.2196/resprot.6864.
  9. Bos I, Vos SJ, Frölich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Engelborghs S, Niemantsverdriet E, De Roeck EE, Tsolaki M, Freund-Levi Y, Johannsen P, Vandenberghe R, Lleó A, Alcolea D, Frisoni GB, Galluzzi S, Nobili F, Morbelli S, Drzezga A, Didic M, van Berckel BN, Salmon E, Bastin C, Dauby S, Santana I, Baldeiras I, de Mendonça A, Silva D, Wallin A, Nordlund A, Coloma PM, Wientzek A, Alexander M, Novak GP, Gordon MF; Alzheimer’s Disease Neuroimaging Initiative, Wallin ÅK, Hampel H, Soininen H, Herukka SK, Scheltens P, Verhey FR, Visser PJ. The frequency and influence of dementia risk factors in prodromal Alzheimer’s disease.Neurobiol Aging. 2017 Aug;56:33-40. doi: 10.1016/j.neurobiolaging.2017.03.034.
  10. Bridel C, Hoffmann T, Meyer A, Durieux S, Koel-Simmelink MA, Orth M, Scheltens P, Lues I, Teunissen CE. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients. Alzheimers Res Ther. 2017 Jun 6;9(1):38. doi: 10.1186/s13195-017-0266-6.
  11. Cha DS, Carmona NE, Mansur RB, Lee Y, Park HJ, Rodrigues NB, Subramaniapillaia M, Rosenblat JD, Pan Z, Lee JH, Lee JG, Almatham F, Alageel A, Shekotokhina M, Zhou AJ, Rong C, Harrison JE, McIntyre RS. Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it). Scandinavian Journal of Pain. 2017:1;62–67. doi: 10.1016/j.sjpain.2016.12.004.
  12. Cha DS, Carmona NW, Subramaniapillai M, Mansur RB, Lee Y, Lee JH, Lee J, Rosenbalt JD, Shekotikhina M, Park C, Rong C, Greer TL, Lam R, Baune BT, Harrison J, McIntye RS. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. Journal of Affective Disorders. J Affect Disord. 2017:222;14-20. doi: 10.1016/j.jad.2017.06.036.
  13. Chakraborty A, de Wit NM, van der Flier WM, de Vries HE. The blood brain barrier in Alzheimer’s disease. Vascul Pharmacol. 2017 Feb;89:12-18. doi: 10.1016/j.vph.2016.11.008. Epub 2016 Nov 25. Review.
  14. Chatterjee M, Nöding B, Willemse EAJ, Koel-Simmelink MJA, van der Flier WM, Schild D, Teunissen CE. Detection of contactin-2 in cerebrospinal fluid (CSF) of patients with Alzheimer’s disease using Fluorescence Correlation Spectroscopy (FCS). Clin Biochem. 2017 Dec;50(18):1061-1066. doi: 10.1016/j.clinbiochem.2017.08.017.
  15. Claus JJ, Staekenborg SS, Holl DC, Roorda JJ, Schuur J, Koster P, Tielkes CEM, Scheltens P. Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer’s disease: Validation in a large memory clinic population. Eur Radiol. 2017 Aug;27(8):3147-3155. doi: 10.1007/s00330-016-4726-3.
  16. Cohn-Hokke PE, Holstege H, Weiss MM, van der Flier WM, Barkhof F, Sistermans EA, Pijnenburg YA, van Swieten JC, Meijers-Heijboer H, Scheltens P. A novel CCM2 variant in a family with non-progressive cognitive complaints and cerebral microbleeds. Am J Med Genet B Neuropsychiatr Genet. 2017 Apr;174(3):220-226. doi: 10.1002/ajmg.b.32468.
  17. Costa A, Bak T, Caffarra P, Caltagirone C, Ceccaldi M, Collette F, Crutch S, Della Sala S, Démonet JF, Dubois B, Duzel E, Nestor P, Papageorgiou SG, Salmon E, Sikkes S, Tiraboschi P, van der Flier WM, Visser PJ, Cappa SF. The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. Alzheimers Res Ther. 2017 Apr 17;9(1):27. doi: 10.1186/s13195-017-0254-x. Review.
  18. Crutch SJ, Schott JM, Rabinovici GD, Murray M, Snowden JS, van der Flier WM, Dickerson BC, Vandenberghe R, Ahmed S, Bak TH, Boeve BF, Butler C, Cappa SF, Ceccaldi M, de Souza LC, Dubois B, Felician O, Galasko D, Graff-Radford J, Graff-Radford NR, Hof PR, Krolak-Salmon P, Lehmann M, Magnin E, Mendez MF, Nestor PJ, Onyike CU, Pelak VS, Pijnenburg Y, Primativo S, Rossor MN, Ryan NS, Scheltens P, Shakespeare TJ, Suárez González A, Tang-Wai DF, Yong KXX, Carrillo M, Fox NC; Alzheimer’s Association ISTAART Atypical Alzheimer’s Disease and Associated Syndromes Professional Interest Area. Consensus classification of posterior cortical atrophy. Alzheimers Dement. 2017 Aug;13(8):870-884. doi: 10.1016/j.jalz.2017.01.014.
  19. Cummings J, Scheltens P, McKeith I, Blesa R, Harrison JE, Bertolucci PH, Rockwood K, Wilkinson D, Wijker W, Bennett DA, Shah RC. Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease.
  20. Size Analyses of Souvenaid in Patients with Alzheimer’s Disease. J Alzheimers Dis. 2017;55(3):1131-1139.
  21. de Leeuw FA, Peeters CFW, Kester MI, Harms AC, Struys EA, Hankemeier T, van Vlijmen HWT, van der Lee SJ, van Duijn CM, Scheltens P, Demirkan A, van de Wiel MA, van der Flier WM, Teunissen CE. Blood-based metabolic signatures in Alzheimer’s disease. Alzheimers Dement (Amst). 2017 Sep 6;8:196-207. doi: 10.1016/j.dadm.2017.07.006.
  22. de Wilde A, van Maurik IS, Kunneman M, Bouwman F, Zwan M, Willemse EA, Biessels GJ, Minkman M, Pel R, Schoonenboom NS, Smets EM, Wattjes MP, Barkhof F, Stephens A, van Lier EJ, Batrla-Utermann R, Scheltens P, Teunissen CE, van Berckel BN, van der Flier WM. Alzheimer’s biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimers Dement (Amst). 2017 Jan 23;6:143-151. doi: 10.1016/j.dadm.2017.01.003. eCollection 2017.
  23. Demuru M, Gouw AA, Hillebrand A, Stam CJ, van Dijk BW, Scheltens P, Tijms BM, Konijnenberg E, Ten Kate M, den Braber A, Smit DJA, Boomsma DI, Visser PJ. Functional and effective whole brain connectivity using magnetoencephalography to identify monozygotic twin pairs. Sci Rep. 2017 Aug 29;7(1):9685. doi: 10.1038/s41598-017-10235-y.
  24. den Haan J, Verbraak FD, Visser PJ, Bouwman FH. Retinal thickness in Alzheimer’s disease: A systematic review and meta-analysis. Alzheimers Dement (Amst). 2017 Jan 25;6:162-170. doi: 10.1016/j.dadm.2016.12.014. eCollection 2017.
  25. Dicks E, Tijms BM, Ten Kate M, Gouw AA, Benedictus MR, Teunissen CE, Barkhof F, Scheltens P, van der Flier WM. Gray matter network measures are associated with cognitive decline in mild cognitive impairment. Neurobiol Aging. 2018 Jan;61:198-206. doi: 10.1016/j.neurobiolaging.2017.09.029.
  26. Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, Dujmovic I, van der Flier W, Frölich L, Galimberti D, Gnanapavan S, Hemmer B, Hoff E, Hort J, Iacobaeus E, Ingelsson M, Jan de Jong F, Jonsson M, Khalil M, Kuhle J, Lleó A, de Mendonça A, Molinuevo JL, Nagels G, Paquet C, Parnetti L, Roks G, Rosa-Neto P, Scheltens P, Skårsgard C, Stomrud E, Tumani H, Visser PJ, Wallin A, Winblad B, Zetterberg H, Duits F, Teunissen CE. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst). 2017 May 18;8:111-126. doi: 10.1016/j.dadm.2017.04.007.
  27. Engels MMA, van der Flier WM, Stam CJ, Hillebrand A, Scheltens P, van Straaten ECW. Alzheimer’s disease: The state of the art in resting-state magnetoencephalography. Clin Neurophysiol. 2017 Aug;128(8):1426-1437. doi: 10.1016/j.clinph.2017.05.012. Epub 2017 May 21. Review.
  28. Engels MMA, Yu M, Stam CJ, Gouw AA, van der Flier WM, Scheltens P, van Straaten ECW, Hillebrand A. Directional information flow in patients with Alzheimer’s disease. A source-space resting-state MEG study. Neuroimage Clin. 2017 Jun 17;15:673-681. doi: 10.1016/j.nicl.2017.06.025. eCollection 2017.
  29. Freeze WM, Jacobs HI, Gronenschild EH, Jansen JF, Burgmans S, Aalten P, Clerx L, Vos SJ, van Buchem MA, Barkhof F, van der Flier WM, Verbeek MM, Rikkert MO, Backes WH, Verhey FR; LeARN project. White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-β. J Alzheimers Dis. 2017;55(1):333-342.
  30. Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR Jr, Nobili F, Nordberg A, Snyder HM, Ten Kate M, Varrone A, Albanese E, Becker S, Bossuyt P, Carrillo MC, Cerami C, Dubois B, Gallo V, Giacobini E, Gold G, Hurst S, Lönneborg A, Lovblad KO, Mattsson N, Molinuevo JL, Monsch AU, Mosimann U, Padovani A, Picco A, Porteri C, Ratib O, Saint-Aubert L, Scerri C, Scheltens P, Schott JM, Sonni I, Teipel S, Vineis P, Visser PJ, Yasui Y, Winblad B. Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. Lancet Neurol. 2017 Aug;16(8):661-676. doi: 10.1016/S1474-4422(17)30159-X. Epub 2017 Jul 11. Review.
  31. Fuermaier AB, Piersma D, de Waard D, Davidse RJ, de Groot J, Doumen MJ, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, Brouwer WH, Tucha O. Assessing fitness to drive-A validation study on patients with mild cognitive impairment. Traffic Inj Prev. 2017 Feb 17;18(2):145-149. doi: 10.1080/15389588.2016.1232809
  32. Geijselaers SLC, Aalten P, Ramakers IHGB, De Deyn PP, Heijboer AC, Koek HL, OldeRikkert MGM, Papma JM, Reesink FE, Smits LL, Stehouwer CDA, Teunissen CE, Verhey FRJ, van der Flier WM, Biessels GJ; Parelsnoer Institute Neurodegenerative Diseases study group. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer’s Disease. J Alzheimers Dis. 2017 Nov 16. doi: 10.3233/JAD-170522.
  33. Golla SSV, Timmers T, Ossenkoppele R, Groot C, Verfaillie S, Scheltens P, van der Flier WM, Schwarte L, Mintun MA, Devous M, Schuit RC, Windhorst AD, Lammertsma AA, Boellaard R, van Berckel BNM, Yaqub M. Quantification of Tau Load Using [18F]AV1451 PET. Mol Imaging Biol. 2017 Dec;19(6):963-971. doi: 10.1007/s11307-017-1080-z.
  34. Gossink FT, Vijverberg EG, Krudop W, Scheltens P, Stek ML, Pijnenburg YA, Dols A. Psychosis in behavioral variant frontotemporal dementia.Neuropsychiatr Dis Treat. 2017 Apr 13;13:1099-1106. doi: 10.2147/NDT.S127863.
  35. Gouw AA, Alsema AM, Tijms BM, Borta A, Scheltens P, Stam CJ, van der Flier WM. EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. Neurobiol Aging. 2017 Sep;57:133-142. doi: 10.1016/j.neurobiolaging.2017.05.017.
  36. Groot C, van Loenhoud AC, Barkhof F, van Berckel BNM, Koene T, Teunissen CC, Scheltens P, van der Flier WM, Ossenkoppele R. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology. 2017 Dec 13. pii: 10.1212/WNL.0000000000004802. doi: 10.1212/WNL.0000000000004802
  37. Hafkemeijer A, Möller C, Dopper EG, Jiskoot LC, van den Berg-Huysmans AA, van Swieten JC, van der Flier WM, Vrenken H, Pijnenburg YA, Barkhof F, Scheltens P, van der Grond J, Rombouts SA. A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer’s Disease. J Alzheimers Dis. 2017;55(2):521-537.
  38. Handels RLH, Vos SJB, Kramberger MG, Jelic V, Blennow K, van Buchem M, van der Flier W, Freund-Levi Y, Hampel H, Olde Rikkert M, Oleksik A, Pirtosek Z, Scheltens P, Soininen H, Teunissen C, Tsolaki M, Wallin AK, Winblad B, Verhey FRJ, Visser PJ. Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers.Alzheimers Dement. 2017 Aug;13(8):903-912. doi: 10.1016/j.jalz.2016.12.015.
  39. Handels RLH, Wimo A, Dodel R, Kramberger MG, Visser PJ, Molinuevo JL, Verhey FRJ, Winblad B. Cost-Utility of Using Alzheimer’s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. J Alzheimers Dis. 2017;60(4):1477-1487. doi: 10.3233/JAD-170324.
  40. Harper L, Bouwman F, Burton EJ, Barkhof F, Scheltens P, O’Brien JT, Fox NC, Ridgway GR, Schott JM. Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. J Neurol Neurosurg Psychiatry. 2017 Nov;88(11):908-916. doi: 10.1136/jnnp-2016-314978.
  41. Harvey PD, Sabbagh M, Harrison JE, Ginsberg HN, Chapman MJ, Manvelian G, Moryusef A, Mandel J, Farnier M. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials. European Heart Journal. 2017:39;374–381. http://dx.doi.org/10.1093/eurheartj/ehx661.
  42. Herukka SK, Simonsen AH, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczyńska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G. Recommendations for cerebrospinal fluid Alzheimer’s disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimers Dement. 2017 Mar;13(3):285-295. doi: 10.1016/j.jalz.2016.09.009. Epub 2016 Oct 27. Review.
  43. Holstege H, van der Lee SJ, Hulsman M, Wong TH, van Rooij JG, Weiss M, Louwersheimer E, Wolters FJ, Amin N, Uitterlinden AG, Hofman A, Ikram MA, van Swieten JC, Meijers-Heijboer H, van der Flier WM, Reinders MJ, van Duijn CM, Scheltens P. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer’s disease: a clinical interpretation strategy. Eur J Hum Genet. 2017 Aug;25(8):973-981. doi: 10.1038/ejhg.2017.87.
  44. Hooghiemstra AM, Bertens AS, Leeuwis AE, Bron EE, Bots ML, Brunner-La Rocca HP, de Craen AJM, van der Geest RJ, Greving JP, Kappelle LJ, Niessen WJ, van Oostenbrugge RJ, van Osch MJP, de Roos A, van Rossum AC, Biessels GJ, van Buchem MA, Daemen MJAP, van der Flier WM; Heart-Brain Connection Consortium. The Missing Link in the Pathophysiology of Vascular Cognitive Impairment: Design of the Heart-Brain Study.Cerebrovasc Dis Extra. 2017 Oct 10;7(3):140-152. doi: 10.1159/000480738.
  45. Hooghiemstra AM, Ramakers IHGB, Sistermans N, Pijnenburg YAL, Aalten P, Hamel REG3, Melis RJF, Verhey FRJ, Olde Rikkert MGM, Scheltens P, van der Flier WM; 4C Study Group. Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study.J Gerontol A Biol Sci Med Sci. 2017 Jun 1;72(6):846-854. doi: 10.1093/gerona/glx003.
  46. Jansen WJ, Handels RL, Visser PJ, Aalten P, Bouwman F, Claassen J, van Domburg P, Hoff E, Hoogmoed J, Leentjens AF, Rikkert MO, Oleksik AM, Smid M, Scheltens P, Wolfs C, Verhey F, Ramakers IH. The Diagnostic and Prognostic Value of Neuropsychological Assessment in Memory Clinic Patients. J Alzheimers Dis. 2017;55(2):679-689.
  47. Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, Mintun MA, Wallin A, Engelborghs S, Na DL, Chételat G, Molinuevo JL, Landau SM, Mattsson N, Kornhuber J, Sabri O, Rowe CC, Parnetti L, Popp J, Fladby T, Jagust WJ, Aalten P, Lee DY, Vandenberghe R, Resende de Oliveira C, Kapaki E, Froelich L, Ivanoiu A, Gabryelewicz T, Verbeek MM, Sanchez-Juan P, Hildebrandt H, Camus V, Zboch M, Brooks DJ, Drzezga A, Rinne JO, Newberg A, de Mendonça A, Sarazin M, Rabinovici GD, Madsen K, Kramberger MG, Nordberg A, Mok V, Mroczko B, Wolk DA, Meyer PT, Tsolaki M, Scheltens P, Verhey FRJ, Visser PJ; Amyloid Biomarker Study Group, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Blennow K, van Buchem MA, Cavedo E, Chen K, Chipi E, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gkatzima O, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Johannsen P, Klimkowicz-Mrowiec A, Köhler S, Koglin N, van Laere K, de Leon M, Lisetti V, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Nordlund A, Novak GP, Paraskevas GP, Perera G, Peters O, Ramakers IHGB, Rami L, Rodríguez-Rodríguez E, Roe CM, Rot U, Rüther E, Santana I, Schröder J, Seo SW, Sorininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Zetterberg H. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry. 2017 Nov 29. doi: 10.1001/jamapsychiatry.2017.3391
  48. Jansen WJ, Wilson RS, Visser PJ, Nag S, Schneider JA, James BD, Leurgans SE, Capuano AW, Bennett DA, Boyle PA. Age and the association of dementia-related pathology with trajectories of cognitive decline. Neurobiol Aging. 2018 Jan;61:138-145. doi: 10.1016/j.neurobiolaging.2017.08.029
  49. Jutten RJ, Harrison J, de Jong FJ, Alemand A, Ritchiee CW, Scheltens Ph Sikkes SAM. A composite measure of cognitive and functional progression in Alzheimer’s disease: Design of the Capturing Changes in Cognition study. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2017;3(1):130-138.
  50. Jutten RJ, Peeters CFW, Leijdesdorff SMJ, Visser PJ, Maier AB, Terwee CB, Scheltens P, Sikkes SAM. Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheimers Dement (Amst). 2017 Mar 31;8:26-35. doi: 10.1016/j.dadm.2017.03.002. eCollection 2017
  51. Konijnenberg E, Fereshtehnejad SM, Kate MT, Eriksdotter M, Scheltens P, Johannsen P, Waldemar G, Visser PJ. Early-Onset Dementia: Frequency, Diagnostic Procedures, and Quality Indicators in Three European Tertiary Referral Centers. Alzheimer Dis Assoc Disord. 2017 Apr-Jun;31(2):146-151. doi: 10.1097/WAD.0000000000000152.
  52. Krudop WA, Dols A, Kerssens CJ, Eikelenboom P, Prins ND, Möller C, Schouws S, Rhebergen D, van Exel E, van der Flier WM, Sikkes S, Scheltens P, Stek ML, Pijnenburg YAL. The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria.J Alzheimers Dis. 2017;60(3):959-975. doi: 10.3233/JAD-170608.
  53. Kun-Rodrigues C, Ross OA, Orme T, Shepherd C, Parkkinen L, Darwent L, Hernandez D, Ansorge O, Clark LN, Honig LS, Marder K, Lemstra A, Scheltens P, van der Flier W, Louwersheimer E, Holstege H, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Holton J, Compta Y, Van Deerlin V, Trojanowski JQ, Serrano GE, Beach TG, Clarimon J, Lleó A, Morenas-Rodríguez E, Lesage S, Galasko D, Masliah E, Santana I, Diez M, Pastor P, Tienari PJ, Myllykangas L, Oinas M, Revesz T, Lees A, Boeve BF, Petersen RC, Ferman TJ, Escott-Price V, Graff-Radford N, Cairns NJ, Morris JC, Stone DJ, Pickering-Brown S, Mann D, Dickson DW, Halliday GM, Singleton A, Guerreiro R, Bras J. Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiol Aging. 2017 Jan;49:214.e13-214.e15. doi: 10.1016/j.neurobiolaging.2016.08.023.
  54. Kunneman M, Pel-Littel R, Bouwman FH, Gillissen F, Schoonenboom NSM, Claus JJ, van der Flier WM, Smets EMA. Patients’ and caregivers’ views on conversations and shared decision making in diagnostic testing for Alzheimer’s disease: The ABIDE project. Alzheimers Dement (N Y). 2017 May 10;3(3):314-322. doi: 10.1016/j.trci.2017.04.002.
  55. Kunneman M, Smets EMA, Bouwman FH, Schoonenboom NSM, Zwan MD, Pel-Littel R, van der Flier WM. Clinicians’ views on conversations and shared decision making in diagnostic testing for Alzheimer’s disease: The ABIDE project. Alzheimers Dement (N Y). 2017 May 10;3(3):305-313. doi: 10.1016/j.trci.2017.03.009.
  56. Lacour A, Espinosa A, Louwersheimer E, Heilmann S, Hernández I, Wolfsgruber S, Fernández V, Wagner H, Rosende-Roca M, Mauleón A, Moreno-Grau S, Vargas L, Pijnenburg YA, Koene T, Rodríguez-Gómez O, Ortega G, Ruiz S, Holstege H, Sotolongo-Grau O, Kornhuber J, Peters O, Frölich L, Hüll M, Rüther E, Wiltfang J, Scherer M, Riedel-Heller S, Alegret M, Nöthen MM, Scheltens P, Wagner M, Tárraga L, Jessen F, Boada M, Maier W, van der Flier WM, Becker T, Ramirez A, Ruiz A. Genome-wide significant risk factors for Alzheimer’s disease: role in progression to dementia due to Alzheimer’s disease among subjects with mild cognitive impairment. Mol Psychiatry. 2017 Jan;22(1):153-160. doi: 10.1038/mp.2016.18.
  57. Leeuwis AE, Benedictus MR, Kuijer JPA, Binnewijzend MAA, Hooghiemstra AM, Verfaillie SCJ, Koene T, Scheltens P, Barkhof F, Prins ND, van der Flier WM. Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer’s disease. Alzheimers Dement. 2017 May;13(5):531-540. doi: 10.1016/j.jalz.2016.08.013.
  58. Leeuwis AE, Hooghiemstra AM, Amier R, Ferro DA, Franken L, Nijveldt R, Kuijer JPA, Bronzwaer ASGT, van Lieshout JJ, Rietberg MB, Veerbeek JM, Huijsmans RJ, Backx FJG, Teunissen CE, Bron EE, Barkhof F, Prins ND, Shahzad R, Niessen WJ, de Roos A, van Osch MJP, van Rossum AC, Biessels GJ, van der Flier WM: on behalf of the Heart Brain Connection study group. Design of the ExCersion-VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment.Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2017 June;3 (2):157–16. DOI: http://dx.doi.org/10.1016/j.trci.2017.02.002
  59. Legdeur N, Binnekade TT, Otten RH, Badissi M, Scheltens P, Visser PJ, Maier AB. Cognitive functioning of individuals aged 90 years and older without dementia: A systematic review. Ageing Res Rev. 2017 Mar 8;36:42-49. doi: 10.1016/j.arr.2017.02.006.
  60. Leijenaar JF, van Maurik IS, Kuijer JPA, van der Flier WM, Scheltens P, Barkhof F, Prins ND. Lower cerebral blood flow in subjects with Alzheimer’s dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging.Alzheimers Dement (Amst). 2017 Nov 2;9:76-83. doi: 10.1016/j.dadm.2017.10.001.
  61. Lemstra AW, de Beer MH, Teunissen CE, Schreuder C, Scheltens P, van der Flier WM, Sikkes SA. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):113-118. doi: 10.1136/jnnp-2016-313775.
  62. Lewczuk P, Riederer P, O’Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. 2017 Oct 27:1-85. doi: 10.1080/15622975.2017.1375556.
  63. López ME, Engels MMA, van Straaten ECW, Bajo R, Delgado ML, Scheltens Ph, Hillebrand A,. Stam CJ, Maestú F. MEG Beamformer-Based Reconstructions of Functional Networks in Mild Cognitive Impairment.Front. Aging Neurosci., 25 April 2017. https://doi.org/10.3389/fnagi.2017.00107
  64. Louwersheimer E, Cohn-Hokke PE, Pijnenburg YA, Weiss MM, Sistermans EA, Rozemuller AJ, Hulsman M, van Swieten JC, van Duijn CM, Barkhof F, Koene T, Scheltens P, Van der Flier WM, Holstege H. Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer’s Disease in a Family with Several Generations of APOE-ɛ4 Homozygosity. J Alzheimers Dis. 2017;56(1):63-74. doi: 10.3233/JAD-160091.
  65. McIntyre RS, Barry H, Baune BT, Best MW, Bowie CR, Cha DS, Culpepper L, Fossati P, Greer TL, Harmer C, Klag E, Lam RW, Lee Y, Mansur RB, Wittchen H-U, Harrison JE. The THINC-integrated tool (THINC-it) screening assessment for cognitive dysfunction: Validation in patients with Major Depressive Disorder. Journal of Clinical Psychiatry, 2017:78;873-881. doi: 10.4088/JCP.16m11329.
  66. Miller AM, Balasa M, Blennow K, Gardiner M, Rutkowska A, Scheltens P, Teunissen CE, Visser PJ, Winblad B, Waldemar G, Lawlor B. Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. J Alzheimers Dis. 2017;60(1):201-210. doi: 10.3233/JAD-170502.
  67. Mo Y, Stromswold J, Wilson K, Holder D, Sur C, Laterza O, Savage MJ, Struyk A, Scheltens P, Teunissen CE, Burke J, Macaulay SL, Bråthen G, Sando SB, White LR, Weiss C, Cowes A, Bush MM, DeSilva G, Darby DG, Rainey-Smith SR, Surls J, Sagini E, Tanen M, Altman A, Luthman J, Egan MF. A multinational study distinguishing Alzheimer’s and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging. Alzheimers Dement (Amst). 2017 Mar 6;6:201-209. doi: 10.1016/j.dadm.2017.02.004.
  68. Molinuevo JL, Rabin LA, Amariglio R, Buckley R, Dubois B, Ellis KA, Ewers M, Hampel H, Klöppel S, Rami L, Reisberg B, Saykin AJ, Sikkes S, Smart CM, Snitz BE, Sperling R, van der Flier WM, Wagner M, Jessen F; Subjective Cognitive Decline Initiative (SCD-I) Working Group. Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2017 Mar;13(3):296-311. doi: 10.1016/j.jalz.2016.09.012.
  69. Morbelli S, Bauckneht M, Scheltens P. Imaging biomarkers in Alzheimer’s disease: added value in the clinical setting. Q J Nucl Med Mol Imaging. 2017 Dec;61(4):360-371. doi: 10.23736/S1824-4785.17.03011-4.
  70. Nathan PJ, Lim YY, Abbott R, Galluzzi S, Marizzoni M, Babiloni C, Albani D, Bartres-Faz D, Didic M, Farotti L, Parnetti L, Salvadori N, Müller BW, Forloni G, Girtler N, Hensch T, Jovicich J, Leeuwis A, Marra C, Molinuevo JL, Nobili F, Pariente J, Payoux P, Ranjeva JP, Rolandi E, Rossini PM, Schönknecht P, Soricelli A, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB; PharmaCog Consortium. Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiol Aging. 2017 May;53:1-10. doi: 10.1016/j.neurobiolaging.2017.01.013.
  71. Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P; SCarlet RoAD Investigators. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther. 2017 Dec 8;9(1):95. doi: 10.1186/s13195-017-0318-y.
  72. Perera G, Pedersen L, Ansel D, Alexander M, Arrighi HM, Avillach P, Foskett N, Gini R, Gordon MF, Gungabissoon U, Mayer MA, Novak G, Rijnbeek P, Trifirò G, van der Lei J, Visser PJ, Stewart R. Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource. Alzheimers Dement. 2017 Jul 21. pii: S1552-5260(17)32523-2. doi: 10.1016/j.jalz.2017.06.2270.
  73. Piersma D, Fuermaier ABM, De Waard D, Davidse RJ, De Groot J, Doumen MJA, Bredewoud RA, Claesen R, Lemstra AW, Scheltens P, Vermeeren A, Ponds R, Verhey F, De Deyn PP, Brouwer WH, Tucha O. Assessing Fitness to Drive in Patients With Different Types of Dementia. Alzheimer Dis Assoc Disord. 2017 Nov 17. doi: 10.1097/WAD.0000000000000221
  74. Reijs BLR, Ramakers IHGB, Elias-Sonnenschein L, Teunissen CE, Koel-Simmelink M, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Johannsen P, Vanderstichele H, Verhey F, Devanand DP, Visser PJ. Relation of Odor Identification with Alzheimer’s Disease Markers in Cerebrospinal Fluid and Cognition. J Alzheimers Dis. 2017;60(3):1025-1034. doi: 10.3233/JAD-170564.
  75. Reijs BLR, Ramakers IHGB, Köhler S, Teunissen CE, Koel-Simmelink M, Nathan PJ, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Vandenberghe R, Johannsen P, Blackwell A, Vanderstichele H, Verhey F, Visser PJ. Memory Correlates of Alzheimer’s Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. J Alzheimers Dis. 2017;60(3):1119-1128. doi: 10.3233/JAD-160766.
  76. Reijs BLR, Vos SJB, Soininen H, Lötjonen J, Koikkalainen J, Pikkarainen M, Hall A, Vanninen R, Liu Y, Herukka SK, Freund-Levi Y, Frisoni GB, Frölich L, Nobili F, Rikkert MO, Spiru L, Tsolaki M, Wallin ÅK, Scheltens P, Verhey F, Visser PJ. Association Between Later Life Lifestyle Factors and Alzheimer’s Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. J Alzheimers Dis. 2017;60(4):1387-1395. doi: 10.3233/JAD-170039.
  77. Rhodius-Meester HFM, Benedictus MR, Wattjes MP, Barkhof F, Scheltens Ph, Muller M, van der Flier WM. MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. Front. Aging Neurosci., 09 May 2017 | https://doi.org/10.3389/fnagi.2017.00117
  78. Sartor J, Bettecken K, Bernhard FP, Hofmann M, Gladow T, Lindig T, Ciliz M, Ten Kate M, Geritz J, Heinzel S, Benedictus M, Scheltens P, Hobert MA, Maetzler W. White Matter Changes-Related Gait and Executive Function Deficits: Associations with Age and Parkinson’s Disease. Front Aging Neurosci. 2017 Jun 30;9:213. doi: 10.3389/fnagi.2017.00213.
  79. Scheltens NME, Tijms BM, Koene T, Barkhof F, Teunissen CE, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Cohn-Sheehy BI, Rabinovici GD, Miller BL, Kramer JH, Scheltens P, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative; German Dementia Competence Network; University of California San Francisco Memory and Aging Center; Amsterdam Dementia Cohort. Cognitive subtypes of probable Alzheimer’s disease robustly identified in four cohorts. Alzheimers Dement. 2017 Nov;13(11):1226-1236. doi: 10.1016/j.jalz.2017.03.002.
  80. Scheltens P, Gillissen F, Bouwman FH, van der Flier WM. Doctor, is my mother suffering from dementia? Ned Tijdschr Geneeskd. 2017;161(0):D2086. Dutch.
  81. Scheltens P, Zwan M, Ossenkoppele R, Bouwman F, van Berckel BN. Amyloid PET imaging in patients with Alzheimer’s disease Ned Tijdschr Geneeskd. 2017;161(0):D808. Dutch.
  82. Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, Mulder SD, Scheltens P, Xiong C, Fagan AM. Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years.Alzheimers Dement. 2017 Jul 12. pii: S1552-5260(17)32516-5. doi: 10.1016/j.jalz.2017.06.2264.
  83. Simonsen AH, Herukka SK, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczyńska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement. 2017 Mar;13(3):274-284. doi: 10.1016/j.jalz.2016.09.008. Epub 2016 Oct 27. Review.
  84. Skillbäck T, Mattsson N, Hansson K, Mirgorodskaya E, Dahlén R, van der Flier W, Scheltens P, Duits F, Hansson O, Teunissen C, Blennow K, Zetterberg H, Gobom J. A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease. Sci Rep. 2017 Oct 17;7(1):13333. doi: 10.1038/s41598-017-13831-0.
  85. Slot RE, Van Harten AC, Kester MI, Jongbloed W, Bouwman FH, Teunissen CE, Scheltens P, Veerhuis R, van der Flier WM. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer’s Disease in Non-Demented Elderly. J Alzheimers Dis. 2017;56(2):687-697. doi: 10.3233/JAD-151068.
  86. Smart CM, Karr JE, Areshenkoff CN, Rabin LA, Hudon C, Gates N, Ali JI, Arenaza-Urquijo EM, Buckley RF, Chetelat G, Hampel H, Jessen F, Marchant NL, Sikkes SAM, Tales A, van der Flier WM, Wesselman L; and the Subjective Cognitive Decline Initiative (SCD-I) Working Group. Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations. Neuropsychol Rev. 2017 Sep;27(3):245-257. doi: 10.1007/s11065-017-9342-8. Epub 2017 Mar 7. Review.
  87. Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, Hartmann T; LipiDiDiet clinical study group. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. 2017 Dec;16(12):965-975. doi: 10.1016/S1474-4422(17)30332-0.
  88. Ten Kate M, Barkhof F, Boccardi M, Visser PJ, Jack CR Jr, Lovblad KO, Frisoni GB, Scheltens P; Geneva Task Force for the Roadmap of Alzheimer’s Biomarkers. Clinical validity of medial temporal atrophy as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017 Apr;52:167-182.e1. doi: 10.1016/j.neurobiolaging.2016.05.024. Review.
  89. Ten Kate M, Barkhof F, Visser PJ, Teunissen CE, Scheltens P, van der Flier WM, Tijms BM. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimers Res Ther. 2017 Sep 12;9(1):73. doi: 10.1186/s13195-017-0299-x.
  90. Tijms BM, Bertens D, Slot RE, Gouw AA, Teunissen CE, Scheltens P, van der Flier WM, Visser PJ. Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects. Ann Neurol. 2017 May;81(5):749-753. doi: 10.1002/ana.24921.
  91. Tijms BM, Ten Kate M, Gouw AA, Borta A, Verfaillie S, Teunissen CE, Scheltens P, Barkhof F, van der Flier WM. Gray matter networks and clinical progression in subjects with predementia Alzheimer’s disease.Neurobiol Aging. 2018 Jan;61:75-81. doi: 10.1016/j.neurobiolaging.2017.09.011.
  92. Tijms BM, Willemse EAJ, Zwan MD, Mulder SD, Visser PJ, van Berckel BNM, van der Flier WM, Scheltens P, Teunissen CE. Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1-42 Analysis Results. Clin Chem. 2017 Dec 5. pii: clinchem.2017.281055. doi: 10.1373/clinchem.2017.281055.
  93. van Dalen JW, Moll van Charante EP, Caan MWA, Scheltens P, Majoie CBLM, Nederveen AJ, van Gool WA, Richard E. Effect of Long-Term Vascular Care on Progression of Cerebrovascular Lesions: Magnetic Resonance Imaging Substudy of the PreDIVA Trial (Prevention of Dementia by Intensive Vascular Care). Stroke. 2017 Jul;48(7):1842-1848. doi: 10.1161/STROKEAHA.117.017207.
  94. van der Flier WM, Kunneman M, Bouwman FH, Petersen RC, Smets EMA. Diagnostic dilemmas in Alzheimer’s disease: Room for shared decision making. Alzheimers Dement (N Y). 2017 May 9;3(3):301-304. doi: 10.1016/j.trci.2017.03.008
  95. van Harten AC, Jongbloed W, Teunissen CE, Scheltens P, Veerhuis R, van der Flier WM. CSF ApoE predicts clinical progression in nondemented APOEε4 carriers. Neurobiol Aging. 2017 Sep;57:186-194. doi: 10.1016/j.neurobiolaging.2017.04.002. Epub 2017 Apr 12.
  96. van Loenhoud AC, Wink AM, Groot C, Verfaillie SCJ, Twisk J, Barkhof F, van Berckel B, Scheltens P, van der Flier WM, Ossenkoppele R. A neuroimaging approach to capture cognitive reserve: Application to Alzheimer’s disease.Hum Brain Mapp. 2017 Sep;38(9):4703-4715. doi: 10.1002/hbm.23695
  97. van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, Wattjes MP, Barkhof F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer’s Biomarkers in Daily Practice (ABIDE) Project. JAMA Neurol. 2017 Oct 16. doi: 10.1001/jamaneurol.2017.2712.
  98. Van Mierlo LD, Wouters H, Sikkes SA, Van der Flier WM, Prins ND, Bremer JA, Koene T, Van Hout HP. Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests. J Alzheimers Dis. 2017;56(1):249-259. doi: 10.3233/JAD-160566.
  99. van Waalwijk van Doorn LJ, Gispert JD, Kuiperij HB, Claassen JA, Arighi A, Baldeiras I, Blennow K, Bozzali M, Castelo-Branco M, Cavedo E, Emek-Savaş DD, Eren E, Eusebi P, Farotti L, Fenoglio C, Ormaechea JF, Freund-Levi Y, Frisoni GB, Galimberti D, Genc S, Greco V, Hampel H, Herukka SK, Liu Y, Lladó A, Lleó A, Nobili FM, Oguz KK, Parnetti L, Pereira J, Picco A, Pikkarainen M, de Oliveira CR, Saka E, Salvadori N, Sanchez-Valle R, Santana I, Scarpini E, Scheltens P, Soininen H, Tarducci R, Teunissen C, Tsolaki M, Urbani A, Vilaplana E, Visser PJ, Wallin AK, Yener G, Molinuevo JL, Meulenbroek O, Verbeek MM. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer’s Disease Patients and Controls after Correction for Ventricular Volumes. J Alzheimers Dis. 2017;56(2):543-555. doi: 10.3233/JAD-160668.
  100. van Wijk N, Slot RER, Duits FH, Strik M, Biesheuvel E, Sijben JWC, Blankenstein MA, Bierau J, van der Flier WM, Scheltens P, Teunissen CE. Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer’s disease dementia. Alzheimers Dement (Amst). 2017 May 16;8:139-146. doi: 10.1016/j.dadm.2017.04.005.
  101. Vandenberghe R, Riviere ME, Caputo A, Sovago J, Maguire RP, Farlow M, Marotta G, Sanchez-Valle R, Scheltens P, Ryan JM, Graf A. Active Aβ immunotherapy CAD106 in Alzheimer’s disease: A phase 2b study.Alzheimers Dement (N Y). 2016 Dec 23;3(1):10-22. doi: 10.1016/j.trci.2016.12.003.
  102. Verfaillie SCJ, Slot RE, Tijms BM, Bouwman F, Benedictus MR, Overbeek JM, Koene T, Vrenken H, Scheltens P, Barkhof F, van der Flier WM. Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. Neurobiol Aging. 2018 Jan;61:238-244. doi: 10.1016/j.neurobiolaging.2017.09.009.
  103. Vijverberg EG, Dols A, Krudop WA, Del Campo Milan M, Kerssens CJ, Gossink F, Prins ND, Stek ML, Scheltens P, Teunissen CE, Pijnenburg YA. Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. Alzheimers Dement (Amst). 2017 Mar 2;7:99-106. doi: 10.1016/j.dadm.2017.01.009.
  104. Vijverberg EGB, Gossink F, Krudop W, Sikkes S, Kerssens C, Prins N, Stek M, Scheltens P, Pijnenburg Y, Dols A. The Diagnostic Challenge of the Late-Onset Frontal Lobe Syndrome: Clinical Predictors for Primary Psychiatric Disorders Versus Behavioral Variant Frontotemporal Dementia. J Clin Psychiatry. 2017 Oct 31. pii: 16m11078. doi: 10.4088/JCP.16m11078.
  105. Vijverberg EG, Pijnenburg AC, Scheltens P, Pijnenburg YA. Chronic traumatic encephalopathy: an old acquaintance in athletes Ned Tijdschr Geneeskd. 2017;161(0):D465. Dutch.
  106. Vijverberg EGB, Schouws S, Meesters PD, Verwijk E, Comijs H, Koene T, Schreuder C, Beekman A, Scheltens P, Stek M, Pijnenburg Y, Dols A. Cognitive Deficits in Patients With Neuropsychiatric Symptoms: A Comparative Study Between Behavioral Variant Frontotemporal Dementia and Primary Psychiatric Disorders. J Clin Psychiatry. 2017 Sep/Oct;78(8):e940-e946. doi: 10.4088/JCP.16m11019.
  107. Vijverberg EGB, Tijms BM, Dopp J, Hong YJ, Teunissen CE, Barkhof F, Scheltens P, Pijnenburg YAL. Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer’s disease.Neurobiol Aging. 2017 Feb;50:77-86. doi: 10.1016/j.neurobiolaging.2016.11.005.
  108. Visser PJ, Tijms B. Brain Amyloid Pathology and Cognitive Function: Alzheimer Disease Without Dementia? JAMA. 2017 Jun 13;317(22):2285-2287. doi: 10.1001/jama.2017.6895.
  109. Vos SJB, van Boxtel MPJ, Schiepers OJG, Deckers K, de Vugt M, Carrière I, Dartigues JF, Peres K, Artero S, Ritchie K, Galluzzo L, Scafato E, Frisoni GB, Huisman M, Comijs HC, Sacuiu SF, Skoog I, Irving K, O’Donnell CA, Verhey FRJ, Visser PJ, Köhler S. Modifiable Risk Factors for Prevention of Dementia in Midlife, Late Life and the Oldest-Old: Validation of the LIBRA Index. J Alzheimers Dis. 2017;58(2):537-547. doi: 10.3233/JAD-161208.
  110. Voyle N, Patel H, Folarin A, Newhouse S, Johnston C, Visser PJ, Dobson RJ, Kiddle SJ; EDAR and DESCRIPA study groups and the Alzheimer’s Disease Neuroimaging Initiative. Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid. J Alzheimers Dis. 2017;55(4):1417-1427. doi: 10.3233/JAD-160707.
  111. Willemse EAJ, van Uffelen KWJ, van der Flier WM, Teunissen CE. Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ1-42, T-tau, and P-tau values. Alzheimers Dement (Amst). 2017 Apr 4;8:45-50. doi: 10.1016/j.dadm.2017.03.005.
  112. Yu M, Engels MM, Hillebrand A, van Straaten EC, Gouw AA, Teunissen C, van der Flier WM, Scheltens P, Stam CJ. Selective impairment of hippocampus and posterior hub areas in Alzheimer’s disease: an MEG-based multiplex network study. Brain. 2017 Mar 16. doi: 10.1093/brain/awx050.
  113. Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FR, Aalten P, van Berckel BN, Scheltens P. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017 Jan 17;9(1):2. doi: 10.1186/s13195-016-0228-4.

Publicaties 2016

Publicaties 2015

Publicaties 2014

Internationale publicaties

Vakpublicaties:

  • van Hout, H. P. J., Macneil Vroomen, J. L., Van Mierlo, L. D., Meiland, F. J. M., Moll van Charante, E. P., Joling, K. J., van den Dungen, P., Droes, R. M., van der Horst, H. E., de Rooij, S. E. J. A.Comparing case management care models for people with dementia and their caregivers: the design of the COMPAS study. Tijdschrift voor gerontologie en geriatrie 2014;45(2):105-16.

Dissertaties:

  • Binnewijzend M.A.A. Functional and perfusion MRI in dementia
    Vrije Universiteit Amsterdam 21 maart 2014.
    Promotoren: F. Barkhof, Ph. Scheltens, copromotor: J.P.A Kuijer
  • de Waal H. Understanding heterogeneity in Alzheimer’s disease: A neurophysiological perspective.
    Vrije Universiteit Amsterdam 25 april 2014.
    Promotoren: Ph. Scheltens, C.J. Stam, copromotoren: W.M. van der Flier, E.C.W. van Straaten.
  • Jongbloed W. Neurodegeneration: Biochemical signals from the brain
    Vrije Universiteit Amsterdam 8 mei 2014
    Promotoren: M.A. Blankenstein, Ph. Scheltens, copromotor: R. Veerhuis
  • Poortvliet-Koedam E.L.G.E. Early-onset dementia: Unravelling the clinical phenotypes.
    Vrije Universiteit Amsterdam 28 mei 2014.
    Promotoren: Ph. Scheltens, copromotoren: Y.A.L Pijnenburg, M.P. Wattjes
  • van Harten A.C. The road less traveled. CSF biomarkers for Alzheimer’s disease: predicting earliest cognitive decline and exploring microrna as a novel biomarker source.
    Vrije Universiteit Amsterdam 7 november 2014.
    Promotoren: Ph. Scheltens, C.B.M Oudejans, copromotoren: W.M. van der Flier, C.E. Teunissen
  • Hooghiemstra A. Early-onset dementia: with exercise in mind
    Vrije Universiteit Amsterdam 3 december 2014
    Promotoren: E.J.A Scherder, Ph. Scheltens, copromotor: L.H.P Eggermont

Publicaties 2013

Internationale publicaties:

  • Bakker, C., de Vugt, M. E., van Vliet, D., Verhey, F. R. J., Pijnenburg, Y. A., Vernooij-Dassen, M. J. F. J., Koopmans, R. T. C. M. The Use of Formal and Informal Care in Early Onset Dementia: Results From the NeedYD Study. American journal of geriatric psychiatry 2013;21(1):37-45. doi:10.1016/j.jagp.2012.10.004
  • Bakker, C., de Vugt, M. E., van Vliet, D., Verhey, F. R. J., Pijnenburg, Y. A., Vernooij-Dassen, M. J. F. J., Koopmans, R. T. C. M. Predictors of the Time to Institutionalization in Young- Versus Late-Onset Dementia: Results From the Needs in Young Onset Dementia (NeedYD) Study. Journal of the american medical directors association 2013;14(4):248-53. doi:10.1016/j.jamda.2012.09.011
  • Barkhof, F., Daams, M., Scheltens, P., Brashear, H. R., Arrighi, H. M., Bechten, A., Morris, K., McGovern, M., Wattjes, M. P. An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. AJNR American journal of neuroradiology 2013;34(8):1550-5. doi:10.3174/ajnr.A3475
  • Benedictus, M. R., Goos, J. D., Binnewijzend, M. A. A., Muller, M., Barkhof, F., Scheltens, P., Prins, N. D., van der Flier, W. M. Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer’s disease. Neurobiology of aging 2013;34(11):2488-94. doi:10.1016/j.neurobiolaging.2013.04.023
  • Binnewijzend, M. A., Kuijer, J. P., Benedictus, M. R., van der Flier, W. M., Wink, A. M., Wattjes, M. P., van Berckel, B. N., Scheltens, P., Barkhof, F. Cerebral Blood Flow Measured with 3D Pseudocontinuous Arterial Spin-labeling MR Imaging in Alzheimer Disease and Mild Cognitive Impairment: A Marker for Disease Severity. Radiology 2013;267(1):221-30. Doi:10.1148/radiol.12120928
  • Boom, M., Olofsen, E., Neukirchen, M., Fussen, R., Hay, J., Groeneveld, G. J., Aarts, L., Sarton, E., Dahan, A. Fentanyl Utility Function: A Risk-Benefit Composite of Pain Relief and Breathing Responses. Anesthesiology 2013;119(3):663-74. Doi:10.1097/ALN.0b013e31829ce4cb
  • Bruggink, K. A., Jongbloed, W., Biemans, E. A. L. M., Veerhuis, R., Claassen, J. A. H. R., Kuiperij, H. B., Verbeek, M. M. Amyloid-beta oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Analytical biochemistry 2013;433(2):112-20. Doi:10.1016/j.ab.2012.09.014
  • Clerx, L., Jacobs, H., I, Burgmans, S., Gronenschild, E., Uylings, H., Echavarri, C., Visser, P., Verhey, F., Aalten, P. Sensitivity of Different MRI-Techniques to Assess Gray Matter Atrophy Patterns in Alzheimer’s Disease is Region-Specific. Current alzheimer research 2013;10(9):940-51. WpR, VUmc NCA-NB
  • Clerx, L., van Rossum, I. A., Burns, L., Knol, D. L., Scheltens, P., Verhey, F., Aalten, P., Lapuerta, P., van de Pol, L., van Schijndel, R., de Jong, R., Barkhof, F., Wolz, R., Rueckert, D., Bocchetta, M., Tsolaki, M., Nobili, F., Wahlund, L. O., Minthon, L., Frolich, L., Hampel, H., Soininen, H., Visser, P. J. Measurements of medial temporal lobe atrophy for prediction of Alzheimer’s disease in subjects with mild cognitive impairment. Neurobiology of aging 2013;34(8):2003-13. Doi:10.1016/j.neurobiolaging.2013.02.002
  • Crutch, S. J., Schott, J. M., Rabinovici, G. D., Boeve, B. F., Cappa, S. F., Dickerson, B. C., Dubois, B., Graff-Radford, N. R., Krolak-Salmon, P., Lehmann, M., Mendez, M. F., Pijnenburg, Y. A. L., Ryan, N. S., Scheltens, P., Shakespeare, T., Tang-Wai, D. F., van der Flier, W. M., Bain, L., Carrillo, M. C., Fox, N. C. Shining a light on posterior cortical atrophy. Alzheimer’s & dementia : the journal of the Alzheimer’s Association 2013;9(4):463-5. Doi:10.1016/j.jalz.2012.11.004
  • Cummings, J. L., Dubois, B., Molinuevo, J. L., Scheltens, P. International Work Group Criteria for the Diagnosis of Alzheimer Disease. Medical clinics of north america 2013;97(3):363-+. Doi:10.1016/j.mcna.2013.01.001
  • Damian, M., Hausner, L., Jekel, K., Richter, M., Froelich, L., Almkvist, O., Boada, M., Bullock, R., De Deyn, P. P., Frisoni, G. B., Hampel, H., Jones, R. W., Kehoe, P., Lenoir, H., Minthon, L., Olde Rikkert, M. G. M., Rodriguez, G., Scheltens, P., Soininen, H., Spiru, L., Touchon, J., Tsolaki, M., Vellas, B., Verhey, F. R. J., Winblad, B., Wahlund, L. O., Wilcock, G., Visser, P. J. Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer’s disease in the european prospective DESCRIPA study. Dementia and geriatric cognitive disorders 2013;36(1-2):1-19. Doi:10.1159/000348354
  • de Haan, W., Mott, K., van Straaten, E. C. W., Scheltens, P., Stam, C. J. Activity Dependent Degeneration Explains Hub Vulnerability in Alzheimer’s Disease. Plos computational biology 2012;8(8):e1002582. Doi:10.1371/journal.pcbi.1002582
  • de Waal, H., Stam, C. J., de Haan, W., van Straaten, E. C. W., Blankenstein, M. A., Scheltens, P., van der Flier, W. M. Alzheimer’s disease patients not carrying the apolipoprotein E epsilon4 allele show more severe slowing of oscillatory brain activity. Neurobiology of aging 2013;34(9):2158-63. Doi:10.1016/j.neurobiolaging.2013.03.007
  • Duits, F. H., Kester, M. I., Scheffer, P. G., Blankenstein, M. A., Scheltens, P., Teunissen, C. E., van der Flier, W. M. Increase in Cerebrospinal Fluid F2-Isoprostanes is Related to Cognitive Decline in APOE epsilon4 Carriers. Journal of Alzheimer’s disease : JAD 2013;36(3):563-70. Doi:10.3233/JAD-122227
  • Elias-Sonnenschein, L. S., Helisalmi, S., Natunen, T., Hall, A., Paajanen, T., Herukka, S. K., Laitinen, M., Remes, A. M., Koivisto, A. M., Mattila, K. M., Lehtimaki, T., Verhey, F. R. J., Visser, P. J., Soininen, H., Hiltunen, M. Genetic Loci Associated with Alzheimer’s Disease and Cerebrospinal Fluid Biomarkers in a Finnish Case-Control Cohort. PloS one 2013;8(4). Doi:10.1371/journal.pone.0059676
  • Frisoni, G. B., Bocchetta, M., Chetelat, G., Rabinovici, G. D., de Leon, M. J., Kaye, J., Reiman, E. M., Scheltens, P., Barkhof, F., Black, S. E., Brooks, D. J., Carrillo, M. C., Fox, N. C., Herholz, K., Nordberg, A., Jack, C. R. J., Jagust, W. J., Johnson, K. A., Rowe, C. C., Sperling, R. A., Thies, W., Wahlund, L. O., Weiner, M. W., Pasqualetti, P., DeCarli, C. Imaging markers for Alzheimer disease: which vs how. Neurology 2013;81(5):487-500. Doi:10.1212/WNL.0b013e31829d86e8
  • Galasko, D., Golde, T. E., Scheltens, P. Progress in Alzheimer’s disease research circa 2013: Is the glass half empty or half full? Alzheimers research & therapy 2013;5(3):26. Doi:10.1186/alzrt180
  • Hooshmand, B., Polvikoski, T., Kivipelto, M., Tanskanen, M., Myllykangas, L., Erkinjuntti, T., Makela, M., Oinas, M., Paetau, A., Scheltens, P., van Straaten, E. C., Sulkava, R., Solomon, A. Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain 2013;136:2707-16. Doi:10.1093/brain/awt206
  • IJsselstijn, L., Papma, J. M., Dekker, L. J., Calame, W., Stingl, C., Koudstaal, P. J., Prins, N. D., Smitt, P. A., Luider, T. M. Serum proteomics in amnestic mild cognitive impairment. Proteomics 2013;13(16):2526-33. Doi:10.1002/pmic.201200190
  • Jacobs, H. I., Visser, P. J., Van Boxtel, M. P., Frisoni, G. B., Tsolaki, M., Papapostolou, P., Nobili, F., Wahlund, L. O., Minthon, L., Frolich, L., Hampel, H., Soininen, H., van de Pol, L., Scheltens, P., Tan, F. E., Jolles, J., Verhey, F. R. The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. Neurobiology of aging 2012;33(1):201. Doi:10.1016/j.neurobiolaging.2010.07.015
  • Jochemsen, H. M., Kloppenborg, R. P., de Groot, L. C. P. G., Kampman, E., Mali, W. P. T. M., van der Graaf, Y., Geerlings, M. I. Homocysteine, progression of ventricular enlargement, and cognitive decline: The Second Manifestations of ARTerial disease-Magnetic Resonance study. Alzheimers & dementia 2013;9(3):302-9. Doi:10.1016/j.jalz.2011.11.008
  • Jochemsen, H. M., Muller, M., Visseren, F. L., Scheltens, P., Vincken, K. L., Mali, W. P., van der Graaf, Y., Geerlings, M. I. Blood Pressure and Progression of Brain Atrophy The SMART-MR Study. JAMA neurology 2013;70(8):1046-53. Doi:10.1001/jamaneurol.2013.217
  • Jokinen, H., Schmidt, R., Ropele, S., Fazekas, F., Gouw, A. A., Barkhof, F., Scheltens, P., Madureira, S., Verdelho, A., Ferro, J. M., Wallin, A., Poggesi, A., Inzitari, D., Pantoni, L., Erkinjuntti, T. Diffusion changes predict cognitive and functional outcome: The LADIS study. Annals of neurology 2013;73(5):576-83. Doi:10.1002/ana.23802
  • Joling, K. J., Bosmans, J. E., van Marwijk, H. W. J., van der Horst, H. E., Scheltens, P., Vroomen, J. L. M., van Hout, H. P. J. The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trial. Trials 2013;14:305. Doi:10.1186/1745-6215-14-305
  • Jongbloed, W., Kester, M. I., van der Flier, W. M., Veerhuis, R., Scheltens, P., Blankenstein, M. A., Teunissen, C. E. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study. Alzheimers & dementia 2013;9(3):276-83. Doi:10.1016/j.jalz.2012.01.004
  • Koedam, E. L. G. E., van der Vlies, A. E., van der Flier, W. M., Verwey, N. A., Koene, T., Scheltens, P., Blankenstein, M. A., Pijnenburg, Y. A. L. Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. Alzheimers & dementia 2013;9(3):269-75. Doi:10.1016/j.jalz.2011.12.007
  • Kohler, S., Hamel, R., Sistermans, N., Koene, T., Pijnenburg, Y. A. L., van der Flier, W. M., Scheltens, P., Visser, P. J., Aalten, P., Verhey, F. R. J., Ramakers, I. Progression to dementia in memory clinic patients without dementia: a latent profile analysis. Neurology 2013;81(15):1342-9. Doi:10.1212/WNL.0b013e3182a82536
  • Kooij, C.H. Van der, Dröes, R.M., Lange, J. de, Ettema, T.P., Cools, H., Tilburg, VanThe implementation of integrated emotion-oriented care; did it actually change the attitude, skills and time spending of trained caregivers? Dementia: The International Journal of Social Research and Practice, 09/2013,12(5):536-550
  • Kreisel, S. H., Blahak, C., Bazner, H., Inzitari, D., Pantoni, L., Poggesi, A., Chabriat, H., Erkinjuntti, T., Fazekas, F., Ferro, J. M., Langhorne, P., O’Brien, J., Scheltens, P., Visser, M. C., Wahlund, L. O., Waldemar, G., Wallin, A., Hennerici, M. G. Deterioration of Gait and Balance over Time: The Effects of Age-Related White Matter Change – The LADIS Study. Cerebrovascular diseases 2013;35(6):544-53. Doi:10.1159/000350725
  • Lehmann, M., Koedam, E. L., Barnes, J., Bartlett, J. W., Barkhof, F., Wattjes, M. P., Schott, J. M., Scheltens, P., Fox, N. C. Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. Neurobiology of aging 2013;34(1):73-82. Doi:10.1016/j.neurobiolaging.2012.03.010
  • Meesters, P. D., Comijs, H. C., Droes, R. M., de Haan, L., Smit, J. H., Eikelenboom, P., Beekman, A. T. F., Stek, M. L. The Care Needs of Elderly Patients With Schizophrenia Spectrum Disorders. American journal of geriatric psychiatry 2013;21(2):129-37. Doi:10.1016/j.jagp.2012.10.008
  • Moleiro, C., Madureira, S., Verdelho, A., Ferro, J. M., Poggesi, A., Chabriat, H., Erkinjuntti, T., Fazekas, F., Hennerici, M., O’Brien, J., Pantoni, L., Salvadori, E., Scheltens, P., Visser, M. C., Wahlund, L. O., Waldemar, G., Wallin, A., Inzitari, D. Confirmatory factor analysis of the Neuropsychological Assessment Battery of the LADIS study: A longitudinal analysis. Journal of clinical and experimental neuropsychology 2013;35(3):269-78. Doi:10.1080/13803395.2013.770822
  • Molinuevo, J. L., Cummings, J. L., Dubois, B., Scheltens, P. Preface. Medical clinics of north america 2013;97(3):XIII-XIXV. Doi:10.1016/j.mcna.2013.01.003
  • Möller, C., Vrenken, H., Jiskoot, L., Versteeg, A., Barkhof, F., Scheltens, P., van der Flier, W. M. Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease. Neurobiology of aging 2013;34(8):2014-22. Doi:10.1016/j.neurobiolaging.2013.02.013
  • Morbelli, S., Perneczky, R., Drzezga, A., Frisoni, G. B., Caroli, A., van Berckel, B. N. M., Ossenkoppele, R., Guedj, E., Didic, M., Brugnolo, A., Naseri, M., Sambuceti, G., Pagani, M., Nobili, F. Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project. Journal of nuclear medicine 2013;54(6):894-902. Doi:10.2967/jnumed.112.113928
  • Muller, M., Jochemsen, H., Visseren, F., Grool, A., Launer, L., van der Graaf, Y., Geerlings, M., I. Low blood pressure and antihypertensive treatment are independently associated with physical and mental health status in patients with arterial disease: the SMART study. Journal of internal medicine 2013;274(3):241-51. Doi:10.1111/joim.12069
  • Okroglic, S., Widmann, C. N., Urbach, H., Scheltens, P., Heneka, M. T. Clinical Symptoms and Risk Factors in Cerebral Microangiopathy Patients. PloS one 2013;8(2). Doi:10.1371/journal.pone.0053455
  • Ossenkoppele, R., Prins, N. D., Pijnenburg, Y. A., Lemstra, A. W., van der Flier, W. M., Adriaanse, S. F., Windhorst, A. D., Handels, R. L., Wolfs, C. A., Aalten, P., Verhey, F. R., Verbeek, M. M., van Buchem, M. A., Hoekstra, O. S., Lammertsma, A. A., Scheltens, P., van Berckel, B. N. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers & dementia 2013;9(4):414-21. Doi:10.1016/j.jalz.2012.07.003
  • Ossenkoppele, R., Prins, N. D., van Berckel, B. N. M. Amyloid imaging in clinical trials. Alzheimers research & therapy 2013;5(4):36. Doi:10.1186/1758-9193-5-36
  • Ossenkoppele, R., van der Flier, W. M., Zwan, M. D., Adriaanse, S. F., Boellaard, R., Windhorst, A. D., Barkhof, F., Lammertsma, A. A., Scheltens, P., van Berckel, B. N. M. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology 2013;80(4):359-65. WpR, VUmc NCA-NB
  • Palm, W. M., Ferrarini, L., van der Flier, W. M., Westendorp, R. G., Bollen, E. L., Middelkoop, H. A., Milles, J. R., van der Grond, J., van Buchem, M. A. Cerebral atrophy in elderly with subjective memory complaints. Journal of magnetic resonance imaging 2013;38(2):358-64. Doi:10.1002/jmri.23977
  • Papma, J. M., Seelaar, H., de Koning, I., Hasan, D., Reijs, A., Valkema, R., Prins, N. D., van Swieten, J. C. Episodic Memory Impairment in Frontotemporal Dementia; A Tc-99m-HMPAO SPECT Study. Current alzheimer research 2013;10(3):332-9. WpR, VUmc NCA-NB
  • Poggesi, A., Gouw, A., van der Flier, W., Pracucci, G., Chabriat, H., Erkinjuntti, T., Fazekas, F., Ferro, J. M., Hennerici, M., Langhorne, P., O’Brien, J. T., Visser, M. C., Wahlund, L. O., Waldemar, G., Wallin, A., Scheltens, P., Inzitari, D., Pantoni, L. Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study. Journal of neurology 2013;260(4):1014-21. Doi:10.1007/s00415-012-6748-3
  • Poil, S. S., de Haan, W., van der Flier, W. M., Mansvelder, H. D., Scheltens, P., Linkenkaer-Hansen, K. Integrative EEG biomarkers predict progression to Alzheimer’s disease at the MCI stage. Frontiers in aging neuroscience 2013;5:UNSP. Doi:10.3389/fnagi.2013.00058
  • Prestia, A., Caroli, A., van der Flier, W. M., Ossenkoppele, R., van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A. E., Carter, S. F., Scholl, M., Choo, I. H., Nordberg, A., Scheltens, P., Frisoni, G. B. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 2013;80(11):1048-56. Doi:10.1212/WNL.0b013e3182872830
  • Prins, N. D., van der Flier, W. M., Brashear, H. R., Knol, D. L., van De Pol, L. A., Barkhof, F., Scheltens, P. Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population. Journal of Alzheimer’s disease : JAD 2013;36(1):79-85. Doi:10.3233/JAD-122233
  • Ramakers, I. H. G. B., Verhey, F. R. J., Scheltens, P., Hampel, H., Soininen, H., Aalten, P., Rikkert, M. O., Verbeek, M. M., Spiru, L., Blennow, K., Trojanowski, J. Q., Shaw, L. M., Visser, P. J. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychological medicine 2013;43(5):911-20. Doi:10.1017/S0033291712001870
  • Ravenscroft, T. A., Baker, M. C., Rutherford, N. J., Neumann, M., Mackenzie, I. R., Josephs, K. A., Boeve, B. F., Petersen, R., Halliday, G. M., Kril, J., van Swieten, J. C., Seeley, W. W., Dickson, D. W., Rademakers, R. Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS. Neurobiology of aging 2013;34(9):UNSP. Doi:10.1016/j.neurobiolaging.2013.04.004
  • Scheltens, P. DEMENTIA Mild cognitive impairment-amyloid and beyond. Nature reviews neurology 2013;9(9):493-5. Doi:10.1038/nrneurol.2013.147
  • Schuitemaker, A., Kropholler, M. A., Boellaard, R., van der Flier, W. M., Kloet, R. W., van der Doef, T. F., Knol, D. L., Windhorst, A. D., Luurtsema, G., Barkhof, F., Jonker, C., Lammertsma, A. A., Scheltens, P., van Berckel, B. N. M. Microglial activation in Alzheimer’s disease: an (R)-PK11195 positron emission tomography study. Neurobiology of aging 2013;34(1):128-36. Doi:10.1016/j.neurobiolaging.2012.04.021
  • Sikkes, S. A. M., Knol, D. L., Pijnenburg, Y. A. L., de Lange-de Klerk, E., Uitdehaag, B. M. J., Scheltens, P. Validation of the Amsterdam IADL Questionnaire (c), a New Tool to Measure Instrumental Activities of Daily Living in Dementia. Neuroepidemiology 2013;41(1):35-41. Doi:10.1159/000346277
  • Sikkes, S. A. M., Pijnenburg, Y. A. L., Knol, D. L., de Lange-de Klerk, E., Scheltens, P., Uitdehaag, B. M. J. Assessment of Instrumental Activities of Daily Living in Dementia: Diagnostic Value of the Amsterdam Instrumental Activities of Daily Living Questionnaire. Journal of geriatric psychiatry and neurology 2013;26(4):244-50. Doi:10.1177/0891988713509139
  • Spies, P. E., Claassen, J. A. H. R., Peer, P. G. M., Blankenstein, M. A., Teunissen, C. E., Scheltens, P., van der Flier, W. M., Rikkert, M. G. M. O., Verbeek, M. M. A prediction model to calculate probability of Alzheimer’s disease using cerebrospinal fluid biomarkers. Alzheimers & dementia 2013;9(3):262-8. Doi:10.1016/j.jalz.2012.01.010
  • Tijms, B. M., Möller, C., Vrenken, H., Wink, A. M., de Haan, W., van der Flier, W. M., Stam, C. J., Scheltens, P., Barkhof, F. Single-Subject Grey Matter Graphs in Alzheimer’s Disease. PloS one 2013;8(3). Doi:10.1371/journal.pone.0058921
  • Tijms, B. M., Wink, A. M., de Haan, W., van der Flier, W. M., Stam, C. J., Scheltens, P., Barkhof, F. Alzheimer’s disease: connecting findings from graph theoretical studies of brain networks. Neurobiology of aging 2013;34(8):2023-36. Doi:10.1016/j.neurobiolaging.2013.02.020
  • van Berckel, B. N., Ossenkoppele, R., Tolboom, N., Yaqub, M., Foster-Dingley, J. C., Windhorst, A. D., Scheltens, P., Lammertsma, A. A., Boellaard, R. Longitudinal Amyloid Imaging Using C-11-PiB: Methodologic Considerations. Journal of nuclear medicine 2013;54(9):1570-6. Doi:10.2967/jnumed.112.113654
  • van de Glind, E. M. M., van Enst, W. A., van Munster, B. C., Olde Rikkert, M. G. M., Scheltens, P., Scholten, R. J. P. M., Hooft, L. Pharmacological treatment of dementia: a scoping review of systematic reviews. Dementia and geriatric cognitive disorders 2013;36(3-4):211-28. Doi:10.1159/000353892
  • van der Vlies, A. E., Staekenborg, S. S., dmiraal-Behloul, F., Prins, N. D., Barkhof, F., Vrenken, H., Reiber, J. H. C., Scheltens, P., van der Flier, W. M. Associations between Magnetic Resonance Imaging Measures and Neuropsychological Impairment in Early and Late Onset Alzheimer’s Disease. Journal of alzheimers disease 2013;35(1):169-78. Doi:10.3233/JAD-121291
  • van Harten, A. C., Smits, L. L., Teunissen, C. E., Visser, P. J., Koene, T., Blankenstein, M. A., Scheltens, P., van der Flier, W. M. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology 2013;81(16):1409-16. Doi:10.1212/WNL.0b013e3182a8418b
  • van Harten, A. C., Visser, P. J., Pijnenburg, Y. A., Teunissen, C. E., Blankenstein, M. A., Scheltens, P., van der Flier, W. M. Cerebrospinal fluid A beta 42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers & dementia 2013;9(5):481-7. Doi:10.1016/j.jalz.2012.08.004
  • van Swieten, J. C., Pijnenburg, Y. The role of the subgenual cingulate cortex in self-appraisal. Journal of neurology neurosurgery and psychiatry 2013;84(2):121. Doi:10.1136/jnnp-2012-303571
  • van Vliet, D., de Vugt, M. E., Aalten, P., Bakker, C., Pijnenburg, Y. A. L., Vernooij-Dassen, M. J. F. J., Koopmans, R. T. C. M., Verhey, F. R. J. Prevalence of Neuropsychiatric Symptoms in Young-Onset Compared to Late-Onset Alzheimer’s Disease – Part 1: Findings of the Two-Year Longitudinal NeedYD-Study. Dementia and geriatric cognitive disorders 2012;34(5-6):319-27. Doi:10.1159/000342824
  • van Vliet, D., de Vugt, M. E., Bakker, C., Pijnenburg, Y. A. L., Vernooij-Dassen, M. J. F. J., Koopmans, R. T. C. M., Verhey, F. R. J. Time to diagnosis in young-onset dementia as compared with late-onset dementia. Psychological medicine 2013;43(2):423-32. Doi:10.1017/S0033291712001122
  • van Vliet, D., de Vugt, M. E., Koehler, S., Aalten, P., Bakker, C., Pijnenburg, Y. A., Vernooij-Dassen, M. J., Koopmans, R. T., Verhey, F. R. Awareness and Its Association With Affective Symptoms in Young-onset and Late-onset Alzheimer Disease: A Prospective Study. Alzheimer disease & associated disorders 2013;27(3):265-71. Doi:10.1097/WAD.0b013e31826cffa5
  • Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., Cedarbaum, J., Grundman, M., Broich, K., Giacobini, E., Dubois, B., Sperling, R., Wilcock, G. K., Fox, N. C., Scheltens, P., Touchon, J., Hendrix, S., Andrieu, S., Aisen, P. Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force. Alzheimer’s & dementia : the journal of the Alzheimer’s Association 2013;9(4):438-44. Doi:10.1016/j.jalz.2013.03.007
  • Verdelho, A., Madureira, S., Moleiro, C., Ferro, J. M., O’Brien, J. T., Poggesi, A., Pantoni, L., Fazekas, F., Scheltens, P., Waldemar, G., Wallin, A., Erkinjuntti, T., Inzitari, D. Depressive symptoms predict cognitive decline and dementia in older people independently of cerebral white matter changes: the LADIS study. Journal of neurology, neurosurgery, and psychiatry 2013;84(11):1250-4. Doi:10.1136/jnnp-2012-304191
  • Vermeiren, A. P. A., Bosma, H., Visser, P. J., Zeegers, M. P., Graff, C., Ewers, M., Frisoni, G. B., Frolich, L., Hampel, H., Jones, R. W., Kehoe, P. G., Lenoir, H., Minthon, L., Nobili, F. M., Rikkert, M. O., Rigaud, A. S., Scheltens, P., Soininen, H., Spiru, L., Tsolaki, M., Wahlund, L. O., Vellas, B., Wilcock, G., Elias-Sonnenschein, L. S., Verhey, F. R. J. The Association Between APOE epsilon 4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. Journal of alzheimers disease 2013;35(2):241-6. Doi:10.3233/JAD-122182
  • Verwey, N. A., Hoozemans, J. J., Korth, C., van Royen, M. R., Prikulis, I., Wouters, D., Twaalfhoven, H. A., van Haastert, E. S., Schenk, D., Scheltens, P., Rozemuller, A. J., Blankenstein, M. A., Veerhuis, R. Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid beta-peptide. Amyloid-journal of protein folding disorders 2013;20(3):179-87. Doi:10.3109/13506129.2013.797389
  • Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., Fagan, A. M. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet neurology 2013;12(10):957-65. Doi:10.1016/S1474-4422(13)70194-7
  • Vos, S. J. B., van Rossum, I. A., Verhey, F., Knol, D. L., Soininen, H., Wahlund, L. O., Hampel, H., Tsolaki, M., Minthon, L., Frisoni, G. B., Froelich, L., Nobili, F., van der Flier, W., Blennow, K., Wolz, R., Scheltens, P., Visser, P. J. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology 2013;80(12):1124-32. Doi:10.1212/WNL.0b013e318288690c
  • Zarei, M., Beckmann, C. F., Binnewijzend, M. A., Schoonheim, M. M., Oghabian, M. A., Sanz-Arigita, E. J., Scheltens, P., Matthews, P. M., Barkhof, F. Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer’s disease. Neuroimage 2013;66:28-35. Doi:10.1016/j.neuroimage.2012.10.071

Vakpublicaties:

  • Gossink, F., Dols, A., Kerssens, C. J., Scheltens, P., Stek, M. L., Pijnenburg, Y. A. L. . Nederlands tijdschrift voor geneeskunde 2013;157(42):A6370. VP, VUmc NCA-NB
  • Huber, E., Meiland, F., Stek, M., Dröes, R.M., Bootsma-vd Wiel, A. De overdracht van GGZ naar verpleeghuis. Continuiteit van zorg voor patiënten met dementie. Tijdschrift voor Ouderengeneeskunde, 2013, 04, 177-181
  • Meesters, P.D., Comijs, C., Dröes, R.M., Haan, L.de, Smit, J. Eikelenboom, P., Beekman, A.T.F., Stek, M. Ouderen met schizoofrenie; zorgbehoeften en zorgvernieuwing. MGv, 68 (4) 2013,174-183.
  • Scheltens, P., Twisk, J. W. R. . Nederlands tijdschrift voor geneeskunde 2013;157(0):A6721. VP, VUmc NCA-NB
  • van der Flier, W. M., Ossenkoppele, R., van Berckel, B. N. M., Scheltens, P. Vroegdiagnostiek van de ziekte van Alzheimer: de rol van Positron Emissie Tomografie (PET). Tijdschrift voor gerontologie en geriatrie 2013;44(4):190-1. VP, VUmc NCA-NB.10.1007/s12439-013-0033-5
  • Verberne, W. R., Snijders, T. J., Liem, K. S., Baakman, A. C., Veldhuijzen, D. S. . Nederlands tijdschrift voor geneeskunde 2013;157(5):A5434. VP, VUmc NCA-NB
  • Verhey, F. R. J., Visser, P. J. . Nederlands tijdschrift voor geneeskunde 2013;157(11):A5596. VP, VUmc NCA-NB

Boekhoofdstukken :

  • A.W. Lemstra, H. Seelaar, J.C. van Swieten. Primary Dementia Syndromes and Parkinsonism. In Oxford textbook of movement Disorders edited by DJ Burns, Oxford 2013

Dissertaties:

  • Goos J.D.C. Microbleeds in dementia: Connecting the dots  Vrije Universiteit Amsterdam 6 februari 2013. Promotoren: Ph. Scheltens, F. Barkhof, copromotor: W.M. van der Flier
  • Ossenkoppele R. Alzheimer PEThology Vrije Universiteit Amsterdam 8 mei 2013. Promotoren: Ph. Scheltens, A Lammertsma, copromotoren: B.N.M. van Berckel, W.M. van der Flier
  • Jochemsen H. Brain under pressure. Influences of blood pressure and angiotensin-converting enzyme on the brain. Vrije Universiteit Amsterdam 4 oktober 2013. Promotoren: Ph. Scheltens, Y. van der Graaf, copromotoren: M. Muler, M.I. Geerlings /li>
  • Van der Vlies A. Cognitive profiles in Alzheimer’s disease. Recognizing its many faces. Vrije Universiteit Amsterdam 27 november 2013. Promotor: Ph. Scheltens, copromotor: W.M. van der Flier
  • Van Rossum I. Diagnosis and prognosis of Alzheimer’s disease in subjects with mild cognitive impairment.  Vrije Universiteit Amsterdam 28 november 2013. Promotor: Ph. Scheltens, copromotor: P.J. Visser

Publicaties 2012

Internationale wetenschappelijke publicaties:

  • Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement 2011;7:270-279.
  • Bateman RJ, Aisen PS, de Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther 2011;3(1):1-13.
  • Brodaty H, Breteler MMB, Dekosky ST, Dorenlot P, Fratiglioni L, Hock C, Kenigsberg P-A, Scheltens P, de Strooper B. The world of dementia beyond 2020. J Am Geriatr Soc 2011;59:923-927.
  • Cardoso MJ, Clarkson MJ, Ridgway GR, Modat M, Fox NC, Ourselin S,and The Alzheimer’s Disease Neuroimaging Initiative. LoAd: A locally adaptive cortical segmentation algorithm. Neuroimage 2011;56:1386-1397.
  • Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Thompson PM, Reiman EM, Jack CR Jr, Fox NC, Jagust WJ, Harvey DJ, Beckett LA, Gamst A, Aisen PS, Petersen RC, Weiner MW, for the Alzheimer’s Disease Neuroimaging Initiative. Impact of apolipoprotein ɛ4-cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimers Dement 2011;7:514-520.
  • Clarkson MJ, Cardoso MJ, Ridgway GR, Modat M, Leung KK, Rohrer JD, Fox NC, Ourselin S. A comparison of voxel and surface based cortical thickness estimation methods. Neuroimage 2011;57:856-865.
  • Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer’s disease: innocent observation or key player? Brain 2011;134:335-344.
  • Echávarri C, Aalten P, Uylings HBM, Jacobs HIL, Visser PJ, Gronenschild EHBM, Verhey FRJ, Burgmans S. Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer’s disease. Brain Struct Funct 2011;215:265-271.
  • Elias-Sonnenschein LS, Viechtbauer W, Ramakers IHGB, Verhey FRJ, Visser PJ. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis.  J Neurol Neurosurg Psychiatry 2011;82:1149-1156.
  • van der Flier WM, Pijnenburg YAL Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer’s disease: the case of the missing APOE ε4 allele. Lancet Neurol 2011;10:280-288.
  • Feldman FH, Scheltens Ph, Dubois B, on behalf of the International Working Group for New Research Criteria for AD.  New lexicon and criteria for the diagnosis of Alzheimer’s disease – Authors’ reply. Lancet Neurol 2011;11:300-301.
  • Fonteijn HM, Clarkson MJ, Modat M, Barnes J, Lehmann M, Ourselin S, Fox NC, Alexander DC.  An event-based disease progression model and its application to familial Alzheimer’s disease. Inf Process Med Imaging 2011;22:748-759.
  • Fox NC, Ridgway GR, Schott JM.Algorithms, atrophy and Alzheimer’s disease. Cautionary tales for clinical trials. Neuroimage 2011;57:15-18.
  • Gao FQ, Swartz RH, Scheltens P, Leibovitch FS, Kiss A, Honjo K, Black SE. Complexity of MRI white matter hyperintensity assessments in relation to cognition in aging and dementia from the sunnybrook dementia study. J Alzheimers Dis 2011;26:379-388.
  • Goos JDC, van der Flier WM, Knol DL, Pouwels PJW, Scheltens P, Barkhof F, Wattjes MP. Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging. Stroke 2011;42:1894-1900.
  • Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, Geurts JJG. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011;82:126-135.
  • Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, K B, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B, for the Oxford Task Force Group. Biomarkers for Alzheimer’s disease therapeutic trials. Prog Neurobiol 2011;95:579-593.
  • van Harten AC, Kester MI, Visser PJ, Blankenstein MA, Pijnenburg YAL, van der Flier WM, Scheltens P. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 2011;49:353-366.
  • Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC,  et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 2011;43:429-436.
  • Jack CR Jr, Barkhof F, Bernstein MA, Cantillon M, Cole PE, Decarli C, Dubois B, Duchesne S, Fox NC, Frisoni GB, Hampel H, Hill DL, Johnson K, Mangin JF, Scheltens P, Schwarz AJ, Sperling R, Suhy J, Thompson PM, Weiner M, Foster NL. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease. Alzheimers Dement 2011;7:474-485.
  • Jansen C, Parchi P, Jelles B, Gouw AA, Beunders G, van Spaendonk RML, van de Kamp JM, Lemstra AW, Capellari S, Rozemuller AJM. The first case of fatal familial insomnia (FFI) in the Netherlands: a patient from Egyptian descent with concurrent 4 repeat tau deposits.  Neuropathol Appl Neurobiol 2011;37:549-553.
  • Jokinen H, Gouw AA, Madureira S, Ylikoski R, van Straaten ECW, van der Flier WM, Barkhof F, Scheltens P, Fazekas F, Schmidt R, Verdelho A, Ferro JM, Pantoni L, Inzitari D, Erkinjuntti T, On behalf of the LADIS Study Group. Incident lacunes influence cognitive decline: The LADIS study. Neurology 2011;76:1872-1878.
  • de Jong-Hagelstein M, van de Sandt-Koenderman WME, Prins ND, Dippel DWJ, Koudstaal PJ, Visch-Brink EG. Efficacy of early cognitive-linguistic treatment and communicative treatment in aphasia after stroke: a randomised controlled trial (RATS-2). J Neurol Neurosurg Psychiatry 2011;82:399-404.
  • Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Twisk JWR, Swinkels SHN, Scheltens P. Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer’s disease: secondary analyses from a randomized, controlled trial. J Nutr Health Aging 2011;15:672-676.
  • Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Twisk JWR, Swinkels SHN, Scheltens P. Efficacy of a medical food on cognition in Alzheimer’s disease: results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging 2011;15:720-724.
  • Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM. Progression from MCI to AD: Predictive value of CSF Abeta42 is modified by APOE genotype. Neurobiol Aging 2011;32:1372-1378.
  • Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ, for the Alzheimer’s Disease Neuroimaging Initiative. (waaronder o.a. Fox N.) Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011;76:69-79.
  • Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodríguez Martinez de Llano S, Edison P, Douglas J, Fox NC, Brooks DJ, Rossor MN. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain 2011;134:293-300.
  • Koedam ELGE, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YAL, Fox N, Barkhof F, Wattjes MP. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 2011;21:2618-2625.
  • Lashley T, Rohrer JD, Bandopadhyay R, Fry C, Ahmed Z, Isaacs AM, Brelstaff JH, Borroni B, Warren JD, Troakes C, King A, Al-Saraj S, Newcombe J, Quinn N, Ostergaard K, Schøder HD, Bojsen-Møller M, Braendgaard H, Fox NC, Rossor MN, Lees AJ, Holton JL, Revesz T. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 2011;134:2548-2564.
  • Lehmann M, Barnes J, Ridgway GR, Wattam-Bell J, Warrington EK, Fox NC, Crutch SJ.  Basic visual function and cortical thickness patterns in posterior cortical atrophy. Cereb Cortex 2011;21:2122-2132.
  • Lehmann M, Crutch SJ, Ridgway GR, Ridha BH, Barnes J, Warrington EK, Rossor MN, Fox NC. Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer’s disease. Neurobiol Aging 2011;32:1466-1476.
  • Leung KK, Barnes J, Modat M, Ridgway GR, Bartlett JW, Fox NC, Ourselin S, and the Alzheimer’s Disease Neuroimaging Initiative. Brain MAPS: An automated, accurate and robust brain extraction technique using a template library. Neuroimage 2011;55:1091-1108.
  • McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement 2011;7:263-269.
  • Mahoney CJ, Rohrer JD, Goll JC, Fox NC, Rossor MN, Warren JD. Structural neuroanatomy of tinnitus and hyperacusis in semantic dementia. J Neurol Neurosurg Psychiatry 2011;82:1274-1278.
  • Maruta C, Guerreiro M, de Mendonça A, Hort J, Scheltens P. The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. Eur J Neurol 2011;18:279-286.
  • Norberg J, Graff C, Almkvist O, Ewers M, Frisoni GB, Frölich L, Hampel H, Jones RW, Kehoe PG, Lenoir H, Minthon L, Nobili F, Olde Rikkert M, Rigaud A-S, Scheltens P, Soininen H, Spiru L, Tsolaki M, Wahlund L-O, Vellas B, Wilcock G, Elias-Sonnenschein LS, Verhey FRJ, Visser PJ. Regional differences in effects of APOE ε4 on cognitive impairment in non-demented subjects. Dement Geriatr Cogn Disord 2011;32:135-142.
  • O’Brien J, Scheltens P. Clinical use of neuroimaging in dementia: an international perspective. Int Psychogeriatr 2011;23(suppl 2):S3-S5.
  • Ossenkoppele R, Tolboom N, Pijnenburg YA, Lammertsma AA, Scheltens P, van Berckel BNM.  Afbeelden van amyloïdplaques in de hersenen met PET. Ned Tijdschr Geneeskd 2011;155:A2981.
  • Ossenkoppele R, van Berckel BNM, Tolboom N, PijnenburgYA, Prins ND, Lemstra AW, Lammertsma AA, Scheltens Ph. Moleculaire beeldvorming bij de ziekte van Alzheimer. Tschr Neurol Neurochir 2011;112:201-208.
  • Ossenkoppele R, van Berckel BNM, Prins ND. Amyloid imaging in prodromal Alzheimer’s disease. Alzheimers Res Ther 2011;3(5):26.
  • Oudega ML, van Exel E, Wattjes MP, Comijs HC, Scheltens P, Barkhof F, Eikelenboom P, de Craen AJM, Beekman ATF, Stek ML. White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients.  J Clin Psychiatry 2011;72:104-112.
  • Pievani M, de Haan W, Wu T, Seeley WW, Frisoni GB. Functional network disruption in the degenerative dementias. Lancet Neurol 2011;10:829-843.
  • van de Pol L, Gertz H-J, Scheltens P, Wolf H. Hippocampal atrophy in subcortical vascular dementia. Neurodegener Dis 2011;8:465-469.
  • Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EGP, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain  2011;134:2456-2477.
  • Rohrer JD, Lashley T, Holton J, Revesz T, Urwin H, Isaacs AM, Fox NC, Rossor MN, Warren J. The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2011;82:1405-1407.
  • Rohrer JD, Lashley T, Schott JM, Warren JE, Mead S, Isaacs AM, Beck J, Hardy J, de Silva R, Warrington E, Troakes C, Al-Sarraj S, King A, Borroni B, Clarkson MJ, Ourselin S, Holton JL, Fox NC, Revesz T, Rossor MN, Warren JD. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 2011;134:2565-2581.
  • Ryberg C, Rostrup E, Paulson OB, Barkhof F, Scheltens P, van Straaten ECW, van der Flier WM, Fazekas F, Schmidt R, Ferro JM, Baezner H, Erkinjuntti T, Jokinen H, Wahlund L-O, Poggesi A, Pantoni L, Inzitari D, Waldemar G, and on behalf of the LADIS study group. Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort. J Neurol Sci 2011;307:100-105.
  • Scheltens P, Rockwood K. How golden is the gold standard of neuropathology in dementia? Alzheimers Dement 2011;7:486-489.
  • Scher AI, Xu Y, Korf ESC, Hartley SW, Witter MP, Scheltens P, White LR, Thompson PM, Toga AW, Valentino DJ, Launer LJ. Hippocampal morphometry in population-based incident Alzheimer’s disease and vascular dementia: the HAAS. J Neurol Neurosurg Psychiatry 2011;82:373-377.
  • Scherder E, Eggermont L, Visscher C, Scheltens P, Swaab D. Understanding higher level gait disturbances in mild dementia in order to improve rehabilitation; ‘Last in – first out’. Neurosci Biobehav Rev 2011;35:699-714.
  • Schmidt R, Schmidt H, Haybaeck J, Loitfelder M, Weis S, Cavalieri M, Seiler S, Enzinger C, Ropele S, Erkinjuntti T, Pantoni L, Scheltens P, Fazekas F, Jellinger K. Heterogeneity in age-related white matter changes. Acta Neuropathol 2011;122:171-178.
  • Schott JM, Warren JD, Barkhof F, Rossor MN, Fox NC. Suspected early dementia. BMJ 2011;343:d5568:1-5.
  • Sikkes SAM, Knol DL, van den Berg MT, de Lange-de Klerk ESM, Scheltens P, Klein M, Pijnenburg YAL, Uitdehaag, BMJ. An informant questionnaire for detecting Alzheimer’s disease: are some items better than others? J Int Neuropsychol Soc 2011;17:674-681.
  • Sims R, Dwyer S, Harold D, Gerrish A, Hollingworth P, Chapman J, Jones N, Abraham R, Ivanov D, Pahwa JS, Moskvina V, Dowzell K, Thomas C, Stretton A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuiness B, Todd S, Johnston JA, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Livingston G, Bass NJ, Gurling H, McQuillin A, Jones L, Holmans PA, O’Donovan M, Owen MJ, Williams J. No evidence that extended tracts of homozygosity are associated with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 2011;156:764-771.
  • Smits LL, Liedorp M, Koene T, Roos-Reuling IEW, Lemstra AW, Scheltens P, Stam CJ, van der Flier WM. EEG abnormalities are associated with different cgnitive profiles in Alzheimer’s disease. Dement Geriatr Cogn Disord 2011;31:1-6.
  • Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 2011;7:367-385.
  • Tabrizi SJ, Scahill RI, Durr A, Roos RAC, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC, and the TRACK-HD investigators. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31-421.
  • Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Gispen-de Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel H. Prevention trials in Alzheimer’s disease: An EU-US task force report. Prog Neurobiol 2011;95:594-600.
  • Verdelho A, Madureira S, Moleiro C, Santos CO, Ferro JM, Erkinjuntti T, Poggesi A, Pantoni L, Fazekas F, Scheltens P, Waldemar G, Wallin A, Inzitari D, and on behalf of the LADIS study(waaronder Scheltens P, van Straaten I, Gouw A, van der Flier W, Visser M). Self-perceived memory complaints predict progression to Alzheimer disease. The LADIS study. J Alzheimers Dis  2011;27:491-498.
  • van Vliet D, de Vugt ME, Bakker C, Koopmans RTCM, Pijnenburg YAL, Vernooij-Dassen MJFJ, Verhey FR. Caregivers’ perspectives on the pre-diagnostic period in early onset dementia: a long and winding road. Int Psychogeriatr 2011;23:1393-1404.
  • de Waal H, Stam CJ, Blankenstein MA, Pijnenburg YAL, Scheltens P, van der Flier WM. EEG abnormalities in early and late onset Alzheimer’s disease: understanding heterogeneity. J Neurol Neurosurg Psychiatry 2011;82:67-71.
  • de Wilde MC, Kamphuis PJGH, Sijben JWC, Scheltens P. Utility of imaging for nutritional intervention studies in Alzheimer’s disease. Eur J Pharmacol 2011;668(suppl.1):S59-S69.
  • Witlox J, Kalisvaart KJ, de Jonghe JFM, Verwey NA, van Stijn MFM, Houdijk APJ, Traast HS, Maclullich AMJ, van Gool WA, Eikelenboom P. Cerebrospinal fluid β-amyloid and tau are not associated with risk of delirium: a prospective cohort study in older adults with hip fracture. J Am Geriatr Soc 2011;59:1260-1267.
  • Dröes, R.M., Van Mierlo, L.D., Meiland, F.J.M., Van der Roest, H.G. Memory problems in dementia: Adaptation and copingstrategies, and psychosocial treatments. Expert Reviews Neurotherapeutics, 2011,11(12)1769-1782.
  • De Boer ME, Dröes RM, Jonker C, Eefsting JA, Hertogh CMPM. Advance directives for euthanasia in dementia: how are they dealt with in Dutch nursing homes? Experiences of physicians and relatives.Journal of the American Geriatrics Society 2011;59(6):989-96.
  • Jansen APD, Van Hout HPJ, Nijpels G, Rijmen F, Dröes RM, Pot AM, Schellevis F, Van Marwijk HWJ, Stalman W. Effectiveness of case management among older adults with early symptoms of dementia and their primary informal caregivers: a randomised clinical trial. International Journal of Nursing Studies 2011 Aug;48(8):933-43.
  • Meiland FJM, Jonker C, Dröes RM. Predictors of effective support in meeting centers for people with dementia and their carers,Nonpharmacological therapies in dementia2010; 1(3):251-270.
  • Monfort JC, Villemur V, Lezy AM, Baron-Laforet S, Dröes RM. From paedophilia to gerontophilia. Lancet 2011; Vol. 377, Jan 22, 300. Van Mierlo LD, Meiland FJM, Dröes RM. Dementelcoach: effect of telephone coaching on carers of community dwelling people with dementia. Int Psychogeriatr. 2011 Oct 14:1-11.

Boek(hoofdstukken) en vakpublicaties:

  • Barkhof F, Fox NC, Bastos-Leite AJ, Scheltens Ph. Neuroimaging in dementia. New York, Springer, 2011. 278 pp.
  • van Exel E, Eikelenboom P, Comijs HC, Kurniawan C, Frölich M, Smit JH, Stek ML, Scheltens P, Eefsting JE, Westendorp  RGJ.  Het immuunsysteem en de ziekte van Alzheimer. Tijdschr Psychiatr 2011;53:637-643.
  • Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P. Alzheimer’s disease. In: Gilhus NE, Barnes M, Brainin M (eds), European handbook of neurological management. Oxford, John Wiley-Blackwell Publishing, 2011:269-281.
  • Kerklaan BJ, Scheltens P, Schoonderwoerd GC, Killestein J, Rozemuller AJM, van der Knaap MS. ‘Adult polyglucosan body disease’: een weinig bekende maar herkenbare wittestofziekte. Tschr Neurol Neurochir 2011;112:25-31.
  • Vos SJB, Visser PJ, Verhey FRJ. De rol van liquormarkers bij de vroege diagnostiek van de ziekte van Alzheimer. Tijdschr Psychiatr 2011;53:647-653.
  • Dijk M van, Weert J van, Dröes RM. De Veder methode. Contact maken door middel van theater. Denkbeeld; Tijdschrift voor Psychogeriatrie, 23, 2011, 2-5.
  • Mierlo L, Dröes RM. Dementelcoach; telefonische ondersteuning voor mantelzorgers van mensen met dementie. Vita Valley, Nieuwsbrief, juli 2011.

Dissertaties:

  • Kester, MI. Biomarkers for Alzheimer’s pathology; monitoring, predicting and understanding the disease.
    Vrije Universiteit Amsterdam 14 januari 2011
    promotoren: Ph Scheltens, MA Blankenstein, copromotor: WM van der Flier
  • Mulder SD. Amyloid associated proteins in Alzheimer’s disease.
    Vrije Universiteit Amsterdam 7 oktober 2011
    promotoren: MA Blankenstein. Ph Scheltens, copromotor: R Veerhuis
  • Sikkes SAM. Measuring IADL in dementia.
    Vrije Universiteit Amsterdam 14 oktober 2011.
    promotoren: Ph Scheltens, BMJ Uitdehaag, copromotoren: YAL Pijnenburg, ESM de Lange-de Klerk
  • Sluimer JD. Visualizing the shrinking brain: longitudinal MR studies in the spectrum of cognitive decline.
    Vrije Universiteit Amsterdam 28 april 2011.
    promotoren: F Barkhof, Ph Scheltens, copromotoren: WM van der Flier, H. Vrenken
  • Van der Roest HG. Care needs in dementia and digital interactive information provisioning.
    Vrije Universiteit Amsterdam 12 oktober 2009
    Promotoren: RM Dröes, C Jonker, copromotoren: FJ Meiland, P. Scheltens

Publicaties 2011

Internationale wetenschappelijke publicaties:

  • Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement 2011;7:270-279.
  • Bateman RJ, Aisen PS, de Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther 2011;3(1):1-13.
  • Brodaty H, Breteler MMB, Dekosky ST, Dorenlot P, Fratiglioni L, Hock C, Kenigsberg P-A, Scheltens P, de Strooper B. The world of dementia beyond 2020. J Am Geriatr Soc 2011;59:923-927.
  • Cardoso MJ, Clarkson MJ, Ridgway GR, Modat M, Fox NC, Ourselin S,and The Alzheimer’s Disease Neuroimaging Initiative. LoAd: A locally adaptive cortical segmentation algorithm. Neuroimage 2011;56:1386-1397.
  • Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Thompson PM, Reiman EM, Jack CR Jr, Fox NC, Jagust WJ, Harvey DJ, Beckett LA, Gamst A, Aisen PS, Petersen RC, Weiner MW, for the Alzheimer’s Disease Neuroimaging Initiative. Impact of apolipoprotein ɛ4-cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimers Dement 2011;7:514-520.
  • Clarkson MJ, Cardoso MJ, Ridgway GR, Modat M, Leung KK, Rohrer JD, Fox NC, Ourselin S. A comparison of voxel and surface based cortical thickness estimation methods. Neuroimage 2011;57:856-865.
  • Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer’s disease: innocent observation or key player? Brain 2011;134:335-344.
  • Echávarri C, Aalten P, Uylings HBM, Jacobs HIL, Visser PJ, Gronenschild EHBM, Verhey FRJ, Burgmans S. Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer’s disease. Brain Struct Funct 2011;215:265-271.
  • Elias-Sonnenschein LS, Viechtbauer W, Ramakers IHGB, Verhey FRJ, Visser PJ. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis.  J Neurol Neurosurg Psychiatry 2011;82:1149-1156.
  • van der Flier WM, Pijnenburg YAL Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer’s disease: the case of the missing APOE ε4 allele. Lancet Neurol 2011;10:280-288.
  • Feldman FH, Scheltens Ph, Dubois B, on behalf of the International Working Group for New Research Criteria for AD.  New lexicon and criteria for the diagnosis of Alzheimer’s disease – Authors’ reply. Lancet Neurol 2011;11:300-301.
  • Fonteijn HM, Clarkson MJ, Modat M, Barnes J, Lehmann M, Ourselin S, Fox NC, Alexander DC.  An event-based disease progression model and its application to familial Alzheimer’s disease. Inf Process Med Imaging 2011;22:748-759.
  • Fox NC, Ridgway GR, Schott JM.Algorithms, atrophy and Alzheimer’s disease. Cautionary tales for clinical trials. Neuroimage 2011;57:15-18.
  • Gao FQ, Swartz RH, Scheltens P, Leibovitch FS, Kiss A, Honjo K, Black SE. Complexity of MRI white matter hyperintensity assessments in relation to cognition in aging and dementia from the sunnybrook dementia study. J Alzheimers Dis 2011;26:379-388.
  • Goos JDC, van der Flier WM, Knol DL, Pouwels PJW, Scheltens P, Barkhof F, Wattjes MP. Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging. Stroke 2011;42:1894-1900.
  • Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, Geurts JJG. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011;82:126-135.
  • Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, K B, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B, for the Oxford Task Force Group. Biomarkers for Alzheimer’s disease therapeutic trials. Prog Neurobiol 2011;95:579-593.
  • van Harten AC, Kester MI, Visser PJ, Blankenstein MA, Pijnenburg YAL, van der Flier WM, Scheltens P. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 2011;49:353-366.
  • Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC,  et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 2011;43:429-436.
  • Jack CR Jr, Barkhof F, Bernstein MA, Cantillon M, Cole PE, Decarli C, Dubois B, Duchesne S, Fox NC, Frisoni GB, Hampel H, Hill DL, Johnson K, Mangin JF, Scheltens P, Schwarz AJ, Sperling R, Suhy J, Thompson PM, Weiner M, Foster NL. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease. Alzheimers Dement 2011;7:474-485.
  • Jansen C, Parchi P, Jelles B, Gouw AA, Beunders G, van Spaendonk RML, van de Kamp JM, Lemstra AW, Capellari S, Rozemuller AJM. The first case of fatal familial insomnia (FFI) in the Netherlands: a patient from Egyptian descent with concurrent 4 repeat tau deposits.  Neuropathol Appl Neurobiol 2011;37:549-553.
  • Jokinen H, Gouw AA, Madureira S, Ylikoski R, van Straaten ECW, van der Flier WM, Barkhof F, Scheltens P, Fazekas F, Schmidt R, Verdelho A, Ferro JM, Pantoni L, Inzitari D, Erkinjuntti T, On behalf of the LADIS Study Group. Incident lacunes influence cognitive decline: The LADIS study. Neurology 2011;76:1872-1878.
  • de Jong-Hagelstein M, van de Sandt-Koenderman WME, Prins ND, Dippel DWJ, Koudstaal PJ, Visch-Brink EG. Efficacy of early cognitive-linguistic treatment and communicative treatment in aphasia after stroke: a randomised controlled trial (RATS-2). J Neurol Neurosurg Psychiatry 2011;82:399-404.
  • Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Twisk JWR, Swinkels SHN, Scheltens P. Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer’s disease: secondary analyses from a randomized, controlled trial. J Nutr Health Aging 2011;15:672-676.
  • Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Twisk JWR, Swinkels SHN, Scheltens P. Efficacy of a medical food on cognition in Alzheimer’s disease: results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging 2011;15:720-724.
  • Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM. Progression from MCI to AD: Predictive value of CSF Abeta42 is modified by APOE genotype. Neurobiol Aging 2011;32:1372-1378.
  • Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ, for the Alzheimer’s Disease Neuroimaging Initiative. (waaronder o.a. Fox N.) Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011;76:69-79.
  • Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodríguez Martinez de Llano S, Edison P, Douglas J, Fox NC, Brooks DJ, Rossor MN. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain 2011;134:293-300.
  • Koedam ELGE, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YAL, Fox N, Barkhof F, Wattjes MP. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 2011;21:2618-2625.
  • Lashley T, Rohrer JD, Bandopadhyay R, Fry C, Ahmed Z, Isaacs AM, Brelstaff JH, Borroni B, Warren JD, Troakes C, King A, Al-Saraj S, Newcombe J, Quinn N, Ostergaard K, Schøder HD, Bojsen-Møller M, Braendgaard H, Fox NC, Rossor MN, Lees AJ, Holton JL, Revesz T. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 2011;134:2548-2564.
  • Lehmann M, Barnes J, Ridgway GR, Wattam-Bell J, Warrington EK, Fox NC, Crutch SJ.  Basic visual function and cortical thickness patterns in posterior cortical atrophy. Cereb Cortex 2011;21:2122-2132.
  • Lehmann M, Crutch SJ, Ridgway GR, Ridha BH, Barnes J, Warrington EK, Rossor MN, Fox NC. Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer’s disease. Neurobiol Aging 2011;32:1466-1476.
  • Leung KK, Barnes J, Modat M, Ridgway GR, Bartlett JW, Fox NC, Ourselin S, and the Alzheimer’s Disease Neuroimaging Initiative. Brain MAPS: An automated, accurate and robust brain extraction technique using a template library. Neuroimage 2011;55:1091-1108.
  • McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement 2011;7:263-269.
  • Mahoney CJ, Rohrer JD, Goll JC, Fox NC, Rossor MN, Warren JD. Structural neuroanatomy of tinnitus and hyperacusis in semantic dementia. J Neurol Neurosurg Psychiatry 2011;82:1274-1278.
  • Maruta C, Guerreiro M, de Mendonça A, Hort J, Scheltens P. The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. Eur J Neurol 2011;18:279-286.
  • Norberg J, Graff C, Almkvist O, Ewers M, Frisoni GB, Frölich L, Hampel H, Jones RW, Kehoe PG, Lenoir H, Minthon L, Nobili F, Olde Rikkert M, Rigaud A-S, Scheltens P, Soininen H, Spiru L, Tsolaki M, Wahlund L-O, Vellas B, Wilcock G, Elias-Sonnenschein LS, Verhey FRJ, Visser PJ. Regional differences in effects of APOE ε4 on cognitive impairment in non-demented subjects. Dement Geriatr Cogn Disord 2011;32:135-142.
  • O’Brien J, Scheltens P. Clinical use of neuroimaging in dementia: an international perspective. Int Psychogeriatr 2011;23(suppl 2):S3-S5.
  • Ossenkoppele R, Tolboom N, Pijnenburg YA, Lammertsma AA, Scheltens P, van Berckel BNM.  Afbeelden van amyloïdplaques in de hersenen met PET. Ned Tijdschr Geneeskd 2011;155:A2981.
  • Ossenkoppele R, van Berckel BNM, Tolboom N, PijnenburgYA, Prins ND, Lemstra AW, Lammertsma AA, Scheltens Ph. Moleculaire beeldvorming bij de ziekte van Alzheimer. Tschr Neurol Neurochir 2011;112:201-208.
  • Ossenkoppele R, van Berckel BNM, Prins ND. Amyloid imaging in prodromal Alzheimer’s disease. Alzheimers Res Ther 2011;3(5):26.
  • Oudega ML, van Exel E, Wattjes MP, Comijs HC, Scheltens P, Barkhof F, Eikelenboom P, de Craen AJM, Beekman ATF, Stek ML. White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients.  J Clin Psychiatry 2011;72:104-112.
  • Pievani M, de Haan W, Wu T, Seeley WW, Frisoni GB. Functional network disruption in the degenerative dementias. Lancet Neurol 2011;10:829-843.
  • van de Pol L, Gertz H-J, Scheltens P, Wolf H. Hippocampal atrophy in subcortical vascular dementia. Neurodegener Dis 2011;8:465-469.
  • Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EGP, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain  2011;134:2456-2477.
  • Rohrer JD, Lashley T, Holton J, Revesz T, Urwin H, Isaacs AM, Fox NC, Rossor MN, Warren J. The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2011;82:1405-1407.
  • Rohrer JD, Lashley T, Schott JM, Warren JE, Mead S, Isaacs AM, Beck J, Hardy J, de Silva R, Warrington E, Troakes C, Al-Sarraj S, King A, Borroni B, Clarkson MJ, Ourselin S, Holton JL, Fox NC, Revesz T, Rossor MN, Warren JD. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 2011;134:2565-2581.
  • Ryberg C, Rostrup E, Paulson OB, Barkhof F, Scheltens P, van Straaten ECW, van der Flier WM, Fazekas F, Schmidt R, Ferro JM, Baezner H, Erkinjuntti T, Jokinen H, Wahlund L-O, Poggesi A, Pantoni L, Inzitari D, Waldemar G, and on behalf of the LADIS study group. Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort. J Neurol Sci 2011;307:100-105.
  • Scheltens P, Rockwood K. How golden is the gold standard of neuropathology in dementia? Alzheimers Dement 2011;7:486-489.
  • Scher AI, Xu Y, Korf ESC, Hartley SW, Witter MP, Scheltens P, White LR, Thompson PM, Toga AW, Valentino DJ, Launer LJ. Hippocampal morphometry in population-based incident Alzheimer’s disease and vascular dementia: the HAAS. J Neurol Neurosurg Psychiatry 2011;82:373-377.
  • Scherder E, Eggermont L, Visscher C, Scheltens P, Swaab D. Understanding higher level gait disturbances in mild dementia in order to improve rehabilitation; ‘Last in – first out’. Neurosci Biobehav Rev 2011;35:699-714.
  • Schmidt R, Schmidt H, Haybaeck J, Loitfelder M, Weis S, Cavalieri M, Seiler S, Enzinger C, Ropele S, Erkinjuntti T, Pantoni L, Scheltens P, Fazekas F, Jellinger K. Heterogeneity in age-related white matter changes. Acta Neuropathol 2011;122:171-178.
  • Schott JM, Warren JD, Barkhof F, Rossor MN, Fox NC. Suspected early dementia. BMJ 2011;343:d5568:1-5.
  • Sikkes SAM, Knol DL, van den Berg MT, de Lange-de Klerk ESM, Scheltens P, Klein M, Pijnenburg YAL, Uitdehaag, BMJ. An informant questionnaire for detecting Alzheimer’s disease: are some items better than others? J Int Neuropsychol Soc 2011;17:674-681.
  • Sims R, Dwyer S, Harold D, Gerrish A, Hollingworth P, Chapman J, Jones N, Abraham R, Ivanov D, Pahwa JS, Moskvina V, Dowzell K, Thomas C, Stretton A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuiness B, Todd S, Johnston JA, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Livingston G, Bass NJ, Gurling H, McQuillin A, Jones L, Holmans PA, O’Donovan M, Owen MJ, Williams J. No evidence that extended tracts of homozygosity are associated with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 2011;156:764-771.
  • Smits LL, Liedorp M, Koene T, Roos-Reuling IEW, Lemstra AW, Scheltens P, Stam CJ, van der Flier WM. EEG abnormalities are associated with different cgnitive profiles in Alzheimer’s disease. Dement Geriatr Cogn Disord 2011;31:1-6.
  • Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 2011;7:367-385.
  • Tabrizi SJ, Scahill RI, Durr A, Roos RAC, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC, and the TRACK-HD investigators. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31-421.
  • Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Gispen-de Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel H. Prevention trials in Alzheimer’s disease: An EU-US task force report. Prog Neurobiol 2011;95:594-600.
  • Verdelho A, Madureira S, Moleiro C, Santos CO, Ferro JM, Erkinjuntti T, Poggesi A, Pantoni L, Fazekas F, Scheltens P, Waldemar G, Wallin A, Inzitari D, and on behalf of the LADIS study(waaronder Scheltens P, van Straaten I, Gouw A, van der Flier W, Visser M). Self-perceived memory complaints predict progression to Alzheimer disease. The LADIS study. J Alzheimers Dis  2011;27:491-498.
  • van Vliet D, de Vugt ME, Bakker C, Koopmans RTCM, Pijnenburg YAL, Vernooij-Dassen MJFJ, Verhey FR. Caregivers’ perspectives on the pre-diagnostic period in early onset dementia: a long and winding road. Int Psychogeriatr 2011;23:1393-1404.
  • de Waal H, Stam CJ, Blankenstein MA, Pijnenburg YAL, Scheltens P, van der Flier WM. EEG abnormalities in early and late onset Alzheimer’s disease: understanding heterogeneity. J Neurol Neurosurg Psychiatry 2011;82:67-71.
  • de Wilde MC, Kamphuis PJGH, Sijben JWC, Scheltens P. Utility of imaging for nutritional intervention studies in Alzheimer’s disease. Eur J Pharmacol 2011;668(suppl.1):S59-S69.
  • Witlox J, Kalisvaart KJ, de Jonghe JFM, Verwey NA, van Stijn MFM, Houdijk APJ, Traast HS, Maclullich AMJ, van Gool WA, Eikelenboom P. Cerebrospinal fluid β-amyloid and tau are not associated with risk of delirium: a prospective cohort study in older adults with hip fracture. J Am Geriatr Soc 2011;59:1260-1267.
  • Dröes, R.M., Van Mierlo, L.D., Meiland, F.J.M., Van der Roest, H.G. Memory problems in dementia: Adaptation and copingstrategies, and psychosocial treatments. Expert Reviews Neurotherapeutics, 2011,11(12)1769-1782.
  • De Boer ME, Dröes RM, Jonker C, Eefsting JA, Hertogh CMPM. Advance directives for euthanasia in dementia: how are they dealt with in Dutch nursing homes? Experiences of physicians and relatives.Journal of the American Geriatrics Society 2011;59(6):989-96.
  • Jansen APD, Van Hout HPJ, Nijpels G, Rijmen F, Dröes RM, Pot AM, Schellevis F, Van Marwijk HWJ, Stalman W. Effectiveness of case management among older adults with early symptoms of dementia and their primary informal caregivers: a randomised clinical trial. International Journal of Nursing Studies 2011 Aug;48(8):933-43.
  • Meiland FJM, Jonker C, Dröes RM. Predictors of effective support in meeting centers for people with dementia and their carers,Nonpharmacological therapies in dementia2010; 1(3):251-270.
  • Monfort JC, Villemur V, Lezy AM, Baron-Laforet S, Dröes RM. From paedophilia to gerontophilia. Lancet 2011; Vol. 377, Jan 22, 300. Van Mierlo LD, Meiland FJM, Dröes RM. Dementelcoach: effect of telephone coaching on carers of community dwelling people with dementia. Int Psychogeriatr. 2011 Oct 14:1-11.

Boek(hoofdstukken) en vakpublicaties:

  • Barkhof F, Fox NC, Bastos-Leite AJ, Scheltens Ph. Neuroimaging in dementia. New York, Springer, 2011. 278 pp.
  • van Exel E, Eikelenboom P, Comijs HC, Kurniawan C, Frölich M, Smit JH, Stek ML, Scheltens P, Eefsting JE, Westendorp  RGJ.  Het immuunsysteem en de ziekte van Alzheimer. Tijdschr Psychiatr 2011;53:637-643.
  • Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P. Alzheimer’s disease. In: Gilhus NE, Barnes M, Brainin M (eds), European handbook of neurological management. Oxford, John Wiley-Blackwell Publishing, 2011:269-281.
  • Kerklaan BJ, Scheltens P, Schoonderwoerd GC, Killestein J, Rozemuller AJM, van der Knaap MS. ‘Adult polyglucosan body disease’: een weinig bekende maar herkenbare wittestofziekte. Tschr Neurol Neurochir 2011;112:25-31.
  • Vos SJB, Visser PJ, Verhey FRJ. De rol van liquormarkers bij de vroege diagnostiek van de ziekte van Alzheimer. Tijdschr Psychiatr 2011;53:647-653.
  • Dijk M van, Weert J van, Dröes RM. De Veder methode. Contact maken door middel van theater. Denkbeeld; Tijdschrift voor Psychogeriatrie, 23, 2011, 2-5.
  • Mierlo L, Dröes RM. Dementelcoach; telefonische ondersteuning voor mantelzorgers van mensen met dementie. Vita Valley, Nieuwsbrief, juli 2011.

Dissertaties:

  • Kester, MI. Biomarkers for Alzheimer’s pathology; monitoring, predicting and understanding the disease.
    Vrije Universiteit Amsterdam 14 januari 2011
    promotoren: Ph Scheltens, MA Blankenstein, copromotor: WM van der Flier
  • Mulder SD. Amyloid associated proteins in Alzheimer’s disease.
    Vrije Universiteit Amsterdam 7 oktober 2011
    promotoren: MA Blankenstein. Ph Scheltens, copromotor: R Veerhuis
  • Sikkes SAM. Measuring IADL in dementia.
    Vrije Universiteit Amsterdam 14 oktober 2011.
    promotoren: Ph Scheltens, BMJ Uitdehaag, copromotoren: YAL Pijnenburg, ESM de Lange-de Klerk
  • Sluimer JD. Visualizing the shrinking brain: longitudinal MR studies in the spectrum of cognitive decline.
    Vrije Universiteit Amsterdam 28 april 2011.
    promotoren: F Barkhof, Ph Scheltens, copromotoren: WM van der Flier, H. Vrenken
  • Van der Roest HG. Care needs in dementia and digital interactive information provisioning.
    Vrije Universiteit Amsterdam 12 oktober 2009
    Promotoren: RM Dröes, C Jonker, copromotoren: FJ Meiland, P. Scheltens

Publicaties 2010

Internationale wetenschappelijk publicaties (peer reviewed):

  • Archer HA, Kennedy J, Barnes J, Pepple T, Boyes R, Randlesome K, Clegg S, Leung KK, Ourselin S, Frost C, Rossor MN, Fox NC. Memory complaints and increased rates of brain atrophy: risk factors for mild cognitive impairment and Alzheimer’s disease. Int J Geriatr Psychiatry 2010;25:1119-1126.
  • Babiloni C, Visser PJ, Frisoni G, De Deyn PP, Bresciani L, Jelic V, Nagels G, Rodriguez G, Rossini PM, Vecchio F, Colombo D, Verhey F, Wahlund L-O, Nobili F. Cortical sources of resting EEG rhythms in mild cognitive impairment and subjective memory complaint. Neurobiol Aging 2010;31:1787-1798.
  • Barnes J, Mitchell LA, Kennedy J, Bastos-Leite AJ, Barker S, Lehmann M, Nordstrom RC, Frost C, Smith JR, Garde E, Rossor MN, Fox NC. Does registration of serial MRI improve diagnosis of dementia? Neuroradiology 2010;52:987-995.
  • Barnes J, Ridgway GR, Bartlett J, Henley SMD, Lehmann M, Hobbs N, Clarkson MJ, Macmanus DG, Ourselin S, Fox NC.  Head size, age and gender adjustment in MRI studies: A necessary nuisance?  Neuroimage 2010;53:1244-1255.
  • Bird CM, Chan D, Hartley T, Pijnenburg YA, Rossor MN, Burgess N. Topographical short-term memory differentiates Alzheimer’s disease from frontotemporal lobar degeneration. Hippocampus 2010;20:1154-1169.
  • Bour AMJJ, Rasquin SMC, Baars L, van Boxtel MPJ, Visser PJ, Limburg M, Verhey FRJ. The effect of the APOE-ε4 allele and ACE-I/D polymorphism on cognition during a two-year follow-up in first-ever stroke patients. Dement Geriatr Cogn Disord 2010;29:534-542.
  • Bouwman FH, Verwey NA, Klein M, Kok A, Blankenstein MA, Sluimer JD, Barkhof F,van der Flier WM, Scheltens P. New research criteria for the diagnosis of Alzheimer’s disease applied in a memory clinic population.  Dement Geriatr Cogn Disord 2010;30:1-7.
  • Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR Jr, Weiner M, DeCarli C, for the Alzheimer’s Disease Neuroimaging Initiative.(waaronder Visser PJ)Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol 2010;67:1370-1378.
  • Chouliaras L, Rutten BPF, Kenis G, Peerbooms O, Visser PJ, Verhey F, van Os J, Steinbusch HWM, van den Hove DLA. Epigenetic regulation in the pathophysiology of Alzheimer’s disease. Prog Neurobiol 2010;90:498-510.
  • Clarkson MJ, Malone IB, Modat M, Leung KK, Ryan N, Alexander DC, Fox NC, Ourselin S. A framework for using diffusion weighted imaging to improve cortical parcellation. Med Image Comput Comput Assist Interv. 2010;13:534-541.
  • Delaloye C, Moy G, de Bilbao F, Baudois S, Weber K, Hofer F, Paquier CR, Donati A, Canuto A, Giardini U, von Gunten A, Stancu RI, Lazeyras F, Millet P, Scheltens P, Giannakopoulos P, Gold G. Neuroanatomical and neuropsychological features of elderly euthymic depressed patients with early- and late-onset. J Neurol Sci 2010;299:19-23.
  • Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010;9:1118-1127.
  • Evans MC, Barnes J, Nielsen C, Kim LG, Clegg SL, Blair M, Leung KK, Douiri A, Boyes RG, Ourselin S, Fox NC, and the Alzheimer’s Disease Neuroimaging Initiative.  Volume changes in Alzheimer’s disease and mild cognitive impairment: cognitive associations. Eur Radiol 2010;20:674-682.
  • Exalto LG, van der Flier WM, Scheltens P, Biessels GJ. Glycemia and levels of cerebrospinal fluid amyloid and tau in patients attending a memory clinic.  J Am Geriatr Soc 2010;58:1318-1321.
  • Fox N. Clinical advances in our understanding and classification of the dementias. J Neurol Neurosurg Psychiatry 2010;81(10):e3,006.
  • Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease.  Nat Rev Neurol 2010;6:67-77.
  • Goos JDC, Henneman WJP, Sluimer JD, Vrenken H, Sluimer IC, Barkhof F, Blankenstein MA, Scheltens PH, van der Flier WM. Incidence of cerebral microbleeds: A longitudinal study in a memory clinic population. Neurology 2010;74:1954-1960.
  • Gordon E, Rohrer JD, Kim LG, Omar R, Rossor MN, Fox NC, Warren JD. Measuring disease progression in frontotemporal lobar degeneration: a clinical and MRI study. Neurology 2010:74: 666-673.
  • Guerreiro RJ, Beck J, Gibbs JR, Santana I, Rossor MN, Schott JM, Nalls MA, Ribeiro H, Santiago B, Fox NC, Oliveira C, Collinge J, Mead S, Singleton A, Hardy J.  Genetic variability inCLU and its association with Alzheimer’s disease.  PLoS One 2010;5(3):e9510.
  • Henley SMD, Ridgway GR, Scahill RI, Klöppel S, Tabrizi SJ, Fox NC, Kassubek J, for the EHDN Imaging Working Group. Pitfalls in the Use of Voxel-Based Morphometry as a Biomarker: Examples from Huntington Disease. AJNR Am J Neuroradiol 2010;31:711-719.
  • Hobbs NZ, Barnes J, Frost C, Henley SMD, Wild EJ, Macdonald K, Barker RA, Scahill RI, Fox NC, Tabrizi SJ. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am J Neuroradiol 2010;31:1036-1041.
  • Hobbs NZ, Henley SMD, Ridgway G, Wild EJ, Barker R, Scahill RI, Barnes J, Fox NC, Tabrizi SJ. The progression of regional atrophy in premanifest and early Huntington’s disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry 2010;81:756-763.
  • Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P, on Behalf of the EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol 2010;17:1236-1248.
  • Hort J, Bartos A, Pirttilä T, Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe.  Eur J Neurol 2010;17:90-96.
  • Hyare H, Wroe S, Siddique D, Webb T, Fox NC, Stevens J, Collinge J, Yousry T, Thornton JS. Brain-water diffusion coefficients reflect the severity of inherited prion disease. Neurology 2010;74:658-665.
  • Jack CR Jr, Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, Schuff N, Krueger G, Killiany RJ, DeCarli CS, Dale AM, Carmichael OW, Tosun D, Weiner MW and the Alzheimer’s Disease Neuroimaging Initiative.  Update on the magnetic resonance imaging core of the Alzheimer’s disease neuroimaging initiative.  Alzheimers Dement 2010;6:212-220.
  • Joling KJ, van Hout HPJ, Schellevis FG, van der Horst HE, Scheltens P, Knol DL, van Marwijk HWJ. Incidence of depression and anxiety in the spouses of patients with dementia: a naturalistic cohort study of recorded morbidity with a 6-year follow-up. Am J Geriatr Psychiatry 2010;18:146-153.
  • Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One 2010;5(11):e13950.
  • Jonsson M, Zetterberg H, van Straaten E, Lind K, Syversen S, Edman A, Blennow K, Rosengren L, Pantoni L, Inzitari D, Wallin A. Cerebrospinal fluid biomarkers of white matter lesions – cross-sectional results from the LADIS study. Eur J Neurol 2010;17:377-382.
  • Kamphuis PJGH, Scheltens P. Can nutrients prevent or delay onset of Alzheimer’s disease? J Alzheimers Dis 2010;20:765-775.
  • Keihaninejad S, Heckemann RA, Fagiolo G, Symms MR, Hajnal JV, Hammers A, Alzheimer’s Disease Neuroimaging Initiative.(waaronder Fox NC) A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). Neuroimage 2010;50:1427-1437.
  • Kester MI, Boelaarts L, Bouwman FH, Vogels RL, Groot ER, van Elk EJ, Blankenstein MA, van der Flier WM, Scheltens P. Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Dement Geriatr Cogn Disord 2010;29:491-497.
  • Kester MI, Verwey NA, van Elk EJ, Scheltens P, Blankenstein MA. Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging 2010;31:539-540.
  • Kester MI, van der Flier WM, Mandic G, Blankenstein MA, Scheltens P, Muller M. Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer’s disease.
  • J Alzheimers Dis 2010;20:1083-1090.
  • Keihaninejad S, Heckemann RA, Fagiolo G, Symms MR, Hajnal JV, Hammers A, Alzheimer’s Disease Neuroimaging Initiative (waaronder Fox N). A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). Neuroimage 2010;50:1427-1437.
  • Koedam ELGE, Van der Flier WM, Barkhof F, Koene T, Scheltens P, Pijnenburg YAL. Clinical characteristics of patients with frontotemporal dementia with and without lobar atrophy on MRI. Alzheimer Dis Assoc Disord 2010;24:242-247.
  • Koedam ELGE, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YAL. Early- versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis 2010;19:1401-1408.
  • Lehmann M, Douiri A, Kim LG, Modat M, Chan D, Ourselin S, Barnes J, Fox NC. Atrophy patterns in Alzheimer’s disease and semantic dementia: A comparison of FreeSurfer and manual volumetric measurements. Neuroimage 2010;49:2264-2274.
  • Lehmann M, Rohrer JD, Clarkson MJ, Ridgway GR, Scahill RI, Modat M, Warren JD, Ourselin S, Barnes J, Rossor MN, Fox NC. Reduced cortical thickness in the posterior cingulate gyrus is characteristic of both typical and atypical Alzheimer’s disease. J Alzheimers Dis 2010;20:587-598.
  • Leung KK, Barnes J, Ridgway GR, Bartlett JW, Clarkson MJ, Macdonald K, Schuff N, Fox NC, Ourselin S, and  the Alzheimer’s Disease Neuroimaging Initiative. Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer’s disease.  Neuroimage 2010;51:1345-1359.
  • Leung KK, Shen KK, Barnes J, Ridgway GR, Clarkson MJ, Fripp J, Salvado O, Meriaudeau F, Fox NC, Bourgeat P, Ourselin S, Increasing power to predict mild cognitive impairment conversion to Alzheimer’s disease using hippocampal atrophy rate and statistical shape models. Med Image Comput Comput Assist Interv. 2010;13:125-132.
  • Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR Jr, Weiner MW, Fox NC, Ourselin S, and the Alzheimer’s Disease Neuroimaging Initiative. Robust atrophy rate measurement in Alzheimer’s disease using multi-site serial MRI: tissue-specifi c intensity normalisation and parameter selection.  Neuroimage 2010;50:516-523.
  • Liedorp M, Stam CJ, van der Flier WM, Pijnenburg YAL, Scheltens Ph. Prevalence and clinical significance of epileptiform EEG discharges in a large memory clinic cohort. Dement Geriatr Cogn Disord 2010;29:432-437.
  • Madureira S, Verdelho A, Moleiro C, Ferro JM, Erkinjuntti T, Jokinen H, Pantoni L, Fazekas F, van der Flier W, Visser M, Waldemar G, Wallin A, Hennerici M, Inzitari D. Neuropsychological predictors of dementia in a three-year follow-up period: data from the LADIS study. Dement Geriatr Cogn Disord 2010;29:325-334.
  • Mihaescu R, Detmar SB, Cornel MC, van der Flier WM, Heutink P, Hol EM, Olde Rikkert MGM, van Duijn CM, Janssens ACJW. Translational research in genomics of Alzheimer’s disease: a review of current practice and future perspectives. J Alzheimers Dis 2010;20:967-980.
  • Modat M, Ridgway GR, Taylor ZA, Lehmann M, Barnes J, Hawkes DJ, Fox NC, Ourselin S. Fast free-form deformation using graphics processing units.
  • Comput Methods Programs Biomed 2010;98:278-184.
  • Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, Scheltens P, Blankenstein MA. Amyloid-β(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 2010;56:248-253.
  • Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, Hack CE, Veerhuis R. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J Alzheimers Dis 2010;20:253-260.
  • Mulder SD, Hack CE, van der Flier WM, Scheltens P, Blankenstein MA, Veerhuis R. Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP) synthesis in Alzheimer’s disease with the use of index values. J Alzheimers Dis 2010;22:1073-1079.
  • Oosterman JM, Vogels RLC, van Harten B, Gouw AA, Poggesi A, Scheltens P, Kessels RPC, Scherder EJA. Assessing mental flexibility: neuroanatomical and neuropsychological correlates of the trail making test in elderly people. Clin Neuropsychol 2010;24:203-219.
  • Petzold A, Verwey NA, van Uffelen K, Blankenstein MA, Teunissen C. Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration. J Neurosci Methods 2010;193:296-299.
  • Petzold A, Chapman MD, Schraen S, Verwey NA, Pasquier F, Bombois S, Brettschneider J, Fox NC, von Arnim CAF, Teunissen C, Pijnenburg Y, Riepe MW, Otto M, Tumani H, Scheltens P, Buee L, Rosso MN. An unbiased, staged, multi-center, validation strategy for Alzheimer’s disease CSF tau levels. Exp Neurol 2010;223:432-438.
  • Polvikoski TM, van Straaten ECW, Barkhof F, Sulkava R, Aronen HJ, Niinistö L, Oinas M, Scheltens P, Erkinjuntti T, Kalaria RN. Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology 2010;75:2071-2078.
  • Prins ND, van Swieten JC. Alzheimer disease: MRI and CSF biomarkers in AD-accuracy and temporal change. Nat Rev Neurol 2010:6:650-651.
  • Prins ND, Visser PJ, Scheltens P. Can novel therapeutics halt the amyloid cascade? Alzheimers Res Ther 2010;2(2):5.
  • Ramakers IHGB, Visser PJ, Aalten P, Kester A, Jolles J, Verhey FRJ. Affective symptoms as predictors of Alzheimer’s disease in subjects with mild cognitive impairment: a 10-year follow-up study.  Psychol Med 2010;40:1193-1201.
  • Ramakers IHGB, Visser PJ, Aalten P, Maes HL, Lansdaal HGM, Meijs CJC, Jolles J, Verhey FR. The predictive value of memory strategies for Alzheimer’s disease in subjects with mild cognitive impairment. Arch Clin Neuropsychol 2010;25:71-77.
  • Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WDJ, Klein M, Blankenstein MA, Scheltens P, Verbeek MM, van der Flier WM. CSF α-synuclein does not discriminate dementia with lewy bodies from Alzheimer’s disease. J Alzheimers Dis 2010;22:87-95.
  • Richard E, Gouw AA, Scheltens P, van Gool WA. Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI. The evaluation of vascular care in Alzheimer’s disease (EVA) study. Stroke 2010;41:554-556.
  • Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, de Liano SR, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-372.
  • Rohrer JD, Ridgway GR, Modat M, Ourselin S, Mead S, Fox NC, Rossor MN, Warren JD. Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neuroimage 2010;53:1070-1076.
  • Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurol 2010;9:793-806.
  • van Rossum IA, ten Houten R. Alledaagse symptomen als uiting van MELAS. Ned Tijdschr Geneeskd 2010;154:A2168.
  • van Rossum IA, Vos S, Handels R, Visser PJ. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis 2010;20:881-891.
  • Salloway SP, Black R, Sperling R, Fox N, Gilman S, Schenk D, Griundman Ml.  Reply from the authors: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2010;74(24):2026-2027.
  • Sanz-Arigita EJ, Schoonheim MM, Damoiseaux JS, Rombouts SARB, Maris E, Barkhof F, Scheltens P, Stam CJ. Loss of ‘small-world’ networks in Alzheimer’s disease: graph analysis of FMRI resting-state functional connectivity. PLoS One 2010;5(11):e13788.
  • Scheltens P, Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM,  Wurtman RJ,  Wilkinson D, Twisk JWR, Kurz A. Efficacy of a medical food in mild Alzheimer’s disease: a randomized, controlled trial. Alzheimers Dement  2010;6:1-10
  • Schmidt R, Ropele S, Ferro J, Madureira S, Verdelho A, Petrovic K, Gouw A, van der Flier WM, Enzinger C, Pantoni L, Inzitari D, Erkinjuntti T, Scheltens P, Wahlund LO, Waldemar G, Rostrup E, Wallin A, Barkhof F, Fazekas F, on behalf of the LADIS study group. Diffusion-weighted imaging and cognition in the leukoariosis and disability in the elderly study.  Stroke 2010;41:e402-e408.
  • Schneider LS, Kennedy RE, Cutter GR, and the Alzheimer’s Disease Neuroimaging Initiative. (waaronder Fox N.)Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement 2010;6:367-377.
  • Schott JM, Bartlett JW, Fox NC, Barnes J, for the Alzheimer’s Disease Neuroimaging Initiative Investigators. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann Neurol 2010;68:825-834.
  • Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC, for the Alzheimer’s Disease Neuroimaging Initiative Investigators. Reduced sample sizes for atrophy outcomes in Alzheimer’s disease trials: baseline adjustment. Neurobiol Aging 2010;31:1452-1462.
  • Schott JM, Frost C, Macmanus DG, Ibrahim F, Waldman AD, Fox NC. Short echo time proton magnetic resonance spectroscopy in Alzheimer’s disease: a longitudinal multiple time point study. Brain 2010;133:3315-3322.
  • Schuitemaker A, Dik MG, Veerhuis R, Scheltens P, Schoonenboom NSM, Hack CE, Blankenstein MA, Jonker C. Inflammatory markers in AD and MCI patients with different biomarker profiles-interpretation of serum and CSF levels. Neurobiol Aging 2010;31:1655.
  • Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD, Foroud T, Pankratz N, Moore JH, Sloan CD, Huentelman MJ, Craig DW, Dechairo BM, Potkin SG, Jack CR Jr, Weiner MW, Saykin AJ and the Alzheimer’s Disease Neuroimaging Initiative.( waaronder Fox N ). Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage 2010;53:1051-1063.
  • Sikkes SAM, van den Berg MT, Knol DL, de Lange-de Klerk ESM, Scheltens P, Uitdehaag BMJ, Klein M, Pijnenburg YAL. How useful Is the IQCODE for discriminating between Alzheimer’s disease, mild cognitive impairment and subjective memory complaints? Dement Geriatr Cogn Disord 2010;30:411-416.
  • Slats D, Spies PE, Sjögren MJC, Visser PJ, Verbeek MM, Rikkert MGM, Kehoe PG. CSF biomarker utilisation and ethical considerations of biomarker assisted diagnosis and research in dementia: perspectives from within the European Alzheimer’s Disease Consortium (EADC). J Neurol Neurosurg Psychiatry 2010;81:124-125.
  • Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, Scheltens P. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging 2010;31:758-764.
  • Smits LL, Liedorp M, Koene T, Roos-Reuling IEW, Lemstra AW, Scheltens P, Stam CJ, van der Flier WM. EEG abnormalities are associated with different cognitive profiles in Alzheimer’s disease. Dement Geriatr Cogn Disord 2010;31:1-6.
  • Staekenborg SS, Su T, van Straaten ECW, Lane R, Scheltens P, Barkhof F, van der Flier WM. Behavioural and psychological symptoms in vascular dementia; differences between small and large vessel disease. J Neurol Neurosurg Psychiatry 2010;81:547-551.
  • Staekenborg SS, de Waal H, Admiraal-Behloul F, Barkhof F, Reiber JHC, Scheltens P, Pijnenburg YAL, Vrenken H, van der Flier WM. Neurological signs in relation to white matter hyperintensity volumes in memory clinic patients.  Dement Geriatr Cogn Disord 2010;29:301-308.
  • Teodorczuk A, Firbank MJ, Pantoni L, Poggesi A, Erkinjuntti T, Wallin A, Wahlund L-O, Scheltens P, Waldemar G, Schrotter G, Ferro JM, Chabriat H, Bazner H, Visser M, Inzitari D, O’Brien JT, on behalf of the LADIS Group. Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study. Psychol Med 2010;40:603-610.
  • Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA. Standardization of assay procedures for analysis of the CSF biomarkers amyloid β(1-42)), tau, and phosphorylated tau in Alzheimer’s disease: report of an International workshop.
  • Int J Alzheimers Dis 2010; Article ID 635053:1-6.
  • Tolboom N, Koedam ELGE, Schott JM, Yaqub M, Blankenstein MA, Barkhof F, Pijnenburg YAL, Lammertsma AA, Scheltens P, van Berckel BNM. Dementia mimicking Alzheimer’s disease owing to a tau mutation: CSF and PET findings.  Alzheimer Dis Assoc Disord 2010;24:303-307.
  • Tolboom N, van der Flier WM, Boverhoff J, Yaqub M, Wattjes MP, Raijmakers PG, Barkhof F, Scheltens P, Herholz K, Lammertsma AA, van Berckel BNM. Molecular imaging in the diagnosis of Alzheimer’s disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. J Neurol Neurosurg Psychiatry 2010;81:882-884.
  • Tsolaki M, Papaliagkas V, Anogianakis G, Bernabei R, Emre M, Frolich L, Visser PJ, Michel J-P, Pirttila T, Olde Rikkert M, Soininen H, Sobow T, Vellas B, Verhey F, Winblad B and the European Alzheimer’s Disease Consortium. Consensus statement on dementia education and training in Europe. J Nutr Health Aging 2010;14:131-135.
  • Verdelho A, Madureira S, Moleiro C, Ferro JM, Santos CO, Erkinjuntti T, Pantoni L, Fazekas F, Visser M, Waldemar G, Wallin A, Hennerici M, Inzitari D, on behalf of the LADIS Study. White matter changes and diabetes predict cognitive decline in the elderly: The LADIS Study. Neurology 2010;75:160-167.
  • Verwey NA, Kester MI, van der Flier WM, Veerhuis R, Berkhof H, Twaalfhoven H, Blankenstein MA, Scheltens P, Pijnenburg YAL. Additional value of CSF amyloid-β40 levels in the differentiation between FTLD and control subjects. J Alzheimers Dis 2010;20:445-452.
  • VITATOPS Trial Study Group (waaronder Eikelenboom JW, Koedam E). B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial.  Lancet Neurol 2010;9:855-865.
  • Vounou M, Nichols TE, Montana G and the  Alzheimer’s Disease Neuroimaging Initiative (waaronder Fox N). Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach. Neuroimage 2010;53:1147-1159.
  • Wild EJ, Henley SMD, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ. Rate and acceleration of whole-brain atrophy in premanifest and early Huntington’s disease. Mov Disord 2010;25:888-895.
  • Wolk DA, Dickerson BC and the Alzheimer’s Disease Neuroimaging Initiative, (waaronder Fox NC) Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer’s disease. Proc Natl Acad Sci U S A 2010;107:10256-10261.
  • Yaqub M, Tolboom N, van Berckel BNM, Scheltens P, Lammertsma AA, Boellaard R. Simplified parametric methods for [18F]FDDNP studies. Neuroimage 2010;49:433-441.
  • Boer ME de, Hertogh C.MPM, Dröes RM, Jonker C, Eefsting JA. Advance directives in dementia: issues on validity and effectiveness. International Psychogeriatrics, 2010 Mar;22(2):201-8.
  • Boer ME, Dröes RM, Jonker C, Eefsting JA, Hertogh CM. Advance directives for euthanasia in dementia: Do law-based opportunities lead to more euthanasia? Health Policy 2010;98:256-262.
  • Bouman AIE, Ettema TP, Wetzels RB, Beek APA. van, de Lange J, Dröes RM. Qualidem: Evaluation of a Dementia-specific Quality of Life Instrument for Persons with Dementia in residential settings; Scalability and Reliability of Subscales used in four Dutch Field Surveys. International Journal of Geriatric Psychiatry 2011 Jul;26(7):711-22.
  • Dröes RM. Mierlo LD van, Roest HG van der, Meiland FJM. Focus and effectiveness of psychosocial interventions for people with dementia in institutional care settings from the perspective of coping with the disease. Non-pharmacological therapies in dementia, 2010;1(2):139-161.
  • Meiland FJM, Reinersmann A, Sävenstedt S, Bergvall-Kåreborn B, Hettinga M, Craig D, Andersson AL, Dröes RM. User-participatory development of assistive technology for people with dementia – from needs to functional requirements. First results of the COGKNOW project. Non-pharmacological therapies in dementia 2010;1(1):71-91.
  • Roest HG van der, Meiland FJ, Jonker C, Dröes RM. User evaluation of the DEM-DISC. Aging and Mental Health, 2010;14(4):461-70.
  • Van Mierlo LD, Van der Roest HG, Meiland FJM, Dröes RM. Personalized Dementia Care; proven effectiveness of psychosocial interventions in subgroups. Ageing Res Rev. 2010 Apr;9(2):163-83.

Boek(hoofdstukken) en vakpublicaties:

  • Boss HM, van den Berg-Vos RM, Scheltens P, Weinstein HC.  Stand van zaken. Vasculaire cognitieve beperking.Ned Tijdschr Geneeskd 2010;154:A1907
  • Gouw, A.A. Proefschriftbespreking: Schade aan kleine hersenvaten op MRI: klinische uitingen en onderligende pathologie.  Tschr Neurol Neurochir 2010;111:180-182.
  • Keulen MA, Uijterwaal MH, Engels MAH, Koene T, Scheltens Ph, Pijnenburg YAL. Taaldiagnostiek bij patiënten met semantische dementie en progressieve niet-vloeiende afasie. Stem-,Spraak- en Taalpathologie 2010;16:239-254.
  • Lemstra E, Eikelenboom P, van Gool P. Cholinerge deficiëtie en cognitie.
  • In: van der Mast R, Heeren T, Kat M, et al. (red.), Handboek ouderen-psychiatrie; 3e dr. Utrecht, de Tijdstroom,2010:511-518.
  • Scheltens Ph. Nog steeds geen pil voor Alzheimer. Ned Tijdschr Geneeskd 2010;154:A1885.
  • Boer ME de, Dröes RM, Jonker C, Eefsting JA, Hertogh CMPM. De beleving van beginnende dementie en het gevreesde lijden. Tijdschrift voor Gerontologie en Geriatrie 2010; 41(5): 194-203.
  • Craig D, Meiland FJM, Passmore AP, Dröes RM. Prevalence and clinical features of dementia. In: Mulvenna MD, Nugent CD. (Eds.), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010, Chapter 2, 15-22.
  • Dröes RM. Omgaan met dementie het psychosociale perspectief. Tijdschrift voor Ouderen-geneeskunde, 2010, 35(5)197-199.
  • Dröes RM. Omgaan met dementie het psychosociale perspectief. Samenvatting oratie.  CaRe-bulletin CaRré, aug 2010.
  • Dröes RM, Bentvelzen SCL, Meiland F, Craig D. Dementia-related and other factors to be taken into account when developing ICT-support for people with dementia – Lessons from field trials, In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 8, 113-130.
  • Gerritsen DL, Dröes RM, Ettema TP, Boelens E, Bos J, Meihuizen L, de Lange J, Schölzel-Dorenbos CJ, Hoogeveen F. Quality of life in dementia, opinions among people with dementia, their professional caregivers, and in literature. Tijdschr Gerontol Geriatr. 2010 Dec;41(6):241-55.
  • Lauriks S, Reinersmann A, Roest H.G. van der, Meiland FJM, Davies RJ, Moelaert F, Mulvenna MD, Nugent CD, Dröes RM. Review of ICT-based services for identified unmet needs in people with dementia, In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 4, 37-62.
  • Martin S, Bengtsson JE, Dröes RM. Assistive technologies and issues relating to privacy, ethics and security. In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 5, 63-78.
  • Meiland F, Dröes RM, Sävenstedt S, Bergvall-Kåreborn B, Andersson AL. Identifying User Needs and the Participative Design Process, In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 6, 79-100.
  • Meiland F, Dröes RM, Sävenstedt S. Measuring the impact of Cognitive Prosthetics on the daily life of people with dementia and their carers In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 14, 207-220.
  • Mierlo L. & Dröes RM. Dementelcoach; telefonische ondersteuning voor mantelzorgers van mensen met dementie. Vita Valley, Nieuwsbrief, juli 2011.
  • Mulvenna MD, Nugent C, Moelaert F, Craig D, Dröes RM, Bengtsson J. Supporting People with Dementia Using Pervasive Healthcare Technologies, In: Mulvenna MD, Nugent, CD. (Eds.), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 1, 3-14.
  • Mulvenna MD, Moelaert F, Meiland F, Sävenstedt S, Hettinga M, Craig D, Bengtsson JE, Dröes RM, Martin S. Designing and Evaluating a Cognitive Prosthetic for People with Mild Dementia. In: Brinkman WP, Neerincx M, (Eds), Caring Technology for the Future: Proceedings of the European Conference on Cognitive Ergonomics, 389 pp, Mediamatica, 2010;11-18.
  • Roest HG van der, Meiland FJM, Dröes RM. Proefschrift: Zorgbehoeften bij dementie en digitale, gepersonaliseerde informatievoorziening voor dementiezorg. Verpleegkunde 2010;(3):25-31
  • Sävenstedt S, Meiland F, Dröes RM, Moelaert F. Evaluation of Cognitive Prosthetics In: Mulvenna MD, Nugent CD. (Eds.), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag 2010, Chapter 13, 197-206.

Dissertaties:

  • Altena E. Mapping insomnia: brain structure, function and sleep intervention.
  • Vrije Universiteit Amsterdam 17 maart 2010
  • promotoren: EJW van Someren, DF Swaab, copromotoren: YD van der Werf, Ph Scheltens
  • Tolboom N. Imaging Alzheimer’s disease pathology in vivo: towards an early diagnosis.
  • Vrije Universiteit Amsterdam 12 februari 2010
  • promotoren: Ph Scheltens, AA Lammertsma. copromotoren: BNM van Berckel, WM van der Flier
  • Verwey NA. Biochemical markers in dementia: from mice to men.
  • Vrije Universiteit Amsterdam 16 april 2010
  • promotoren: Ph Scheltens, MA Blankenstein. copromotoren: WM van der Flier, R Veerhuis
Top
Volg ons via